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Abstract 
The effect of light on plants is fundamental to our understanding of the biological world. 
Photo-activated processes within botanical cells are controlled by two distinct colours; red 
light provides the energy required for photosynthesis, and blue light stimulates responses of 
the cell (growth, stomatal opening, etc.) necessary for biological progression. The key step in 
blue-light controlled processes has recently been determined to be the formation of a 
covalent bond between a tightly-bound molecule of flavin and a conserved cysteine residue 
within a photosensitive protein domain, which causes a physical change to the protein 
structure upon irradiation. 
 
This research was undertaken to examine light-stimulated covalent bond formation in 
phototropic proteins using two approaches. Firstly, two analogues of riboflavin 
(5-deazariboflavin and 1-deazariboflavin) were chemically synthesised, converted to the 
appropriate cofactor form (flavin mononucleotide; FMN), and incorporated into the 
photosensitive domain. The results of this were startling; while 1-deazaFMN inactivated the 
photosensitive domain to all wavelengths of light, 5-deazaFMN allowed control of the 
domain’s behaviour using two separate wavelengths of light, creating a biophotonic 
nanoswitch. 
 
The second approach was based upon mutagenesis of the amino acid responsible for bond 
formation, introducing several alternative residues in place of the reactive cysteine. All 
mutants were found to be inactive to irradiation (including those incorporating either of the 
deazaFMN analogues), providing further evidence to support the current “radical pair” 
mechanism of photoadduct formation. 
 
During the synthesis of the flavin analogues, several reactions were found to be inefficient, 
and a large number of alternative reactions were studied. Additionally, a new route to several 
flavin analogues was devised and tested, and while unsuccessful, provides a foundation upon 
which to base a future examination of their synthesis. Finally, the synthesis of a novel 
riboflavin analogue (5-deaza-8-demethyl-riboflavin) was completed, allowing comparison 
with the synthesis of 5-deazariboflavin.  
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dNTP deoxynucleotide triphosphate (ATP, GTP, CTP, TTP) 
DTT dithiothreitol 
dTTP deoxythymidine triphosphate, see dNTPs 
EtBr* ethidium Bromide (not bromoethane; by convention) 
EDTA ethylenediaminetetraacetic acid 
Et2O diethyl ether 
EtOAc ethyl acetate 
EtOH ethanol 
FAD flavin adenine dinucleotide 
FMN flavin mononucleotide 
GTP guanosine-5’-triphosphate 
GuHCl guanidinium hydrochloride 
GuSCN guanidinium thiocyanate 
HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-
b]pyridinium 3-oxid hexafluorophosphate 
HCl hydrochloric acid 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
IPTG isopropyl-1-thio-β-D-galactopyranoside  
KOH potassium hydroxide 
LB (growth media) Leuria-Bertani media for bacterial growth 
Me methyl; functional group 
MeOH methanol 
MES 2-(N-morpholino)ethanesulfonic acid 
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MOPS 3-(N-morpholino)propanesulfonic acid 
NAD+ nicotinamide adenine dinucleotide 
NADP+ nicotinamide adenine dinucleotide phosphate 
NaOH sodium hydroxide 
PMSF phenylmethylsulfonyl fluoride 
Ph phenyl; functional group 
PIPES piperazine-N,N′-bis(2-ethanesulfonic acid) 
PLP pyridoxal 5’-phosphate 
POCl3 phosphorous (V) oxychloride 
Pyr pyridine 
Rf riboflavin 
riboaniline 3,4-dimethyl-N-(ribityl)-aniline 
SDS sodium dodecyl sulphate 
TAE (buffer) tris base, acetic acid and EDTA buffer 
TB (growth media) “terrific broth” media for bacterial growth 
TCP 2,4,6-trichloropyrimidine 
TCPyr 2,4,6-trichlropyridine 
TEA (chemical synthesis) triethylamine 
TEA (buffer) triethanolamine buffer 
TEMED tetramethylethylenediamine 
TFA trifluoroacetic acid 
THF tetrahydrofuran 
Tris (buffer) tris(hydroxymethyl)aminomethane 
TTP thymidine triphosphate 
Vitamin B2 riboflavin 
Vitamin B12 cobalamin 
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Non-Chemical Abbreviations & Glossary of terms 
Å Angstrom 
Alkyl-DOB alkylimino-de-oxo-bisubstitution 
APSCI Atmospheric Pressure Chemical Ionisation; see Mass 
Spectrometry 
aq. aqueous 
AsLOV2 recombinant PHOT1-LOV2 domain of Avena sativa 
atm atmosphere 
b.p. base pair 
Ca-RfK-FADS recombinant bifunctional RfK-FADS protein from 
Corynebacterium ammoniagenes 
CI Chemical Ionisation; see Mass Spectrometry 
CD Circular Dichroism 
c. v. column volumes 
Da Dalton; unit of mass equal to 1.0 g mol-1 
DFT Density Functional Theory 
EI Electron Impact ionisation; see Mass Spectrometry 
ENDOR Electron Nuclear Double Resonance spectroscopy 
EPR  Electron Paramagnetic Resonance spectroscopy 
ESI Electrospray Ionisation; see Mass Spectrometry 
FADS FAD Synthetase; enzymatic domain 
FMN-AT FMN Adenyl Transferase; enzymatic domain 
FPLC Fast Protein Liquid Chromatography 
FT-IR Fourier Transform Infrared spectroscopy 
HPLC High-Performance Liquid Chromatography 
IMAC Immobilised Metal Affinity Chromatography 
IR Infrared spectroscopy, see FT-IR 
ISC Inter-system crossing 
k.b.p kilobase pair 
kDa kilo Dalton; unit of mass equal to 1000 Daltons (1 kg mol-1) 
LOV Light-Oxygen-Voltage domain 
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MB maltose-binding domain 
MCS Multiple Cloning Site 
MS Mass Spectrometry 
m- / meta-  aromatic substituent position 
MWt Molecular Weight, used for protein / DNA markers 
MRE Mean Residue Ellipticity, for normalisation of CD data 
MRW Mean Residue Weight, for calculation of MRE 
NMR Nuclear Magnetic Resonance spectroscopy 
NT Nucleotidyl Transferase; enzymatic domain 
o- / ortho-  aromatic substituent position 
OD Optical Density 
OOF Out Of Frame; codon frameshift of DNA 
ORF Open Reading Frame 
p- / para- aromatic substituent position 
PCR Polymerase Chain Reaction 
PHOT phototropin domain 
ppm parts per million 
ppb parts per billion 
QM Quantum Mechanical 
RF Retention Factor; used with TLC 
RfK Riboflavin Kinase; enzymatic domain 
RNA ribonucleic acid 
RNAP RNA polymerase 
RPM Rotations per Minute 
RT Room Temperature OR Retention Time 
SDM Site Directed Mutagenesis 
SDS-PAGE SDS-denaturing Polyacrylamide Gel Electrophoresis 
Sp-RfK recombinant RfK domain from Schizosaccharomyces pombe 
t-, tert-  structural feature, e.g. t-butyl 
TLC Thin Layer Chromatography 
UV-Vis Ultra Violet-visible spectroscopy 
w.r.t with respect to 
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Chapter 1 - Introduction 
1.0.1 Synopsis 
In this chapter, an introduction to the topics discussed within this thesis is made, 
comprising the photocycle of a flavin-mediated plant phototropin, and the chemical 
synthesis of riboflavin analogues. A review of the current literature in these fields is 
presented, in order to give a foundation for the results presented in subsequent 
chapters of this thesis. Due to the separate strands of research performed, linked by 
flavin and the analogues 5-deazaflavin and 1-deazaflavin, this chapter has been 
divided into two sections to give a clear introduction to each topic. 
 
1.0.2 Motivation 
The study of phototropism is of significant interest to current research in the field of 
biophotonics, with potential applications throughout molecular biology. Examination 
of the mechanism and photo-physical effects of phototropism has previously been 
based largely on spectroscopic examination and protein mutagenesis studies. Instead, 
an alternative approach to understanding the mechanism of phototropism using 
artificial cofactors has the potential to give further insight to this biological processes. 
 
The synthesis of riboflavin analogues has been a topic of some contention in the 
literature for several decades. No improvement to the synthesis of 5-deazariboflavin 
has been reported since the seminal work of Carlson and Kiessling5 (2004); the 
revisiting of this work is somewhat overdue, and may afford more efficient methods 
to produce riboflavin analogues for use in future studies. Furthermore, the synthesis 
of 1-deazariboflavin is inefficient, and may benefit from further study. 
 
Therefore, an examination of the synthesis of several riboflavin analogues, and their 
incorporation into several phototropin domains (both wild-type and mutant) was 
performed to address these key questions. 
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1.1 Introduction to Phototropins 
1.1.1 Overview of Phototropism 
The growth and behaviour of plants is a complex subject, which has been of significant 
interest to science since the time of Charles Darwin (1809-1882). One of the earliest 
discoveries within this field was the influence of light upon intracellular processes 
(such as respiration and growth) of plants, which was first described by the German 
botanist Julius von Sachs in 1887. Through carefully controlled experiments, he was 
able to use separate colours of light to determine that while red-yellow light was 
responsible for plant respiration6, “the mechanical actions of light on plants are due 
chiefly or exclusively to the highly refrangible, blue portion of the spectrum” 7. Thus, 
the first description of phototropism of plants under blue light irradiation was made.  
 
The reason for the influence of blue light on plant movement and growth was initially 
unknown, until the later identification of the plant hormones, comprising auxins, 
cytokinins, gibberellins, ethylene and abscisic acids8. While animal hormones are 
produced in specific glands and are transported to their site(s) of action (within blood 
or lymph fluids), all plant cells are capable of producing their own hormones9, which 
may therefore be thought of as systemically disperse. The turning movement of leaf, 
flower and stem direction (tropism) towards light is controlled by differential levels of 
auxins within the cells (causing asymmetric levels of growth across the growing plant 
tip (coleoptile) or other tissue, leading to its bending), which is controlled by light – 
hence the term “phototropism”. 
  
The predominant theory of phototropism is based on the parallel work of Cholodny 
and Went between 1920-194010,11. This suggested that photo-stimulation of the 
coleoptile induces a “lateral translocation of auxin” from the more heavily irradiated 
side of the tip to the dark-side of the plant, leading to the observation of tropism. 
While this theory has come under increased scrutiny within the last 30 years12,13, its 
continued use as a model remains valid according to experimental evidence14–16.  
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The key step of phototropism is the initial perception of blue light by the coleoptile, 
which alters auxin levels in the irradiated tissue and causes the tropism effect. This 
photosensing function is performed by photosensitive proteins, known as 
phototropins, whose role is to detect light and translate this signal into a physical 
effect. These phototropins may therefore be thought of as protein-derived “switches”. 
Along with their roles in phototropism, a number of other cellular processes also 
utilise phototropins to perform other roles, including organelle migration17–19, 
stomatal opening20–22, or other processes necessary for life or evolutionary success. 
 
The phototropin proteins isolated from plants each appear to possess a similar action 
spectrum, first identified by Johnston23. These spectra resemble UV-visible absorption 
spectra, although a relative rate of physiological activity (such as tropism) induced by 
a specific wavelength of light is used in place of absorbance; a representative example 
is given in figure 1 below24. When compared to the UV-visible absorption spectra of 
isolated phototropin domains (Avena sativa, Arabidopsis thaliana, and Adiantum 
capillus-veneris25), a remarkable similarity may be observed. 
 
 
Figure 1: The Action Spectrum [left] of Avena coleoptiles (describing relative 
movement per quantum at a given wavelength) shown by Curry et al. in “Physiology 
of Plant Growth and Development” (1969)24 bears close resemblance to the UV-
visible absorbance spectrum of recombinant Avena sativa PHOT1-LOV2 domain, 
recorded during this research 
 
0.00
0.04
0.08
0.12
0.16
0.20
0.24
320 360 400 440 480 520
Wavelength, nm
 5 
 
As shown in fig. 1, the action spectrum of the Avena phototropin is almost identical in 
wavelength to the absorbance spectrum observed, suggesting a direct link between 
the UV-visible absorbance of the protein, and its phototropic behaviour.  
 
1.1.2 Phototropin Structure 
The gene encoding phototropism in plants has been identified as occurring at the 
nonphototropic hypocotyl (nph1) locus26, so-named because it was identified by 
mutagenic knock-out. The corresponding plant phototropin protein is termed 
PHOT27,28. 
 
The phototropin protein comprises several separate domains, each with a discrete 
function; typically, a photoactive domain is directly coupled to an effector domain, 
such as a protein kinase27,29 (fig. 2, vide infra). Upon irradiation of the photosensitive 
domain, a physical change takes place which activates (or deactivates) the function of 
the coupled effector domain, causing the downstream signalling effect. 
 
The photosensitive agent responsible for the spectra shown in fig. 1 has been 
identified as a chromophore located within the photosensitive domain, able to absorb 
incident light of a specific wavelength and undergo an interaction with the protein to 
initiate the signalling effect. As described above, earlier experimental evidence 
demonstrated that phototropism is controlled by blue light, and so the chromophore 
must have a corresponding absorbance in the blue region of the spectrum. The UV-
visible and action spectra each show a major absorbance at approximately 450 nm, 
and the photosensitive agent within phototropins has been identified as based upon 
a flavin moiety (see section 1.2), which has a strong absorbance in this region of the 
spectrum. 
 
The absorbance of light by flavin stimulates formation of a covalent bond between 
itself and a cysteine residue in close proximity to the flavin chromophore (fig. 3(b) 
below). This cysteine residue is highly conserved throughout all phototropins, with the 
flavin-cysteine bond formation fundamental to the behaviour of the protein25,29–31. 
Mutant proteins of several photoreceptor families, where the cysteine has been 
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replaced with an unreactive alternative amino acid (such as glycine or alanine), have 
each been reported to lack photoactivity upon blue-light irradiation4,31,32. 
 
Several distinct photoreceptor families are found throughout nature; while PHOT-
based photoreceptors are similar across several genera (e.g. Avena sativa, Arabidopsis 
thaliana, and Adiantum capillus-veneris25), using the same flavin cofactor (flavin 
mononucleotide, FMN), alternative photoreceptors such as cryptochrome22,33, 
BLUF34–36 or VVD37,38 also exist based around the alternative flavin cofactor, flavin 
adenine dinucleotide (FAD). The differences in structure between the flavins does not 
vastly alter the photoreceptor’s spectral characteristics (as the point of modification 
occurs at the terminal end of the ribityl side-chain; see section 1.2). However, 
significant differences in protein sequence and structure of the FAD-based 
phototropins makes direct comparison between FMN and FAD-based photoreceptors 
difficult. Subsequent discussion is therefore dedicated to the PHOT-based 
photoreceptors. 
 
The complete phototropin protein is comprised of several sub-units, with separate 
photosensitive and effector domains. PHOT1 from Avena sativa comprises two 
signalling domains (LOV1 and LOV2), which are coupled to a serine / threonine kinase 
by a C-terminal linking section from the LOV2 domain. This linking section, known as 
the J-α helix, plays a key role in the transduction of the signal from the photoactive 
domain39–42, as the photo-stimulated bond formation between flavin and the protein 
domain causes undocking of this α-helical section from the secondary structure of the 
LOV2 domain43, allowing activation of the coupled protein kinase. The photo-
controlled docking / undocking process occurs with both high specificity and 
selectivity; examination by NMR shows a relative ratio of docked to undocked J-α helix 
of 98.4 : 1.6 in the dark state, and a similar ratio of 9 : 91 in the light state44. 
Mutagenesis of the J-α helix has shown that when modified to prevent interaction 
with the LOV2 domain, the coupled kinase is active even without photoirradiation45, 
confirming the role of this helical region on phototropism. 
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As the LOV2 domain of PHOT1 is responsible for the initial translation of light 
stimulation into a physical response, this domain (along with the coupled J-α helix) has 
become the primary target for phototropin research. The DNA encoding this single 
domain has been identified, isolated, characterised and expressed using recombinant 
techniques1,4,46, allowing the characterisation of the structure and behaviour of the A. 
sativa LOV2 domain43,47,48.  
 
Figure 2: Schematic representations of PHOT1, (not to scale), in the dark [above] and 
light [below] states. In the dark state, interaction between the J-α helix and the LOV2 
domain prevent activation of the coupled protein kinase. Upon irradiation of LOV2, 
the J-α helix is released from the domain, allowing activation of the coupled kinase 
domain 
 
Figure 3(a): Two views of the dark-state crystal structure of the AsLOV2 domain in 
the dark state, from Protein DataBank sequence 2V0U48. The J-α helix is highlighted 
in purple 
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Figure 3(b): Expanded view of flavin within the photoactive site of AsLOV2 in the dark 
state, from Protein DataBank sequence 2V0U48. The reactive cysteine residue (with 
the sulphur atom highlighted in yellow) is in close proximity to the flavin 
 
1.1.3 Mechanism of Phototropin Photoreaction 
Two mechanisms for bond formation have been considered within the literature; 
originally, flavin-protein bond formation was believed to occur via a nucleophilic 
attack of the photo-excited flavin (described as the “nucleophilic” or “ionic” 
mechanisms)30,49. However, experimental evidence has led to this mechanism being 
superseded by an alternative, which more closely matches observed results. 
 
As flavin is as an efficient chromophore (due to a large delocalised system of 
electrons), the absorption of light allows excitation of an electron from the ground 
state to a primary (singlet) excited state. As the stability of the excited state in flavin 
is relatively high, it is possible for an excited electron to undergo intersystem crossing 
(ISC), giving a triplet excited state for the radical flavin. This photo-induced radical may 
then combine with a cysteinyl radical to form a covalent bond between the flavin and 
the protein; this is known as the “radical pair” mechanism)4,46.  
 
A schematic representation for the proposed nucleophilic mechanism30 is shown in 
figure 4 below. This suggests that photoexcitation of flavin allows deprotonation of 
the cysteinyl group by the N5 position of flavin, with the deprotonated cysteinyl 
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sulphur attacking flavin at position C4a to form the covalent adduct. This was devised 
based upon earlier molecular orbital calculations for flavin50 which suggest an increase 
in the relative basicity of position N5 of flavin upon photoexcitation to the lowest 
singlet or triplet states. 
 
Figure 4: Schematic representation of a nucleophilic mechanism for flavin-cysteine 
photoadduct formation, proposed by Crosson and Moffat30. The interaction between 
flavin and cysteine may proceed either in a concerted manner (as shown), or as a 
sequential reaction (also referred to as the “ionic” mechanism), due to stabilisation of 
the charged intermediates by neighbouring residues within the protein 
 
However, several flaws with the nucleophilic or ionic mechanisms have been found. 
While initial evidence suggested a partial protonation of the FMN triplet state over a 
nanosecond timescale51, more recent experimental evidence suggests that this is not 
the case, as the lifetime of the flavin triplet state has been found to persist for several 
nanoseconds without showing evidence of protonation52. Furthermore, no clear 
consensus has been reached about whether the transferred proton originates from 
cysteine30,53, or another source47.  
 
On the other hand, the contrasting radical pair mechanism46 described above has 
found significant favour in the recent literature, due to an overwhelming number of 
supporting results. The stability of the excited flavin radical within phototropin to 
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protonation over extended timescales52, density-functional theory (DFT)54 and 
quantum-mechanical55 calculations of the energies and permissible reactions of both 
ground-state and excited flavin within the phototropin, supplemented by the 
experimental observation of neutral FMNH• semiquinone radicals in wild-type and 
mutant phototropins using electron paramagnetic resonance (EPR)4,46, each support 
the proposed radical pair mechanism. 
 
Figure 5: Proposed mechanism for the photocycle of the AsLOV2(WT) domain, 
originally described by Schleicher et al.46. Several steps may be bidirectional (or lead 
directly back to dark-state A) due to alternative pathways for radiative decay from 
excited states B-D 
 
The photoreversion of the light-state occurs spontaneously, with a half-life of 28-32 
seconds upon cessation of irradiation31,56. This short lifetime ensures that the coupled 
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protein kinase is only active during illumination, although it has been shown that the 
lifetime of the undocked state of the J-α helix may be modulated by the mutation of 
various residues within the domain by altering the stability of the docked J-α helix56,57. 
Imidazole has also been shown as being particularly effective at increasing the rate of 
photoreversion of the illuminated species58, thus careful consideration to address 
each of these factors is necessary in the design of subsequent experiments. 
 
1.2 Introduction to Flavins 
1.2.1 Flavin Structure  
The term “flavin” (derived from the Latin ‘flavus’, meaning yellow) describes a 
complex biological molecule containing a tricyclic isoalloxazine structure, as shown in 
figure 6 below. This unique structure permits the use of flavins for a diverse range of 
functions; they may act as a redox cofactor59–63, a light accepting chromophore (as 
described above), in the detoxification and removal of free-radicals and peroxides 
within the cell64, or as a signal transducer during programmed cell death 
(apoptosis)65,66. 
 
Figure 6: Structure and atomic numbering of flavin [left] and riboflavin [right]. 
Numbering proceeds clockwise from the ordinarily-substituted N10 position; ring-
connecting carbon positions (4a, 5a, 9a and 10a) are numbered according to the 
preceding position. As only the D-enantiomer of ribose is found in nature, the side-
group of riboflavin derived from this retains this stereochemistry, and is assumed in 
all subsequent figures 
 
The simplest flavin product formed by nature is riboflavin (vitamin B2; figures 6 and 7). 
This name is a portmanteau of ribose (the prosthetic group is derived from the 
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pentose sugar D-ribose) and flavin, which are linked at the N10 position of the 
isoalloxazine (figure 6 above). As the D-ribityl group is originally derived from the sugar 
ribose (which is only present in nature as the D-enantiomer), the original 
stereochemistry of this group is retained throughout all biological forms of flavin, and 
provides a tool for recognition of the flavin by flavoproteins. 
 
The biosynthesis of riboflavin begins using GTP67 (figure 7), and occurs via a similar 
pathway across plant, bacterial and fungal species68,67,69,70. However, all flavoenzymes 
use forms of riboflavin which are further modified, known as flavin cofactors.  
Figure 7: Biosynthetic formation of riboflavin, described by Bacher et al.67. GTP is 
dephosphorylated, before divergence of the bacterial and fungal routes. However, 
each intermediate leads to the same product, which is further modified by 
incorporation of additional ribulose-5-phosphate, leading to riboflavin 
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1.2.2 Flavin Cofactor Forms and Enzymatic Phosphorylation 
Two derivatives of riboflavin (shown in figure 8) are used by nature as enzymatic 
cofactors. These are flavin mononucleotide (FMN; also known as riboflavin 5’-
monophosphate) and flavin adenine dinucleotide (FAD; also known as riboflavin 5’-
adenosine diphosphate), and are each formed by enzymatic phosphorylation of 
riboflavin). In addition to significantly improved solubility, incorporation of phosphate 
or adenosine diphosphate groups acts as a convenient recognition tool for the protein, 
and allows secure retention of the desired cofactor by providing an ionic interaction 
between polar amino acids and the charged phosphate group(s). 
 
 
Figure 8: Structures of riboflavin, FMN and FAD 
 
Formation of FAD from riboflavin in vivo is performed sequentially; FMN is produced 
initially by Riboflavin Kinase (RfK), before further modification to FAD by a Nucleotidyl 
Transferase (NT) or an FMN Adenyltransferase (FMN-AT). Conventionally, the NT and 
FMN-AT domains are both commonly referred to as FAD synthetase (FADS) domains71. 
 
The precise route of FAD formation differs between prokaryotic and eukaryotic cells, 
as eukaryotic cells typically use separately expressed RfK and FADS domains to 
perform each reaction. In contrast, the majority of prokaryotic cells utilise a combined 
protein containing both domains. The reason for this remains largely unknown, 
although recent advances in the statistical analysis of DNA sequences (using methods 
such as genome mining) may shed light on the reason for this apparent divergence. 
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In terms of protein structure, the RfK domain of the bifunctional prokaryotic enzyme 
maintains a strong homology with the RfK domain expressed by eukaryotic cells72–75. 
While the FMN formed within the RfK domain of the bifunctional enzyme must be 
released and re-bound separately by the NT domain73 (as there is no shuttling 
mechanism to transfer the substrate between domains74,75), their close proximity 
assists cofactor transport.  
 
However, the FADS domains are remarkably different. While the structure of the 
eukaryotic domain is classified as an FMN-AT domain72, the prokaryotic FADS domain 
is defined by its structure as an NT domain74,76,77. The crucial difference between these 
distinctions is that while the FMN-AT produces FAD unidirectionally (figure 9), the NT 
domain catalyses both forward and reverse reactions (figure 10). 
 
The reverse reaction (FAD to FMN) occurs as the NT domain stabilises the transition 
state of the FMN-FAD reaction74,75. It has been postulated that this allows the 
bifunctional protein to perform a further regulatory role in the maintenance of 
intracellular stores of the flavin cofactors78,79. Thus, if an intracellular deficit of either 
flavin cofactor occurs in the prokaryotic cell, this protein is able to rapidly use any 
source of flavin to meet the demand, providing a useful feedback mechanism for the 
cell and allowing ready supply of both cofactors at all times73,78,79. 
Figure 9: Formation of FMN from riboflavin by a eukaryotic RfK enzyme, and the 
conversion of FMN to FAD by a separate FMN-AT enzyme. Each enzyme works 
independently. Note that formation of FAD by an FMN-AT enzyme is unidirectional 
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Figure 10: Formation of both FMN and FAD by a bifunctional prokaryotic RfK-FADS 
protein. The production of both cofactors is linked by the bidirectional functionality of 
the NT domain, allowing the cell to maintain a ready supply of both cofactors using a 
single protein. Each catalytic domain is located at separate sites of the protein; FMN 
formed by the RfK is released and re-bound separately by the NT domain 
 
1.2.3 Flavin Redox Behaviour 
The isoalloxazine moiety of each cofactor is a particularly good chromophore, due to 
the extended delocalisation of electrons throughout its planar, sp2 hybridised 
structure. Flavin compounds are able to accept photons of visible wavelengths (445-
450 nm) and thus appear yellow in colour. However, not all flavin-mediated processes 
are light-dependant. Instead, flavin may be easily reduced at positions N1 and N5 
(linked via C10a and C4a) to a “hydroquinone” form, by acceptance of 2 protons and 
2 electrons, forming FMNH2 or FADH2 (commonly referred to as Flox and Flred, 
respectively; fig.11(a)). A penalty of this is the loss of aromaticity, demonstrated by 
the UV-visible absorption of FMNH2 compared to FMN; loss of conjugation leads to 
greatly reduced extinction coefficient and significant blue-shifting of the spectrum, 
demonstrated by the migration of the Flox absorbance of FMN from 445 nm 
(ε = 12 200 M-1 cm-1) to 395 nm (ε = 2 250 M-1 cm-1) for Flred80 shown in fig. 11(b). As 
the loss of aromaticity is energetically unfavourable, this allows the flavin to perform 
both electron transfer and energy transfer, recognised via its important role in the 
electron transport chain. 
 16 
 
 
Figure 11(a): structure of quinone-form Flox, semiquinone form FlH• and 
hydroquinone Flred 
 
Figure 11(b): UV-visible absorption spectrum of flavin in oxidised and reduced states, 
at neutral and basic pH, shown by Ghisla et al.80 
 
While other redox cofactors (such as NADH / NADPH) perform similar redox reactions 
to flavin, flavin has been shown to allow a stable radical intermediate state81–83, known 
as the flavin semiquinone (FlH•). The stability of this intermediate allows the 
sequential transfer of single electrons in the electron transport chain, which is 
necessary due to the limitation of iron-sulphur clusters (used to mediate electron 
transport) to accept only a single electron. This is in contrast to other redox cofactors, 
which perform only two-electron transfers. 
 
Due to the wide distribution of flavin throughout nature and its importance for a 
diverse range of enzymatic processes, several chemists of the early 20th century 
attempted the total synthesis of riboflavin. This was successfully completed by Paul 
Karrer in 193584, who was subsequently awarded the Nobel Prize for Chemistry in 
1937 for this and the associated synthesis of carotenoids and vitamin A. The method 
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described by Karrer, shown in figure 12, has several themes which are revisited in 
subsequent syntheses of flavin (and its analogues). 
 
Figure 12: Synthetic route for the total synthesis of riboflavin reported by Karrer84. 
“(RN2)X” refers to one of a number of diazonium salts used by Karrer 
 
1.2.4 Flavin Analogue Structure and Behaviour 
After the identification of the structure of flavin and its successful total synthesis, 
subsequent experimentation was performed to create structural analogues of the 
compound, to allow the deduction of the mechanisms of flavoproteins. 
 
As the ribityl side-chain of riboflavin was incorporated as a complete unit during 
Karrer’s synthetic method (and it does not play a significant role in the 
electrochemistry of the flavin), it was possible to easily substitute this for similar 
alternatives, to examine its role in protein binding85,86. However, the results of this 
were of limited use (as the recognition and incorporation of flavin cofactors was found 
to be strongly linked to the D-ribityl group), and so direct modification of the flavin 
structure was used to better assess the behaviour of flavin. 
 
The role of the two nitrogen positions (N1 and N5) was found to be key to the 
chemistry of flavin, as these positions may each be protonated (forming the 
semiquinone or hydroquinone form; see above), as well as potentially forming 
hydrogen bond donor-acceptor bridges. The significant difference in lability between 
the N-H bond and the C-H bond, and its exploitation by the flavoprotein, made the 
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examination of these positions using stable analogues crucial for mechanistic 
investagations87. When the nitrogen atoms at positions N1 and N5 were (individually) 
isoelectrically substituted for CH units to form the corresponding carba-deazaflavins 
(also known as deazaflavins; figure 13), a demonstrable loss of function was observed 
in protein samples using the incorporated synthetic analogues. 
 
 
Figure 13: Structures of riboflavin, 5-deazariboflavin and 1-deazariboflavin, showing 
incorporation of a CH unit in place of a nitrogen atom 
 
The UV-visible spectra of the 1-deaza- and 5-deazaflavins compared to the original 
spectrum of riboflavin is shown in figure 14. The major absorbance of FMN (at 447 nm) 
is blue-shifted by approximately 50 nm for 5-deazaFMN, while it is red-shifted by 
90 nm for 1-deazaFMN. The extinction coefficient of 5-deazariboflavin 
(ε400 = 12500 M-1 cm-1)88 remains the same as riboflavin, whereas the extinction 
coefficient of 1-deazariboflavin is significantly lower (ε535 = 6800 M-1cm-1)88. 
 
Figure 14: UV-visible absorbance spectra of FMN (yellow), 5-deazaFMN (blue) and 1-
deazaFMN (purple). The spectra of the flavin analogues are either blue or red shifted 
compared to FMN, while displaying similar spectral characteristics 
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One of the key reasons for the loss of function with 5-deazaflavins, as reported by 
Edmondson et al.89, is that the N5 position is crucial for the stabilisation of a radical 
semiquinone state of the flavin. Theoretical calculations for 5-deazariboflavin suggest 
the semiquinone state is “energetically highly unfavourable” 90,91, a conclusion 
supported by experimental evidence where no semiquinone state is observed92. 
However, 5-deazaflavin does retain the ability to undergo two-electron transfers, 
shown by acceptance of hydride from both chemical (e.g. borohydride) and enzymatic 
(e.g. NADPH reductase) sources93–96. However, physical changes to the flavin analogue 
upon incorporation of an additional substituent at C(H)5 would lead to significant 
distortion of the (previously planar) isoalloxazine structure, providing a significant 
energetic barrier to formation of this species.  
 
Figure 15: Structure of reduced flavin, compared to reduced 5-deazariboflavin. The 
incorporation of hydrogen at position C5 of the deazaflavin causes significant 
distortion of the flavin molecule 
 
While 5-deazaflavins have been successfully utilised to elucidate the mechanism of 
several flavoprotein-catalysed reactions, 1-deazaflavins have been less well studied. 
This is largely due to the difficulty of their synthesis (often formed as a side-product 
during alternative syntheses, with yields below 10 %, see below), along with their 
limited use as mechanistic probes. 1-deazariboflavin has been found to undergo both 
one- and two-electron redox processes97, with the only difference being a slightly 
more negative redox potential (Em(1-deazaFAD) = -280 mV98; Em(FAD) = -208 mV)99. 
The significant differences in UV-visible absorption spectra compared to native or 
5-deazaflavins (figure 14), along with an observed lack of fluorescence97,100,101 has 
generally precluded their use in cases where the flavin acts as a chromophore 
(although they have recently been successfully used for this purpose102). 
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1.2.5 Flavin Analogue Synthesis 
The synthesis of riboflavin devised by Karrer84 (shown in figure 12, vide supra) has 
provided the foundation for subsequent syntheses of the riboflavin analogues 5-
deazariboflavin 7 and 1-deazariboflavin 8. The original method describes the reductive 
amination of 3,4-dimethylaniline 1 with D-ribose, followed by incorporation of an 
amine (via a diazonium species, with the remaining nitrogen eventually becoming 
position N5 of the flavin) ortho to the ribitylated amine 2. Finally, alloxan 5 was reacted 
with intermediate species 4, resulting in formation of riboflavin 6. 
 
Some steps of this synthesis have been developed, while other aspects of the method 
have been retained. Improvements to individual reactions or alternative routes have 
been developed largely due to the advancement knowledge of organic chemistry; for 
instance, the use of protecting group theory affords an alternative method for 
formation of intermediate 22 (figure 23). 
 
1.2.6 5-Deazariboflavin Synthesis 
The initial reductive amination of D-ribose by 3,4-dimethylaniline 1 has been rationally 
improved through extensive experimentation103,104, culminating in the method of 
Carlson and Kiessling5 whereby the use of sodium cyanoborohydride (Na[CNBH3]) 
afforded reliable formation of the ribitylated aniline without the previously required 
use of high pressure hydrogenation with Pt/Pd catalysis. Alternative hydrides (such as 
sodium triacetoxyborohydride, Na[(OAc)3BH]) have been successfully reported to 
improve reductive aminations in some cases105, and the results of their use as a 
potential candidate to replace cyanoborohydride for this reaction are discussed in 
subsequent sections of this thesis. 
 
The key step in the synthesis of 5-deazariboflavin is the successful incorporation of 
carbon at position 5 of the isoalloxazine. Relatively few methods were known to 
permit incorporation of a carbon substituent to an aromatic ring; therefore early 
syntheses utilised an aniline with a protected functionalised carbon at the ortho- 
position (figure 17, intermediate 9). The initial method for the synthesis of 5-
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deazariboflavin 7 described by O’Brien et al.103 reported a somewhat difficult 
condensation between 4,5-dimethyl-N-ribitylanthraniladehyde 10 and barbituric acid 
11. A similar reaction was also reported for the synthesis of 1,5-dideazariboflavin, 
using 2,4,6-piperidinetrione106 in place of barbituric acid. However, several undesired 
side-products were identified within the reaction mixture, leading to lower yields of 
5-deazaflavin overall. 
 
Figure 17: Synthetic method for formation of 5-deazariboflavin 7 devised by  
O’Brien et al.103 
 
A breakthrough in the formation of 5-deazariboflavin was made during the 
preparation of riboflavin and riboflavin-N5-oxide via a bicyclic intermediate 13 (figure 
18), reported by Yoneda et al.107,108. This identified an alternative method for reliably 
incorporating the uracil-moiety of flavin using 6-chlorouracil 12, with subsequent 
introduction of an amine (to give the eventual N5 nitrogen atom) by nitration or 
nitrosation giving the respective riboflavin or riboflavin-N5-oxide. As 6-chlorouracil 12 
is functionalised at position 6, attack by the ribitylated amine is directed towards this 
position, lowering the potential for undesired side-product formation. This method 
paved the way for future synthesis of 5-deazariboflavin using an electrophilic carbon 
species for the incorporation of carbon in bicyclic intermediate 13, in vastly improved 
yields over previous reactions. 
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Figure 18: Formation of bicyclic intermediate 13, originally reported by  
Yoneda et al.107,108 
 
A number of methods to perform the closure of the central pyridine ring have been 
presented in the literature. The treatment of bicyclic intermediate 13 using trimethyl 
orthoformate (in the presence of a catalytic quantity of p-toluenesulfonic acid; 
figure 19) produced with bis(methoxymethylene)-protected 5-deazariboflavin 15109. 
Removal of the methoxylmethylene groups afforded 5-deazariboflavin 7 in yields up 
to 46 % (two steps) from bicyclic intermediate 13. 
 
Figure 19: Closure of the central pyridine ring of 5-deazariboflavin performed using 
trimethyl-orthoformate 14109. Unintended protection of the ribityl side-chain 
necessitated subsequent deprotection, although this was performed in high yield, 
affording 5-deazariboflavin 7 in 46 % yield overall 
 
An alternative to the use of trimethyl orthoformate was the use of the Vilsmeier-Haack 
reagents, phosphorus oxychloride (POCl3) and dimethylformamide (DMF)110, to 
introduce the formyl group to the bicyclic intermediate 16 (figure 21). This method, 
reported by Yoneda et al.111,112 (in 57 % yield) uses the reaction between POCl3 and 
DMF to form a reactive chloriminium intermediate species (figure 20), which is 
particularly susceptible to nucleophilic attack. Upon reaction with bicyclic 
intermediate 16 and hydrolysis of the resultant bicyclic iminium species (16a) to the 
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formylated species (16b), an intramolecular reaction (followed by elimination of 
water) may furnish 5-deazaflavin 7. Thus, this method has been successfully used to 
prepare 5-deazariboflavin5,100. 
 
Figure 20: Chloriminium species formed by reaction between POCl3 and DMF 
 
 
Figure 21: Formation of 5-deazaflavin from bicyclic intermediate 16 utilising the 
Vilsmeier-Haack reagents, as reported by Yoneda et al.111,112. “R” corresponds to a 
tetra-acetylated D-ribityl group 
 
As shown, several stages in the formation of 5-deazariboflavin 7 remain poorly 
understood, with few advancements made since development of the original 
synthetic route103. Therefore, a rational re-examination of each stage may be of 
particular interest to the scientific community, and assist in the identification of the 
most effective route for this compound’s synthesis. 
 
1.2.7 1-Deazariboflavin Synthesis 
The synthesis of 1-deazariboflavin 8 has been sparsely covered within the literature, 
(compared to the alternative isoelectric analogue 5-deazariboflavin 7, vide supra). The 
“modern” method described by Carlson and Kiessling5 (repeated by Mansurova et 
al.100) is essentially identical to the method for the synthesis of 1-deazalumichrome 21 
(a flavin lacking a substituent at position N10) originally used by Ashton et al.104 27 
years previously, shown in figure 22 below.  
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Figure 22: Synthetic route to 1-deazalumichrome 21 reported by Ashton et al.104 in 
1977, and which was the basis for contemporary syntheses of 1-deazariboflavin 
 
This method was successfully utilised within the original study to furnish 
1-deazariboflavin utilising a ribitylated derivative 22 of the initial diamine, although 
the yield of 1-deazariboflavin 8 in this case was reported as 14 % over the two steps 
shown in figure 22 (compared to 19 % for 1-deazalumichrome 21)104.  
 
An alternative route for the formation of 1-deazariboflavin 8 was also presented by 
Ashton et al.104, whereby ribitylated diamine 22 (figure 23) was instead condensed 
with 2,4,6-piperidinetrione 23 to furnish 1-deazariboflavin tetraacetate 24, again 
isolated in 14 % yield. However, the major product of this reaction was in fact found 
to be 3-deaza-riboflavin tetraacetate 25, obtained in 36 % yield. This appears 
somewhat counterintuitive when the relative availability of the carbonyl positions of 
2,4,6-piperidinetrione is considered, as two carbonyl groups are available α- to the 
nitrogen of the piperidine heterocycle, compared to one in the γ- position. However, 
the relative electrophilicity of the two carbonyl positions is considerably different, 
with the carbonyl group at the γ- position being a significantly more effective 
electrophile. It is important to note that although each amine would be expected to 
be a weak nucleophile, if 2,4,6-piperidinetrione 23 was attacked at either position by 
the free amine of ribitylated diamine 22, neither product would be formed, and so the 
desired product must only be formed by attack of 2,4,6-piperidinetrione 23 by the 
secondary (ribitylated) amine. As the primary product of this reaction is the formation 
of 3-deazaflavin 25, rather than the desired 1-deazaflavin 24, this method has been 
largely abandoned, with no further reference made in the literature. 
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Figure 23: Alternative route for the synthesis of 1-deazaflavin developed by Ashton et 
al.104; R1 refers to a D-ribityl group, while R2 describes the tetra-acetylated derivative 
of this group. The predominant product of this reaction was 3-deazariboflavin 
tetraacetate 25, rather than 1-deazariboflavin tetraacetate 24 
 
As described above, the recent method5 for the synthesis of 1-deazariboflavin relies 
heavily on the original work of Ashton et al.104. However, a description of the initial 
ribitylation of the starting material 4,5-dimethylbenzene-1,2-diamine 18 by Carlson 
and Kiessling5 has been useful in providing reliable conditions for the initial de-
symmetrisation of the compound using Boc-protection prior to ribitylation via a 
reductive amination, preventing formation of a 1,2-diribitylated species. Additionally, 
Carlson and Kiessling discovered that substitution of the previous base (K2CO3) with 
an alternative (Cs2CO3), and the use of an additional solvent (CH2Cl2, alongside DMF 
used previously), allowed the yield for the subsequent reaction to be improved from 
20 % to 55 % (figure 24). However, this yield remains mediocre, and thus improvement 
to this step may lead to improved efficiency in the synthesis of 1-deazariboflavin 8. 
 
  
Figure 24: Improved coupling conditions between ribitylated diamino compound 22 
with 2-bromo-3-oxoglutarate 19 affords improved reliability for the formation of 
bicyclic intermediate 22, when compared to the previous method of Ashton et al.104. 
R1 refers to a proton, while R2 describes a D-ribityl group  
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1.3 Aims and Objectives 
 
In order to accomplish the goals described in the motivation for this thesis (section 
1.0.2), a number of individual objectives were set, as described below. The outcome 
of each objective is given and discussed in subsequent sections of this thesis.  
 
(1) Performing and examining potential optimisations for the synthesis of 
5-deazariboflavin, 1-deazariboflavin and other related flavin analogues. 
 
(2) Devising a new route for the synthesis of additional analogues of riboflavin. 
 
(3) Expressing, purifying and determining optimal conditions for a riboflavin 
kinase protein, necessary to perform the phosphorylation of the chemically 
synthesised riboflavin analogues to the FMN cofactor form. 
 
(4) Expressing, purifying and devising a reliable method to produce quantities of 
recombinant PHOT1-LOV2 from A. sativa containing native FMN, sufficient for 
later examination. 
 
(5) Determination of conditions for cofactor exchange within the expressed 
protein, and incorporation of the FMN analogues prepared in earlier stages. 
 
(6) Creating, expressing and purifying a range of C450X mutants of PHOT1-LOV2, 
including incorporation of FMN analogues within mutant protein samples. 
 
(7) Performing spectroscopic examination of the samples formed in stages 4 to 6, 
to obtain evidence for the mechanism of the PHOT1-LOV2 protein photocycle. 
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Chapter 2 
Results and Discussion – 
Chemical Synthesis 
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2.0 Results and Discussion - Chemical Synthesis 
2.0.1 Introduction 
In this chapter, the syntheses of 5-deazariboflavin, 1-deazariboflavin and 8-demethyl-
5-deazariboflavin are discussed. The synthetic method used to produce these 
compounds has been analysed, improvements found are described, and other 
unsuccessful reactions also noted in order to improve the overall understanding of 
this area.  
 
Additionally, an alternative pathway with the potential to produce 4 riboflavin 
analogues (1-deazariboflavin, 1,5-dideazariboflavin, 3-deazariboflavin and 
3,5-dideazariboflavin) from a single starting material is described. This was devised 
using the benefit of similar reactions performed previously, requiring the synthesis of 
pyridine-based compounds in place of 6-chlorouracil. As several stages of this method 
were intensively studied during the synthesis of 5-deazariboflavin, their application to 
this route may have enabled the formation of other riboflavin analogues which have 
seldom (if ever) been prepared. While the formation of the compounds required was 
unsuccessful under all conditions examined, the work described here may provide the 
basis for a future synthesis of these compounds.  
 
2.1 Synthesis of 5-deazariboflavin 
2.1.0 Introduction 
Figure 25: Overall Synthetic Route to 5–deazariboflavin 39 
 
The synthesis of this analogue was based upon the route described by Erin E. Carlson 
and Laura L. Kiessling5, which has been repeated, studied, and undergone 
experimental optimisation to better understand the formation of 5-deazariboflavin 
39, achieved with a reported yield of 16.2 % overall. This built upon decades of 
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comprehensive study by numerous devoted organic chemists, and inevitably few 
stones have been left unturned in finding improvements to the yield or a simplification 
of the synthesis. However, significant experimentation has been performed to better-
understand each step of this reaction. 
 
2.1.1 Formation of 3,4-dimethyl-N(ribityl)-aniline 33 
2.1.1.1  Reaction overview 
This step involves the reductive amination of D-ribose facilitated by the attack of 
nitrogen from 3,4-dimethylaniline 31 (figure 26), proceeding via an alkylimino-de-oxo-
bisubstitution113 (alkyl-DOB) reaction. This is followed by reduction of the Schiff-base 
intermediate to the corresponding amine using Na[CNBH3], producing 
3,4-dimethylriboaniline 33 with a yield of 65 %. While this is lower than previously 
reported5,100, this yield was incredibly reliable, with over 50 repetitions at varying 
scales found to be consistent within ± 2 %. This poses questions of the yields described 
elsewhere for this reaction, and so extensive investigation was performed to obtain a 
better understanding of factors affecting product formation. 
 
 
Figure 26: Reaction between 3,4-dimethylaniline 31 and D-ribose 32 led to Schiff-
base intermediate 31b, which was subsequently reduced to give 3,4-dimethyl-
N(ribityl)-aniline 33 
 
The alkyl-DOB reaction describes the formation of the imine intermediate 31b, in 
which the nucleophilic amine attacks the electrophilic carbonyl position of D-ribose 
followed by a proton transfer. Water is subsequently eliminated across the newly-
formed C-N bond, resulting in Schiff-base intermediate 31b, which is reduced by 
cyanoborohydride to give 3,4-dimethyl-N(ribityl)-aniline 33. As originally described, 
this reaction is performed as a “one-pot” reaction (where all reactants are added 
together at the beginning of the reaction). 
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It was noted that upon solvent removal and acidification of the resultant residue prior 
to extraction, the addition of ethyl acetate triggered spontaneous precipitation of 
high-purity 3,4-dimethyl-N(ribityl)-aniline 33. Interestingly, this has not been observed 
or reported elsewhere5,100, although similar precipitation of this compound had been 
observed in aqueous solution during an earlier synthesis of 5-deazariboflavin109 (albeit 
during a different stage in the reaction). The majority of the 3,4-dimethyl-N(ribityl)-
aniline 33 formed during the reaction was isolated as a precipitate, with the extraction 
protocol previously described used to ensure the greatest possible level of product 
recovery. However, in all cases this was far below those yields previously reported5,100. 
 
Due to the complex mechanism of this reaction, numerous factors may have been 
responsible for the observed reduction in yield, and so a wide survey of conditions 
was undertaken, which are summarised in tables 1-3 and described below. Factors 
examined include examination of Schiff-base intermediate formation (including the 
use of an organic catalyst), and whether performing the reaction using a “one-pot” 
method gave a lower yield than a multiple-step method. Also studied was the effect 
of a range of other solvents and conditions upon the reaction, including those in which 
reactants were insoluble, and solvents which were not anhydrous. Finally, 
replacement of the reducing agent was attempted, to determine whether 
cyanoborohydride was optimal.  
 
As described in table 1 below, reaction scale was found to have little effect on the 
reaction. Reactions using 0.83 mM (100 mg) to 75 mM (9.0 g) of 3,4-dimethylaniline 
31 were performed successfully in yields up to 65 %. Time had a marginal effect on 
reaction efficiency, with longer times (72 hours) than previously reported (48 hours) 
making little difference. However, significantly extended reaction times (96 hours) did 
appear somewhat detrimental to product formation, although no immediate cause 
was found. Heating at reflux was necessary, with no product formation observed when 
the reaction was performed at room temperature. 
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Scale 
(mM) 
Solvent Temperature Conditions Atmosphere 
Time 
(hours) 
Yield 
(%) 
12.5 MeOH reflux  Ar/N2 48 57 
25 MeOH reflux  Ar/N2 48 65 
25 MeOH reflux  Ar/N2 72 64 
75 MeOH reflux  Ar/N2 72 63 
0.83 MeOH reflux  Ar/N2 72 65 
0.83 MeOH reflux  Ar/N2 96 48 
0.83 MeOH RT  Ar/N2 72 0 
0.83 MeOH reflux Undried solvent Air 72 22 
0.83 MeOH reflux AcOH catalyst, 
0.2 eq. 
Ar/N2 24 32 
0.83 MeOH reflux AcOH catalyst, 
0.2 eq. 
Ar/N2 48 19 
12.5 MeOH reflux DMAP catalyst, 
0.2 eq. 
Ar/N2 72 39 
Table 1: Conditions used to examine formation of ribitylated product 33. “Scale” 
refers to the quantity of 3,4-dimethylaniline 31 used. “RT” refers to room 
temperature, approx. 15 °C. Each reaction was performed using 2 equivalents of both 
D-ribose and the reducing agent Na[(CN)BH3]. All solvents were thoroughly dried 
before use (unless explicitly stated), as described in section 5.1.3 
 
As the original reaction conditions were found to give the greatest yields, an appraisal 
of the reactivity of the reagents was undertaken. The amine group of aniline 31 has 
an aryl substituent, and so the lone pair of electrons from the nitrogen atom (residing 
in a p-orbital) is delocalised throughout the aromatic π-bonding system. This lowers 
the electron density of the amine, thus reducing its nucleophilicity; the pKa of 
3,4-dimethylaniline is 5.28114 to 5.29115, whereas the pKa of the structurally similar 
(non-aromatic) amine cyclohexylamine is 10.64116,117. Therefore, initial attack at the 
carbonyl carbon (C1) of D-ribose by 3,4-dimethylaniline 31 would be expected to be 
poor compared to other nucleophiles, and may be assisted by catalysis.  
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2.1.1.2  Effects of catalysis 
The use of acid catalysis was initially considered, as this is suggested by the 
mechanism. Acidification was expected to activate the carbonyl carbon (C1) of 
D-ribose by protonation of the carbonyl-oxygen, assisting attack of the weakly 
nucleophilic amine. However, results obtained using a catalytic volume of glacial acetic 
acid (table 1) demonstrated a decreased in the yield of product 33 (32% in 24 hours), 
and which decreased further with extended reaction times (19 % in 48 hours). This 
result is interesting, as the reaction appears to reach its maximum efficiency 
significantly faster than the uncatalysed reaction; however this was at expense of a 
substantially reduced yield. Shorter reaction times did not show complete 
consumption of starting materials (by TLC) before 24 hours. 
 
The likely reason for this decrease is that the presence of H+ in the reaction mixture 
also caused protonation of the amine, further decreasing its nucleophilicity and 
preventing its reaction with D-ribose. Even though only a catalytic volume 
(0.2 equivalents) of acid was used, this appeared sufficient to significantly affect the 
outcome of the reaction. This result, although somewhat understandable, is 
somewhat contradictory to both the reaction mechanism and other reported results 
for similar reductive aminations105,118,119, where addition of a catalytic volume of acid 
is necessary for efficient reaction. However, the effect observed experimentally has 
been described by Abdel-Magid et al.105. They reported during a thorough review of 
reductive aminations that whilst the presence of acid in a reaction between an amine 
and a ketone generally increased the rate of reaction, in the case of an amine reacting 
with an aldehyde, addition of AcOH to slow reactions such as those with weak 
nucleophiles tended to lead to a significant (approximately 50%) reduction in product 
formation. This mirrors the result obtained experimentally; although while Abdel-
Magid et al. suggest the principal by-product of the reaction is the reduced 
aldehyde105, the major products from this reaction were unreacted aniline 31 and a 
complex mixture of polymerised sugars.  
 
Addition of a base to the reaction was also attempted, in order to deprotonate the 
reactive amine and thus enhance its nucleophilicity. However, a catalytic amount of 
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DMAP added to the reaction drastically decreased the formation of compound 33, 
similarly to addition of AcOH. Reaction time was related to product formation as with 
the non-acidified mixture, with no product observed at 24 hours and little at 48 hours; 
72 hours gave a yield of only 39 %, which was not improved using longer reaction 
times.  
 
2.1.1.3  Schiff-base formation 
Another structural feature of the starting material 31 was the presence of two methyl 
groups at positions meta and para with respect to the amino group. The effect of alkyl 
substituents of aromatic rings are to activate positions ortho and para to themselves, 
while deactivating meta positions, by enhancing the electron density of these 
positions. This is discussed in greater depth in section 2.3.1, where repetition of the 
reaction using an aniline containing a single methyl-substituent at the para position 
(p-toluidine 49) gave some improvement to the reaction yield (72 %, compared to 65 % 
previously). This evidence suggested that the presence of the meta methyl group in 
3,4-dimethylaniline 31 plays some part in reducing the efficiency of the reaction, as it 
is likely to effectively cancel-out the activating effect from the methyl group para to 
the reactive amine group. 
 
While aromatic delocalisation played a large role in the poor nucleophilicity of the 
amine, it was hoped that it would assist formation of 33 by enhancing the stability of 
the Schiff base intermediate 31b (containing an extended conjugated pi-electron 
system), thus promoting its formation. However, the Schiff base formed in this 
reaction was not possible to isolate, suggesting a transient existence. Late addition of 
the reducing agent (including reactions containing acid catalyst, previously shown to 
decrease reaction times) also failed to furnish improved yields; 51 % was obtained 
without acidification, compared to 23 % with acidification (31 % and 7 %, respectively, 
when repeated using Na[(AcO)3BH]). 
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Scale 
(mM) 
Reducing 
Agent 
Conditions 
Time 
(hours) 
Yield 
(%) 
25 Na[CNBH3]  48 65 
0.83 Na[(AcO)3BH]  48 19 
0.83 Na[CNBH3] Reducing agent added after 4 hrs 48 51 
0.83 Na[CNBH3] AcOH added at 0 hrs; reducing 
agent added after 4 hrs 
24 23 
0.83 Na[(AcO)3BH] Reducing agent added after 4 hrs 48 31 
0.83 Na[(AcO)3BH] AcOH added at 0 hrs; reducing 
agent added after 4 hrs 
24 7 
0.83 Na[CNBH3] MgSO4 added, 5 eq 48 64 
0.83 Na[(AcO)3BH] MgSO4 added, 5 eq 24 28 
0.83 Na[(AcO)3BH] MgSO4 added, 5 eq 48 54 
Table 2: Conditions used to examine formation of ribitylated product 33. “Scale” 
refers to the quantity of 3,4-dimethylaniline 31 used. Each reaction was performed 
using 2 equivalents of both D-ribose and the reducing agent described, under an 
atmosphere of Ar / N2 in thoroughly dried refluxing MeOH 
 
2.1.1.4  Effect of water on the reaction 
One of the key steps in all reductive aminations is the loss of water to produce an 
imine (or Schiff base) intermediate. The use of anhydrous conditions is typical105,118,120, 
assisting the reaction by forcing the equilibrium to the right (towards product 
formation). For the reaction between 3,4-dimethylaniline 31 and D-ribose 32, 
methanol was originally used as the solvent. It was able to fully dissolve each of the 
starting materials, and withstand sufficient heating (under reflux conditions) to allow 
the reaction to proceed. While MeOH is a good solvent for the reaction, its high 
polarity allows the dissolution of relatively large quantities of water (175 ppm for 
“wet” methanol, compared to 22.4 ppm for “wet” dichloromethane121). Since 
elimination of water to form the Schiff base is integral to formation of product 33, the 
importance of anhydrous conditions was examined.  
 
As originally described5, there is no mention of whether the reaction should be 
performed under anhydrous conditions; however, it was found that performing the 
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reaction using undried solvent reduced the yield to 22 % (table 1, vide supra). 
Subsequent reactions were therefore performed in flame-dried glassware under an Ar 
or N2 atmosphere using pre-dried solvent. Methanol was dried by distillation over 
CaH122 and storage over molecular sieves (3 Å) for a minimum of 5 days, as it has been 
reported that this reduced the residual water content to below 10.5 ppm121. Solvent 
prepared in this manner gave optimal yields of product 33. 
 
As the use of undried solvent greatly reduced product yield, experiments were 
performed to examine if the removal of water eliminated upon formation of the Schiff 
base played any role on reaction yield. Due to the small quantities involved 
(1 equivalent of water is equivalent to 0.015 mL when performed at scales of 
0.83 mM), the use of specialised equipment such as a Dean-Stark apparatus for the 
constant distillation of the reaction solvent was considered to be of negligible benefit. 
Instead, the use of desiccants was examined.  
 
MgSO4 was selected due to its particularly fast-acting nature when compared to other 
drying agents, along with its ability to sequester up to 7 equivalents of water123. 
However, it was found that addition of 5 equivalents of MgSO4 to the reaction mixture 
(performed with cyanoborohydride) gave a yield of 64 % – identical to the yield 
obtained without desiccant. This result suggests that MgSO4 does not affect the 
reaction, and that the small volume of water generated by the reaction was 
adequately solubilised by the bulk solvent. However, results when using Na[(AcO]3BH] 
were more interesting, as yields obtained with addition of a similar quantity of MgSO4 
significantly improved the reaction yield (from 19 % to 54 %, table 2), and is discussed 
further in section 2.1.1.6 below. The presence of water within the Na[(AcO]3BH] used 
for experimentation was discounted (as freshly purchased reagent gave the same 
result). As the use of these conditions was still similar or less efficient than the original 
conditions using cyanoborohydride, they were not explored further. 
 
2.1.1.5  Solvent effects 
Another factor investigated was the effect of the solvent on the reaction. As described 
above, methanol was used in the original method5, although a number of alternative 
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solvents were examined to determine if the yield would be improved when using 
them. These results are summarised in table 3.  
 
Scale 
(mM) 
Reducing 
Agent 
Solvent Temperature Conditions 
Time 
(hours) 
Yield 
(%) 
25 Na[(CN)BH3] MeOH reflux  48 65 
0.83 Na[(CN)BH3] EtOH reflux  68 44 
0.83 Na[(CN)BH3] isopropanol reflux  72 49 
0.83 Na[(CN)BH3] CH2Cl2 reflux  48 8 
0.83 Na[(CN)BH3] CHCl3 reflux  72 33 
0.83 Na[(CN)BH3] MeCN RT  48 0 
0.83 Na[(CN)BH3] MeCN reflux  48 8 
0.83 Na[(CN)BH3] MeCN reflux AcOH catalyst, 
0.2 eq. 
24 0 
0.85 Na[(CN)BH3] THF RT  72 0 
0.85 Na[(CN)BH3] THF reflux  48 12 
0.85 Na[(AcO)3BH] THF RT  72 0 
0.85 Na[(AcO)3BH] THF reflux  48 18 
Table 3: Conditions used to examine formation of ribitylated product 33. “Scale” 
refers to the quantity of 3,4-dimethylaniline 31 used. “RT” refers to room 
temperature, approx. 15 °C. All reactions were performed using 2 equivalents of 
D-ribose and the reducing agent under an Ar/N2 atmosphere, using thoroughly dried 
solvents (section 5.1.3) 
 
THF, dichloromethane and chloroform each failed to dissolve the reactants at reflux, 
which may have contributed to the generally poor yields observed. Although 
acetonitrile solubilised the compounds at reflux, yields obtained were lower than 
those when using both THF and chloroform. EtOH was in turn slightly less effective 
than isopropanol, with both alcohols affording reasonable yields of product 33 – 
although MeOH remained optimal.  
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These results indicated the importance of a protic, polar solvent for this reaction. 
Aprotic solvents (both polar and non-polar) were generally unable to afford 
reasonable yields for the reaction, although the yield obtained using chloroform was 
somewhat surprising.  
 
2.1.1.6  Reducing agent 
In several cases, the reducing agent (sodium cyanoborohydride, Na[CNBH3]) was 
replaced the similar compound sodium triacetoxyborohydride (Na[(AcO)3BH]). This is 
a similar mild reducing agent, and has been widely used in other reductive aminations 
as a direct replacement for cyanoborohydride105. This is due to its significantly reduced 
toxicity (as there is no risk up hydrogen cyanide release upon hydration or 
acidification), and it is reportedly more stable to common reaction conditions (such as 
extended periods at reflux)105, making it more appropriate for a “one-pot” synthesis 
where the intermediate is not isolated before elimination of water. 
 
However, the yields obtained using this reducing agent were consistently lower than 
those achieved using cyanoborohydride, with the only exception to this found in the 
presence of MgSO4. The reason for the general decrease observed using 
triacetoxyborohydride may be found in the extensive study of reductive aminations 
reported by Abdel-Magid et al. 105 using this reducing agent, where over 120 reductive 
aminations are described. While almost all were improved by replacement of 
cyanoborohydride for triacetoxyborohydride, they report that for reactions using 
unreactive or aryl amines, cyanoborohydride does give improved yields over 
triacetoxyborohydride (although the reasons for this remain unexplored). This is 
generally in line with the experimental results obtained.  
 
2.1.1.7  Summary – formation of 3,4-dimethyl-N(ribityl)-aniline 33 
A number of potential modifications to the original reaction method were attempted, 
although none has given any improvement to reaction yield. A range of factors was 
examined, including the use of catalysis, alternative solvents, different reducing 
agents, and the benefits of a “one-pot” method over separate additions of reagents. 
The main effect observed was the influence of water, although the use of dried 
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solvents appeared sufficient to prevent this. Therefore, as no yield for the formation 
of 3,4-dimethyl-N(ribityl)-aniline 33 was obtained above 65 %, questions must be 
raised regarding the yields reported previously5,100. 
 
2.1.2 Formation of 6-chlorouracil 35 
The synthesis of 6-chlorouracil 35 was originally performed according to the 
procedure described by M. Mansurova et al.100. This was a simple hydrolysis of 
2,4,6-trichloropyridine 34 performed using aqueous NaOH, producing 6-chlorouracil 
35 in moderate yield (isolated by precipitation and purified by recrystallisation). 
However, yields for this reaction were often poor, with significant potential for 
degradation via tautomerisation or other routes. Therefore, a full survey of reaction 
conditions was performed. A number of trends were observed, summarised in table 4 
(vide infra), and which are discussed below.  
 
 
Figure 27: Hydrolysis of 2,4,6-trichloropyrimidine 34 to form 6-chlorouracil 35, which 
degraded quickly in aqueous solution to a range of products, including tautomer 35b 
 
Extension of the reaction times (from 12 to 72 hours) under similar conditions gave a 
demonstrable increase in reaction yield. However, with greater reaction times (96 
hours), a drastic fall in the percentage of isolated product was observed, which is 
attributed to the re-aromatisation of the pyrimidine ring by tautomerisation, or 
degradation of 6-chlorouracil in the highly basic environment; numerous 
unidentifiable products were recovered, but not analysed further due to instability 
and difficulty in their separation. At high concentrations of base (discussed separately 
later), the effect of durations longer than 48 hours was negligible, with little 
enhancement to reaction yields obtained at 72 hours, due to faster initial reaction. 
 
 
 39 
 
 Scale 
(mM) 
Solvent Base 
Concentration 
(M) 
Time 
(hours) 
Reaction 
Temperature 
Yield 
(%) 
1 2.5 H2O / HO- NaOH 2.0 12 100 °C 35 
2 35 H2O / HO- NaOH 2.2 48 100 °C 65 
3 82 H2O / HO- NaOH 2.5 48 100 °C 52 
4 10 H2O / HO- NaOH 2.0 72 100 °C 56 
5 22 H2O / HO- NaOH 5.0 72 100 °C 71 
6 8.5 H2O / HO- NaOH 2.6 96 100 °C 12 
7 1.7 H2O / HO- NaOH 1.0 48 100 °C 4 
8 1.7 H2O / HO- NaOH 3.0 48 100 °C 39 
9 1.7 H2O / HO- NaOH 5.0 48 100 °C 68 
10 1.7 H2O / HO- NaOH 5.0 48 RT 0 
11 1.7 H2O / HO- KOH 1.0 48 100 °C 20 
12 1.7 H2O / HO- KOH 3.0 48 100 °C 37 
13 1.7 H2O / HO- KOH 5.0 48 100 °C 52 
14 1.7 H2O / HO- KOH 5.0 48 RT 0 
15 1.7 H2O / HO- Mg(OH)2 3.0 72 100 °C 0 
16 3 
toluene;  
H2O / HO- 
NaOH 2.5 72 100 °C 21 
17 8.2 
DCM;  
H2O / HO- 
NaOH 2.5 72 40 °C 14 
18 10 H2O / HO- NaOH 5.0 48 100 °C 
64, 
81* 
 
Table 4: Conditions examined for the formation of 6-chlorouracil 35. “Scale” refers to 
the quantity of 2,4,6-trichloropyrimidine 34 used. “RT” describes room temperature, 
approx. 15 °C. Reaction 18 gave a yield of 64 % when the product was isolated by 
precipitation alone; further extraction using EtOAc (described below) allowed 
recovery of additional product, increasing the yield to 81 % (combined) 
 
Temperature was found to have a broadly linear influence on the reaction. At ambient 
temperatures (typically 15-20 °C), no product formation was observed, while at reflux 
(100 °C) the reaction successfully produced 6-chlorouracil 35. Higher temperatures 
were not examined due to the need for a hydroxylic base for the reaction; while it was 
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found that from the biphasic reaction using dichloromethane and NaOH (where a 
temperature of 40 °C was used due to the volatility of DCM), a modest yield of 
6-chlorouracil 35 was obtained. If solvent effects are discounted, this suggests that 
increasing temperature lead to an improvement to reaction yield, with elevated 
temperatures allowing most efficient reaction. 
 
The reaction solvent in most cases was aqueous NaOH, which acted as both solvent 
and reactive base for the hydrolysis. However, as 2,4,6-trichloropyrimidine 34 is only 
sparingly soluble in refluxing hydroxide, performing the reaction in organic solvents 
(toluene and dichloromethane) was attempted. Each of these reactions was 
performed as a biphasic mixture with the aqueous base; however even with vigorous 
stirring low yields were obtained. Examination of these mixtures using TLC indicated 
that 2,4,6-trichloropyrimidine 35 was generally localised within the organic solvent 
(particularly in the case of toluene), potentially reducing product yield because of poor 
mixing between the two phases. It was hoped that as 6-chlorouracil 35 may be more 
soluble in polar solvents, it would be retained within the aqueous layer after 
formation; however it was observed to re-dissolve in both organic layers, indicating a 
previously unreported affinity for these solvents. The use of a phase-transfer 
catalyst124–126 to improve mixing was considered but discounted, as 6-chlorouracil 35 
often formed large aggregated structures within the mixture (vide infra), which 
physically prevented effective mixing of the layers.  
 
A further trend was noted, with an increase in hydroxylic base concentration (up to 5 
M) facilitating a greater yield of 6-chlorouracil 35. Several alternative hydroxylic bases 
were considered, including KOH and Mg(OH)2. However, the poor solubility of 
Mg(OH)2 in water led to no product formation after 72 hours. KOH was successful at 
furnishing 6-chlorouracil 35, especially at lower concentrations (1 M) – where a yield 
of 20 % was obtained, compared to the yield produced using NaOH under the same 
conditions being 4 % – although at high concentrations (5 M), the effectiveness of KOH 
was significantly below that of NaOH.  
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It was noted during this reaction was that in almost all cases, an insoluble plaque was 
observed to precipitate out of solution above the reaction solvent after 12-18 hours. 
Mass spectrometry and NMR (1H and 13C) data suggests that this was comprised 
primarily of 6-chlorouracil 35, although this was highly contaminated with other 
materials (such as a mass of 163.95 and characteristic isotope pattern indicating an 
intermediate dichlorinated compound). Manual disruption of this plaque allowed 
greater contact with the solvent, and it slowly re-dissolved over approximately 8 
hours. The formation of this plaque, and its slow re-dissolution suggests high stability 
of this aggregated structure.  
 
 
Figure 28: 1H NMR of 6-chlorouracil 35, visualised using Mestrelab MESTREC127. 
Resonances for each N-H are visible (12.10, 11.32 ppm), with the single C-H 
resonance at 5.77 ppm. No lower resonances were observed for this compound 
 
One probable influence on the formation of 6-chlorouracil 35 is the strong hydrogen 
bond donor-acceptor motif of the uracil ring. Uracil is a nucleobase present in RNA 
(similar to thymine found in DNA), forming a hydrogen-bond pair with adenine. 
However, as uracil has both hydrogen bond donor and acceptor moieties, uracil-uracil 
mismatches are possible, with the stability of this inter-molecular effect utilised to by 
nature to stabilise elements of RNA secondary structure128–130 (as shown in fig. 29). 
This intra-molecular effect is also likely to occur with free uracil in solution, minimising 
entropy by forming aggregated structures.  
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Figure 29: Mismatch hydrogen-bonding of uracil (left), as found in secondary 
structures of RNA 128–130. This may potentially extend between several molecules, 
leading to an aggregated “polymeric” structure (right) for 6-chlorouracil 35. 
 
The strong influence of uracil’s hydrogen bond donor-acceptor motif is further 
enhanced by a number of potential resonance structures, with each having a differing 
effect on the overall aromaticity of uracil131. The ionic effect of these resonance 
structures would be expected to improve the strength of bonding between molecules 
of uracil, supporting potential aggregation of the compound. When the effect of the 
high electronegativity of the chlorine withdrawing electron density from the uracil ring 
is considered for 6-chlorouracil 35, it may stabilise some charged resonance forms, 
further enhancing the aggregation of the compound.  
 
 
Figure 30: Uracil 68, with resonance-contributing structures as described by Galvão 
et al.131. Note the increasing level of aromaticity of structures 68a-c 
 
Upon isolation, 6-chlorouracil 35 was found to be particularly unstable, with near-total 
degradation to a complex mixture of products observed after 7 days at RT. To prevent 
degradation before reaction with 3,4-dimethyl-N(ribityl)-aniline 33, 6-chlorouracil 35 
was originally used immediately upon precipitation. However, it became clear that the 
compound retained quantities of water, with a detrimental effect on the subsequent 
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reaction. Drying 6-chlorouracil 35 under high vacuum for 8 hours improved the yield 
of the subsequent reaction from between 0-30% to 55%. 
 
In order to find a swifter method to remove water from 6-chlorouracil 35, azeotropic 
distillation of the product (from EtOH or toluene, approximately 100 mL per 1 g crude 
product) gave a similar improvement to the subsequent reaction as drying under high 
vacuum, although the use of elevated temperature was not ideal as this may promote 
tautomerisation.  
 
An alternative method to isolate 6-chlorouracil 35 from the reaction mixture was 
discovered by TLC examination of the mother liquor from the precipitation, revealing 
significant quantities of the product remaining in solution. Trituration using hexane, 
diethyl ether, toluene or other solvents was ineffective, and the lyophilised product 
was found to be particularly impure. However, extraction of the aqueous solution with 
EtOAc allowed isolation of 6-chlorouracil 35 from the mixture, enhancing the overall 
yield by up to 17 %. As this previously unreported method was both convenient and 
efficient at furnishing pure 6-chlorouracil 35, the reaction method was adjusted to 
reflect this. The use of extraction using EtOAc (following filtration if precipitation upon 
acidification was observed), gave 6-chorouracil in yields up to 81 %. 
 
2.1.3  Formation of bicyclic intermediate 36 
The coupling of 3,4-dimethyl-N(ribityl)-aniline 33 and 6-chlorouracil 35 is one of the 
steps of this synthesis which has been particularly contentious in the literature. At 
least three distinct routes (with numerous variations) have been described; each 
stating that their method is an improvement over previous routes. It is difficult to 
imagine that the weakly nucleophilic ribitylated nitrogen will readily attack 
6-chlorouracil, and thus the yields reported for this reaction have remained moderate. 
Isolation of the intermediate bicyclic product 36 is difficult due to the similar polarities 
of the product, intermediates and reagents; however, acetylation of the bicyclic 
intermediate 37 immediately after reaction allows purification by FC.  
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Due to the competing reactions described in the literature, each of the three methods 
to perform this coupling was performed in order to determine the optimal route. 
 
2.1.3.1  Catalysis using malononitrile 
Initially, the method of Carlson and Kiessling (72 hours, refluxing MeOH, malononitrile 
catalyst, anhydrous conditions) was repeated, which furnished product 36 in low yield 
(35 %, after acetylation). This reaction was found to be particularly sensitive to the 
presence of water; when non-dried solvents were used, only starting materials were 
observed (by TLC) within the reaction mixture after 72 hours, and bicyclic intermediate 
36 was not obtained. As described above, ensuring that 6-chlorouracil 35 was 
thoroughly dried gave a marked improvement to the yield of this reaction, reaching 
55 % (after acetylation). 
 
The addition of malononitrile appears necessary for effective reaction; very low yields 
(10-15 %) of product 36 were obtained when the reaction was performed without this 
compound. Addition of malononitrile was first reported by Carlson and Kiessling5, who 
justify its use by its influence on a previous reaction132, where malononitrile assists 
the coupling of conjugated vinyl halides. The mechanism of this malononitrile-catalysis 
has not been discussed in the literature, however similar reactions of malononitrile 
may shed light on its role in this case.  
  
Some evidence is available that malononitrile may act as a reasonable nucleophile 
(assisted by palladium catalysis), especially in the displacement of aryl halogens133,134 
(fig. 31). As cyanide is an effective leaving group during nucleophilic substitutions 
(often preferentially to halogens)134, it may be reasonably expected that di-nitriles 
such as malononitrile will be an even more effective leaving group. Thus in formation 
of 36, malononitrile may activate 6-chlorouracil, allowing reaction with poor 
nucleophile of 3,4-dimethyl-N(ribityl)-aniline 33.  
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Figure 31: Scheme for reaction between a substituted aryl bromide and 
malononitrile, described by Schnyder et al.133. “R” describes several aromatic 
substituents (electron withdrawing and donating) at various positions of the 
aromatic ring. The resultant aryl malononitriles were synthesised in yields up to 92 % 
 
One difficulty with the use of malononitrile is an apparent instability to the reaction 
conditions; optimal results were obtained when portions were added regularly 
throughout the course of the reaction. When monitoring by TLC, the reaction was 
found to be incomplete after the described 72 hours, with each of the starting 
materials visible up to 120 hours. Typically, the reaction was allowed to continue for 
144 hours before work-up to maximise product formation. Notably, a characteristic 
blue fluorescence was observed for the bicyclic intermediate 36 when examined by 
TLC at 365 nm, due to significant extension of the chromophore.  
 
An attempted modification to this reaction was the addition of 1.2 eq. of a base (either 
triethylamine (TEA) or 4-dimethylaminopyridine (DMAP)), to aid deprotonation the 
aryl amine of 3,4-dimethyl-N(ribityl)aniline 33. This was intended to enhance the 
amine’s nucleophilicity, and to remove acid generated by the reaction. However, in 
both cases no enhancement to the yield was made; yields decreased to 34 % and 21 % 
respectively (isolated after acetylation; principal side-products observed were 
acetylated starting materials).  
 
Thus, the principal conclusion from the study of this method is that the reaction was 
particularly susceptible to both the presence of water or base, and should be 
performed with exclusion of both.  
 
2.1.3.2  Solvent-free coupling 
An alternative route used to form bicyclic intermediate 36 utilised a high-temperature 
solvent-free heating method to achieve formation of the bicyclic product108. This 
simple method required heating of reactants 33 and 35 (with vigorous mixing) at 
 46 
 
185 °C for 15 minutes, followed by washing with diethyl ether and water to remove 
unreacted starting materials, furnishing the bicyclic compound in reported yields up 
to 75 % 108.  
 
Figure 32: Solvent-free heating of 3,4-dimethyl-N(ribityl)aniline 33 and 6-chlorouracil 
35 afforded formation of intermediate 36 
 
Evolution of acidic vapours indicated a reaction between the two compounds. It was 
found that when performed at scales below 0.75 mmol, quantitative yields of bicyclic 
compound 36 were obtained. However, when performed using greater quantities of 
reactants, product formation was inefficient and frequently failed to give any 
isolatable product. This may be due to the instability of the ribityl group of 
3,4-dimethyl-N(ribityl)aniline 33 at high temperatures, indicated by formation of a 
dark-brown caramel-like residue, and shifts in the 1H NMR of peaks assigned to this 
functional group from compound recovered from the reaction. Alternatively, the 
reduction in yield may be due simply to the difficulty of efficiently mixing large 
quantities of the reagents without solvent. Therefore, while this method appears to 
show some promise, its application to preparative-scale production of the bicyclic 
intermediate 36 was not possible in its current form. 
 
2.1.3.3  Reaction in aqueous solution 
The third method which was attempted in order to facilitate the coupling between 
3,4-dimethyl-N(ribityl)aniline 33 and 6-chlorouracil 35 was first reported in 1978 by 
W. T. Ashton et al.109, with a variation reported in contemporary literature in 1997 by 
Frier et al.135. The original method describes performing the coupling reaction in 
refluxing water, producing 36 with a yield of 57 %; while the modern interpretation 
(using a similar 3,4-dimethyl-N(hexyl)-aniline, and using a 50:50 mixture of water and 
dioxane) reports a yield of 63 %. During the course of this project these reactions were 
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repeated using 3,4-dimethyl-N(ribityl)-aniline 33, however in all cases no product 
formation was identified, with starting materials (or degradation products) recovered 
after 72 hours. 
 
 
Figure 33: While formation of intermediate 36 was possible in anhydrous methanol, it 
was not possible to form the product in aqueous solution or solvent mixtures  
 
The apparent failure of the reaction under these conditions was somewhat expected, 
as it was previously found in the case of the malononitrile-catalysed coupling 
described above that anhydrous conditions are crucial for effective reaction between 
the two reagents. Even the small quantities of water retained within 6-chlorouracil 35 
from its prior precipitation had been found to have a dramatic effect on the yield of 
bicyclic compound 36. Further work may assist in identifying the reasons for this. 
 
2.1.3.4  Summary 
The study of these three methods to perform the coupling between 6-chlorouracil 35 
and 3,4-dimethyl-N(ribityl)-aniline 33 confirmed the use of the solvent-free method 
to perform the reaction in quantitative yield on an analytical scale, although it was not 
possible to use this reaction to furnish bicyclic intermediate 36 on a preparative scale, 
possibly due to insufficient mixing of the reagents. The method reported by Carlson et 
al.5 performed in MeOH using malononitrile catalyst was found to be optimal, and was 
therefore used to prepare the bicyclic intermediate, in yields up to 55 % (including the 
subsequent acetylation). 
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After solvent removal from the coupling reaction, all material was used for the 
subsequent protection, typically without prior purification. This was originally 
attempted by recrystallisation (as described by Carlson and Kiessling5), or using FC 
over silica. However, product isolation was not possible by recrystallisation (as 
unreacted starting materials continually co-crystallised); although FC was possible on 
small scales, for spectroscopic purposes.  
 
2.1.4  Protection of bicyclic intermediate 36 
The protection of the D-ribityl group was performed to prevent reaction during the 
subsequent ring-closure using POCl3. Almost all previous syntheses of riboflavin 
analogues use the same protection method described by Carlson et al.5, where the 
ribityl hydroxyl groups were protected by acetylation. 
 
2.1.4.1  Potential alternative protection strategies  
The use of other protecting groups was considered, with the structural arrangement 
of the hydroxyl groups (1,2,3,4-relative to each other) leading to the interesting 
possibility of using cyclic protecting groups to protect the two pairs of diols, either 1,2 
or 1,3 to each other. However, using these would have been difficult for several 
reasons. Firstly, the presence of both 1,2- and 1,3-diols within the ribityl group would 
cause complications during the reaction, leading to a mixture of different products 
with many not fully protecting all four hydroxyl groups of the ribityl chain. Secondly, 
while some cyclic protecting groups are resistant to harsh acidic conditions, due to 
their stability strongly basic conditions are often required for their removal – but 
riboflavin is particularly unstable in basic conditions136–138.  
 
Furthermore, other cyclic protecting groups such as dioxolanes alter the 
stereochemistry of the original hydroxyl group upon formation139. While in most cases 
stereochemistry is recovered upon deprotection, due to the importance of the 
stereochemistry of the D-enantiomer of ribose for recognition and binding by 
flavoproteins, damage to this functionality was particularly unattractive.  
 
 49 
 
A previous method to perform the ring closure of the bicyclic compound which also 
resulted in the protection of the ribityl chain was using trimethylorthoformate109, 
shown in figure 34 and discussed previously in chapter 1.2.6. This was unsuitable, as 
the bis(methoxymethylene) protecting groups are easily removed under acidic 
conditions, and the reported yield for the ring-closure reaction using 
trimethylorthoformate was 47 % 109; significantly lower than the 64 % obtained by 
Carlson et al.5 using POCl3 / DMF.  
 
 
Figure 34: Triethylorthoformate 69 successfully incorporated bis(methoxymethylene) 
protection for the ribityl side-chain of intermediate 36 while also allowing closure of 
the central pyridine ring of 5-deazariboflavin 39 (above), however this was less 
efficient than acetylation followed by the Vilsmeier-Haack method (below) 
 
After acetylation, purification of 37 by FC was much more convenient, using the 
slightly polar mixture of CHCl3 and MeOH in a ratio of 20 : 1 (v/v). This was significantly 
less polar than that required to separate the starting materials for the reaction, as the 
polarity of the ribityl chain is vastly decreased by acetylation. Therefore, while 
protection of the ribityl chain was useful to prevent unwanted reaction in subsequent 
steps, it also allowed convenient purification of product 37. 
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2.1.4.2  Examination of protection conditions 
Protection of bicyclic compound 36 was originally performed using acetic anhydride 
in pyridine, acting as both solvent and catalyst139,140. As each of the four hydroxyl 
groups required protection, a 1.25 molar excess (5 equivalents) of acetic anhydride 
was used, which is not greater than that reported for numerous other acetylations139. 
However, even after FC and numerous rounds of extraction into dichloromethane, it 
was found that pyridine often contaminated the product, making purification and 
assignment (particularly by NMR) difficult. Therefore, numerous alternative 
conditions were examined, as described in table 5. 
 
 Scale 
(mmol) 
Bulk 
Solvent 
Catalyst Acetate source Temp. Reaction Time 
(hrs) 
Yield 
(%) 
1 6.0 Pyridine Pyridine acetic anhydride RT 16 47 
2 0.5 CH2Cl2 Pyridine acetic anhydride RT 16 55 
3 0.5 CH2Cl2 - acetic anhydride RT 24 (incomplete) 15 
4 0.5 CH2Cl2 TEA acetic anhydride RT 16 24 
5 0.5 CH2Cl2 DMAP acetic anhydride RT 16 31 
6 0.5 CH2Cl2 Imidazole acetic anhydride RT 16 41 
7 4.5 CH2Cl2 Pyridine acetic anhydride RT 16 54 
8 0.5 THF Pyridine acetic anhydride RT 16 45 
9 0.4 THF TEA acetic anhydride RT 2 36 
10 0.4 THF TEA acetic anhydride RT 16 41 
11 0.5 CH2Cl2 Pyridine acetyl chloride RT 4 0 * 
12 0.5 CH2Cl2 Pyridine acetyl chloride 0 °C 4 0 * 
13 0.5 CH2Cl2 Pyridine acetyl chloride -78 °C 4 0 * 
Table 5: Reactions performed to establish the optimal protocol for acetylation of 
intermediate 36. “Scale” refers to the number of moles of riboaniline 33 used for the 
initial formation of bicyclic 36, formed according to the method described in section 
6.1.3.1; all yields reported were obtained over two steps. 0.2 equivalents of catalyst 
were used in all cases. 5 equivalents (1.25 molar excess) of acetic anhydride was 
used, while 4.1 equivalents (1.03 molar excess) of acetyl chloride were used 
 
Without the catalytic effect of pyridine, the acetylation of bicyclic intermediate 36 by 
acetic anhydride (in dichloromethane) was incomplete after 24 hours, while the 
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presence of 0.2 equivalents of pyridine (again using dichloromethane as the bulk 
solvent) gave optimal yields after 16 hours. Reactions were not performed for greater 
than 16 hours, due to the formation of undesired side-products (principal among 
these was N-acetylated 3,4-dimethyl-N(ribityl)-aniline, indicating rupture of the 
crucial xylidine-uracil bond, which has been reported to be acid-sensitive5). 
 
Using dichloromethane as the reaction solvent was particularly beneficial, as the 
acetylated product was readily soluble in the organic solvent. While dissolution of the 
starting material required a solvent with higher polarity than dichloromethane, the 
catalytic volume of pyridine required for efficient reaction was sufficient to allowing 
dissolution of the starting material within the bulk solvent. Yields obtained using dilute 
pyridine in dichloromethane were in fact greater than those obtained when using 
pyridine as a lone solvent (55 % vs. 47 %), and this effect applied on all scales (from 
0.4 mmol to 4.5 mmol), with little difference.  
 
Furthermore, this method allowed convenient purification by extraction against 
aqueous solutions, due to the greatly reduced volume of base to be removed. It was 
further found that this extraction process enabled isolation of the desired product in 
good purity (as unreacted materials from previous steps were also removed to the 
aqueous layer), without requiring chromatographic procedures such as FC, thus saving 
a considerable amount of time. 
 
As described above, it was found that a small volume of base (0.2 molar equivalents) 
was sufficient to catalyse the reaction and allow effective acetylation. However, a 
number of other organic bases (triethylamine, DMAP and imidazole) were evaluated 
against pyridine in order to determine if a more effective replacement was possible, 
as each has been widely reported to assist acetylation reactions141. Each base was 
used as a direct replacement for pyridine in the reaction, although some problems 
with solubility occurred; both pyridine and triethylamine each allowed the starting 
material to dissolve in the reaction solvent, while the solid bases DMAP and imidazole 
had no effect. In these cases, the solvent was gently warmed to allow dissolution of 
the starting material, and the reaction was started as a slight suspension if necessary. 
 52 
 
A further complication was that the use of both imidazole and DMAP required lengthy 
purification by FC after the reaction to remove the catalyst. 
 
The use of stronger bases has been reported to reduce the time required for 
acetylations; in an example described by Klemenc142, DMAP was found to be able to 
catalyse acetylation of morphine (to heroin) in under 10 minutes at room 
temperature, in contrast to 2 hours at reflux using pyridine. However, a similar effect 
was not observed in this case. In contrast, a general trend inversely related to the 
strength of the base was found: while pyridine is the weakest base (pKa 5.2), the yield 
obtained using this was greatest; as pKa of the base increased, the yield of product 
decreased. This may be due to the stability of the active intermediate species (in the 
case of reaction with pyridine, intermediate 71a, figure 35), which dissociates upon 
attack by the group undergoing protection. Although stronger bases would be 
expected to react more readily with acetic anhydride to form the activated species, 
the increased stability of the intermediate makes it more difficult for the ribityl group 
to react. This result therefore suggests that the nucleophilicity of the group to be 
protected must be balanced against the strength of base used, which may form a more 
stable intermediate.  
 
 
Figure 35: Reaction between pyridine and acetic anhydride forms the intermediate 
species 71a, which assists acetylation of the ribityl-hydroxyl groups 
  
As an alternative to the use of dichloromethane, THF was examined in its place, where 
it was found to give yields only slightly lower those obtained previously. Interestingly, 
while triethylamine appeared to be less effective than pyridine in dichloromethane 
(24 % after 16 hours in dichloromethane, vs. 55% using pyridine); using THF, 
triethylamine gave 41 % after 16 hours, and 36 % after only two, which is very close 
to the yield obtained using pyridine in THF (45 %). A probable reason for the differing 
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yields when using dichloromethane and THF is the increase in polarity of THF relative 
to dichloromethane, which more adequately solubilised the reactants and facilitated 
a fast initial reaction. However, the overall reaction yield remains inferior to the yield 
obtained using dichloromethane/pyridine, supporting the supposition that the 
stronger base is less effective as a catalyst.  
 
After determination of the optimal conditions for this reaction, it was repeated using 
the (significantly more reactive) reagent acetyl chloride. However, even using the 
minimum quantity (4.1 equivalents) at reduced temperatures (-78 °C), and with 
careful monitoring throughout the course of the reaction, the formation of a wide 
variety of unwanted side-products was observed without formation of protected 
product 37. Principal among these was evidence of acetylation of the amine group at 
the expense of either the ribityl side-chain or the uracil moiety, with a high proportion 
of N-acetylated derivative of 3,4-dimethyl-N(ribityl)-aniline again recovered. 
Therefore, the use of acetyl chloride was not explored further, and acetic anhydride 
in a mixture of dichloromethane and pyridine was used to perform this reaction.  
 
2.1.4.3  Undesired Acetylation 
As described above, five equivalents of acetic anhydride were used to protect the four 
hydroxyl groups of the D-ribityl side chain. However, during careful examination of the 
spectroscopic data, it was apparent that on some occasions, a previously unreported 
side-product was formed, with potentially damaging consequences for the synthetic 
route. In a number of cases, the slight excess of acetic anhydride led to additional 
acetylation of the uracil ring. Initial examination by NMR did not show a preference 
for acetylation of either amino group of the uracil moiety, with a mixture of both 
generally observed. This led to a more complex NMR structure of the acetylated 
compound 37, which was incredibly difficult to separate from the undesired side-
products by FC due to their very similar polarities. 
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Figure 36: Acetylation of the ribityl side-chain of bicyclic compound 36 often led to 
acetylation of the uracil moiety. No preference for either amine position was noted 
 
The removal of acetyl protecting groups from amines is notoriously difficult139, due to 
a strong conjugation effect. However, (as discussed in greater detail later) the 
conditions used for the final step of the reaction were found to be sufficient to 
overcome this, and thus the presence of undesired acetylation did not affect the 
outcome of subsequent reactions. 
 
2.1.5  Ring closure at position C5 of the isoalloxazine  
2.1.5.1  Previously reported methods 
The insertion of a carbon atom at position C5 of the flavin ring is key to the final 
structure of 5-deazariboflavin, but is one of the most complex steps of the synthesis. 
Previous syntheses of 5-deazariboflavin utilised alternative strategies to afford 
formation of 5-deazariboflavin; either using triethylorthoformate109 (discussed 
above), or with a starting material already containing a functionalised carbon at this 
position (2-amino-N(ribityl)-4,5-dimethylbenzaldehyde 73b, fig. 37)103,106. The 
presence of a reactive carbonyl group required protection to prevent unwanted 
reaction during the course of the synthesis, which was performed using a tosylated 
hydrazide group, removed immediately prior to coupling with 6-chlorouracil103 (or an 
analogue106), to form a 5-deaza-flavin product. 
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Figure 37: Scheme for reported formation of 1,5-dideazarboflavin 75 from protected 
2-amino-N(ribityl)-4,5-dimethylbenzaldehyde 73106. This is deprotected in situ, before 
addition of 2,4,6-piperidine trione 66; condensation furnished the flavin analogue 
 
The insertion of the eventual C5-carbon of 5-deazariboflavin used for this reaction was 
originally devised by F. Yoneda et al. in 1976 111. This reaction performed the ring-
closure of the central ring of isoalloxazine using the Vilsmeier-Haack reagents POCl3 
and DMF110. POCl3 activates DMF, which is then attacked by an electrophilic substrate 
(generally an arene143–145). DMF acts as both a reactant and the reaction solvent.  
 
2.1.5.2  Position of Formylation 
The formyl group formed by this reaction undergoes a secondary attack by either the 
neighbouring xylidine or uracil ring (vide infra), which closes the central pyridine ring 
of the isoalloxazine analogue; final elimination of water allows aromaticity across the 
flavin system.  
 
 
Figure 38: Formylation of intermediate 37 (R = D-ribose tetraacetate) using the 
Vilsmeier reagents (POCl3 and DMF); attack by the xylidine ring allows formation of 
the 5-hydroxyl-deazaflavin intermediate (not shown), leading to 5-deazaflavin 38 
 
Interestingly, a strong argument is made by Yoneda et al.111 for the initial formylation 
of the uracil moiety of bicyclic compound 37, rather than formylation of the xylidine 
ring. This is somewhat contrary to initial expectations, as the principal reported use of 
the Vilsmeier-Haack reaction is the formylation of aromatic molecules143–145 (although 
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this is disputed by some sources which report that this reaction fails with benzenes146). 
On the other hand, the formylation of non-aromatic alkenes using these reagents is 
widely reported, particularly when activated by neighbouring (or conjugated) electron 
donating groups147–149.  
 
The mechanism of attack by an activated alkene is the same as that performed by an 
arene ring, especially when enhanced by an electron donor. Key amongst the evidence 
presented by Yoneda et al.111 is that the formylation of 6-chlorouracil (to 6-chloro-5-
formyluracil) prior to reaction with 3,4-dimethyl-N(ribityl)-aniline 33 successfully 
produced 5-deazariboflavin 39 in moderate yield. Hence, upon bond formation 
between the amine and chlorinated position of uracil, the formylated uracil moiety 
must be susceptible to an intramolecular attack by the xylidine ring, to close the 
central ring of the flavin analogue. The pre-formylation of uracil was not considered 
during this study, as the yields obtained by Yoneda et al. for this reaction are 
substantially lower than those obtained without prior formylation of 6-chlorouracil 
(from 57 % to 37 %111). However, it may be useful to re-examine this method to 
confirm this result, as it may significantly simplify this synthesis. 
 
2.1.5.3  Relative Positions of the Methyl Groups of the Xylidine Moiety 
In order to furnish 5-deazariboflavin 39, an important consideration of the relative 
geometry of the xylidine moiety of bicyclic intermediate 37 is necessary. Rotation 
around the C-N bond originating from 3,4-dimethyl-N(ribityl)-aniline 33 changes the 
position of methyl groups relative to position of C5 in the final 5-deazaflavin structure. 
The two positions of the aniline ortho to the amino bond are non-equivalent due to 
the neighbouring methyl groups, and so two potential products may have been 
formed by this reaction – the desired 5-deazariboflavin 39 (i.e. 7,8-dimethyl), and 
5-deaza-6-methyl-8-demethylriboflavin 76 (fig. 39).  
 
However, the only reported product from this reaction was 5-deazariboflavin 39, 
which is confirmed by spectroscopic evidence show in figure 40. 
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Figure 39: Rotation around the C-N bond of bicyclic intermediate 37 offers two 
positions (2 or 6) of the xylidine ring for attack at the formylated uracil; the pro-5-
deazariboflavin structure (above) and the pro-5-deaza-6-methyl-8-demethylriboflavin 
structure (below), however only 5-deazariboflavin 39 is observed experimentally 
 
Evidence confirming the formation of 5-deazariboflavin was obtained from the 
splitting pattern and coupling constants in the aromatic region of the proton NMR 
spectrum, shown in figure 40. The spectrum of 5-deazariboflavin 39 (fig. 40, black) 
shows no splitting of the proton resonances, with some possible peak broadening of 
the resonances at 8.05 ppm and 7.95 ppm indicating relative para coupling. Compared 
to the proton NMR spectrum of 3,4-dimethyl-N(ribityl)-aniline 33 (fig.40, blue), which 
shows relative ortho, para and ortho+para coupling (from left to right), it is clear that 
if compound 76 was formed, the aromatic resonances observed would be expected to 
each have doublet multiplicity, with a coupling constant of approximately 7 Hz. 
 
Figure 40: Proton NMR spectra of 5-deazariboflavin 39 (black, above), and 3,4-
dimethyl-N(ribityl)-aniline 33 (blue, below) 
 
There are several possible reasons for why the 5-deazaflavin form is preferred by the 
reaction, although these were not examined closely during this research. One likely 
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reason is the activation of position 6 of the xylidine ring (figure 39) by a donating effect 
from the methyl substituent at position 3. Similar activation has already been shown 
to play some effect amino group activation in the reductive amination of aromatic 
amines 3,4-dimethylaniline 31 and 4-methylamine 49, discussed in sections 2.1.1 and 
2.3.1. Additionally, the effect of delocalisation of electrons from the ribitylated amine 
across the aromatic ring gives this C-N bond considerable π-character, providing a high 
energetic barrier for rotation around this bond. Thus, the arrangement of methyl 
groups leading to 5-deazariboflavin formation may be favoured, and lead to the 
formation of the single observed product. 
 
2.1.5.4  Isolation of 5-deazariboflavin tetraacetate 38 
A key improvement to this reaction was made using an organic extraction procedure 
to isolate further product 38 (fig. 38, vide supra) from the mother liquor after 
precipitation. However, the first extraction also isolated unreacted staring materials; 
5-deazariboflavin tetraacetate 38 was isolated by acidification (protonating the flavin 
analogue), which was separated from other contaminants by extraction into water. 
Deprotonation allowed re-extraction using CHCl3, and isolation of further 
5-deazariboflavin tetraacetate 38. The yield obtained using this method was 72 %, 
which is greater than the yield obtained previously (64 % 5). 
 
2.1.6 Deprotection of 5-deaza(tetraacetyl)riboflavin 38 
Deprotection of the acetylated flavin was conveniently performed using methanol 
saturated with ammonia. This was performed with care taken to exclude all light from 
the sample, generally using foil-lined glassware in the dark. It was found that the 
reaction proceeded quickly and efficiently at room temperature, with a typical 
reaction time of 6 hours. As both NH3 and MeOH are volatile, these were easily 
removed at reduced pressures, along with ammonium acetate formed during the 
course of the deprotection. 
 
While similar methods are reported elsewhere for the removal of acetyl protection 
from hydroxyl groups139,150, one key question of this reaction is whether it was 
possible to remove the unintended amino- acetylation of the uracil moiety observed 
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from protection of the ribityl chain, described above. The stability of the acetamide 
group is generally exceptionally high, and stable to hydrolysis under acidic and basic 
conditions139,151–154. However, careful scrutiny of the spectroscopic data from this 
reaction showed the complete removal of all acetyl groups present before the 
reaction, forming 5-deazariboflavin 39; therefore these conditions were suitable for 
hydrolysis of this bond. 
 
2.1.7 Conclusion – Synthesis of 5-deazariboflavin 
During this section, the optimal route for the synthesis of 5-deazariboflavin 39 was 
identified, and used to furnish the product in 16.2 % yield overall. Several reactions 
were found to be particularly difficult, and where necessary thorough surveys of 
experimental conditions and reagents were performed in order to better understand 
the reactions. One of the more intriguing results obtained has been the formation of 
a previously unreported acetylated intermediate during acetyl protection of the ribityl 
chain; however, it has been determined that this has no effect on subsequent 
reactions, and is readily removed using the standard deprotection procedure 
described in section 6.1.6.  
 
Future work which may be of benefit to this synthesis would be the examination of 
the outcome for potential for the acetylation of 6-chlorouracil 35 prior to coupling 
with 3,4-dimethyl-N(ribityl)-aniline 33, as there is some evidence in the literature108,111 
that this may give improved yields for the coupling reaction. Likewise, formylation of 
35 prior to the coupling reaction may further improve the reaction efficiency, by 
potentially removing the need for protection, deprotection, or ring closure steps111.  
 
2.2 Synthesis of 1-deazariboflavin 
2.2.0 Introduction 
This section describes the method used to synthesise 1-deazriboflavin, following the 
original route of Carlson and Kiessling5. Few approaches for the synthesis of this 
analogue exist in the literature, and so this study has been performed to bolster the 
further the understanding of this reaction. In this section, the improvements made 
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and the rationale behind various methods is described, which has enabled overall yield 
to be improved from 11.0 % reported elsewhere5 to 61.3 %.  
 
 
Figure 41: Overall scheme for the synthesis of 1-deazariboflavin 48 
 
2.2.1 Protection of 2-amino-4,5-dimethylphenylamine 40 
Mono-protected product 42 was produced in very high yields (92 %), in excess of those 
quoted previously (66 % 5, 90 % 100). A side-product commonly reported5 for this 
reaction is the protection of both amino groups, however this was not observed using 
the conditions reported in section 6.2.1. A strict stoichiometric amount of t-Boc 
anhydride was used, along with careful monitoring of the reaction using TLC, which 
showed completion at shorter times than previously reported (3 hours).  
 
Commonly, protection of amine functionality using the Boc- group is performed with 
heating at reflux139; however the diamine used for this reaction reacts readily at room 
temperature. Cooling of the reaction mixture was considered in the event that di-
protection was observed as reported5, however as this was not the case it was not 
necessary. Purification of protected product 42 was performed using flash 
chromatography, with very good separation between the desired product and other 
reaction contents enabling swift purification. 
 
2.2.2 Ribitylation of Boc-protected intermediate 42 
The asymmetric protected diamine 42 was ribitylated using the most effective 
conditions found for synthesis of 3,4-dimethyl-N(ribityl)-aniline 33, described in 
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section 2.1.1. However, the yield for this reaction was significantly improved, from 
65 % previously to 94 % using the protected diamine, providing further evidence that 
the weak nucleophilicity of the nitrogen atom in 3,4-dimethylaniline 31 plays a 
significant role in poor yields obtained when undergoing reductive amination, as the 
donating effect of the protected ortho- amine of diamine 42 appears to considerably 
enhance the efficiency of the ribitylation. 
 
 
Figure 42: Comparison of reductive aminations for 3,4-dimethylaniline 31 and Boc-
protected diamine 42. When performed ceteris paribus, vast improvement in the 
yield of 43 was found, suggesting an ortho-donating effect from the protected amine 
 
The greatest difficulty with this reaction was the lability of the Boc- protecting group 
of product 43 to the acidic conditions used in the reaction work-up. The use of acid is 
necessary to ensure complete reduction of the Schiff-base intermediate, however (as 
was found later), this group was successfully cleaved using 1 M hydrochloric acid. 
Therefore, this stage of the reaction was performed as swiftly as possible, in order to 
maximise product yield. 
 
Furthermore, while the purification of 3,4-dimethyl-N(ribityl)-aniline 33 caused 
spontaneous precipitation of the pure product, no precipitation of the similar Boc-
protected product 43 was observed during this reaction, believed to be due to the 
increase in solubility afforded by the protecting group. Final yields of the purified 
compound reached 94 %, which was reliably reproduced at all scales between 0.8 
mmol and 50 mmol. 
  
 62 
 
2.2.3 Deprotection of 1-(N-ribityl),2-(N-Boc)-diamino-4,5-dimethylbenzene 43 
Removal of the Boc- protecting group was originally performed as previously reported, 
using 4 M HCl in dioxane. While other protocols for this deprotection typically use less 
concentrated conditions (2 M aqueous HCl)139, the suggested reagent is generally used 
to only perform this reaction under oxygen-free or anhydrous conditions139,155. 
Interestingly, the synthetic method of Carlson makes no mention or justification for 
the use of air-free conditions. 
 
A plausible reason for performing this reaction with the exclusion of oxygen was found 
in the results of Barry et al.156 and Maggio-Hall et al.157, describing the formation of 
5,6-dimethylbenzimidazole (DMB) 44b as a ligand for vitamin B12 biosynthesis. They 
report that this compound may be formed by a complex “oxidative cascade” from 
riboflavin, via the deprotected ribitylated diamine 44, simply by aerobic oxidation156. 
This was also reportedly possible using catalytic amount of a mild oxidising agent, such 
as potassium ferricyanide157; providing a plausible explanation for performing the 
deprotection under air-free conditions. 
 
 
Figure 43: Proposed formation  of 5,6-dimethylbenzimidazole 44b via an oxidative 
cascade156,157 from riboflavin 6 and intermediate 44 (formed during this synthesis)  
 
The use of 4 M HCl in dioxane was reasonably efficient (giving yields up to 78 %), 
although slow, with reaction times of 16 hours necessary. As an oxygen-free 
environment was originally considered necessary, an alternative method used HCl 
(gas) generated alongside the reaction vessel, and bubbled through an anhydrous 
solution of the compound (in THF, MeOH or dioxane). This proved significantly more 
effective (with reaction complete after 30 minutes, forming the compound as the 
hydrochloride salt), although the use of strong acid was undesirable due to the 
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potential risk of undesired dehydration of the ribityl group. While this was not 
observed, the high risk of this led to examination of other deprotection strategies. 
 
As the use of oxygen-free conditions limited the availability of methods to perform 
the deprotection, an examination into the degradation of deprotected diamine 44 to 
dimethylbenzimidazole 44b was performed to assess to influence of atmospheric 
quantities of O2. Deprotected amine 44 previously formed under anhydrous 
conditions was stirred at RT in a continually-aerated aqueous solution, and formation 
of DMB 44b was indeed observed; however, this reaction was found to be particularly 
slow and ineffective (less than 10 % conversion to DMB 44b at 96 hours). Therefore, 
as the degradation of intermediate 44 was found to be very slow, the use of simplified 
deprotection conditions was possible. 
 
Principal among these was the use of 2 M aqueous HCl; using this reagent, it was 
possible to furnish a quantitative yield of deprotected amine 44 within two hours. 
Importantly, no formation of DMB 44b was observed, and so this reaction step was 
used for subsequent reactions. Lower concentrations (1 M, 0.5 M) of the acid were 
also successful at facilitating deprotection, requiring an increase in reaction duration. 
 
Purification of the product using this method was not performed, as product purity 
(assessed by NMR) was greater than 98 %. No justification for the previously described 
extraction (using Et2O) could be found, as the products from Boc-deprotection are CO2 
and isobutylene – both volatile gasses, readily removed by lyophilisation. Upon 
evaporation of the ethereal layer, nothing was isolated; thus extraction was 
unnecessary, and no longer performed. 
 
As discussed above, although the risk of oxidative degradation was found to be low, 
the subsequent coupling of intermediate 44 to diethyl-2-bromo-3-oxoglutarate 46 
was performed immediately in order to mitigate any possible degradation.  
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2.2.4 Formation of diethyl-2-bromo-3-oxoglutarate 46 
It was found that performing this reaction according to the original method of Carlson 
et al.5 was ineffective. As with reaction 3.2.3 above, no explicit mention of anhydrous 
conditions was made – although the reaction was reportedly performed under a 
stream of CO2. The reaction was initially performed as described, assuming anhydrous 
conditions, at 65° C.  
 
Mass Spectrometry data for the product of this reaction indicated that a significant 
proportion of both mono- and di- brominated products was formed, which were 
immediately identifiable due to the characteristic isotope pattern of bromine (79Br and 
81Br). The presence of di-brominated oxoglutarate 46c (figure 44) may have caused 
difficulties during subsequent reaction steps, which is discussed in further detail 
below. Evidence suggesting formation of the di-brominated species alongside the 
desired mono-brominated species was also found for the original reaction conditions 
at room temperature and at 0 °C; therefore, the use of elevated temperatures did not 
assist the formation of the desired product. 
 
 
Figure 44: Methods for the bromination of diethyl-3-oxoglutarate 45. The original 
method (above) led to formation of a mixture containing mono and dibrominated 
compounds, with a potential detrimental effect on subsequent reaction steps 
 
An alternative method to produce brominated product 46 reported the use of strict 
anhydrous conditions in dried dichloromethane at room temperature158. Bromine was 
used as the determinant reactant (a large excess was used previously5), added 
dropwise over 10 minutes. Using this procedure, it was possible to produce 
brominated product 46 effectively; an acidic vapour (believed to be HBr) was observed 
when the flask was opened to the air, and allowed to freely disperse before 
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subsequent purification. This was performed by FC using a short plug of silica, allowing 
fast and reliable isolation of mono-brominated compound 46 in high yield (assessed 
by NMR due to short product lifetime). The reaction was further improved by cooling 
the mixture to -78 °C, before allowing gradual warming (to RT) of the mixture after 45 
minutes. Using this method, no evidence of di-bromination was observed, allowing 
subsequent steps to be performed without the risk of undesired side-reactions. 
 
2.2.5 Coupling of diethyl-2-bromo-3-oxoglutarate 46 and deprotected aniline 44 
The efficient coupling of deprotected amine 44 and diethyl-2-bromo-3-oxoglutarate 
46 was crucial to the success of this synthesis, but had previously been particularly 
difficult to achieve. The reaction proceeds by attack of the deprotected amino group 
of 44 at the bromine-functionalised position of glutarate 46, which then undergoes 
intramolecular attack from the secondary (ribitylated) amine.  
  
Figure 45: Original method to produce intermediate 47 reported by Carlson and 
Kiessling5, using intermediate 44 and diethyl-2-bromo-3-oxo-glutarate 46 
 
When this reaction was performed using brominated glutarate 46 formed using the 
original synthetic method (which also produced the di-brominated species 46b), 
product 47 was obtained in poor yields (35 %). The presence of the dibrominated 
species allows several undesired reactions to occur, drastically affecting the formation 
of the intended product, and forming a number of difficult to separate side-products. 
However, when the reaction was repeated using purified bromoglutarate 46 formed 
by the improved technique described above (section 2.2.4) yields up to 55 % were 
obtained, in line with the original method5. 
 
Isolation of the final product 47 by extraction against an organic solvent was found to 
be particularly difficult due to the amphoteric nature of the product, facilitating 
 66 
 
formation of an emulsion. The use of alternative solvents for extraction (including 
Et2O, petroleum ether, CH2Cl2 or CHCl3) made little difference; this problem was 
eventually overcame by addition of large quantities of saturated NaCl solution to the 
mixture, which assisted phase separation. 
 
The effect of the base added to the reaction was examined using a range of 
alternatives, including several other carbonates (NaHCO3, Na2CO3, K2CO3 and Cs2CO3), 
hydroxylic bases (NaOH, KOH), and organic bases (pyridine, imidazole and DMAP). 
Cs2CO3 remained the most effective base, with neither of the hydroxylic bases, 
imidazole or DMAP facilitating product formation. The most likely reason for this is 
that each of these is a more effective nucleophile than the relatively weak aromatic 
amine, with the stable intermediate formed preventing progress of the reaction. 
 
Base Yield (%) 
Cs2CO3 55 
Cs2CO3 + DMAP (0.2 eq) 22 
K2CO3 34 
Na2CO3 14 
NaHCO3 11 
Pyridine 4 
Imidazole 0 
DMAP 0 
NaOH 0 
KOH 0 
Table 6: Yields obtained for the formation of 47 using alternative bases for the 
reaction between deprotected aniline 44 and diethyl-2-bromo-3-oxoglutarate 46 
 
While DMAP alone was ineffective for this reaction, it was also used alongside Cs2CO3 
to assess any phase-transfer effect124–126 between the immiscible solvent layers (DMF 
and CH2Cl2). Even in low concentrations (0.2 equivalents), the reaction yield was 
reduced to 22 %, from 55 % previously, demonstrating that this was not suitable for 
phase transfer. As each of the reactants appeared to reside preferentially in the 
separate solvent layers (44 in DMF; 46 in CH2Cl2), the use of a solvent combination 
which allowed greater mixing was sought. 
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It was found that deprotected compound 44 was soluble in several polar solvents 
(DMF, H2O, MeOH), while it was almost completely insoluble in dichloromethane or 
other organic solvents. Conversely, diethyl-2-bromo-3-oxoglutarate 46 was soluble in 
several organic solvents, but insoluble in polar solvents. A survey of numerous 
combinations of these solvents was performed, described in table 7 (below). It was 
found that an equivolume mixture of MeOH and dichloromethane was optimal, 
allowing isolation of compound 47 in 77 % yield; a significant improvement over the 
previous reported yield of 55 %. This is attributed to the slight miscibility of the two 
solvents, allowing improved contact between the two reactants and facilitating 
improved yields of product 47.  
 
Organic 
Solvent 
Secondary 
Solvent 
Yield (%) 
CH2Cl2 DMF 55 
CH2Cl2 MeOH 77 
CH2Cl2 EtOH 44 
CH2Cl2 H2O 8 
CH2Cl2 DMSO 0 
CH2Cl2 Hexane 0 
CHCl3 MeOH 65 
CHCl3 DMF 39 
Et2O MeOH 16 
Et2O H2O 11 
Table 7: Solvent mixtures used to examine the coupling of deprotected ribitylated 
aniline 44 and diethyl-2-bromo-3-oxoglutarate 46. All reactions were carried out as 
described in section 6.2.5.2, using 250 mg (925 µM) of the determinant reactant. All 
solvents were used in equivolume ratios; the mixture of CH2Cl2 and hexane did not 
allow dissolution of starting materials, and was performed as a suspension. 
 
2.2.6 Ring closure of bicyclic intermediate 47, forming 1-deazariboflavin 48 
This reaction was performed to close the isoalloxazine moiety of the flavin analogue 
at the 3- position, using NH3 dissolved in MeOH. As the reaction required the 
formation of two amide bonds, it was expected to be particularly slow and ineffective, 
 68 
 
with the method reported by Carlson and Kiessling reporting a yield of 33 % for their 
small-scale reaction (56 µmol of the starting material)5. 
 
While the initial bond formation using the original method was expected to be 
ineffective (vide infra), once one amide had been formed, the second (intramolecular) 
reaction to close the ring would be expected to occur much more readily. This is likely 
due to a much greater effective concentration of the amine, and is supported by 
evidence from other syntheses which report that intramolecular formation of amides 
is particularly favoured (with some reactions proceeding spontaneously159) when 
formation of a cyclic product occurs140.  
 
The creation of an amide bond is typically a difficult reaction to perform by synthetic 
chemistry approaches. Low reactivity between the reactant carbonyl and amine 
groups prevents reaction even under reasonably harsh conditions, which is ordinarily 
overcome by either (or both) the use of coupling agents to assist the reaction, or the 
use of reactants with significantly higher reactivity (such as an acyl chloride in place of 
a carboxylic acid)140,160. In biological systems, several enzymes exist to assist and 
promote amide formation (for instance during protein biosynthesis), which utilise 
carbonyl group activation to promote reaction.  
 
Intermediate 47 contains two ethyl esters; upon amide formation, the ethanolate 
group of these is replaced by an amine. However, this leaving group is relatively poor 
compared to other functionalities; for amide formation, alkyl esters generally “cannot 
be considered as activated species” (stated by Montalbettli and Falque140). Of the few 
reliable conditions found in the literature to both remove the ester and facilitate 
effective amide formation, the use of Lewis Acid (TiCl4) catalysis161 allow both 
reactions to occur in a limited number of cases.  
 
Based on the poor potential for this reaction, in concert with the previously reported 
low yields5, it was suspected that in this case the reaction would remain ineffective. 
Therefore, the potential use of coupling agents was explored for utilisation if required. 
The formation of amide bonds (as peptides) in Solid-phase Peptide Synthesis (SPPS) 
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utilises coupling agents to allow reaction between a carboxylic acid and an amine of 
two amino acids, which undergo sequential reaction (with functionality protected by 
various protecting groups) with other amino acids to form peptides. These reactions 
are ordinarily performed using mild reaction conditions (so as not to interfere with 
side-groups or structural features), and so the use of a coupling agent such as HATU162 
is required to catalyse the reaction, giving efficient reactions at room temperature 
(even with sterically-hindered reagents)140.  
 
 
Figure 46: HATU structure, supplied as a salt (typically PF6). This reagent allows the 
formation of a reactive ester with a (deprotonated) carboxylic acid, acting as a good 
leaving group and thus enabling attack of an amine to form an amide bond 
 
While the use of a coupling agent such as HATU may have enhanced the formation of 
1-deazariboflavin 48, a potential problem was the presence of two ethyl esters in 
compound 47. If each was to react to form the relevant amide, the isoalloxazine 
moiety would remain unclosed at position 3 (77, fig. 47). Ring closure would be 
unlikely to occur spontaneously, due to the high stability of the newly-formed amide 
bonds; although this method may allow formation of 1-deaza- (or other-
functionalised) riboflavin analogues with an enlarged uracil moiety, such as compound 
78 suggested in figure 47. 
 
 
Figure 47: The use of a coupling agent to enhance formation of 48 may lead to the 
formation of diamide 77, which (due to the stability of the newly-formed amide 
bonds) may not close at the 3- position to form 1-deazariboflavin 48. However, this 
may instead allow the formation of ring-expanded isoalloxazine analogues by 
bridging the two amides, e.g. product 78. 
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It was found experimentally that it was possible to form 1-deazariboflavin 48 using the 
original reaction conditions, with extended reaction times (72 hours, vs. 48 previously) 
furnishing 1-deazariboflavin 48 in yields up to 51 %. While already a significant 
improvement over previous reported yield, observations made during the course of 
the reaction indicated that further improvement may be possible. 
 
 
Figure 48: Optimal reaction conditions for the formation of 1-deazariboflavin 48 
 
Originally, gaseous ammonia was dissolved in MeOH at -5 °C. However, it was found 
during formation of 1-deazariboflavin 48 that a significant proportion of the ammonia 
swiftly evaporated from the mixture, leaving little remaining by the end of the 
reaction. Instead, addition of further portions of solvent saturated with ammonia 
through the course of reaction improved 1-deazariboflavin yields up to 63 %, 
suggesting that concentration of ammonia may play a key part in the success of the 
reaction. The use of a dry ice / acetone bath (-78 °C) to reduce the temperature of the 
methanol further during dissolution of ammonia allowed condensation of the vapours 
(ammonia boils at -33 °C). A 1:1 ratio of ammonia in methanol was found to be 
possible, and as the mixture was gently warmed to RT, no significant immediate 
evaporation was observed. Naturally this did occur over time, and was replaced by 
addition of a further aliquot of solvent after 36 hours of reaction. In this manner, 
formation of 1-deazariboflavin 48 in yields up to 92 % was possible; a vast 
improvement over 33 % previously reported5.  
 
2.2.7  Conclusion – Synthesis of 1-deazariboflavin 
The successful formation of 1-deazariboflavin 48 was performed, with an overall yield 
of 61.3%. This is far superior to other syntheses (11.0 % 5; 21 % 100), and was possible 
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due to the exhaustive study of each reaction, allowing significant optimisation, with 
two exceptional improvements identified. 
 
Future work which may be performed based on these results is the examination of the 
final ring-closure reaction using several alternative nucleophiles in place of ammonia, 
such as alkyl- or other functionalised amines. If successful, this would allow the 
construction of a library of 1-deaza-3(N-functionalised)-flavin analogues, which may 
be of significant interest.  
 
 
Figure 49: Potential derivatives of 1-deazariboflavin with substituted N(3) positions, 
formed using N-functionalised reagents 
 
2.3 Synthesis of 8-demethyl-5-deazariboflavin 
This analogue was synthesised using the same route described for 5-deazariboflavin 
above, using 4-methylaniline 49 (commonly referred to as p-toluidine) as the initial 
reactant in place of 3,4-dimethylaniline 31. This had an interesting effect on several 
reaction steps, providing further evidence that the poor nucleophilicity of the 
aromatic amine of the anilines is largely responsible for the low yields observed. 
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Figure 50: Overall synthetic route to 8-demethyl-5–deazariboflavin 54 
 
2.3.1 Reductive amination of 4-methylaniline 49 
This step was performed using the optimal conditions found during the similar 
reaction described in section 2.1.1. However, the yield for this reaction using the same 
method was 72 %; a slight (7 %) enhancement over the analogous reaction using 
3,4-dimethylaniline 31.  
 
 
Figure 51: Comparison in reductive amination of 4-methylaniline 49 and 
3,4-dimethylaniline 31 indicated the influence of the meta methyl group of 31 
reduces the yield of the reaction 
 
This result was expected, due to the effect of the methyl substituents of the aromatic 
ring affecting the nucleophilicity of the amino group of the aniline. For 
3,4-dimethylaniline 31, the methyl substituents are meta and para with respect to the 
reactive amine, whereas 4-methylaniline 49 only contains the para methyl group. As 
alkyl substituents of aromatic systems behave as electron donors, their presence 
activates positions of the aromatic ring which are ortho and para to themselves, 
making these positions more nucleophilic. On the other hand, meta positions are 
deactivated by this effect.  
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Figure 52: Schematic representation of the donating effect of an alkyl group (R) on 
benzene. Two resonance forms are possible, allowing localisation of electron density 
at positions ortho or para with respect to the donating group, and thus increasing the 
electron density available to a substituent (R’) at these positions. Furthermore, 
positions meta to the donating group obtain a partial positive charge, reducing the 
nucleophilicity of substituents at these positions 
 
For 3,4-dimethylaniline 31 the methyl groups present at positions meta and para with 
respect to the amino group leads to a conflict between activation and deactivation 
effects. While the methyl group at position 3 (meta) is deactivating to the amine, the 
methyl at position 4 (para) is activating. However, 4-methylaniline 49 contains only a 
para-methyl group, which confers the activating effect of the (electron donating) 
methyl group without the meta-deactivating effect; the nucleophilicity of the amine 
of 4-methylaniline 49 is thus slightly increased compared to 3,4-dimethylaniline 31, 
allowing an improved yield for the reductive amination. 
 
This may be further tested in future work using several aromatic molecules with 
substituents at alternative positions with respect to the reactive amine, such as 
2-methylaniline, 3-methylaniline or phenylamine. If the above hypothesis is true, it 
would be expected that in each case a reduced yield of the ribitylated product would 
be obtained.  
 
2.3.2  Coupling of ribitylated aniline 50 and 6-chlorouracil 35 
As with the ribitylation described above, this reaction was performed using the 
optimal conditions found previously, in refluxing anhydrous MeOH (section 6.1.3.1; 
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discussed in section 2.1.3). 6-chlorouracil 35 used for this reaction was formed using 
the optimal conditions found previously, and isolated using the novel organic 
extraction method described in section 6.1.2.3.  
 
 
Figure 53: Overview of the coupling of 4-methyl(N-ribityl)-aniline 50 and 6-
chlorouracil 35 
 
This reaction proceeded in a very similar manner to the analogous reaction performed 
earlier, with formation of a fluorescent product (under irradiation at 365 nm), and 
completion identified by TLC at a similar reaction time. As before, bicyclic product 51 
from this reaction was used without isolation or purification, as the amphoteric nature 
of the product caused considerable difficulty with purification by methods including 
organic / aqueous extraction and FC. As the subsequent step (protection of the ribityl 
functionality using acetyl protecting groups) reduced this effect, reliable purification 
was performed at that stage, allowing accurate assessment of the reaction yield over 
two steps. 
 
2.3.3 Protection of ribityl side-chain of intermediate 51 
The acetylation of intermediate product 51 was performed using a mixture of pyridine 
and dichloromethane, as described in section 2.1.4.2. However, a slightly greater 
excess of acetic anhydride was used (1.5 equiv. per hydroxyl group; 1.25 equiv. 
previously), to prophylactically ensure complete protection of the ribityl side-chain 
even in the case of acetylation of the uracil moiety (as had been previously observed). 
Although this additional acetylation would originally have been considered a problem 
(due to the notorious stability of acetamides), previous results (section 6.1.5) 
demonstrated that this would not affect the outcome of the subsequent ring closure, 
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and that it was possible to remove unwanted acetylation at the same time as 
deprotection of the ribityl chain (section 6.1.6).  
 
 
Figure 54: Acetylation of the ribityl side-chain of 51 using acetic anhydride 
 
The spectroscopic data for this reaction clearly showed no undesired additional 
acetylation of the uracil moiety, and so the yield of product 52 obtained after 
purification was 79 % (over two steps). This is a significant improvement over that 
obtained from the analogous reactions performed using 3,4-dimethyl-N(ribityl)-
aniline 33, which gave a yield of 55 %. As both reactions were performed ceteris 
paribus (with scale adjusted proportionally), this difference in yield is again likely to 
be due to the effect of the methyl substituents of the N(ribityl)anilines on the 
nucleophilicity of the reactive amine.  
 
2.3.4 Formation of 8-demethyl-5-deaza-(tetraacetyl)riboflavin 53 
The use of the Vilsmeier-Haack method was again used to close the central ring of the 
isoalloxazine analogue, using a mixture of POCl3 and DMF to first formylate 
intermediate 52, which underwent an intramolecular reaction to close the central ring 
of the flavin analogue. As discussed in section 2.1.5 above, the position of formylation 
is a source of debate within the literature; isolation or further study of the formylated 
intermediate species was not deemed to be possible due to a potentially transient 
existence (due to the reactivity of this group), and the hazards associated with POCl3 
necessitating neutralisation of this before chromatographic separation and analysis. 
Alternatively, formylation of the xylidine or uracil moieties prior to coupling may assist 
the understanding of this reaction (as a similar protected formylated intermediate was 
utilised during earlier syntheses of 5-deazariboflavin111,112); this is discussed alongside 
other potential future work in chapter 7.1.3.  
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The yield for this reaction was found to be 87 %, which is a significant improvement 
over the yield of 72 % obtained when using bicyclic intermediate 37 (fig. 55). This 
provides evidence to assist the understanding of the formylation reaction, discussed 
below. 
 
 
Figure 55: Ring closure of the isoalloxazine moiety of the 5-deazaflavin compounds. 
“R” denotes a D-ribityl(tetraacetate) group 
 
As discussed for several reactions above, the relative arrangement of the methyl 
substituents of 3,4-dimethylaniline appear to play a significant role on the outcome of 
the reactions during this synthesis. While generally appearing to be detrimental to 
other steps of the reaction, one benefit of the 3-methyl group of intermediate 37 is 
that with respect to the desired position of formylation (position 6 of the aromatic 
ring), it is para, and thus activating. The increase in electron density at this position 
would be expected to assist reaction at this position with the formylation agent (or 
formylated intermediate), and may be key to ensuring the correct relative 
arrangement of the methyl groups in the isoalloxazine structure of 5-deazariboflavin, 
discussed in section 2.1.5.3.  
 
In the case of the reaction performed to produce 8-demethyl-5-deaza-riboflavin, no 
group is present on the xylidine ring to direct formylation. If formylation of the 
aromatic moiety does occur (as opposed to the uracil moiety, vide supra), this may 
take place at either position 2 or position 3 of the symmetrical aniline. Attack by 
position 2 would lead to the desired product, while position 3 would lead to formation 
of an alternative undesired product. As the lone methyl group present (which is ortho-
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, para- activating) would be expected to favour attack by position 3 of the aromatic 
ring to react with the formylating agent, this would lead to a low yield of the target 
compound. 
 
 
Figure 56: Two structural isomers for the formylation of bicyclic intermediate 52 at 
the xylidine ring exist; only 52a will lead to the formation of 8-demethyl-5-
deazariboflavin 54. Without the directing effect previously present when using the 
analogous compound 37 (vide supra), 52b would be expected to predominate if 
formylation of the xylidine moiety occurred (rather than formylation of the uracil) 
  
As demonstrated by the spectroscopic data, the target isoalloxazine analogue 53 was 
indeed formed by this reaction. This result therefore implies that the formylation 
stage of the reaction initially takes place at the uracil ring, before ring closure via an 
intramolecular attack. While uncommon, some sources do report the formylation of 
non-aromatic alkenes using the Vilsmeier-Haack reagents, particularly when activated 
by neighbouring electron donating groups147–149 (discussed in depth in section 2.1.5). 
Thus, the early results of Yoneda et al.111 appear to be accurate, and potentially 
applicable to future syntheses of 5-deazaflavins. 
 
Furthermore, one of the greatest enhancements to the method used to isolate 
5-deazariboflavin tetraacetate 38 was the augmentation of spontaneously-
precipitated product with further product isolated from the solution. This method was 
adopted for the 8-demethyl compound 54, which was isolated using organic 
extraction before separation from starting materials and other contaminants by FC.  
 
2.3.5 Formation of 8-demethyl-5-deazariboflavin 54 
The deprotection of the acetylated intermediate 53 to form 8-demethyl-5-
deazariboflavin 54 was performed using the same solvent mixture (NH3 in MeOH) as 
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before. Again, extra care was taken to exclude light from the sample, due to the 
potential for flavin to be degraded under basic conditions when exposed to light. 
 
As with the analogous reaction (section 2.1.6), this reaction proceeded quickly and 
efficiently at room temperature, with a typical reaction time of 6 hours furnishing the 
target compound in 58 % yield. This is in comparison to a yield of 63 % obtained during 
the synthesis of 5-deazariboflavin 39, although it may be possible to improve slightly 
upon this, bringing the yield of 54 more closely in line with that of 39. 
 
2.3.6 Conclusions – Synthesis of 8-demethyl-5-deazariboflavin 
The total synthesis of the novel riboflavin analogue 8-demethyl-5-deazariboflavin has 
been reported, based upon the thoroughly-studied synthesis of 5-deazariboflavin. The 
target compound was successfully synthesised in 28.7 % yield overall, which is 
significantly greater than that obtained using the optimal method to form 
5-deazariboflavin (16.2 %), using the same synthetic route and reaction conditions. 
This direct comparison of the syntheses provides evidence that the methyl groups of 
3,4-dimethylaniline 31 play a key role in the nucleophilicity of the reactive amine 
during several stages of the synthesis of 5-deazariboflavin. The initial reaction steps 
(described in sections 2.3.1 and 2.3.2) were both significantly improved using 
4-methylaniline 49, indicating that the meta-methyl group (with respect to the amine) 
plays a direct role in reduction of reaction yield. To further support this conclusion, it 
would be interesting to repeat the synthesis using 3-methylaniline and 3,5-dimethyl-
aniline, in order to provide further evidence of this effect. 
 
2.4 Attempted formation of multiple riboflavin analogues using a 
single synthetic method 
2.4.0 Introduction 
In this section, a potential route for the synthesis of four riboflavin analogues 
(1-deazariboflavin, 1,5-dideazariboflavin, 3-deazariboflavin and 3,5-dideazariboflavin) 
is described. This was attempted (unfortunately without success), to devise a novel 
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route to these four analogues using minor adjustments to reactions previously 
examined during the synthesis of 5-deazariboflavin.  
 
Two reactions crucial for the success of this method were the synthesis of pyridine-
based analogues of uracil, and their efficient coupling to 3,4-dimethyl-N(ribityl)-
aniline 33. As formation of these pyridine compounds was expected to produce two 
structural isomers (58a and 58b, fig. 57) from the same starting material, it was 
anticipated that this would enable formation of the four riboflavin analogues with 
little wastage. As 1-deazariboflavin had been synthesised earlier (5.2), it was intended 
to use for direct comparison of the effectiveness between both two routes. 
 
Numerous methods were attempted (including the use of several alternative 
functionalized uracil analogues, and the use of adjusted reaction conditions) to furnish 
the products; however in all cases the key coupling reaction was a failure, preventing 
examination of later synthetic steps. Although this method therefore proved 
unsuccessful, the results obtained are reported in order to provide a foundation for 
future work into the formation of these four riboflavin analogues, where it may be of 
significant use to others.  
 
Reactions A and D of figure 57 (below) describe the coupling between the uracil 
analogues and ribitylated aniline 33. Upon formation of the bicyclic intermediates, 
two methods are available to close the central ring of the isoalloxazine: (i) using the 
Vilsmeier-Haack method (successfully used to form 5-deazariboflavin and 8-demethyl-
5-deazariboflavin) via reactions C and F; or (ii) using NaNO2 (previously reported by 
Yoneda et al. during their study of isoalloxazine formation107,108) via reactions B and E. 
Therefore, from the two intermediates 82 and 85, four riboflavin analogues may be 
produced. 
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Figure 57: Proposed synthetic route to four riboflavin analogues (3-deazariboflavin 
83, 3,5-dideazariboflavin 84, 1-deazariboflavin 48 and 1,5-dideazariboflavin 86) from 
two pyridine-based analogues (58a and 58b) of uracil.  
 
2.4.1  Reaction overview 
The crucial reaction for the success of this method was the coupling between the 
functionalised uracil analogue and the ribitylated analogue. As conditions for the 
successful analogous coupling between 3,4-dimethyl-N(ribityl)-aniline 33 and 
6-chlorouracil 35 had been found previously (section 2.1.3), this method was used as 
the basis for the novel reactions.  
 
As described above, experimental results suggests that the primary reason for the 
moderate yield obtained during the original reaction (55 %, including subsequent 
acetylation) was the low reactivity of the ribitylated amine, lowered further by the 
presence of a methyl group meta to this position. When 4-methyl-N(ribityl)-aniline 50 
(section 2.3.2) was utilised for the coupling with 6-chlorouracil 35, the yield improved 
to 79 % (including acetylation); while 4-methyl-N(ribityl)-aniline 50 was clearly more 
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successful at furnishing the desired product, its use in the novel synthetic route under 
consideration (fig. 57) would lead to the formation of 8-demethyl- flavin analogues. 
Although the potential formation of a suite of novel 8-demethyl-X-deaza- (or 
8-demethyl-X,Y-dideaza-) flavin compounds was particularly interesting, these were 
less desirable for the initial evaluation of the synthetic route, as the spectroscopic 
characteristics of the products are unknown. It was therefore decided that 
3,4-dimethyl-N(ribityl)-aniline 33 would be sufficiently reactive to give an initial 
representation of whether the proposed synthetic method would be successful, and 
which could be performed using alternative regents if desired. 
 
2.4.2 Formation of 2,4,6-trichloropyrimidine 57 
As each of the desired products lacked a nitrogen atom within the uracil moiety of the 
isoalloxazine structure, the uracil analogues necessary were derived from single-
nitrogen heterocyclic compounds (pyridines or piperidines). In order to closely follow 
the well-studied previous synthesis of 6-chlorouracil 35 from 2,4,6-trichloropyrimidine 
34, 2,4,6-trichloropyridine 57 was required for the initial reactions, which was 
synthesised in good yield (78 % over two steps) from the inexpensive starting material 
2,6-dichloropyridine 55.  
 
 
Figure 58: Formation of 2,4,6-trichloropyridine 57 proposed by Kaneko et al.163 
 
Following the method devised by Kaneko et al.163, synthesis of 2,4,6-trichloropyridine 
57 entailed initial activation of the 2,6-dichloropyridine 55 via formation of an N-oxide 
intermediate 56 using hydrogen peroxide in TFA, before chlorination of the 
intermediate using refluxing POCl3 to furnish product 57. Each reaction was swift and 
efficient, with simple purification; although FC was originally performed, due to the 
crystalline nature of all products it was possible to successfully purify these using 
recrystallisation. 
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This sequence of reactions was necessary, as it was found that direct treatment of 
2,6-dichloropyridine 55 using the chlorinating agent without prior activation failed to 
produce the desired product (section 6.4.1.3). The formation of the N-oxide permits 
chlorination of the pyridine ring by selectively reducing the electron density of the 
pyridine. As a dative bond is formed between nitrogen oxygen to form the oxide, 
electron density is withdrawn from the aromatic system at positions ortho and para 
to the nitrogen. As both ortho positions (2 and 6) are already occupied by chlorine, the 
para position is the only possible site for chlorination, leading to the single isomer 
product 57 obtained in very high yield. Similar N-oxide activation of pyridines prior to 
halogenation has been reported elsewhere164–166 with an interesting adjunct; the 
converse reaction (chlorination of 4-substituted pyridines, such as 4-methylpyridine, 
at the ortho position) is also only possible using the analogous N-oxide 
intermediate166. 
 
An alternative route to prepare 2,4,6-trichloropyridine 57 was devised by Schlosser et 
al.167. 2,6-dichloropyridine 55 was treated with n-butyllithium at -75 °C and iodine to 
form 2,6-dichloro-4-iodopyridine 87 (figure 59) in 64 % yield. The moderate yield was 
attributed to the undesired formation of the alternative 3-iodo product in place of the 
4-iodo compound, in a relative ratio of 5:2. The iodine group of intermediate 87 was 
subsequently replaced by chlorine using a mixture of isobutylmagnesium chloride and 
N-chlorosuccinimide, forming 2,4,6-trichloropyridine 57. 
 
 
Figure 59: Alternative synthetic route to 57 devised by Schlosser et al.167. Formation 
of 4-iodo-2,6-dichloropyridine 87 was hampered by the undesired formation of 3-iodo 
isomer 88 
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The choice of butyllithium by Schlosser et al.167 to perform the lithium-halogen 
exchange is interesting, as the reaction of pyridine 55 with n-butyllithium would be 
expected to form a number of intermediates leading to several undesired products. 
For unsubstituted pyridine, although the relative acidity of the proton position ortho 
to the nitrogen atom is the weakest of the three proton positions, the potential for 
coordination of lithium by nitrogen favours lithiation at this position. However, as both 
ortho positions of 2,6-dichloropyridine are already substituted, attack must occur at 
either of the remaining positions (meta or para). These are favoured either kinetically 
or thermodynamically (respectively)168, with relative proportions of each product 
controlled by the reaction conditions; this was observed by Schlosser et al.167, with a 
slight excess of the para- species formed (in a ratio of 5:2).  
 
However, as the method of Schlosser et al. was much less efficient overall than the 
method of Kaneko et al. (60 %, compared to 78 % (respectively), from starting material 
55), and may have formed undesired 3-substiuted side-products, the method of 
Kaneko et al. was used to form 2,4,6-trichloropyridine 57.  
 
2.4.3 Attempted conversion of 2,4,6-trichloropyridine 57 to 58a and 58b 
The formation of 6-chlorouracil 35 from 2,4,6-trichloropyrimidine 34 described earlier 
(section 2.1.2) used a high concentration of hydroxylic base to facilitate hydrolysis of 
the pyrimidine ring, forming 6-chlorouracil 35 in yields up to 81 %. Chlorination served 
to activation the pyrimidine for attack by hydroxide, with the remaining chlorine being 
used to direct formation of the desired bicyclic product 36 upon reaction with 
3,4--dimethyl-N(ribityl)-aniline 33. Overreaction (hydrolysis of all three chlorine 
groups) was not observed under any condition examined, or with unrealistically 
extended reaction times (up to 120 hours). 
 
The most successful conditions for production of 6-chlorouracil 35 (5M NaOH, 48 
hours at reflux) were found to be unsuccessful at furnishing the desired products 58a 
and 58b when applied to 2,4,6-trichloropyridine 57. Instead, a large proportion of 
unreacted 57 was recovered (66 %), along with an unidentified white crystalline solid 
(138 mg, 31 % based on later MS evidence, vide infra). While it was originally hoped 
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that this would be one (or a mixture) of the intended products, mass spectrometry 
presented an m/z value of 162.93. This strongly indicated a dichlorinated intermediate 
with the molecular formula C5H3Cl2NO (162.96), further supported by relative isotope 
patterns for 35Cl and 37Cl observed. However, even with reaction times up to 144 
hours, this remained the dominant product, with no mono-chlorinated product 
(determined by MS) obtained. 
 
 
Figure 60(a): Conditions previously used to form 6-chlorouracil from 2,4,6-
trichloropyrimidine were unsuccessful at furnishing either 58a or 58b 
 
 
Figure 60(b): Several possible structural isomers of C5H3Cl2NO (89a-e) exist, formed 
from 2,4,6-trichloropyridine 57 
 
The 1H NMR structure of the isolated solid (shown in figure 61 below) showed two 
aromatic resonances at 6.76 and 6.69 ppm, indicating two differing proton 
environments and therefore a lack of symmetry for the molecule. Relative intensity of 
each resonance suggested a single proton, which agrees with the structure for 
compound 89b. The splitting pattern of each proton signal (with coupling constants of 
1.6 Hz for both peaks), suggests relative meta potitioning of the protons, which is the 
conformation expected for the majority of possible structural isomers (89a-89e).  
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Figure 61: 1H NMR spectrum of the product from reaction 3.4.2, showing the relative 
positioning of the proton resonances. From the left, these are the solvent residual 
peak (CDCl3) at 7.26 ppm, a pair of doublets (6.76, 6.69 ppm; each 1H, with J = 1.6 
Hz), and a broad singlet (1.66 ppm, 1H; not shown). An expansion of the region 6.80-
6.60 ppm is provided, demonstrating a small coupling constants for each resonance 
 
As 89b was the only product formed by this reaction, even using vastly extended 
reaction times (144 hours), this method appeared unsuitable for formation of 58a or 
58b. When the reaction was repeated using 2,6-dichloropyridine 55 (section 6.4.3), no 
product was observed after 48 hours, with near-quantitative recovery of the starting 
material. Due to the failure of this reaction to produce the desired products, it was 
decided to abandon this method and instead investigate the synthesis of other 
nitrogen-based heterocycles.  
 
2.4.4  Formation of 2-chloro-4,6-dimethoxypyridine 
The conversion of 2,4,6-trichloropyridine 57 to the dimethoxy-derivatives 60 or 61 was 
performed using the method previously reported by Kaneko et al.163. The product 
again retained a single chlorine, which was intended to direct attack of 3,4-dimethyl-
N(ribityl)-aniline 33, for formation of the corresponding bicyclic intermediates (figure 
63, vide infra). However, a complication reported with this method was the formation 
of a secondary product, 4-chloro-2,6-dimethoxypyridine 61163 (a structural isomer of 
the intended product, fig. 62). The mixture of products 60 and 61 were found in 
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relative ratios of 7:3; no evidence of 2,4,6- trimethoxypyridine was found using these 
conditions.  
 
 
Figure 62: Formation of 2-chloro-4,6-dimethoxypyridine 60 and 4-chloro-2,6-
dimethoxy-pyridine 61 from 2,4,6-trichloropyridine 57, in a ratio of 7:3 (respectively) 
 
Interestingly, results described by Schlosser et al.167 report that reaction of sodium 
ethoxide with 2,4,6-trifluoropyridine under similar conditions to those used to form 
60 and 61 led to the regioselective formation of a single product, 4-ethoxy-2,6-
difluoropyridine. The use of an alternative nucleophile, dimethylamine, in reaction 
with both 2,4,6-trifluoropyridine and 2,4,6-trichloropyridine also reportedly led to the 
sole formation of the 4-dimethyl-2,6-dihalogen compounds167. This result is 
unexplained, and is at odds with the results reported by Kaneko et al.163 and confirmed 
during this work, which clearly demonstrate the successful formation of 
dimethoxypyridines 60 and 61, with no mono-methoxypyridine intermediate 
observed upon completion of the reaction. 
 
2.4.5  Attempted coupling between 3,4-dimethyl-N(ribityl)-aniline 33, and 
dimethoxypyridine compounds 60 or 61. 
The coupling between 3,4-dimethyl-N(ribityl)-aniline 33, and either 2-chloro-4,6-
dimethoxypyridine 60 or 4-chloro-2,6-dimethoxypyridine 61 as shown in figure 63 
below, was attempted in order to facilitate the formation of the bicyclic intermediates 
62 or 63. Removal of the methyl groups was to be performed later upon successful 
formation of the final riboflavin analogues, to prevent unintended reaction at these 
positions.  
 
Each of the three coupling methods examined previously for the formation of 36 
(section 2.1.3) were examined to facilitate these reactions, however none was able to 
permit product formation. In all cases, only unreacted starting materials were 
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recovered after reaction times significantly longer than necessary for the equivalent 
coupling using 6-chlorouracil 35, indicating that these reagents were not sufficiently 
reactive to allow product formation. 
 
 
Figure 63: Attempted reaction between 33 and 60 or 61, to give bicyclic 
intermediates 62 or 63. All conditions examined failed to give the desired products 
 
Failure to form either product 62 or 63 suggests that the nucleophile (3,4-dimethyl-
N(ribityl)-aniline 33) is not sufficiently reactive to attack reactants 60 or 61, which may 
be predicted based upon the aromaticity of compared to 6-chlorouracil 35. While 
pyridines typically contain less electron density throughout the aromatic ring 
compared to benzenes (due to the electrophilic nature of the nitrogen heteroatom), 
it is still a much greater density than for the non-aromatic uracil compound used 
previously, potentially preventing reaction with 3,4-dimethyl-N(ribityl)-aniline 33. 
 
Furthermore, the effect of conjugation possible with 6-chlorouracil 35 may also play a 
key role in this reaction. The carbonyl oxygens of uracil are able to act as an ‘electron 
sink’ (via enolate formation) upon nucleophilic attack, and thus stabilise the reactive 
intermediate; whereas no such facility is possible with intermediates 60 and 61 due to 
the methyl substituents. Thus, the uracil form is significantly more susceptible to 
nucleophilic attack than the aromatic methoxy-pyridines. 
 
As described in section 2.1.3.1, the malononitrile-catalysed reaction between 
3,4-dimethyl-N(ribityl)-aniline 33 and 6-chlorouracil 35 was expected to proceed via 
displacement of the chlorine of 6-chlorouracil 35 by malononitrile, before attack of 33 
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leading to formation of the bicyclic product. This was based upon the reported 
reaction of malononitrile with vinyl halides132, or with aryl halogens in a similar 
displacement-type reaction133,134 (fig. 64). 
 
 
Figure 64: Scheme for reaction between a substituted aryl bromide and 
malononitrile, described by Schnyder et al.133. “R” describes several aromatic 
substituents (electron withdrawing and donating) at various positions of the 
aromatic ring. The resultant aryl malononitriles were synthesised in yields up to 92 % 
 
However, while the reaction of malononitrile with vinyl halides or 6-chlorouracil 35 
proceeded without assistance132, the method of Schnyder et al.133 for displacement of 
aryl halogens described the use of Pd catalysis. This was not attempted, due to the 
risk of damage to the alcohol groups of the ribityl side-chain169–172.  
 
 
Figure 65: Intended formation of intermediates 62 and 63 via malononitrile 
displacement of chlorine from 60 or 61; formation of 62 and 63 was not observed 
 
As neither product 62 or 63 was formed by this reaction, it suggests that malononitrile 
90 was not able to form the activated intermediate species 60a or 61a (fig. 65). This 
was supported by spectroscopic examination of the products from the reaction, where 
both 60 and 61 were recovered in high yield. However, this route may be successful if 
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the incorporation of malononitrile 90 could be performed (with additional catalysis), 
and the activated intermediates isolated without degradation. These compounds may 
be more sensitive to attack by 3,4-dimethyl-N(ribityl)-aniline 33, potentially giving a 
viable route to 62 and 63. 
 
2.4.6  Formation of 2,4,6-piperidinetrione 66 
As two likely reasons for the failure of the reaction between 3,4-dimethyl-N(ribityl)-
aniline 33 and dimethoxychloropyridines 60 or 61 were the difficultly in nucleophilic 
attack (due to the high electron density of the aromatic ring), and the lack of a 
conjugate form for the bicyclic intermediate, the use of an unsaturated compound 
such as 2,4,6-piperidine trione 66 may have allowed successful formation of bicyclic 
products 67a or 67b (figure 66). As before, nucleophilic attack at either position α or 
γ to the nitrogen of the piperidine-trione would furnish two useful bicyclic 
compounds, potentially providing a method to form several riboflavin analogues. 
Therefore, the synthesis of 66 was performed, as shown in figure 67. 
 
 
Figure 66: Coupling between 3,4-dimethyl-N(ribityl)-aniline 33 and 2,4,6-piperidine 
trione 66 may have produced both bicyclic products 67a and 67b. However, no 
conditions were found to permit this reaction. “R” describes a D-ribityl group 
 
The formation of piperidine-trione 66 was described in great detail in work by 
Weinstock et al.106, alongside their reported synthesis of 1,5-dideazariboflavin 75. This 
was performed by cyclisation of diethyl-2-cyano-3-iminoglutarate 65 (referred to 
synonymously as ethyl-β-imino-α-cyanoglutarate in earlier literature), synthesised 
according to the procedure of Baron et al.173 via a bimolecular condensation of 
ethylcyanoacetate 64 in refluxing NaOEt (fig. 67). Cyclisation was achieved using 
relatively harsh conditions (refluxing 12 M HCl, followed by boiling in NaOH), 
furnishing the sodium salt of piperidine-trione 66 in a yield of 73 %.  
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Figure 67: Synthesis of 2,4,6-piperidine-trione 66, via ethyl-β-imino-α-cyanoglutarate 
65 formed from elthylcyanoacetate 64 
 
The formation of product 66 as the sodium salt was reported to be crucial to the 
stability, as the pure isolated compound appeared highly susceptible to oxidation by 
air174, and readily underwent intermolecular attack with other molecules to form a 
bimolecular compound which was reportedly inactive106; isolation of 66 as the sodium 
salt prevented this. 
 
2.4.7  Attempted coupling of ribitylated aniline 33 and piperidine trione 66 
The reported formation of 1,5-dideazariboflavin 75 devised by Weinstock et al.106 
using 2,4,6-piperidinetrione 66 was used as the basis for examination of an analogous 
route to intermediates 67a and 67b. The original method (summarised in figure 68) 
describes the use of a tosylated hydrazido-N(ribityl)-aniline analogue 73, with the tosyl 
hydrazide protecting the functionality of the aldehyde. This was necessary as at this 
time, the Vilsmeier-Haack method of formylation had not yet been applied to this 
synthesis. The protecting group was removed immediately prior to the reaction with 
2,4,6-piperidinetrione 66.  
 
Figure 68: Scheme for reported formation of 1,5-dideazarboflavin 75 from protected 
2-amino-N(ribityl)-4,5-dimethylbenzaldehyde 73106, which was deprotected in situ 
before addition of 2,4,6-piperidine trione 66; condensation furnished 1,5-didezaflavin  
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It was hoped that the use of 3,4-dimethyl-N(ribityl)-aniline 33 would react similarly to 
tosylated hydrazido-N(ribityl)-aniline analogue 73, with attack at either α or γ 
positions of 2,4,6-piperidinetrione 66 forming one (or both) of the bicyclic 
intermediates 67a or 67b described in figure 66 above. 
 
While 66 was previously isolated as the sodium salt, it was readily reconstituted in 
mildly acidic solution immediately prior to reaction106; the reaction between 73b and 
66 was also performed in acidified aqueous solution. However, aqueous solution was 
previously found during this research to be unsuitable (section 2.1.3.3) for reaction 
between 3,4-dimethyl-N(ribityl)-aniline 33 and 6-chlorouracil 35, and so when these 
conditions were applied to the reaction between 33 and 66 (which required a small 
proportion of methanol to aid dissolution of 33), again no reaction was observed. 
 
Figure 69: Attempted reaction between 33 and 66 as described by Weinstock et al.106 
for their formation of 1,5-dideazariboflavin 75 failed to furnish either 67a or 67b 
 
Several additional routes the form the bicyclic compounds were also examined, 
including the use of the previously successful solvent-free heating method, or 
performing the reaction in an anhydrous organic solvent, using a crown ether to 
allow dissolution of the salt of 66. However, each reaction again failed to produce 
the desired products. In all cases, starting materials (or degraded side-products) 
were isolated in near-quantitative yield.  
 
Figure 70: Alternative routes attempted to form 67a and 67b 
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This result was somewhat difficult to understand, due to the precedent for the similar 
reaction set by Weinstock et al.106 (figure 68). Furthermore, 2,4,6-piperidinetrione 66 
was expected to be significantly more susceptible to nucleophilic attack by 3,4-
dimethyl-N(ribityl)-aniline 33 than either of the dimethoxypyridine species discussed 
earlier (section 2.4.5). Thus, the lack of reaction between 33 and 66 indicates that this 
must be due to another reason, with the poor nucleophilicity of 33 initially suspected. 
However, while reactions performed using 4-methyl-N(ribityl)aniline 49 were 
generally significantly more efficient due to the enhanced nucleophilicity of the amine, 
even using this reagent it was not possible to facilitate coupling with 66. Therefore, 
while the low nucleophilicity of the aniline is undoubtedly some hindrance to the 
reaction, it is likely that an additional factor (or factors) are also to blame, and thus 
this reaction is therefore worthy of further study. The activation of 2,4,6-
piperidinetrione 66 (for example, via tosylation) may allow the reaction to proceed by 
providing an enhanced leaving group, potentially allow formation of the intermediate 
compounds 67a or 67b and leading to the riboflavin analogues described in fig. 57. 
 
2.4.8  Conclusion – attempted formation of multiple riboflavin analogues 
In this section, the formation of several heterocyclic molecules was discussed, for use 
as analogues of 6-chlorouracil 35. While these were typically produced in moderate 
yield, no enhancements to the reactions were sought, as their primary purpose was 
to test a novel synthetic pathway potentially leading to several riboflavin analogues. 
 
Reaction of these uracil analogues with 3,4-dimethyl-N(ribityl)-aniline 33 was 
intended to provide two bicyclic intermediates 67a and 67b, which may have each 
been used to prepare two analogues of riboflavin as described in section 2.4.0. 
However, no heterocycle was successfully coupled to 3,4-dimethyl-N(ribityl)-aniline 
33. While frustrating, useful information regarding conditions and outcomes was 
recovered for each reaction, which may allow future work in this area to proceed more 
rapidly. Key to this may be the reliable formation and functionalization of 2,4,6-
piperidinetrione 66 to assist coupling with 33, finally allowing successful formation of 
the bicyclic intermediates as a precursor for flavin analogue synthesis. 
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Chapter 3 - Results and Discussion - Molecular Biology 
3.0.1 Introduction 
In this chapter the results obtained within the field of Molecular Biology are reported 
and discussed. These results include detail of the expression and purification of a 
bifunctional (prokaryotic) riboflavin kinase-FAD synthetase from Corynebacterium 
ammoniagenes, and a monofunctional (eukaryotic) riboflavin kinase protein from 
Schizosaccharomyces pombe. The formation of the phosphorylated riboflavin 
analogues (FMN and FAD) by these enzymes is compared and discussed, as while FMN 
was the desired cofactor form for future studies, the FAD form was the predominant 
product of the bifunctional enzyme, thus requiring additional treatment before use. 
 
Additionally, the expression, purification and photo-reaction of the PHOT1-LOV2 
domain from Avena sativa is detailed. This domain has been studied using both the 
wild type protein, and a series of mutants in which the active cysteine residue (C450) 
was modified.  
 
Each AsLOV2 sample was studied containing their native cofactor (FMN), and 
reconstituted with both the 1-deaza-FMN and 5-deaza-FMN analogues, allowing 
collection of evidence to support the understanding of the LOV domain photocycle.  
 
3.1 C. ammoniagenes Bifunctional Rf Kinase – FAD-Synthetase  
3.1.1 Protein expression and purification 
This protein, first isolated by Hagihara et al.175,176, was expressed using the plasmid 
expression vector pMAL-C2, provided as a ready-to-use construct (prepared 
previously177) by the project supervisor. This vector allowed expression of the C. 
ammoniagenes enzyme as a fusion protein with an N-terminal maltose-binding (MB) 
domain, with a weight of approx. 66 kDa for the fusion protein (~28 kDa for the MB 
domain; 38 kDa for the RfK-FADS). The Ca-RfK-FADS gene was initially expressed in E. 
coli XL1-blue (see fig. 71 below) in moderate yield, although later expression in E. coli 
strain BL21 significantly improved protein yields.   
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The MB domain allowed isolation of the recombinant protein by affinity 
chromatography over amylose resin. Elution was performed using a maltose-
containing buffer, which competitively bound to the MB domain, releasing the protein 
from the resin. Due to the efficiency of the overexpression, several binding cycles were 
typically necessary, due to the limited capacity of the amylose resin. 
 
Each fraction of the flow-through from the column was scrutinised immediately using 
UV spectroscopy (280nm) and SDS-PAGE. When the column capacity had been 
reached, it was possible to visualise unbound protein passing through the column; 
those fractions found to contain residual protein were reserved and re-bound later. 
Protein fractions were dialysed into buffer RfK 3 (section 5.2.7) and concentrated by 
ultrafiltration over a 30 kDa membrane. The purified protein was found to be stable 
in solution at 4°C for 1 week, after which a loss of activity and precipitation was 
observed. Attempts were made to flash-freeze the protein before storage at -80°C, 
but the thawed protein exhibited a total loss of activity. 
 
 1 2 3     4 5 6 7 
 
 
Figure 71: SDS-PAGE Gel of recombinant C. ammoniagenes RfK-FADS. 
Lane 1 - molecular weight marker (SM0431); lane 2 - whole cell lysate; lanes 4 and 5 - 
flow-through from column (showing unbound protein, due to column capacity being 
reached); lanes 6 and 7 – purified bifunctional Ca-RfK-FADS protein (66 kDa) 
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3.1.2 Phosphorylation of riboflavin analogues using bifunctional RfK-FADS 
Phosphorylation of riboflavin (and the synthesised 5-deazariboflavin analogue) by the 
Corynebacterium ammoniagenes RfK-FADS produced a mixture of both FMN and FAD 
cofactor forms. This was expected, as this enzyme is used within the cell to regulate 
and maintain intracellular stores of both flavin cofactors78,79. However, while the FMN 
form was required for incorporation into the AsLOV2 domain, this appeared to be the 
minor product of the enzyme. An in-depth examination of this phosphorylation was 
therefore performed to determine the optimal to form the FMN analogue. 
 
During the course of the enzymatic reaction, it was determined (assayed using TLC) 
that upon initial formation of FMN, this compound rapidly underwent further reaction 
to form FAD. Thus, FMN concentration appeared to remain lower than FAD 
concentration throughout the reaction. As the reaction proceeded, the relative 
proportion of FAD increased while RF concentration decreased, eventually leading to 
a sample containing FAD as the predominant constituent. Upon consumption of all 
riboflavin (or deaza-analogue), the NT domain of the protein appeared to remain 
active for some time, catalysing the interconversion between FAD and FMN to reach 
an eventual equilibrium of the phosphorylated products. 
 
 
Figure 72: TLC of true riboflavin (green fluorescence; RF = 0.81) and 5-deaza-products 
from enzymatic reaction with Ca-RfK-FADS (blue fluorescence). 5-deazariboflavin (RF 
= 0.83), 5-deazaFMN (Rf = 0.70) and 5-deazaFAD (Rf = 0.16) were identified; 5-
deazaflavin bound by the enzyme is also observed (Rf = 0.0) 
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Due to the complex nature of the reaction, the rate of flavin turnover by this enzyme 
was not examined during this project. However, the kinetics reported by Efimov et 
al.73 for the reactions catalysed by Ca-RfK-FADS describe that for the conversion of 
riboflavin to FMN, a kcat of 0.41 ± 0.9 s-1 (with an indeterminate rate for the reverse 
reaction) is reached; for the interconversion of FMN to FAD, a kcat of 0.300 ± 0.023 s-1 
(with a slightly decreased kcat for the reverse reaction of 0.270 ± 0.023 s-1) is possible. 
These reported rates suggest a more rapid formation of FMN than FAD (as the rate of 
FMN to FAD conversion is lower than the rate of FMN formation from riboflavin, and 
is decreased further by the rate of the reverse reaction), rather than the 
experimentally observed greater titres of FAD than FMN. However, this difference 
may be explained by the presence of a large excess of ATP within the experimental 
reaction mixture, which would adversely affect the kinetics of several steps (according 
to Le Chatelier’s Principle) and thus increase the overall rate of FAD formation. 
 
3.1.3 Cofactor purification 
Preparative-scale purification of the phosphorylated deaza-analogues was somewhat 
difficult. Whilst it was possible to assay the reaction using TLC (silica stationary phase), 
the mobile phase (3:1:1 mixture of isopropanol, H2O and AcOH; respectively) 
necessary for adequate separation rendered this process unsuitable for purification 
on a preparative scale. The high polarity of the flavin cofactors (due to the 
incorporated phosphate or adenosine diphosphate groups) led to a strong interaction 
with the silica stationary phase using a less polar mobile phase. However, the use of 
“reversed phase” (i.e. hydrophobic-covered silica matrix) stationary phases was 
successfully used to separate the products of the enzymatic mixture on a preparative 
scale, using HPLC. Whereas before, the most polar component of the reaction mixture 
(FAD) was retained for the longest by the silica matrix (resulting in the lowest retention 
factor value, RF), reversed-phase chromatography allowed the more highly polar FAD 
to be eluted before less polar cofactor forms. 
 
HPLC was performed using similar methods to those previously described178,179, after 
removal of the enzyme by passing the mixture over an amylose column (and 
confirmed by SDS-PAGE). The conditions were adjusted to allow good separation of 
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the reaction components, with FAD, FMN and riboflavin forms eluting with retention 
times of 7.35-9.45 minutes, 20.05-20.90 minutes, and 28.70-29.70 minutes 
respectively, shown in figure 73. The peak area of the HPLC indicated formation of 
FAD, FMN and riboflavin in relative ratios of 25 : 1 : 3, respectively.  
 
Figure 73: HPLC trace of 5-deazaFAD formed by the Ca-RfK-FADS, observed at 400nm. 
Conditions and retention times are described fully in section 7.1.5 
 
After lyophilisation, product purity was very high, although a typical HPLC run only 
isolated between 0.5-1.5 mg of purified products. Therefore, repeated rounds of HPLC 
were necessary to isolate the compound in sufficient quantities for experimental use. 
 
3.1.4 Conversion of 5-deazaFAD to 5-deazaFMN 
As the FAD-cofactor form was isolated as the major enzymatic component, conversion 
to the FMN form was required for use in the AsLOV2 domain. Eukaryotic cells typically 
utilise an alkaline phosphatase, which strips the adenosenyl-monophosphate moiety 
from FAD to give FMN, and was successfully employed for isolation of 5-deazaFMN by 
a colleague during a short side-project (Dr. Hannah Collins, University of Kent), using 
commercially available Phosphodiesterase I from Crotalus atrox (Western 
Diamondback Rattlesnake).  
 
Hydrolysis of the phosphoanhydride was followed by UV-visible observation of the 
sample, with a blue-shift of approx. 5 nm for FMN compared to FAD, coupled to an 
increased absorbance (due to an increase in extinction coefficient88).  For FAD, the 
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adenine ring (held in close proximity to the flavin by the flexible ribityl chain) 
undergoes a degree of π-π stacking with isoalloxazine, which has a small effect on the 
electrochemistry and thus induces a spectral shift; cleavage of the AMP moiety 
removes this effect. Dephosphorylation was confirmed by HPLC and MS. 
 
 
Figure 74: UV-visible spectra showing dephosphorylation of 5-deazaFAD (left), and 
FAD (right), recorded by Dr. Hannah Collins (University of Kent) using 
Phosphodiesterase I from C. atrox. An approximate 5nm blue-shift in flavin 
absorbance (previously 404 nm or 445 nm respectively) indicated hydrolysis of the 
phosphoanhydride. Spectra were recorded at 10 min. intervals with reaction 
complete after 30 mins using 4 units of enzyme per flavin equivalent 
 
The use of large-scale enzymatic hydrolysis of the FAD cofactor analogues was 
considered, but discounted due to the discovery of alternative conditions to hydrolyse 
the phosphoanhydride bond. An acidified buffer (containing a strong acid, such as 
trichloroacetic acid (TClA) or trifluoroacetic acid (TFA)) had been previously reported 
to hydrolyse FAD to FMN within 1 hour180,181. This was successfully used to 
quantitatively hydrolyse 5-deazaFAD (within 1 hour, using 1 % (v/v) TFA), although 
subsequent purification by HPLC was again necessary to ensure isolation of the 
desired cofactor. 
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Figure 75: HPLC chromatographs of 5-deazaFAD, 5-deazaFMN and 5-deazariboflavin, 
observed at 400nm (above), and 5-deazaFMN formed by treatment of 5-deazaFAD 
with 1 % TFA (below). Conditions and retention times described in section 7.1.5 
 
Direct production of the FMN analogue by inactivation of the FADS domain of the 
bifunctional RfK-FADS was also considered. However, as only the key residues for 
catalysis within the riboflavin kinase domain have so far been reported182 (which are 
relatively easily determined due the homology between other prokaryotic and 
eukaryotic riboflavin kinases), this was deemed to be a divergence from the aim of 
this project, and was thus not attempted. 
 
3.1.5 Conclusion - bifunctional Ca-RfK-FADS  
Conditions were found for the successful expression and purification of the Ca-RfK-
FADS protein. However, several difficulties were encountered, associated with the 
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bifunctional nature of the enzyme (producing FAD as major product, rather than 
FMN). An effective method to hydrolyse the FAD produced to FMN was found; 
however the time-consuming purification procedures to isolate the desired cofactor 
analogue rendered this route inefficient. Thus, an alternative method was sought, to 
perform the phosphorylation of the riboflavin analogue to the FMN form more swiftly 
and effectively. 
 
3.2  S. pombe Riboflavin Kinase 
During a collaboration with Professor Martin Warren and Dr. Hannah Collins 
(University of Kent, Canterbury) on a side-project, I was gifted a plasmid construct 
containing the riboflavin kinase gene from Schizosaccharomyces pombe. This is a 
eukaryotic riboflavin kinase of 166 residues183, which had been inserted into a pET-
14b vector by Dr. Hannah Collins. The Sp-RfK protein catalyses the formation of FMN 
from riboflavin, and was successfully used with 1-deazariboflavin and 5-
deazariboflavin to produce the respective FMN analogues. 
 
3.2.1 Protein expression and purification 
Expression of a gene contained within the multiple cloning site (MCS) of pET-14b is 
controlled by a T7 promoter sequence, for which the E. coli expression strain BL21 is 
optimised, resulting in efficient transcription of the target gene. Immediately 
upstream of the MCS is a sequence for the expression of an N-terminal 6 x His 
polyhistidine tag, which is expressed as a fusion partner at the N-terminus of the 
target protein. The polyhistidine tag allowed convenient protein isolation (for 
purification, and removal after use) using an IMAC procedure. 
 
In order to maintain the plasmid, it was immediately transformed into E. Coli XL1-blue 
(for plasmid storage, with an efficiency of 1.20 x 105 transformants per µg DNA), and 
BL21(DE3) (for protein expression, with an efficiency of 4.81 x 104 transformants per 
µg DNA). Expression of the protein was performed with high yields in both LB and TB 
media, with the polyhistidine tag allowing separation of the target protein from the 
cell lysate using a high-throughput method over nickel-chelating resin (Sepharose Fast 
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Flow), discussed below. Enzyme concentration was estimated using an extinction 
coefficient (ε) value of 21,890 M-1 cm-1 at 280 nm (calculated using the ExPASy 
ProtParam tool184 using calculations defined elsewhere185).  
 
Swift purification of the expressed protein was performed using a column of Ni-
Sepharose Fast Flow resin. This resin is optimised for use in high-pressure systems 
(such as FPLC), and so it was possible to use a peristaltic pump to pass a large volume 
(50 mL) of filtered cell lysate over the column swiftly, without damaging the system. 
After binding and washing, retained protein was eluted from the column using a buffer 
containing a high concentration of imidazole, which competed with the histidine 
residues of the protein and weakened its interaction with the resin, causing elution. 
Fractions containing the desired protein were identified by SDS-PAGE, and 
concentrated (if required) by ultrafiltration, followed by dialysis or treatment using a 
desalting column to remove all traces of imidazole. 
 
 
Figure 76: SDS-PAGE of purified Sp-RfK (18.9 kDa), compared to gel marker SM0431 
 
3.2.2 Formation of 1-deaza and 5-deaza FMN using Sp-RfK  
It was found that the expressed S. pombe RfK (Sp-RfK) successfully phosphorylated 
riboflavin and the synthesised 1-deaza and 5-deaza analogues much more efficiently 
than the previous bifunctional Ca-RfK-FADS. When assayed by the original creator of 
the plasmid construct (Dr. Hannah Collins, University of Kent), it was found that 1 nmol 
of purified protein was able to turn over a minimum of 130 nmol of riboflavin within 
1 hour. No literature studies of this enzyme were available with which to compare this 
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result at the time of writing; however a similar result was observed for both 1-
deazariboflavin and 5-deazariboflavin (130 nm of the flavin analogue per nmol of Sp-
RfK was incubated in the presence of the enzyme and ATP; after 1 hour no riboflavin 
analogue remained, assayed by TLC).  
 
The purified Sp-RfK was found to be most active at 37 °C, and was stable to storage in 
solution at 4 °C for 7 days or to lyophilisation. The reconstituted enzyme from 
lyophilisation had only slight loss of activity, and in this case a turnover of 100 nmol 
per nmol of enzyme was assumed for the subsequent enzymatic step. For large-scale 
preparation of the deaza-FMN analogues, very high (> 99%) yields were obtained using 
only 1.2 equivalents of ATP, with reaction times under 4 hours. 
 
Removal of Sp-RfK from the mixture after completion of the reaction was 
straightforward, as the polyhistidine tag again allowed retention of the protein when 
the mixture was applied to a Ni-chelating resin. After protein removal, the solution 
was lyophilised and re-suspended in the minimum volume of water to allow 
purification by HPLC, as before. Alternative methods to isolate the purified product 
(such as “cofactor trapping” 186, based on in situ product removal (ISPR)187,188) were 
considered, but were deemed to have an unacceptably low specificity to be used 
without further intensive study. 
  
3.2.3 Conclusion – formation of FMN analogues using Sp-RfK  
The Sp-RfK gene (supplied by a collaborator, Dr. Hannah Collins, University of 
Canterbury), was expressed and purified in very high yield, and used to successfully 
phosphorylate the 1-deaza- and 5-deaza- analogues of riboflavin formed previously.  
Cofactor formation was successfully achieved using as little as 1 nmol of protein per 
130 nmol of riboflavin analogue, with 1.2 equivalents of ATP, rendering this enzyme 
significantly more efficient than the Ca-RfK-FADS described in section 3.1. Purity of the 
FMN analogue formed by this reaction was very high (greater than 99 % by HPLC). 
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3.3 AsLOV2 Sample Preparation 
3.3.1 Introduction to the AsLOV2 construct 
The Avena sativa PHOT1-LOV2 gene was previously incorporated into a modified 
pNCO113 vector by others prior to this work. Modification of the pNCO113 plasmid 
vector189 was first performed by Kay et al.4 by insertion of the gene encoding 
hisactophilin from Dictyostelium discoideum190 in the MCS of the plasmid, between 
EcoRI and BamHI restriction sites. The pNCO113-HISACT plasmid was further modified 
by Kay et al. to incorporate a thrombin cleavage site, followed by modification of 
cysteine 49 of hisactophilin to serine (pNCO113-HISACT(C49S)). Modification of 
hisactophilin was necessary to remove the only cysteine residue of the protein, 
ensuring that the results of future studies using AsLOV2 were due only to the effects 
of the conserved cysteine of the LOV domain. Finally, the Avena sativa PHOT1-LOV2 
gene was incorporated between BamHI and HindIII sites within the MCS of the 
modified vector by M. Fisher, to give the final plasmid pNCO113-HISACT(C49S)-
AsLOV21,4, which was provided by the project supervisor to enable further study of 
this flavoprotein.  
Figure 77: Schematic representation of the hisactophilin-AsLOV2 construct (not to 
scale). “T5 Pro, lacO” refers to the T5 promoter and lac operator, followed by “Rbs”, 
the ribosomal binding site. HISACT and AsLOV2 domains are linked by 6 residues 
 
Expression of this plasmid results in a fusion construct of hisactophilin and AsLOV2, 
comprising a total of 297 amino acids with a mass of 34.3 kDa; 133 residues for 
hisactophilin (15.5 kDa)190, the 6-residue linker sequence Leu-Val-Pro-Arg-Gly-Ser (0.6 
kDa), and 158 residues for AsLOV2 (18.2 kDa)4. This plasmid is subsequently referred 
to as “pNCO-AsLOV2”, and when expressed, the resulting fusion protein is referred to 
as AsLOV2 for brevity, as (in almost all of cases) the hisactophilin tag was retained (see 
section 3.3.3). In later sections, mutated variants of the wild-type protein are referred 
T5 Pro, lacO Rbs HISACT AsLOV2 
Thrombin, 
BamHI EcoRI HindIII 
5’ 3’ 
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to as AsLOV2(C450X), where X corresponds to an amino acid substituted for the 
original reactive cysteine. 
 
As previously described in section 1.1, the LOV2 domain of A. sativa undergoes a 
conformational change upon irradiation with blue light (440 - 450 nm). The 
absorbance of this wavelength by the flavin chromophore stimulates bond formation 
between the cofactor and a neighbouring cysteine residue within the active site of the 
protein. This may be conveniently observed photometrically, as the photoadduct lacks 
the flavin absorbance at 445 nm, although this spontaneously recovers upon cessation 
of irradiation. Covalent bond formation initiates the physical undocking of an α-helix 
(known as the J-α helix) from the central protein β-sheet, which allows activation of 
the coupled protein kinase in the full-length phototropin.  
Figure 78: Two views of the dark-state crystal structure of the AsLOV2 domain, from 
Protein DataBank sequence 2V0U48. The J-α helix is highlighted in purple; FMN 
(orange) is located within the central binding site of the domain, in close proximity to 
the sulphur atom (gold) of the reactive cysteine residue 
 
As recombinant protein expression terminates at the C-terminus of the J-α helix, 
irradiation of the sample causes this helix to become free within solution, leading to a 
corresponding decrease in α-helicity upon successful photoadduct formation. Thus, 
the photochemical and physical effects of the LOV2 domain’s reaction with flavin may 
be measured using UV-visible and CD spectroscopy; both are convenient, fast and non-
destructive methods, which do not affect the protein sample under analysis. 
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3.3.2 Expression strain selection 
Prior to use, the pNCO-AsLOV2 construct was sequenced, including regulatory regions. 
For initial protein expression, the plasmid was transformed into E. coli strain 
BL21(DE3) cells, although (as fully described in section 3.3.5) expression of  
AsLOV2(WT) using this strain was found to be unreliable (AsLOV2(C450X) mutants 
were also not reliably expressed in this strain). While several approaches were taken 
to understand and address this problem (vide infra), the use of alternative E. coli 
strains was examined to improve protein expression. 
 1 2 3 4 
 
Figure 79: SDS-PAGE gel of AsLOV2(WT). 
Lane 1 - weight marker; lane 2 - cell lysate; lane 4 - purified AsLOV2 (34.3 kDa) 
 
Initially, two derivatives of BL21(DE3) were examined (BL21(DE3) STAR, and BL21(DE3) 
[pLysS], where co-plasmid pLysS assists in regulation of transcription of other plasmids 
within the cell), however no improvement in protein expression was found. Instead, 
strain M15191 (a derivative of E. coli K12), was examined for use with both the wild-
type and mutant plasmids. The name is derived from the deletion of a single amino 
acid (M15) in the lacZ gene, which is part of the larger lac operon; this deletion renders 
the lac operon ineffective for metabolism of lactose, assisting in the regulation of 
genes under control of a lac promoter. This is of particular use for plasmids under 
control of a T5 expression system, as a lac promoter sequence is incorporated into the 
sequence of T5 (see section 3.3.2.1). Furthermore, strain M15 used for this project 
also contained the repressor-plasmid pRep4, which assisted in the regulation of 
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protein expression by causing expression of the lac repressor protein (encoded by the 
lacI gene192), until addition of IPTG to the cell culture caused inactivation of this gene 
and simultaneously permitted transcription of the (previously blocked) plasmid gene. 
 
A second alternative strain used in place of BL21 was strain JM101193. As for M15, this 
is also a derivative of E. coli K12, but is a less popular choice for plasmid expression 
due to poor regulation of lactose production within the cell, often leading to 
unregulated induction with consequent low levels of recombinant protein production. 
However, it is often successful at expression of difficult genes, due to the retention of 
a variety of non-optimised transcriptional machinery193–195. 
 
Expression of wild-type AsLOV2 using M15[pRep4] was found to be generally as 
effective as strain BL21(DE3) used previously, while expression of the mutant plasmids 
remained low in this strain. However, the use of strain JM101 was able to successfully 
allow reliable expression of each mutant formed as described in section 3.3.4, with 
the expression methodology itself described in greater detail in section 3.3.5. 
 
Two reasons for the experimentally-observed poor levels of expression were 
identified following a detailed analysis of the plasmid vector and the DNA sequence of 
the AsLOV2 gene, and are described below. 
 
3.3.2.1  Plasmid promoter sequence 
The promoter sequence of the pNCO-AsLOV2 plasmid, originally derived from 
bacteriophage T5196, was not ideally suited for use in E. coli strains optimised for 
alternative promoter sequences. Strain BL21(DE3) was originally developed by 
incorporation of the T7 RNA polymerase (RNAP) from bacteriophage λ197 (see section 
5.7.1 for genotype), and is thus optimised for expression of genes under control of a 
T7 promoter, such as pET-14b used for the successful expression of Sp-RfK (section 
3.2) previously.  
 
The T5 promoter sequence is significantly longer than other promoter sequences 
commonly used for recombinant gene expression as it contains an embedded lac 
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operator, which is more usually sited immediately downstream of the promoter. Little 
homogeneity is found between promoter sequences, as they are specific to a sigma-
factor (σ-factor) responsible for identification of the promoter, and initial binding of 
the RNA polymerase (RNAP). For effective expression of recombinant genes within 
bacterial systems, the host cell requires both an appropriate σ-factor and RNAP, and 
so development of strains which express high levels of a defined RNAP has been used 
to optimise expression for a specific corresponding plasmid. 
 
5'-TCATAAAAAATTTATTTGCTTTGTGAGCGGATAACAATTATAATA-3' 
5'-TAATACGACTCACTATAGGGAGA-3' 
Figure 80: T5 promoter sequence, with Lac operator sequence the promoter 
underlined (above), and T7 bacteriophage promoter sequence(below) 
 
A promoter sequence may occasionally be recognised by an RNAP which is not 
optimised for the sequence for a number of reasons, although transcription from 
these is significantly less effective198. The high specificity of the T7 bacteriophage 
RNAP is well reported199–201, with single point mutations to the polymerase completely 
preventing the expression of genes under control of the T7 promoter202,203. Therefore, 
as the specificity of the T7 RNAP is very high, it is unlikely for reliable expression of 
genes under control of a T5 promoter to proceed in strains optimised for the T7 
promoter sequence.  
 
This would explain the inconsistency observed with the expression of AsLOV2, and was 
addressed using two alternative E. coli strains for expression (M15 and JM101; vide 
supra), which are not optimised for expression using a single promoter sequence.  
 
3.3.2.2  Codon optimisation 
Another potential reason for the inconsistent expression of AsLOV2 was due to an 
apparent oversight in the DNA sequence of the AsLOV2 gene. When originally isolated 
and incorporated within the plasmid1,4, no consideration was made for the codon-
optimisation of the AsLOV2 gene for expression in E. coli; instead, the original codons 
were retained from the host species. Codon utilisation by plants is significantly 
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different to the codons utilised by prokaryotes (typically at the third base pair of the 
codon204) with a preference for guanine and cytosine rather than adenine and thymine 
in this position205. Although the standard genetic code remains the same (leading to 
the correct amino acid sequence in the translated protein), the utilisation of each 
codon combination is specific to the host (with full details available for Avena 
sativa204,205 and E. coli206). Thus, the use of rarely-utilised codons will lead to retarded 
or failed expression, furnishing lower levels of the recombinant protein.  
 
Similar difficulties have been encountered for other flavin-mediated phototropin 
domains, including Arabidopsis thaliana PLP207 and PAS/LOV domains208, where 
mutation of each sequence to optimise codon usage vastly improved protein yields. 
As the effect of codon optimisation was not considered during this project (due to the 
previously reported successful expression1,4), this discussion is intended to assist 
future work. 
 
Utilising the web-based OPTIMIZER tool209 (based upon methodology described 
elsewhere210), the optimal codon usage of the AsLOV2 gene was compared to the 
codon-usage of E. coli K12. This generated an alignment report (shown in full in 
appendix 2) which suggests that of the 477 nucleotides (159 codons) of the AsLOV2 
gene, 97 mutations (20 % of all nucleotides) would be necessary to fully optimise the 
gene for expression in E. coli. This startling result demonstrates the difference in 
codon usage, with significant mutagenesis of the AsLOV2 gene necessary to improve 
the efficiency of expression in bacterial hosts. 
 
3.3.3 Influence of Hisactophilin on AsLOV2 photocycle 
The primary role of the N-terminal Hisactophilin protein was to act as a convenient 
tag for IMAC purification, as the high number of histidine residues (31 out of 118 190) 
ensures this protein has an exceptionally strong affinity for metal ligands. This allowed 
isolation of the target protein using IMAC (also used to purify Sp-RfK, described earlier 
in section 3.2.1). A discussion of the IMAC protocol is given in section 3.3.6 below. 
 
 110 
 
Cleavage of hisactophilin from AsLOV2 was possible using the protease thrombin, 
which selectively cleaves the amino acid sequence 5’-Leu-Val-Pro-Arg-Gly-Ser-3’, 
between arginine and glycine, with very high specificity. This sequence was used to 
link the proteins during original construction of the hisactophilin-AsLOV2 construct4, 
and gave an effective method for the selective removal of the protein tag, if desired. 
 
An additional benefit of using hisactophilin instead of a shorter affinity protein (such 
as 6xHis) was a reported enhancement to both the stability and the photochemistry 
of the AsLOV2 domain. During the work detailing the original plasmid formation4, a 
calmodulin-binding protein (CBP)25,31 construct was also produced, and used to 
compare the properties of the AsLOV2 photocycle when coupled to either protein. 
During these studies, an inactive mutant of the AsLOV2 domain (C450A) was used to 
prevent formation of the photoproduct. 
 
Spectral measurements of the ground (i.e. dark) state of AsLOV2(C450A) made using 
both CBP and hisactophilin-fusion constructs, were reported to be essentially 
unaffected by the presence of either tagging protein4. However, hisactophilin-tagged 
AsLOV2(C450A) gave a significantly higher radical yield upon illumination, compared 
to either CBP-fused, or free- AsLOV2(C450A) (shown in table 8, below). As radical 
formation is key to the photoreaction of the AsLOV2 domain, the retention of 
hisactophilin therefore gave two beneficial effects: (i) improved protein stability, 
enabling storage and reliable observation over extended periods; and (ii) an enhanced 
radical yield for the protein, improving the sensitivity of photometric measurements. 
 
While the results presented by Kay et al.4 (table 8, below) support the retention of 
hisactophilin during spectroscopic examination, the photoquenching they report 
using the C450A mutant domain is not normally observed56,139,211,212; furthermore, this 
was also not observed during this project using an AsLOV2(T418I, C450A) double 
mutant. However, it was assumed that the reported effect of the hisactophilin on the 
C450A mutant would be identical for the wild-type protein, and that along with the 
improved protein stability, its retention would be generally beneficial. Therefore, the 
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majority of the experiments reported in this thesis were performed using the 
hisactophilin-AsLOV2 fusion protein. 
 
Protein Sample Condition Radical Yield (%) 
LOV2 C450A-HISACT Aerobic 90 
Anaerobic 92 
Aerobic + EDTA 97 
Anaerobic + EDTA 100 
LOV2 C450A-CBP Aerobic 29 
Anaerobic 57 
LOV2C450A Aerobic 20 
Anaerobic 56 
Table 8: Reproduced from “Table II” of the paper by Kay et al.4, listing the relative 
radical yields of AsLOV2(C450A) as the lone domain and with hisactophilin (HISACT) 
or calmodulin binding protein (CBP) fusion partners. Radical yields were normalised 
to the greatest radical yield (HISACT, in anaerobic solution with additional EDTA) 
 
3.3.4 Site Directed Mutagenesis (SDM) 
Several mutant proteins were designed and expressed during this project, each with 
mutation to the single cysteine residue of the AsLOV2 domain which is responsible for 
formation of a covalent bond with flavin during the phototropin photocycle. These 
C450X mutants (where X indicates the alternative amino acid incorporated) used 
alanine, serine, methionine, glycine and aspartic acid in place of cysteine, and were 
formed by mutation of the codon within the original plasmid via whole-plasmid 
mutagenesis using the polymerase chain reaction (PCR) method of Weiner et al.213. 
This method was used due to much shorter turnaround times compared to 
mutagenesis of the isolated gene, however, this method has two associated risks. 
Firstly, there is potential for undesired mutation at a random position of the plasmid 
by incorrect incorporation of a nucleotide by the DNA polymerase. Secondly, PCR cycle 
times may be required to be significantly extended (to 15 or 20 minutes per cycle) to 
allow replication of many kilo-bases of DNA. To mitigate these risks, all mutant 
products were sequenced to confirm the identity of the target gene, and a range of 
times for the elongation phase of the PCR was used to find the optimal duration.  
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Mutagenesis was performed using purified DNA (previously maintained in E. coli strain 
XL1-blue before isolation). Prior to mutagenesis, the wild-type (also referred to as 
template) DNA was sequenced to confirm its fidelity, along with a phenotypical 
examination (via expression) to confirm that the protein expressed was fully 
functional. As E. coli strain XL-1 blue contains both dam+ and dcm+ genes, all DNA 
within the cell (including plasmid DNA) is methylated at both adenosine and cytosine 
nucleobases (respectively) by DNA methylases. However, the “daughter” DNA formed 
by the Pfu polymerase during the PCR process remained unmethylated, giving a useful 
differential to allow selection of only the mutant DNA from the PCR mixture. The 
parental (methylated) DNA was successfully removed by digestion using DpnI 
restriction endonuclease, which cuts methylated DNA (recognising adenosenyl 
methylation in the sequence 5’-GA*TC-3’). Therefore, only daughter DNA remained 
after digestion, which was expected to have incorporated the desired mutation. 
 
To perform mutation using the PCR, two primers were required, each complimentary 
to the sense or antisense template DNA strands and containing the desired mutation 
as a mismatch in the codon encoding the amino acid to be modified. In all cases, 
primer length was 40 b.p., in order to give a sufficient overlap on both sides of the 
mismatch to allow strong binding of the primer during the annealing phase of the PCR 
cycle. Sixteen complete cycles of the PCR were used to give optimal yields of DNA.  
 
As described above, one of the greatest risks of whole-plasmid mutagenesis is the 
potential for undesired additional mutation of the daughter DNA by the polymerase 
enzyme, which becomes more likely with longer DNA sequences or additional cycles 
of the PCR. Therefore, selection of an appropriate DNA polymerase (DNAP) was key. 
Numerous DNAPs are available, with Taq (from Thermus aquaticus214) and Pfu (from 
Pyrococcus furiosus215) being most common. Although Taq performs elongation more 
rapidly than Pfu (1,000 nucleobases in 10 seconds using Taq216, versus a 
recommended allowance of  1 minute per 1,000 nucleobases with Pfu), Taq has a 
significantly lower reported fidelity for replicated DNA (1.1 x 10-4  spontaneous 
mutations per base pair per duplication for Taq217, compared to 1.3 x 10-6 for Pfu218). 
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This is due to the presence of 3’  5’ exonuclease activity for Pfu, removing incorrectly 
incorporated nucleobases during replication; Pfu was thus used for mutagenesis. 
 
Following digestion with DpnI, portions of each PCR mixture were transformed into E. 
coli XL1-blue, with successful transformants identified by growth on LB-agar plates 
containing ampicillin. Initially, no transformants were obtained, which was 
determined to be due to the DNA polymerase working less efficiently than expected 
and thus requiring longer times to complete DNA replication. An elongation time of 8 
minutes was originally used, which was gradually increased to fifteen minutes per PCR 
cycle, giving optimal yields of the full-length DNA product. Agarose gel electrophoresis 
(figure 81) confirmed formation of correctly-sized daughter DNA, which was 
subsequently successfully transformed into XL1-blue with reasonable efficiency (3.3 x 
103 to 4.7 x 104 transformants per µg of DNA). Small liquid cultures were used to 
provide sufficient quantities of DNA for sequencing. 
 
 1 2 3-5 6 7 8 9 10 11-13 14 15  
 
 
Figure 81: Agarose gel of PCR products from AsLOV2 mutagenesis. All DNA (except 
lane 2) nicked using BamHI restriction endonuclease.  
Lane 1 - 1 k.b.p. DNA ladder; lane 2 - undigested plasmid DNA; lanes 3-5 - DNA 
products with PCR elongation times of 8, 10 and 12 minutes (respectively); lane 6 - 
C450A mutant (4.2 kBp.); lane 7 - C450S mutant; lane 8-C450M mutant; lane 9 - 
C450G mutant; lane 10 - C450D mutant; lanes 14,15 - AsLOV2(WT) (4.2 k.b.p.) 
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Sequencing of C450S, C450G, C450D and C450M mutants confirmed successful 
mutagenesis, with no other mutation found throughout in the gene compared to the 
template DNA. However, sequencing data for the C450A mutant showed a 
spontaneous mutation present in all transformant colonies sequenced. This was a 
single nucleobase (C to T) mutation in codon 418, which previously encoded threonine 
(sequence ACT). The effect of the mutation changed this codon to ATT, which instead 
encodes isoleucine, leading to an undesired double-mutant. However, as the effect of 
this mutation was expected to be minimal, and the effects of the AsLOV2(C450A) 
mutant are particularly well characterised4,31,54,208,219, the AsLOV2(T418I, C450A) 
double mutant was used in its place. 
 
 5'- GTC  ATT  ACT GAC  CCA-3' 5'-Val Ile Thr Asp Pro-3' 
 5'- GTC  ATT  ATT  GAC  CCA-3' 5'-Val Ile Ile Asp Pro-3' 
Figure 82: DNA and translated protein sequences of AsLOV2(WT) (above), and 
undesired double mutant AsLOV2(T418I, C450A) (below). Mutation site is underlined 
 
3.3.5 Expression of wild-type and mutant AsLOV2 proteins 
After sequencing of the PCR products, the mutant plasmids were transformed into a 
number of E. coli strains (BL21(DE3), BL21(DE3) STAR, BL21(DE3)[pLysS], M15[pRep4] 
and JM101) to evaluate relative rates of expression, as discussed in section 3.3.2. 
While E. coli strains BL21(DE3) and M15[pRep4] were found to be reasonably effective 
at expression of AsLOV2(WT), the expression of the mutant derivatives was 
particularly unreliable in these strains. This was not believed to be due to the effect of 
mutagenesis (as the codon selected for mutation was optimised to be the most-used 
codon for E. coli), but for other reasons discussed earlier in sections 3.3.2.1 and 
3.3.2.2. Protein yields obtained using strain JM101 were acceptable, and so this was 
used to express all mutant plasmids. 
 
Culture growth for over-expression was performed in a liquid medium. In all cases, 
protein yields were greatest using a highly enriched medium, with typical wet cell 
masses (for BL21(DE3) pNCO113-AsLOV2(WT)) of 18-26 g L-1 in TB medium, compared 
 115 
 
to 6-8 g L-1 using LB medium; similar results were obtained for mutant plasmids within 
strain JM101. Successful over-expression was indicated visually (and observable 
photometrically at 445-450 nm) by the vivid yellow colour of the cells, as a result of 
FMN incorporation within the overexpressed protein. The temperature (post-
induction) appeared to play a role in the yield of protein obtained, with 16-18 °C found 
to be optimal. At elevated temperatures, a significant amount of misfolded or 
otherwise unstable protein was found in the cell lysate, which spontaneously 
precipitated upon lysis or caused rapid culture death during expression. As 
incorporation of FMN within AsLOV2 was integral to protein stability (the apoprotein 
spontaneously precipitated, see section 3.3.9.2), the use of lower temperatures aided 
AsLOV2 expression by allowing the cell sufficient opportunity to form the FMN 
required for incorporation within the recombinant protein. Notably however, 
supplementation of the growth medium with either riboflavin or FMN was not found 
to assist protein expression. 
 
Other attempts were made to improve levels of protein expression, including 
performing all stages of cell growth with the exclusion of light (due to the 
photoreaction of the expressed AsLOV2 protein), using increased concentrations of 
IPTG (up to 5 mM), or using freshly-transformed competent cells. However, no 
conditions were found to significantly improve protein yields; while it was possible to 
produce sufficient levels for use during this project, protein expression remained 
unreliable. This supports the earlier argument (section 3.3.2.1 and 3.3.2.2) that sub-
optimal promoter sequence or codon usage within the plasmid dramatically affects 
expression of the protein. 
 
3.3.6 Purification of expressed AsLOV2 samples 
All expressed AsLOV2 proteins (WT and C450 mutants) were lysed using sonication, 
although a more gentle procedure than previously used was necessary, as vigorous 
lysis led to fragmentation of the fusion protein.  
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 1 2 3 
 
Figure 83: Comparison of AsLOV2(WT) lysed and purified gently (lane 2; see section 
7.3.2), and AsLOV2(WT) lysed using the same protocol as Sp-RfK purification and 
collected in the flow-through from IMAC purification (lane 3) 
 
Lysis and purification was performed at pH 8.0, which was found to be optimal to 
minimise the effects of pH-dependent protein aggregation. At this pH, the excited 
state of the photoreaction is also reported to be optimally stabilised (at physiological 
temperature)219. The crude lysate solution (which exhibited a strong yellow colour; 
figure 84) was purified using a high-throughput IMAC method (section 5.6.7.2). Due 
to the strong affinity of hisactophilin for metals, the protein became immobilised on 
nickel-chelating resin, while other non-tagged proteins passed through the column 
unimpeded. Two types of resin were evaluated: Ni-NTA® and Ni-Sepharose® fast flow. 
NTA resin was found to be greatly inferior to Sepharose resin, as it appeared unstable 
under the pressure applied to the column using a peristaltic pump.  
  
As the target protein exhibited a strong yellow colour (due to the presence of FMN 
within the LOV domain), binding of this protein was observed visually as the vivid 
yellow lysate (figure 84, left) was rapidly decolourised (figure 84, right) by passing over 
the resin column. The binding of the yellow protein to the blue column produced a 
characteristic green colour, which aided assessment of the column capacity.  
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Figure 84 [left image]: Vivid yellow AsLOV2(WT) crude lysate solution (left), and 
almost colourless flow-through from the column after protein binding (right) 
Figure 85 [right image]: AsLOV2(WT) immobilised on Ni-chelating Sepharose resin. 
The green colour localised at the top of the resin bed indicated retention of AsLOV2 
 
After binding and washing of the retained protein samples, the AsLOV2 domains (wild-
type or mutant) containing the native cofactor FMN were eluted from the column 
using a high concentrations of imidazole (0.5-1.0 M). After elution, protein-containing 
fractions were dialysed or applied to a desalting column, to remove imidazole. 
 
3.3.7 Removal of imidazole 
The effect of imidazole on the photoreaction of LOV domains is remarkable. It is able 
to dramatically increase the rate of reversion for the photoadduct, with this effect 
observed in a broad range of LOV domains including Avena sativa LOV1 and LOV258, 
Neurospora crassa VIVID (VVD) LOV39, and  Solano lycopersicum LOV/LOV protein 
(LLP)207. In S. lycopersicum LLP, an imidazole concentration of 200 mM decreased the 
half-life for the photoproduct approximately 64 fold (from 65.4 minutes to 61.4 
seconds)207. However, for A.sativa LOV2, a considerably lower imidazole 
concentration (20 mM) caused a much greater increase (100-fold) in the rate of 
photoadduct reversion58. 
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Several potential mechanisms have been proposed in the literature, including the 
direct action of a base (either intra- or extra- protein)58, interruption of the hydrogen 
bonding network58, or a steric interaction stabilising the ground state of the 
complex220. The predominant mechanism, postulated by Alexandre et al.58 (shown in 
figure 86), is supported by their analysis of the protein crystal structure, where a 
potential tunnel and cavity was found to within 4-5 Å of flavin (under certain kinetic 
models), of a sufficient size to permit theoretical incorporation of imidazole in the 
reactive site.58 
 
Figure 86: Ionic mechanism proposed by Alexandre et al.58 for the imidazole-
catalysed reversion of the FMN-LOV photoadduct 
 
As the presence of these reported voids may be dynamic (expanding and contracting 
due to structural changes of the protein in “dark” and “light” states), the incorporation 
of imidazole via these is expected to be temporary, related to its concentration in 
solution. Thus, removal of imidazole from the protein solution was crucial for the 
accuracy of further studies.  
 
While dialysis was appropriate for large volumes of protein solutions (up to 250 mL), 
the time required to perform the requisite number of repetitions (typically 8-10) made 
this method particularly time-consuming. Alternatively, the use of size-exclusion or 
desalting columns was both swift and effective, but limited by the volume of protein 
sample which could be accommodated by the column (typically 5-10 mL per loading). 
A combination of both techniques was used to remove imidazole from protein 
samples, with dialysis remaining the preferred method for large-scale purification.  
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3.3.8 Spectroscopic determination of protein concentration 
Estimation of AsLOV2 concentration within a sample was performed photometrically 
using the absorbance of the chromophore within the domain. While free-FMN in 
solution has an extinction coefficient (ε) of 12500 M-1 cm-1  at 445 nm88, the effects of 
binding within the LOV domain cause a slight red-shift of the flavin absorbance to 447 
nm, and an enhancement of the extinction coefficient to 13800 M-1 cm-1, as 
determined by Salomon et al.31. Cofactor binding is indicated by resolution of the 
spectrum between 400-500 nm, showing two distinct vibronic side-bands at 422 nm 
and 473 nm (figure 87). These each correspond to vibronic energy levels for low 
energy singlet (excited) states of FMN219, and appear highly resolved as only a single 
environment exists for the bound cofactor. 
 
 
Figure 87: UV-visible absorption spectra of free FMN in solution (left), and FMN 
bound within AsLOV2(WT) (right). While FMN exhibits a single broad absorbance at 
445 nm, the spectrum of the protein-bound cofactor resolves to reveal three 
absorbances in the same region, with the major resonance remaining at 447 nm 
 
It is interesting that the LOV1 domain from the same PHOT protein (which is 
somewhat similar in structure to the LOV2 domain) gives an extinction coefficient of 
12200 M-1 cm-1 at 449 nm31; much closer to the value for the free cofactor in solution. 
This is reportedly due to differences between each domain in the flavin binding site, 
with LOV1 appearing  to influence the cofactor less than LOV231. A value of 
400 425 450 475 500
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400 425 450 475 500
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13800 M-1 cm-1 at 447 nm was thus used (without correction) to estimate the 
concentration of AsLOV2 samples containing FMN.  
 
For the evaluation of protein samples containing either 5-deazaFMN or 1-deazaFMN, 
protein concentration was estimated based upon the ‘enhancement ratio’ between 
the extinction coefficient value for protein-bound FMN (13800 M-1 cm-1 31) and free-
solution FMN (12500 M-1 cm-1  88) of 1.104. Therefore, using 5-deazaFMN, the protein 
concentration was estimated using an extinction coefficient of 13800 M-1 cm-1 at 404 
nm (from 12500 M-1 cm-1 at 404 nm unbound 88), and for 1-deazaFMN, protein 
concentrations were derived using an extinction coefficient of 7507 M-1 cm-1  at 535 
nm (from 6800 M-1 cm-1 at 535 nm unbound 88). 
 
3.3.9 Cofactor exchange within the AsLOV2 domain 
3.3.9.1 Protein denaturation 
This process was performed after the protein was immobilised on Ni-sepharose resin 
(used previously to purify the protein sample). Denaturing was originally attempted 
using solutions of three denaturing agents, at varying concentrations: urea (4.0-8.0 
M), guanidinium hydrochloride (0.5-6.0 M) and guanidinium thiocyanate (0.5-4.0 M). 
Urea did not cause elution of FMN from the bound protein, and guanidinium 
hydrochloride was found to be unsuitable at all concentrations (due to the high 
concentration of chloride present in solution causing instability of the resin). However, 
guanidinium thiocyanate was found to be successful at denaturing the bound protein, 
causing immediate release of the native cofactor. This compound has been previously 
used to successfully denature recombinant proteins221–223, with an optimal 
concentration between 1.8 and 4 M reported. During this research, it was found that 
thiocyanate concentrations as low as 0.5 M were able to cause displacement of the 
native cofactor, typically within 3-5 column volumes. 
 
In order to ensure complete removal of the native flavin (along with traces of the 
denaturing agent), the bound apoprotein was washed with 2 column volumes of the 
washing buffer, or a saline solution (up to 2 %). This was key to the effectiveness of 
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the subsequent cofactor exchange, as the presence of remaining thiocyanate may 
have prevented successful renaturing of the protein.  
 
3.3.9.2  Incorporation of artificial cofactors 
The washed denatured protein was immediately treated using a solution of the 
purified FMN analogue (typically 20 mM), dissolved in the same buffer or saline 
solution used to wash the protein sample. The solution was continuously re-circulated 
over the column (with exclusion of light) at a low flow rate for a minimum of 4 hours, 
although times up to 16 hours gave greater analogue incorporation yields.  
 
Successful incorporation of the synthetic cofactor allowed the previously denatured 
protein to re-form around the introduced cofactor. Subsequently, the column was 
washed to remove any unbound flavin analogue, and the reconstituted protein eluted 
as before (section 3.3.6). Each eluted protein adopted the characteristic colour and 
UV-visible characteristics of the cofactor introduced, allowing convenient 
identification of protein-containing fractions. 
 
Removal of imidazole from samples containing synthetic cofactors was not performed 
immediately, due to the rapid precipitation of any apoprotein present within the 
mixture. This was found to be incredibly unstable due to the lack of structural integrity 
in the absence of the cofactor, and thus precipitated rapidly from solution. This 
allowed conveniently separation of the holo- and apo- protein forms, ensuring that 
subsequent examination of the protein samples was not influenced by this. Typical 
incorporation efficiencies above 80 % (estimated photometrically) were obtained 
using this method. 
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Figure 88: UV-visible absorbance spectra of AsLOV2(WT) containing 5-deazaFMN 
(top, blue), native FMN (centre, orange) and 1-deazaFMN (bottom, purple) 
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3.3.10    Conclusions – expression, preparation and purification of AsLOV2 samples 
The expression and purification of the AsLOV2(WT) domain was performed, with some 
difficulty. Expression was found to be inconsistent, and was examined using a number 
of alternative E. coli host strains. However, little enhancement was made for the 
expression of the wild-type protein, with evidence found to suggest that the non-
optimised codon usage of the gene was responsible. However, sufficient quantities of 
the protein for study were obtained by expression using nutrient-rich mixtures, and 
purified using the IMAC protocol described.  
 
Additionally, the site directed mutagenesis of the original plasmid was performed, 
producing four desired mutants (AsLOV2(C450S, M, G and D)), and a single double-
mutant (AsLOV2(T418I,C450A)). These were each expressed in strain JM101 (which 
was found to be most efficient), and also purified using the IMAC method used for the 
wild-type protein. 
 
Furthermore, the artificial cofactors 5-deazaFMN and 1-deazaFMN were successfully 
incorporated into samples of each expressed protein, enabling subsequent 
photometric examination of the samples.  
 
3.4 Photometric Examination of AsLOV2 (Wild-Type and Mutant), 
using Native FMN, 5-deazaFMN and 1-deazaFMN 
3.4.0  Introduction 
Protein samples prepared as described in section 3.3 were used to examine the 
photoreaction of the AsLOV2 domain. Two approaches were made: firstly, 
synthetically produced cofactors 5-deazaFMN and 1-deazaFMN were incorporated 
within AsLOV2(WT), to examine their effect on the photocycle of the domain. 
Secondly, the effects of mutating the reactive cysteine residue (C450) of AsLOV2 were 
examined, to determine if photoadduct formation was possible with similar amino 
acids. Each mutant was further examined with the artificially synthesised cofactors, to 
provide additional evidence. 
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Samples were examined using UV-visible and CD spectroscopy as appropriate. The 
strong UV-visible absorbance of the flavin chromophore allowed swift non-destructive 
analysis of photoadduct formation, with any stimulated physical effects observed by 
CD. Irradiation of samples was performed as described in section 5.6.8.2.  
 
A range of protein concentrations was used, calculated using the methodology 
described in section 3.3.8, with the spectral effects of irradiation appearing relative to 
protein concentration. Due to the strong absorbance of FMN, typical protein 
concentrations between 15-20 µM were used for UV-visible spectroscopy of samples 
containing FMN or 5-deazaFMN, while a concentration of 25-35 µM was used for 
those containing 1-deazaFMN. All CD values were normalised using Mean Residue 
Ellipticity (MRE, [θ]mrw), based upon a Mean Residue Weight (MRW) of 115.9, and 
calculated according to the formula given below, to account for the differences in 
sample concentration. 
 
 [θ]mrw = (MRW x θobs ) / 10 x d x c 
 
Figure 89: Formula for calculation of MRE for normalisation of CD data, where MRW 
corresponds to Mean Residue Weight of the protein, θobs is the observed ellipticity, d 
is the path length (in centimetres) and c is the concentration of the solution, in g mL-1 
 
 
3.4.1 Photoreaction of AsLOV2(WT) with native FMN 
3.4.1.1  UV-visible spectroscopy results 
AsLOV2(WT) containing the native cofactor (FMN), expressed and purified as above 
(with retention of hisactophilin) was examined using UV-visible spectroscopy and CD, 
to obtain a basis for comparison with other results.  
 
As shown in figure 90 below, the behaviour of the expressed AsLOV2-hisactophilin 
construct was found to be almost identical to that of the original plant domain, with 
irradiation of the sample at 447 nm leading to quenching of the flavin absorbance at 
447 nm (and the associated vibronic side-bands). When irradiation ceased, the “dark-
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state” (pre-irradiation) spectrum recovered spontaneously, with an approximate half-
life of 30 seconds. This was in line with other similar results (28-32 seconds)31,56.  
 
 
 
Figure 90: Photocycle of AsLOV2(WT) containing FMN. Irradiation of the sample at 
447 nm caused quenching of the flavin absorbance from the “dark” state (orange) to 
the “light” state (blue). Recovery to the pre-irradiation spectra occurred with a half-
life of ~30 seconds 
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3.4.1.2  CD spectroscopy results 
The physical effect of flavin-protein bond formation in LOV domains has been 
thoroughly described in the literature40,207,219,224,. A partial unwinding of the J-α helix 
has been previously demonstrated using FT-IR and polarimetry225–227, which is 
stimulated by photoirradiation of the domain. This effect was observed using CD 
spectroscopy of AsLOV2(WT) containing native FMN (fig. 91). Upon irradiation, the 
mean residue ellipticity in the region 240-205 nm decreased, indicating an overall 
decrease in α-helicity of the protein sample, which recovered to pre-irradiation levels 
within 600s (20 half-lives).  
 
Based upon an analysis of the crystal structure of the AsLOV2 domain (PDB structure 
2V0U48), 22 residues (of a total of 52 helical residues; thus 42.3 %) are within the J-α 
helix. The reduction in MRE observed was 30.9 % (at 208 nm), which although lower 
than predicted, is reasonable considering the short half-life of the light-state sample. 
Overall, the expected trend for a loss of ellipticity is broadly in line with expectations. 
  
Figure 91: CD Spectrum of native FMN within the AsLOV2(WT)-hisactophilin protein 
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3.4.2 Photoreaction of AsLOV2(WT) with 5-deazaFMN 
3.4.2.1  UV-visible spectroscopy results 
The UV-visible spectrum of the AsLOV2(WT) domain was affected by the incorporation 
of 5-deazaFMN. The dark-state spectrum was blue-shifted by approximately 50 nm, in 
line with the shift observed between free FMN and 5-deazaFMN in solution. 
 
Upon irradiation at 404 nm (the wavelength of 5-deazaflavin corresponding to 447 nm 
of FMN), a decrease in absorbance was observed in an analogous manner to 
AsLOV2(WT) containing the native cofactor (figure 90). However, the photoproduct 
formed was found to be stable, and did not revert spontaneously; both the fully-
irradiated “light state” and partially irradiated intermediate states were stable for 
over 72 hours. Furthermore, this result was also observed in the presence of up to 200 
mM imidazole. 
 
 
Figure 92: UV-visible spectrum of light-state formation of 5-deazaFMN within 
AsLOV2(WT); the primary absorbance is at 404nm, with two side-bands at 428 nm 
and 384 nm. The dark-state sample (orange) was irradiated at varying intervals using 
monochromatic light (404 nm), which caused a sequential decrease in the 
absorbance spectra observed (green, dashed), until the sample became fully 
photobleached (blue) 
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Figure 93: UV-visible absorption spectra of the light-state photoadduct of 5-
deazaFMN-AsLOV2(WT). After irradiation at 404 nm from the dark-state (orange, 
dotted), the light-state spectrum obtained immediately following irradiation (blue, 
above) remained unchanged after 72 hours (green, below) in the dark at 4 °C 
 
While the photoadduct was found to be stable, it was not immediately apparent if the 
dark-state spectrum would be recoverable. Numerous wavelengths were examined in 
order to determine if this may be achieved photometrically, with light in the ultraviolet 
region of the spectrum found to be effective at inducing reversion of the photoadduct. 
After somewhat exhaustive study, it was found that 313 nm was the optimal 
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wavelength to facilitate recovery of the spectral and physical properties of the dark-
state sample.  
 
 
Figure 94: UV-visible spectrum of the dark-state recovery of 5-deazaFMN within 
AsLOV2(WT). The stable light-state sample (shown in blue) was irradiated 
periodically using monochromatic light (313 nm), facilitating reversion of the sample 
(sequentially; green, dashed) until the pre-irradiation spectrum (orange) was 
recovered. Note that the absorbance recovered is identical to that of the pre-
irradiation dark state (figure 92), indicating that the photoreaction was both 
temporary and fully reversible 
 
3.4.2.2  CD spectroscopy results 
Examination of the 5-deazaFMN-AsLOV2(WT) sample using CD spectroscopy 
demonstrated a similar loss of ellipticity as found with native-FMN-AsLOV2(WT)225–227 
(section 3.4.1.2). However, the magnitude of the change was markedly different. 
While the reduction in ellipticity observed with the native cofactor was 30.9 % (at 208 
nm), the 5-deazaFMN sample gave a 42.2% reduction at the same wavelength. As 
discussed above, the J-α helix is estimated to contain 42.3 % of the helical residues of 
the protein, and thus the observed loss of ellipticity very closely matches the predicted 
value. As found using UV-visible spectroscopy, the light-state sample was found to 
have no change in ellipticity over extended periods (600 seconds; 20 half-lives for 
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AsLOV2(WT) containing native FMN). As before, irradiation at 313 nm allowed 
recovery of the pre-irradiation spectrum.  
 
 
Figure 95: CD Spectrum of 5-deazaFMN within the AsLOV2(WT) domain. Upon 
irradiation, ellipticity in the region 240-200 nm decreased, indicating a decrease in α-
helicity of the protein sample. This was found to be stable, with no change to the CD 
spectrum after 600 seconds. Irradiation of the sample at 313 nm allowed recovery of 
the dark state spectrum 
 
 
These results indicate that the photo-reaction with 5-deazaFMN was successful at 
forming a covalent photoadduct with the AsLOV2(WT) domain, as it resulted in the 
release and subsequent loss of helicity for the J-α helix as reported for the native-FMN 
containing protein225–227. As observed using UV-visible spectroscopy, the resultant 
photoadduct remained stable, with no spontaneous recovery of helicity. Recovery of 
the dark state was again facilitated by irradiation at 313 nm. 
 
 
  
-12
-8
-4
0
4
8
190 200 210 220 230 240 250
M
ea
n
 R
es
id
u
e 
El
lip
ti
cy
 /
 1
0
3
, d
eg
.c
m
2
.d
m
o
l-1
Wavelength, nm
1 - Dark state (pre-irradiation)
2 - Light state (after irradiation at 404 nm)
3 - Light state (600 seconds post irradiation)
4 - Dark state (after irradiation at 313nm)
 131 
 
3.4.2.3  5-deazaFMN – AsLOV(WT) discussion 
Control of the photoreaction between 5-deazaFMN and AsLOV2(WT) using two 
wavelengths of light (404 nm and 313 nm) is due to the energy provided by photons 
of these wavelengths providing the energy to allow specific electronic transitions to 
take place. While the commonly accepted mechanism for the LOV domain photocycle 
suggests an intermediate triplet-state (section 1.1.3), direct transition between a 
ground-state singlet (S0) and excited triplet (Ti) state is forbidden (due to opposing 
electronic spins), and are thus ordinarily reached via an excited singlet state (S i). An 
appreciation of the photophysics of flavin was therefore undertaken.  
 
The lowest-energy S0Si transition (1[π,π*]) calculated for riboflavin has a 
wavenumber of 22.5 x 10-3 cm-1, equating to a wavelength of 444.4 nm228. Assuming 
a negligible effect of the C5’-phophate group of FMN on the photophysical properties 
of the flavin ring (as suggested by their near-identical UV-visible absorption spectra88, 
vide supra), this value is remarkably close to the wavelength required to stimulate 
bond formation between AsLOV2(WT) and FMN (447 nm). As expected, no direct 
S0Ti transition is reported for riboflavin within reasonable limits of this wavelength 
– 3[π,π*] calculated from 21.7 x 10-3 cm-1 as 460.8 nm; 3[n,π*] calculated from 
22.8 x 10-3 cm-1 as 438.6 nm228.  
 
It is likely that the small difference between the observed wavelength and that 
calculated from the energy of the S0Si transition may be due to the local conditions 
within the protein binding site, suggesting that this transition is responsible for the 
photoreaction of the domain. If true, formation of the flavin triplet state within the 
protein (to allow cofactor-protein bond formation) must occur as a result of 
intersystem crossing (ISC), and not a direct (spin-forbidden) photo-initiated S0Ti 
transition. 
 
The use of EPR to identify a flavin radical formed upon irradiation46, combined with 
other evidence, has allowed the deduction of the mechanism shown in figure 96 
below. The theoretical calculations described above appear to compliment this, 
supporting the currently accepted mechanism for the AsLOV2-domain photocycle.  
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Figure 96: Mechanism for the photocycle of the AsLOV2(WT) domain (containing 
native FMN), proposed by Schleicher et al.46, from dark-state “A” to light-state “E”. 
Irradiation of the AsLOV2 domain does not cause direct formation of the FMN triplet 
state; which is instead formed by an SiTi transition via intersystem crossing (ISC). 
Although reactions are shown as unidirectional, some may be bidirectional or lead 
directly to dark-state A via alternative pathways for radiative decay 
 
  
 133 
 
Assuming similar behaviour of 5-deazariboflavin compared to riboflavin (and thus also 
the phosphorylated cofactors), the lowest-energy calculated S0Si transition (1[π,π*]) 
is reported at 25.0 x 10-3 cm-1, equivalent to a wavelength of 400.0 nm91. As before, 
this value is remarkably close to the wavelength required to initiate reaction between 
5-deazaFMN and the phototropin domain (404 nm), with the difference potentially 
accounted for by local effects within the protein. Again, no S0Ti transition for 5-
deazariboflavin has been calculated with a similar energy to this wavelength (between 
430 nm and 360 nm), implying that a triplet state intermediate for 5-deazaFMN may 
only be formed via intersystem crossing rather than direct photo stimulation. This is 
particularly interesting, since a S0Ti transition (usually spin-forbidden) may have 
explained the exceptional stability of the 5-deazaFMN-AsLOV2(WT) photoadduct. 
 
As the 5-deazaFMN-AsLOV2 photoadduct only reverts to the dark state with 
irradiation at 313 nm, this wavelength must be implicated in providing the requisite 
energy to facilitate cleavage of this bond, and which may also require an intermediate 
triplet-state. This would provide a sufficient barrier to the photoreversion to “lock” 
the conformation of the light-state photoadduct, and thus may play more of a role in 
the stability of the intermediate than the photo-formation step. 
 
As before, two potential transitions for 5-deazariboflavin were found at similar 
energies to this wavelength – a S0Si transition (1[π,π*]) with a wavenumber of 31.9 
x 10-3 cm-1 (313.5 nm), or a S0Ti transition (3[π,π*]) with a wavenumber of 31.1 x 10-
3 cm- 1 (321.5 nm)91. While the (1[π,π*]) transition is very close to the expected value, 
the presence of a S0Ti transition of similar energy is highly significant. As a ground-
state singlet to excited-state triplet transition is ordinarily a spin-disallowed process, 
the process is unlikely to occur spontaneously, and thus the potential for 
photoreversion would be incredibly low. This may be a key reason for the stability of 
the 5-deazaFMN-AsLOV2(WT) photoadduct, however further work is necessary to 
confirm this suggestion. 
 
During the preparation of this thesis, similar work has been reported by Silva-Junior 
et al.102, describing the incorporation of 5-deazaFMN into the LOV domain of YtvA, 
 134 
 
reaching similar conclusions. While the 5-deazaFMN-AsLOV2(WT) construct has been 
shown to be most effectively controlled at 404 nm and 313 nm, Silva-Junior et al. 
report that photocontrol of 5-deazaFMN-YtvA was performed at 396 nm and 334 nm. 
A mechanism based upon various photophysical calculations performed is shown in 
figure 97 below.  
Figure 97: Proposed mechanism for 5-deazaFMN-YtvA-LOV shown as reported by 
Silva-Junior et al.102 (letters added to aid discussion), based largely upon that of the 
native-FMN AsLOV2(WT) photocycle (figure 96), although the wavelengths reported 
are somewhat different to those found during this project 
 
That rationale for the wavelengths reported by Silva-Junior et al. is unclear, as the 
S0S1 transition wavelengths of 5-deazariboflavin are well characterised91. 
Furthermore, their mechanism reports two separate potential modes of 
photoreversion, from a singlet-state (E; figure 97), or from a triplet state (F) formed 
by a second ISC after irradiation of the light-state protein. As described above, two 
transitions are possible for 5-deazariboflavin in this region (S0Si transition (1[π,π*]) 
at 313.5 nm, or S0Ti transition (3[π,π*]) at 321.5 nm91), although the wavelength 
reported by Silva-Junior et al. is closer to the wavelength required for direct formation 
of an excited triplet state, and thus may support this theory. However, further work is 
necessary to conclusively confirm this mechanism. 
 135 
 
 
One further interesting alternative was also suggested within this mechanism. 
Intermediate G (figure 97) instead shows covalent bond formation between cysteine 
and 5-deazaFMN at position C5 of the 5-deazaflavin. As has been shown (by both NMR 
and crystallographic studies43,48,54), it is the C4a position of FMN which reacts with 
cysteine in a LOV domain, but in the case of 5-deazaflavin , this requires the C5 position 
to act both as a base (deprotonating the reactive cysteine), and as an acid (losing this 
proton upon reversion to the dark state). This appears somewhat unlikely, based upon 
an appreciation of the behaviour and strength of a C-H bond compared to an N-H 
bond; consequently, the mechanism proposed may not be the correct pathway for 
photoadduct formation. As an alternative, it is possible that position C5 of the 
deazaflavin may instead behave as a conjugate acceptor, and thus itself be labile to 
nucleophilic attack from cysteine. This is assisted by the relative positioning of the 
uracil moiety of the deazaflavin, which may to act as an electron sink for the reaction. 
Several potential conjugate partners are shown in figure 98.  
 
Figure 98: Several potential conjugate partners exist for the reaction between 5-
deazaFMN and LOV. It is possible that the consequential transfer of hydrogen (from 
cysteine) may occur at positions C4a (G), N1 (H), or C4(O) (J); forms H and J allow 
retention of the sp2 hybridisation of position C4a 
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3.4.3  5-deazaFMN reactivity with glutathione and cysteine 
In order to provide further evidence to support or refute the potential conjugate 
addition theory, a series of experiments were performed in order to examine whether 
FMN or 5-deazaFMN would react spontaneously, or with photoirradiation, to form an 
adduct with a short cysteine-containing peptide (glutathione), or free cysteine (fully 
reduced) in solution. The peptide glutathione229 was chosen as although it is small and 
has a simple sequence (5’-Gly-Cys-Glu-3’), it behaves as a strong thiolic nucleophile. 
Its role in nature is to react preferentially with conjugate acceptors, reducing the risk 
of inactivation of labile groups within cells230–232. 
 
UV-visible spectroscopy was again used as a convenient and fast method of 
determining whether a reaction had taken place, due to an expected photoquenching 
and / or band shift of the flavin absorbance upon successful bond formation. 
 
Solutions of FMN, 5-deazaFMN and 5-deazariboflavin were each treated with 
glutathione or cysteine solutions (both in their fully reduced state, at concentrations 
of 50 mM or 150 mM, respectively), however no spontaneous reaction with any flavin 
was observed photometrically. Irradiation using the wavelength of light appropriate 
to cause covalent bond formation within the AsLOV2 domain (447.5 nm for FMN; 404 
nm for 5-deazaflavins) also failed to give any change in the UV-visible spectra 
recorded, even with extended irradiation times. Other wavelengths were also 
examined, but no changes in the UV-visible spectra were observed. 
 
Failure to form an adduct therefore suggests that a more complex reaction may be 
occurring than a simple conjugate addition of the reactive cysteine of AsLOV2 to 5-
deazaFMN. However, these experiments do not conclusively rule this out, as other 
factors (such as the surrounding hydrogen-bonding network of the domain) may be 
contributory.  
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3.4.4 Photoreaction of AsLOV2(WT) with 1-deazaFMN 
3.4.4.1  Spectroscopic results 
As with the native cofactor FMN and 5-deazaFMN shown above, the successful 
incorporation of 1-deazaFMN within the AsLOV2(WT) domain was indicated by a 
resolution of the flavin absorbance spectrum, to reveal three resonances at 535, 503 
and 570 nm, as demonstrated in figures 99(a) and 99(b) below. 
 
 
 
Figure 99(a) [above]: UV-visible absorbance spectrum of 1-deazaFMN free in solution 
(dark purple) and 1-deaza-FMN bound within the AsLOV2(WT) domain (pink) 
Figure 99(b) [below]: UV-visible absorbance spectrum of native FMN within the 
AsLOV2(WT) domain (orange) 
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Interestingly, while the second-most predominant side-band of both native FMN and 
5-deazaFMN–AsLOV2 has a longer wavelength than the central absorbance (see 
figures 90 and 92, respectively), this is reversed for 1-deazaFMN-LOV2 (figure 99(a)). 
No reason for this could be found, although it was believed to be unrelated to the 
function of the cofactor within the domain, and may also be noted in the spectra 
presented by Silva-Junior et al.102. 
 
However, whereas both native FMN and 5-deazaFMN have been shown to form a 
photoadduct with the protein under irradiation with distinct wavelengths of light, no 
such adduct was found when 1-deazaFMN–AsLOV2(WT) samples were irradiated 
using any wavelength of light between 260 nm and 750 nm. No changes to either the 
UV-visible spectrum or CD spectrum (which was identical to the dark-state FMN–
AsLOV2(WT) spectrum shown in fig. 91) were found. Therefore, 1-deazaFMN 
appeared to prevent photoswitching of the AsLOV2(WT) domain; a similar result was 
also reported by Silva-Junior et al.102 using the YtvA protein. 
 
3.4.4.2  1-deazaFMN–AsLOV(WT) discussion 
Very little discussion of the photophysics of 1-deazaflavins has been made in the 
literature, almost certainly due in part to the previous difficulty of their synthesis, and 
their limited application to flavin-catalysed processes (vide supra). 
 
However, since its early syntheses, 1-deazaflavin has been reported to prevent 
generation of a stable triplet-state97. A discussion of this has been performed by 
Slavov et al.101 and Salzmann et al.233, with numerous calculations performed to 
predict the energies and relative positions of the singlet and triplet transition bands 
possible for the molecule.  
 
Calculations by Slavov et al.101 predict that as for both riboflavin and 5-deazariboflavin, 
both the lowest-lying triplet state (T1; due to a 3[ππ*] transition), and the second 
triplet state (T2; 3[nπ*]) lie below the energy of the S1 transition, and so each may 
be populated via intersystem crossing from an excited singlet state. On the other 
hand, Salzmann et al.233 have determined that only the T1 state of 1-deazaflavin lies 
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below the S1 level, and thus the 3[ππ*] is the only possible route for formation of a 
triplet state in 1-deazaflavin.  
 
Furthermore, both authors report that the rate of ISC is too slow to permit a transition 
from S1T1 levels, with the energy of the transition therefore lost via internal 
conversion or radiative decay233. The slow rate of intersystem crossing was 
determined by Slavov et al.101 by measurement of the fluorescence quantum yields of 
1-deazariboflavin, which was found to be incredibly low (0.002, compared to 0.27 for 
riboflavin233), demonstrating that for 1-deazaflavins this is not the predominant route 
for energy loss from an excited state. 
 
When this evidence is applied to 1-deazaFMN within AsLOV2, it may be inferred that 
as a maximum of two available triplet states of 1-deazaflavin (3[ππ*]) lie lower than 
the energy of the S1 state, and that the rate of intersystem crossing between the 
singlet excited state and triplet excited state is too slow to permit the transition, no 
reaction should be expected. The absence of an observed 1-deazaFMN triplet state is 
particularly useful in this case, as it provides further evidence to support the triplet-
state mechanism of the AsLOV2 photoreaction. If the alternative nucleophilic 
mechanism (postulated by Crosson and Moffat30; see section 1.1.3) was true, it would 
be expected that 1-deazaFMN would also form an adduct with the AsLOV2 domain, 
which was not observed under any condition attempted.  
 
Finally, the results obtained have also been confirmed by the work of Silva-Junior et 
al.102, within the LOV domain of YtvA. They report similar findings for 1-deazaFMN 
within the YtvA LOV domain as found in this study using the LOV2 domain of A.sativa, 
which further supports the radical-pair mechanism of photoadduct formation (vide 
supra). 
 
3.4.5 AsLOV2(C450X) mutants, incorporating 5-deazaFMN and 1-deazaFMN 
3.4.5.1  Spectroscopic results 
Examination of each mutant protein formed as described in section 3.3.4 with each of 
the three cofactors (native FMN, 5-deazaFMN and 1-deazaFMN) was performed, with 
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the UV-visible spectral results summarised in table 9 below, for brevity. A 
representative spectrum of native-FMN-AsLOV2(C450M) is shown in figure 100, 
below. While the dark-state spectra of the mutant proteins were similar to those of 
the wild-type protein (with similar vibronic side-bands observed), under no condition 
examined was it possible to observe any photoswitching behaviour from any mutant 
protein containing either of the three cofactors examined.  
Protein 
Sample 
Cofactor Primary 
Absorbance 
Wavelength, nm 
Vibronic Side-Band Wavelength, nm 
Most Intense Least Intense 
Wild-Type native FMN 447 473 422 
 5-deazaFMN 404 428 384 
 1-deazaFMN 535 503 570 
C450M native FMN 447 472 421 
 5-deazaFMN 404 428 383 
 1-deazaFMN 535 502 570 
C450S native FMN 447 473 422 
 5-deazaFMN 404 428 384 
 1-deazaFMN 535 503 571 
C450D native FMN 448 474 422 
 5-deazaFMN 404 428 384 
 1-deazaFMN 535 503 570 
C450G native FMN 447 473 422 
 5-deazaFMN 404 427 383 
 1-deazaFMN 535 502 571 
C450A(T418I) native FMN 447 473 422 
 5-deazaFMN 404 428 384 
 1-deazaFMN 533 502 570 
 
Table 9: Key spectral features of all AsLOV2 samples examined. The primary 
absorbance (related to the original absorbance of the cofactor) is reported, along 
with the wavelengths observed for the two characteristic vibronic side-bands. All 
samples (except wild-type AsLOV2 containing native FMN or 5-deazaFMN) were 
inactive to photoirradiation 
 
While all mutant proteins were found to be inactive to photoirradiation for durations 
previously used to cause formation of the photoadduct, it was found that when 
continually irradiated for exceptionally extended periods (up to 1 hour), the 
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absorbance observed steadily decreased, giving a “pseudo-bleached” state (via stable 
intermediate stages), similar to the effect seen with 5-deazaFMN in AsLOV2(WT). 
However, this was found to be due to destruction of the flavin by continual irradiation 
at high intensity; simultaneous observation of significant protein precipitation was 
also observed, with no recovery of the dark-state spectrum possible. This decrease in 
absorbance was not due to formation of a stable photo-adduct. 
 
Figure 100: UV-visible absorption spectra of native FMN–AsLOV2(WT)] in the dark 
state (orange), and after irradiation at 447 nm (blue) [above], and native FMN–
AsLOV2(C450M) [below]. The mutant dark state (black) initially remained after 
irradiation at 447 nm; vastly extended irradiation times led to some decrease in 
absorbance via stable intermediate stages (green) to a pseudo-photobleached state 
(red), which did not revert to pre-irradiation levels; examination of the sample 
indicated that loss of absorbance was due to destruction of the flavin and consequent 
precipitation of the apoprotein 
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3.4.5.2  AsLOV2(C450X) mutant discussion 
The failure of each mutant to give a photoadduct with any cofactor demonstrates the 
importance of the cysteine group for formation of the photoadduct. Interestingly, the 
behaviour of the sulphur atom of cysteine appears key, since methionine and serine 
mutants both failed to allow photoadduct formation. While methionine’s methylated 
sulphur group may prevent formation of the adduct for steric reasons, serine is almost 
identical in structure to cysteine, with an oxygen atom substituted for sulphur. 
 
The ability of the thiolic amino acid to undergo the photoreaction while the hydroxylic 
does not may be due to the difference in spin-orbit coupling between sulphur and 
oxygen. This is due to the electronic arrangement of the heavier sulphur atom, with 
the effect of reducing the unfavourability in the unpairing of electron spins, as the 
additional energy levels required for electrons become degenerate234,235. 
Furthermore, the increased mass of sulphur reduces the orbital angular momentum 
necessary for singlet to triplet state conversion236 (via intersystem crossing), allowing 
sulphur to more easily adopt an excited triplet state. This is an important 
consideration for the photocycle of LOV domains, as a radical pair mechanism requires 
each reactant to be of the same excitation state. As photoirradiation of flavin 
stimulates triplet state formation, the reduced energetic barrier to the adoption of an 
excited triplet state by cysteine permits bond formation between the flavin and 
protein. 
 
3.4.6  Conclusions – Spectroscopic investigation of AsLOV2 domain 
The results shown in section 3.4.2 demonstrate that incorporation of the artificial 
cofactor 5-deazaFMN within the AsLOV2(WT) domain allows full control of the 
phototropin using two wavelengths of light. Stability of both the light and dark states 
was found, and remained even in the presence of high concentrations of imidazole 
(previously reported to catalyse the photoreversion of the photoadduct58). It may be 
possible to further develop this for practical uses in molecular biology, as LOV domains 
are rapidly becoming a common functional tool to examine and control both in 
vivo32,211 and in vitro237 processes. As the rapid reversion of the light-state of AsLOV2 
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containing the native cofactor necessitates constant illumination or significant 
mutation of the protein to prolong the functional effect39,56,57, this may be potentially 
damaging for the cell or system under analysis. Therefore, the incorporation of 5-
deazaFMN may allow a controlled regulation of the protein without constant 
irradiation. 
 
Furthermore, the artificial cofactor within the AsLOV2 domain may facilitate the 
preparation of protein crystals in the light-state suitable for examination using X-ray 
crystallography, potentially revealing important structural information. While a high 
quality dark-state crystal structure has been obtained48, and a low resolution dark and 
light structures have been partially elucidated by NMR43, the collection of high 
resolution structural detail for the light-state has not yet been possible due to the 
requirement for constant irradiation during growth. The use of the stable light-state 
afforded by incorporation of 5-deazaFMN would allow collection of this data, which 
may give fresh insight for the behaviour of the domain.  
 
On the other hand, 1-deazaFMN prevented formation of a photoadduct with 
AsLOV2(WT) upon irradiation at any wavelength examined (260-750 nm), which 
appears to be largely due to the inability of this analogue to adopt triplet state upon 
irradiation. However, this supports the radical pair mechanism of flavin-LOV 
photoreaction, as 1-deazaFMN would be expected to form the photoadduct via the 
ionic mechanism proposed by Crosson and Moffat30. 
 
Examination of each mutant protein (section 3.3.4) with each cofactor showed no 
photoadduct formation under any condition, providing some evidence for the unique 
role that sulphur plays within the domain. These results may be built upon using the 
inactive cofactor 1-dezaFMN within the AsLOV2(WT) domain; as 1-deazaFMN does 
not readily form a triplet-state under irradiation, it would be possible to isolate any 
triplet-state formation of cysteine using techniques such as Electron Paramagnetic 
Resonance (EPR), and allow deduction of the point at which triplet state formation 
occurs (prior to or during irradiation), which may further the understanding of this 
part of the LOV domain photocycle mechanism.  
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Chapter 4 - Conclusions and Future Work 
Overall, the conditions set in the motivation and aims for this project (sections 1.0.2 
and 1.3) have been met. The syntheses of 5-deazariboflavin, 1-deazariboflavin and 8-
demethyl-5-deazariboflavin have been reported and optimised (particularly in the 
case of 1-deazariboflavin), along with foundations laid for the synthesis of several 
alternative analogues of riboflavin. After successful enzymatic phosphorylation, 5-
deazaFMN and 1-deazaFMN were incorporated into the AsLOV2 domain, and used to 
examine the photocycle of this protein. The results of these studies have enabled the 
confirmation of the triplet-state mechanism of photoadduct formation, and 
demonstrated the potential for development of this as a tool for use in molecular 
biology and optogenetics using a synthetic cofactor. 
 
4.1 Conclusions - Organic Synthesis 
4.1.1 5-deazariboflavin synthesis 
Figure 101: Overall synthetic route to 5–deazariboflavin 39 
 
The formation of 5-deazariboflavin 39 is among the most popular of all flavin analogue 
syntheses described in the literature, with decades of synthetic work leading to the 
optimal route described by Carlson and Kiessling5. While subsequent syntheses100 
based upon this method have reported inflated yields without any change or 
enhancement to the original reaction conditions, the exhaustive study of conditions 
described in this thesis confirm the yields of Carlson and Kiessling, forming the target 
compound in 16.2 % yield overall.  
 
The most significant result obtained during the synthesis of 5-deazariboflavin 39 was 
obtained during the protection of the ribityl chain of intermediate 36 by acetylation, 
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where the previously unreported acetylation of the uracil moiety of bicyclic compound 
37 was occasionally observed. This was found to have no effect on subsequent 
reactions, and the N-acetyl groups were removed using the same deprotection 
conditions used to remove the hydroxyl protecting groups. It does however indicate 
that future syntheses of riboflavin analogues may be able to utilise a fully-protected 
uracil moiety, which is supported by some evidence in the literature108,111, and may 
enable more efficient coupling between 3,4-dimethyl-N(ribityl)-aniline 33 and 6-
chlorouracil 35. 
 
4.1.2 1-deazariboflavin synthesis 
 
Figure 102: Overall scheme for the synthesis of 1-deazariboflavin 48 
 
The synthesis of 1-deazariboflavin 48 was performed in 61.3 % yield, which is a vast 
improvement over previous methods (11.0 % 5; 21 % 100). This exceptional 
improvement was due to the enhancements made during two key reactions: firstly, 
the coupling of the deprotected intermediate 44 and brominated oxoglutarate 46, and 
secondly, closure of the final ring of intermediate 47 at the N(3) position. For both 
reactions, adjustments to the reaction solvent led to the improvements, by allowing 
more ready solubilisation of reactants in the first case, or using a greater 
concentration of ammonia in the second. 
 
It may be of particular interest to repeat this method using several alternative 
nucleophiles for the final step of the reaction. This would allow the construction of a 
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suite of novel 1-deaza-3(N-functionalised) analogues, which may be of interest both 
as structural analogues of flavin, and by using electron donating or withdrawing 
groups to tune the electrochemical properties of the flavin.  
 
4.1.3 8-demethyl-5-deazariboflavin synthesis 
Figure 103: Scheme for the synthesis of 8-demethyl-5–deazariboflavin 54 
 
The novel synthesis of 8-demethyl-5-deazariboflavin 54 has been described, based 
upon the optimal method for the synthesis of 5-deazariboflavin 39, using 4-
methylaniline 49 in place of 3,4-dimethylaniline 33. Use of 4-methylaniline 49 led to a 
significant improvement in overall yield (28.7 %, versus 16.2% for 5-deazariboflavin), 
and assisted the discussion of the efficiency of 5-deazariboflavin synthesis by allowing 
consideration of the relative activating or deactivating positions of the aromatic ring.  
 
Furthermore, this also showed that the synthetic route described may tolerate 
alternative starting materials, and it would therefore be particularly interesting to 
apply a number of alternatives (such as 3-methylaniline or 3,5-dimethylaniline) to 
form a range of other riboflavin analogues. 
 
4.2 Conclusions - Molecular Biology 
4.2.1 C. ammoniagenes Ca-RfK-FADS 
The expression and purification of the bifunctional Ca-RfK-FADS protein was 
performed successfully, in high yield. However, the use of this enzyme to 
phosphorylate riboflavin analogues was less successful.  
 
While the enzyme worked efficiently, the predominant product of the enzymatic 
reaction was the FAD cofactor form, rather than the desired FMN form. This required 
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lengthy purification using preparative-scale HPLC, followed by chemical hydrolysis of 
the phosphoanhydride bond, and re-purification. Therefore, an alternative method to 
isolate the FMN form of the deaza analogues was sought. 
 
4.2.2 S. pombe RfK 
The expression of the Sp-RfK gene, and its purification, were again performed 
successfully, in very high yield. Phosphorylation of 5-deazariboflavin and 1-
deazariboflavin was swift and efficient; 1 equivalent of protein was able to turn over 
130 equivalents of the flavin cofactor within 4 hours. 
 
The purity of the FMN analogues formed by this enzyme were assessed by HPLC, and 
found to typically be over 99 % of the total flavin content of the reaction mixture. 
Purification was ordinarily performed via preparative-scale HPLC, although due to the 
high purity of the product this may not have been strictly necessary. 
 
4.2.3 A. sativa LOV2 preparation 
Expression of the AsLOV2(WT) protein was generally unreliable. Several factors may 
have been responsible, although two likely reasons were that (i) the plasmid vector 
containing the gene used a different promoter sequence to that which the expression 
cell strain was optimised for; or (ii) the AsLOV2(WT) gene had not been optimised for 
expression in E. coli.  
 
To address these factors, expression was attempted in E. coli strains BL21(DE3), 
BL21(DE3)-STAR, BL21(DE3) [pLysS], M15 [pRep4] and JM101. Each strain generally 
performed poorly, although strains BL21(DE3) and M15 [pRep4] were found to be the 
most reliable strains for expression of the wild-type protein. Furthermore, an analysis 
of the AsLOV2(WT) gene was performed using the web-based OPTIMIZER tool209,210, 
which showed poor codon optimisation for E. coli. Of the 477 nucleotides of the gene, 
97 mutations would have been required to fully-optimise the gene for E. coli, 
suggesting that this may play a large role in the poor expression of the gene. 
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Several mutants of the AsLOV2 gene were formed, replacing the cysteine residue at 
position 450 (of the full-length phototropin) with either alanine, serine, methionine, 
glycine or aspartic acid (abbreviated to C450A, S, M, G or D). In the case of the alanine 
mutant, an undesired mutation occurred during the PCR process, leading to an 
unintended double-mutant (AsLOV2(T418I, C450A)). However, as the behaviour of the 
C450A mutant has been previously well characterised, this was not considered to be 
detrimental. 
 
Expression of each of these mutants was performed in E. coli strain JM101 (which gave 
optimal yields), although this was also unreliable due to poor regulatory control within 
the cell often resulting in early induction of the plasmid. 
 
Conditions were found to allow incorporation of the synthetic FMN analogues within 
each of the AsLOV2 protein samples. This was performed effectively, resulting in 
protein samples containing either native FMN, 5-deazaFMN or 1-deazaFMN. These 
each adopted the colour of the cofactor they contained, which was reflected by the 
UV-visible spectra. The spectra obtained were found to be resolved (compared to the 
spectrum of the free cofactor), to reveal two vibronic side-bands either side of the 
central absorbance, which was indicative of protein binding. Crucially, the apoprotein 
form was found to be unstable in solution, and rapidly precipitated; thus, this did not 
influence subsequent spectroscopic examination. 
 
4.2.4 Examination of the AsLOV2 domain  
Samples of the AsLOV2(WT) domain containing each cofactor were examined using 
UV-visible and CD spectroscopy. The results for native-FMN samples showed 
formation of a light-state upon irradiation at 447 nm (the wavelength of the FMN 
chromophore), with photo-bleaching of the sample observed by UV-visible 
spectroscopy, and a partial loss (30.9 %) of ellipticity observed in the CD spectrum 
commensurate with unwinding of the J-α helix of the protein (which accounted for 
42.3 % of the helical residues). The irradiated “light” state of the sample was unstable, 
and decayed to pre-irradiation levels (with recovery of pre-irradiation spectra) with an 
approximate half-life of 30 seconds. 
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When 5-deazaFMN was incorporated within the AsLOV2(WT) domain, irradiation at 
the wavelength of the flavin chromophore (404 nm) led to photo-bleaching of the 
sample as with the native-FMN protein. However, the irradiated state was found to 
be fully stable for periods over 72 hours post-irradiation, and in the presence of a 
catalyst for the reversion. Furthermore, the loss of ellipticity observed in the CD 
spectrum was found to be 42.2 %, which closely matches the percentage of residues 
which make up the J-α helix of the protein (42.3 %). Reversion of the 5-deazaFMN 
photoadduct was found to be possible using irradiation at 313 nm, which allowed 
recovery of the dark-state spectra. 
 
Incorporation of 1-deazaFMN fully inactivated the AsLOV2(WT) domain to all 
wavelengths of light. This analogue, which is unable to form a triplet-state, therefore 
acts as an inhibitor to the photoreaction, and thus supports the currently-accepted 
radical pair mechanism of photoadduct formation. 
 
Each mutant protein, containing either cofactor, was found to be inactive to 
photoirradiation at all wavelengths. While this was expected for mutants lacking a 
reactive residue (C450A, T418I and C450G), it was more surprising that methionine, 
serine and aspartic acid also failed to react with the bound cofactor. The replacement 
of cysteine with serine indicates that the sulphur atom is key to the photoreaction, as 
sulphur possesses several energy levels of similar energy and has a relatively low 
barrier for intersystem crossing (necessary to form a triplet state, to bond with triplet-
state flavin) via spin-orbit coupling. 
 
Suggested future work in this area would be the coupling of 5-deazaFMN-containing 
AsLOV2(WT) to a functional domain, in order to examine whether the observed 
photoreaction allows control of a physical process. This may result in the development 
of a key tool for optogenetics and molecular biology, allowing manipulation of 
complex systems using two wavelengths of light. 
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Chapter 5 
Materials and Methods 
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5.1 Chemical suppliers, solvent and reagent purification  
Several methods for the purification of the reagents and solvents used for this 
research were obtained from the widely-used reference text “Purification of 
Laboratory Chemicals” by W. F. Armarego and C. Chai122, which have been 
supplemented by experimentally-derived methods where possible. 
 
5.1.1 Chemical suppliers  
Solid compounds and solvents were of high purity (98 % or above), purchased from 
Acros Organics, Sigma-Aldrich, Fischer Scientific, Fluka, Alfa Aesar and Novabiochem; 
generally used without further purification (exceptions detailed below or in relevant 
experimental section). Isotopically labelled compounds were obtained as follows: 13C-
carbonyl-dimethyformamide was supplied by Sigma-Aldrich; 13C-C6 glucose and 
15NH4Cl were supplied by Cambridge Isotope Laboratories; deuterated solvents for 
NMR were supplied by Sigma Aldrich (CDCl3, acetone-D6, MeOD) and Fischer (DMSO-
D6, MeOD, D2O). 
 
5.1.2 Desiccants 
Molecular sieves were prepared either by (i) heating in an oven at 300 °C for a 
minimum of 48 hours, followed by storage under high vacuum (< 10-2 Torr) for a 
minimum of 4 hours238,239; alternatively, by (ii) successive rounds of heating in a 
domestic microwave oven, followed again by storage under high vacuum for a 
minimum of 6 hours. Dryness was confirmed by addition of water to a small number 
of dried sieves; exothermic reaction indicated successful drying. Other desiccants used 
include silica, as used for Flash Chromatography, and alumina. 
 
5.1.3 Solvent Purification 
Methanol was distilled over CaH2122 and further dried using 3 Å molecular sieves121. 
Other methods are available, but are reportedly less efficient121, and may potentially 
lead to formation of undesirable methoxides240,241. Pyridine was dried by storage over 
4 Å molecular sieves in the dark for 24 hours. Triethylamine was distilled over CaH2 at 
atmospheric pressure. DMSO was dried using 4 Å molecular sieves or standing over 
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alumina, followed by reflux over CaH2 and distillation122,242. Anhydrous THF, MeCN, 
CH2Cl2, toluene and hexane were collected from an MBraun MB SPS-800 solvent 
purification system. THF was further dried by storage over 3 Å molecular sieves. 
 
Sodium methoxide and ethoxide were freshly prepared using sodium which had been 
stored under mineral oil. The protective oil was removed by washing in a bath of 
anhydrous hexane and the oxidised surface material was scraped away, before 
cautious portionwise addition of the cleaned metal to the pre-dried stirring solvent. 
 
5.1.4 Recrystallisation 
3,4-dimethylaniline was recrystallised from ligroin122, or from warmed 60 % (v/v) 
aqueous EtOH. Special care was necessary due to the low melting point (51 °C) of the 
compound. 6-chlorouracil was initially recrystallised from a 40 % solution of EtOH in 
water. However, due to the instability of this compound in aqueous conditions, 
purification by recrystallisation is not recommended. 2,6-dichloropyridine was 
purified by recrystallisation from absolute EtOH122. 2,4,6-trichloropyridine was 
recrystallised from 75 % or 50% EtOH in water. Extreme care are was necessary due 
to the low melting point of the compound (33-36 °C). 
 
4-dimethylaminopyridine (DMAP) was recrystallised from toluene122 or EtOAc. 
Imidazole was recrystallised from CH2Cl2 or petroleum ether (40-60). p-Tosyl chloride 
was recrystallised from an equivolume mixture of petroleum ether (40-60) and 
toluene. 18-crown-6 was recrystallised from acetonitrile; several rounds of 
recrystallisation were necessary to ensure complete removal of water. 
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5.2 Buffers and Solutions for Molecular Biology 
5.2.1 Media for bacterial growth 
LB (Leuria-Bertani) 
10 gL-1  tryptone 
5 gL-1  yeast extract 
5 gL-1  NaCl 
H2O, to final volume 
 
TB (Terrific Broth) 
This is made up in two parts. The masses given are sufficient for 1 L (total volume) of 
growth medium once combined. Each component is sterilised separately, and mixed 
immediately prior to use. 
Component A (per litre final volume) 
12 g  tryptone 
24 g yeast extract 
4 mL glycerol 
900 mL H2O 
 
Component B (per litre final volume) 
2.31 g KH2PO4 
12.54 g K2HPO4 
100 mL  H2O 
 
M9 minimal media 
Starred solutions were sterile-filtered using MillexGP syringe filters (0.22 µ metre). 
Compounds in squared-brackets were added after sterilisation – by autoclave or 
sterile filter as appropriate. 
 
M9 minimal medium (complete) (1 L) 
100 mL M9 Salts (10 x) 
1 mL 1 M MgSO4* 
0.1 mL 1 M CaCl2 
1 mL trace element solution 
[10 mL 20 % w/v glucose (aqueous) ] 
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M9 salts (10 x, 1 L)* 
150 g Na2HPO4 
30 g KH2PO4 
5 g NaCl 
[10 g NH4Cl ] 
 
In the case of isotopically enriched mixtures, the 13C-glucose and / or 15NH4Cl were 
omitted from the initial mixtures, and added aseptically immediately before 
introduction of the starter-culture. 
 
Trace elements (1000 x, 100 mL)* 
1.6 g MnCl2.4H2O 
1.5 g CuCl2.2H2O 
2.7 g CoCl2.6H2O 
3.0 g FeCl2 
4.0g Na-citrate.2H2O 
10 mg Zn(OAc)2.2H2O 
5 mg disodium edetate (EDTA.Na2) 
 
Enriched Minimal Media mixtures 
M9 + supplemental vitamins 
M9 minimal media made up as above, plus 
2.5 mL L-1 vitamin mixture * 
 
Vitamin Mixture (250 x, 1 L)* 
50 mg pyridoxal 5’-phosphate (monohydrate) 
10 mg thiamine hydrochloride 
20 mg 4-aminobenzoic acid 
20 mg D-pantothenic acid (hemicalcium salt) 
10 mg biotin 
10 mg folic acid 
5 mg cyanocobalamin 
20 mg riboflavin 
50 mg niacin 
270 mg ZnCl2 
 
When expression of labelled riboflavin was desired, the supplemental riboflavin 
(underlined) was omitted from the vitamin mixture. 
 156 
 
 
M9Y Media * 
M9 minimal media made up as above, plus 
5 g L-1 yeast extract 
10 mg L-1 FeCl2.6H2O 
Mixture was filtered prior to use. 
 
M9 + Amino acid(s) 
M9 minimal media made up as above, plus 
50 mg L-1 desired amino acid, dissolved in minimal volume H2O* 
Up to three amino acids were supplemented in this manner. 
 
5.2.2 Buffers for Chemically Competent Cells 
Super-competent Cells 
Buffer Tfb I 
100 mM RbCl 
50 mM  MnCl2 
30 mM KOAc 
10 mM CaCl2 
15 % (w/v) glycerol 
H2O, to final volume 
adjusted to pH 5.8 using dilute (0.2 % v/v) acetic acid 
N.B. manganese chloride was added after pH adjustment to prevent precipitation. 
Solution was sterile-filtered and stored at RT, but chilled to 4 °C before use. 
 
Buffer Tfb II 
10 mM MOPS 
75 mM CaCl2 
10 mM RbCl 
15 % (w/v) glycerol 
H2O, to final volume 
adjusted to pH 6.5 using KOH with caution 
Solution was sterile-filtered and stored at RT, but chilled to 4 °C before use. 
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Simple (CaCl2) Method for Competent Cells 
Buffer Ca for calcium-only competent cells 
10 mM PIPES 
60 mM CaCl2 
15 % (w/v) glycerin 
H2O, to final volume 
adjusted to pH 7.0 
Solution was sterile-filtered and stored at RT, but chilled to 4 °C before use. 
N.B. cells produced using this method were most competent after 12-24 hours stored 
in this buffer, on ice 
 
5.2.3 Buffers for Protein and DNA Separation 
SDS-PAGE Resolving Gel Buffer (1L) 
1.5 M Tris base 
100 μL 10% w/v aqueous solution of SDS 
adjusted to pH 8.0 
H2O, to final volume 
 
SDS-PAGE Stacking Gel Buffer (1L) 
0.5 M Tris base 
100 μL 10% w/v aqueous solution of SDS 
adjusted to pH 6.8 
H2O, to final volume 
 
SDS-PAGE Running Buffer 
250 mM Tris base 
1.5 M glycine 
35 mM SDS 
adjusted to pH 8.3 
H2O, to final volume 
  
 158 
 
SDS-PAGE Sample Buffer 
60 mM Tris HCl 
5 % (w/v) SDS 
10 % (w/v) sucrose 
30 % (v/v) glycerol 
3 % (v/v) β-mercaptoethanol 
0.02 % (w/v) Bromophenol blue 
 
Ammonium Persulfate Solution (1 mL, 10% w/v) 
100 mg APS 
1 mL H2O 
This solution was not stable for storage of greater than 4 days at -80 °C. 
 
SDS-Resolving Gel (12 %) 
4.0 mL Bis-acrylamide, 30% solution 
3.4 mL H2O 
2.5 mL Resolving gel buffer 
75 µL 10 % APS solution 
5 µL TEMED 
 
SDS-Resolving Gel (15 %) 
5.0 mL Bis-acrylamide, 30% solution 
2.4 mL H2O 
2.5 mL Resolving gel buffer 
75 µL 10 % APS solution 
5 µL TEMED 
 
SDS- Stacking Gel (5 %) 
1.7 mL Bis-acrylamide, 30% solution 
5.7 mL H2O 
2.5 mL Stacking gel buffer 
75 µL 10 % APS solution 
10 µL TEMED 
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Coomassie (AKA Brilliant) Blue Staining Solution for SDS gels 
0.25 % (w/v) Coomassie Blue R-250 
45% (v/v) MeOH 
9 % (v/v) AcOH 
H2O, to final volume 
 
Destaining Solution (overnight) 
15 % (v/v) MeOH 
7.5 % (v/v) AcOH 
H2O, to final volume 
 
Destaining Solution (heating method) 
50 % (v/v) EtOH 
10 % (v/v) AcOH 
H2O, to final volume 
 
TAE (50x concentration) 
2 M Tris base 
1 M glacial acetic acid 
100 mM EDTA 
adjusted to pH 8.2 
H2O, to final volume 
 
Agarose Gel (1 % w/v, for plasmids up to 8 kBp) 
0.5 g Agarose 
50 mL TAE buffer (diluted) 
 
Sample Dye Buffer (100 mL) 
30 % (v/v) glycerol 
100 µL 0.6 % (w/v) aqueous Bromophenol blue solution 
H2O, to final volume 
 
Ethidium Bromide Solution (100 mL) 
100 µg Ethidium Bromide 
H2O, to final volume 
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5.2.4 Buffers for Alkaline Lysis of Bacterial Cells, and Precipitation of DNA 
Solution I 
50 mM glucose 
25 mM Tris base 
10 mM EDTA 
adjusted to pH 8.0 
 
Solution II 
0.2 M NaOH 
1% (w/v) SDS 
 
Solution III 
3 M  KOAc 
adjusted to pH 5.2 
 
TE Buffer (10 x) 
100 mM Tris HCl 
10 mM  Na2EDTA 
H2O to 100 mL 
adjusted to pH 8.2 
 
Ethanol Precipitation of intracellular DNA 
7.5 M NH4OAc 
adjusted to pH 7.0 
EtOH, as required 
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5.2.5 Buffers for Bacterial Lysis and Purification using Spin Columns 
These buffers are used following the protocol of the QIAGEN ‘miniprep’ plasmid 
purification kit. 
Buffer P1 (suspension buffer) 
50 mM Tris HCl 
10 mM EDTA 
100 μg / mL RNase A 
adjusted to pH 8.0 
stored at 2-5°C 
 
Buffer P2 (lysis buffer) 
0.2 M NaOH 
1% (w/v) SDS 
 
Buffer N3 (neutralisation buffer) 
4 M guanidinium HCl 
0.5 M KOAc 
adjusted to pH 4.2 
 
Buffer PB (wash buffer I) 
5 M guanidinium HCl 
20 mM Tris HCl 
38% (v/v) EtOH 
adjusted to pH 6.6 
 
Buffer PE (wash buffer II) 
20 mM NaCl 
2 mM Tris HCl 
80% (v/v) EtOH 
adjusted to pH 7.5 
 
Buffer EB (elution buffer) 
10 mM  Tris HCl 
adjusted to pH 8.5 
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5.2.6 Restriction Endonuclease Buffers 
NEBuffer 1 (10x) 
100 mM Tris HCl 
100 mM MgCl2 
10 mM DTT 
pH adjusted to pH 7.0 
 
NEBuffer 2 (10x) 
100 mM Tris HCl 
500 mM NaCl 
100 mM MgCl2 
10 mM DTT 
pH adjusted to pH 7.9 
 
NEBuffer 3 (10x) 
500 mM Tris HCl 
1 M NaCl 
100 mM MgCl2 
10 mM DTT 
pH adjusted to pH 7.9 
 
NEBuffer 4 (10x) 
200 mM Tris-OAc 
500 mM K-OAc 
100 mM Mg-(OAc)2 
10 mM DTT 
pH adjusted to pH 7.9 
 
BSA Storage Buffer (for storage of 1x dilution from BSA (100x) solution) 
20 mM KPO4 
50 mM NaCl 
100 µM EDTA 
5% (v/v) glycerol 
adjusted to pH 7.0 
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5.2.7 Buffers for Purification of C. ammoniagenes RfK-FADS  
Cell Lysis Buffer 
Cell Lysis was performed using the binding / washing buffer RfK 1. 
 
Buffer RfK 1 (binding / washing) 
50 mM KH2PO4 
5 mM EDTA 
5 mM Na2SO4 
adjusted to pH 8.0 
 
Buffer RfK 2 (elution) 
Buffer RfK1, plus 
45 mM maltose (to a final concentration of 50 mM 
0.02% (w/v) NaN3  
adjusted to pH 8.0 
 
Buffer RfK 3 (dialysis) 
50 mM Tris Base 
50 mL NaCl 
0.02% (w/v) NaN3  
adjusted to pH 7.5 
 
Buffer RfK 4 (for enzymatic conversion of riboflavin to FMN / FAD) 
50 mM Tris Base 
50 mM NaCl 
30 mM MgCl2 
100 µM Purified Ca-RfK-FADS (in buffer RfK 3). 
[n] mM riboflavin / riboflavin analogue – up to 1 mg / mL 
[n x 5] mM Adenosine triphosphate  
adjusted to pH 7.5 
 
The minimum volume of buffer RfK 4 was used to dissolve riboflavin (or analogue). 
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5.2.8 Buffers for IMAC purification of 6xHIS tagged S. pombe Rf kinase 
Buffer SpRfKLYS (cell lysis buffer) 
50 mM Tris HCl 
100 mM NaCl 
adjusted to pH 8.0 
H2O, to final volume 
 
Buffer SpRfK 1 (binding buffer) 
20 mM Tris HCl 
500 mM NaCl 
10 mM imidazole 
adjusted to pH 8.0 
H2O, to final volume 
 
Buffer SpRfK 2 (washing buffer) 
20 mM Tris HCl 
500 mM NaCl 
50 mM Imidazole 
adjusted to pH 8.0 
H2O, to final volume 
 
Buffer SpRfK 3 (elution buffer) 
20 mM Tris HCl 
500 mM NaCl 
400 mM imidazole 
adjusted to pH 8.0 
H2O, to final volume 
 
Buffer SpRfK 4 (storage buffer) 
20 mM Tris HCl 
100 mM NaCl 
adjusted to pH 8.0 
H2O, to final volume 
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Buffer SpRfK 5 (FMN formation buffer) 
Buffer SpRfK 1, plus 
10 mM MgSO4 
5 mM ATP 
1 mM riboflavin / riboflavin analogue 
100 μM SpRfK protein 
H2O to Vtot  Minimum volume used to dissolve riboflavin / riboflavin analogue 
  
5.2.9 Buffers for IMAC Purification of Hisactophilin-tagged A. sativa LOV2 
Buffer LOVR (resuspension buffer) 
10 mM NaH2PO4 
0.9% (v/v) NaCl 
adjusted to pH 7.5 
 
Buffer LOVLYS (cell lysis buffer) 
50 mM NaH2PO4 
300 mM NaCl 
10 mM Imidazole 
adjusted to pH 8.0 
 
Buffer LOVA (binding & washing buffer) 
50 mM NaH2PO4 
300 mM NaCl 
10 mM Imidazole 
0.02% (w/v) NaN3 
adjusted to pH 8.0 
 
Buffer LOVB (denaturing buffer) 
Buffer LOVA, plus  
4.5 M  Guanidine thiocyanate 
adjusted to pH 8.0 
 
  
 166 
 
Buffer LOVC (elution buffer) 
Buffer LOVA, plus  
490 mM  imidazole (total solution concentration of 1M) 
adjusted to pH 8.0 
 
Buffer LOVD 20x (dialysis buffer, to remove imidazole and perform photometric 
analysis) 
100 mM NaH2PO4 
200m M NaCl 
0.4% (w/v) NaN3 (added after spectroscopic analysis) 
adjusted to pH 8.0 
 
Buffer LOVE (cleavage buffer for removal of Hisactophilin) 
50 mM NaH2PO4 OR Tris HCl (dependant on current sample buffer) 
200 mM NaCl 
2.5 mM CaCl2 
[n] mM HISACT-AsLOV2 fusion protein – up to 0.5 mg / mL 
[n x 5] units thrombin  
adjusted to pH 7.5 
 
 
5.3 TLC Systems 
All TLCs were performed on Merck TLC Silica Gel (60 Å) plates with aluminium foil 
backing. TLCs were observed using a Spectroline ENF-240C/FE Dual Wavelength lamp 
providing UV light (254nm & 365 nm). TLC plates were also developed for visual 
examination using appropriate chemical staining: ninhydrin (for compounds with 
amine functionality), dinitro-phenylhydrazine (DNPH, for aldehydes and ketones), 
cerium molybdate (CAM, also known as or Hanessian’s Stain, for general visualisation), 
or iodine (for other functionalities, in particular aromatics), as appropriate. RF values 
of each product determined is given in the relevant experimental section.  
 
 
 
 167 
 
5.4 Instruments Used 
5.4.1 Instruments Used - Synthetic Chemistry  
Balance (Analytical) KERN ALS 220-4N (accurate to 0.05 mg) 
Centrifuge (up to 4 000 rpm) Thermo Electron Corporation IEC CL31R Multispeed 
Centrifuge (up to 4000 rpm) 
Centrifuge (up to 11 000 rpm) Hettich Zentrifugen Rotina 38 R (up to 11 000 rpm) 
Fluorimeter Perkin Elmer LS 55 Luminescence Spectrometer 
Freeze Dryer Thermo Electron Corporation ModulyoD coupled to 
ThemoSavant RV8 belt-driven high vacuum (< 0.1 mBar) 
oil pump  
HPLC Dionex Ultimate 3000 system (complete) 
HPLC Dionex P680 HPLC Pump with Dionex UVD170U Variable 
Wavelength Detector 
IR Spectrometer Jasco FT/IR-660 Plus 
Mass Spectrometer Waters LCT Premier XE TOF 
Melting Point Gallekamp Variable Heater 
NMR Spectrometer Brüker AVANCE DPX 250 MHz 
NMR Spectrometer Brüker Fourier 300 MHz 
NMR Spectrometer Brüker AVANCE DPX 400 MHz (Shielded) 
NMR Spectrometer Brüker AVANCE DPX 400 MHz (ULTRA-Shielded) 
NMR Spectrometer Brüker AVANCE DPX 500 MHz (ULTRA-Shielded) 
pH Meter HANNA Instruments pH 209 meter 
Polarimeter Schmidt + Haensch UniPol L-Series polarimeter 
Press (for KBr disk formation) GRASEBY SPECAC (15 tonne) 
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Rotary Evaporator   
(water cooled) 
Heidolph Laborota 4000 Efficient (complete system), 
coupled to a VAKUUBRAND GmbH & Co. MZ-2C Pump, and 
controlled by a Heidolph feedback pressure sensor 
Rotary Evaporator  
(dry ice / acetone cooled) 
Bücki Rotavapor RE 120, with Köttermann waterbath, 
coupled to VAKUUBRAND GmbH & Co. Membrane and 
Vacuum pumps 
Solvent Drying Machine MBraun MB SPS-800 
Ultrasonic Bath Grant XB3 Ultrasonic Bath 
Stirrer/ Heating Plate IKA-WERKE RCT basic heating / stirring block, with 
removable IKA-WERKE ETS-D4 fuzzy temperature 
feedback probe 
TLC Visualisation Lamp Spectroline ENF-240C/FE Dual Wavelength (254nm & 365 
nm) 
UV Spectrometer Jasco UV-660 Spectrophotometer 
Vacuum Pump Oerlikon TRIVAC mechanical high vacuum (< 10^-2 Torr) 
oil pump  
Water Purification System Elga Purelab Ultra systems (Ω < 15.0) 
Water Purification System Elga Purelab Ultra-pure (Ω < 5.0) 
 
 169 
 
5.4.2 Instruments Used - Molecular Biology 
Agarose Gel Electrophoresis Bio-Rad mini-PROTEAN® Tetra system 
Autoclave Astell Scientific ASA-260 
Autoclave Astell Scientific AMA-260BT with SPL-400 USB 
Balances Kern ALJ 120-4 (to 0.1 mg) 
Balances Mettler Toledo AB204-5 (to 0.1 g) 
Cell Counter (UV-visible) SHIMADZU BioSpec-mini DNA/RNA/Protein Analyzer 
Centrifuge (Large Volume) Sorvall RC-5 Plus 
Centrifuge (Large Volume) Sorvall RC-6 Plus 
     Rotors Sorvall SLA-3000 
     Rotors Sorvall SS-34 
     Rotors Piramoon Technologies FIBERLite F21-8x50y 
     Rotors Thermo Scientific FIBERLite F10-4x1000 LEX 
Centrifuge (Bench-top) JENCONS-PLS Spectrafuge 24D (ambient 
temperature) 
Centrifuge (Bench-top) Eppendorf Centrifuge 5424 (with cooling) 
Circular Dichroism Applied Photophysics Chirascan instrument, coupled 
to Applied Physics Circular Dichroism Photomultiplier 
and Scanning Emission Monochromator 
Fermenter LAMBDA Minifor Laboratory Fermenter 
Fluorimeter see section 5.4.1 
FPLC Amersham Biosciences ÄKTA FPLC System, fitted with 
UPC-900, Inv-907, P-920, M-925 and Frac-950 
(autosampler) units 
Gel Visualisation Syngene Bio Imaging "Geneflash" lightbox, Syngene 
UP-895MD Video Graphic Printer 
Heating Block JENCONS-PLS SB1 mono digital block heater; 2 block 
model 
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IMAC Column Housing GE Healthcare XK 16/20 Column, fitted with Quicklock 
AK 16 adaptors 
Incubators New Brunswick Scientific Innova 43 
Incubators New Brunswick Scientific Innova 44 (variable 
temperature) 
Ion Exchange Chromatography Dionex ICS-3000 system 
Nanodrop Spectrometer Thermo Scientific NANODROP 1000 
Spectrophotometer 
Peristaltic Pump Watson-Marlow 101U/P Pump 
pH Meter HANNA Instruments pH 209 meter 
Plate Oven Heraeus Instruments Variable Temperature 
SDS-PAGE Gel Casting Hoefer Scientific Instruments SE 250 MIGHTY Small II 
See-Saw Rocker Labortechnik KS501 digital 
Sonnicator Vibra-cell SONICS 
Thermocycler (PCR) JENCONS-PLS TECHNE Touchgene Gradient 
Thermocycler (PCR) Biometra TGradient 96 
Thermomixer Block Eppendorf Thermomixer "comfort" 
UV-Visible Spectroscopy see section 5.4.1 
Vacuum Pump (filtration & 
degassing) 
Fischer-Biotech Roto-Vac 3 
Vortex Mixer Vortex Genie  
Warm Water Bath Grant SUB28 Unstirred Water Bath 
Water Purification System see section 5.4.1 
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5.5 Techniques and Methods – Chemical Synthesis 
5.5.1 General experimental techniques 
Chemical reactions were performed in glassware fitted with ground “quick-fit” joints; 
those in close proximity to reaction mixtures were not sealed using grease as is 
common practice but instead using a Teflon or PTFE gasket to prevent contamination 
of the reaction mixture. 
 
Reaction vessels were heated using solid aluminium heating blocks turned specifically 
to fit the size of flask used, or within a bath of silicon oil for complex-shaped glassware. 
Heating was monitored using an IKA-WERKE ETS-D4 fuzzy temperature probe 
mounted within a port of the heater block / bath, coupled electronically to the IKA-
WERKE RCT basic heater / magnetic stirrer apparatus. 
 
In the case of reactions performed to the exclusion of air and / or moisture, flame-
dried glassware was used, which had been heated under high vacuum for a minimum 
of 4 hours. Reagents were powdered and pre-dried, and added immediately after 
flame-drying, under a stream of N2 followed by further cycles of high-vacuum and 
flushing with Ar and N2 to ensure removal of air and moisture. Dry reactions were 
performed under Ar, with pressure release afforded by a N2 bubbler. Solvents (section 
5.1.3) used for air-free reactions were added to the sealed flask using syringes or 
canulae through rubber septa.  
 
“High Vacuum” refers to ultra-low vacuum pressure (< 10-2 Torr), provided by an 
Oerlikon TRIVAC mechanical oil-pump. This was connected via a custom-built Schlenk-
type manifold (including a N2-cooled trap) to the reaction vessels using double-oblique 
connections, with the alternative position supplying N2 gas and protected by a 
pressure-release bubbler. 
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5.5.2 Purification methods (chemical synthesis) 
5.5.2.1  Thin Layer Chromatography (TLC) 
Analysis by TLC is discussed in detail in section 5.3 above. 
 
5.5.2.2  Flash Chromatography (FC) 
Purification by FC was performed using a gel of silica formed using an appropriate 
solvent mixture, and technical grade silica gel (pore size 60 Å, 234-400 mesh size, 40-
63 µm particle size). This was retained between a layers of sand and glass sinter within 
a glass column, and pressurised using a hand pump. Fractions of an appropriate 
volume were collected before analysis by TLC to indicate fraction composition. 
 
5.5.2.3  High Performance Liquid Chromatography (HPLC) 
HPLC Analysis was performed using a complete Dionex UltiMate 3000 system, 
including a variable wavelength UV-visible detector, or using a Dionex P680 HPLC 
pump system coupled to a Dionex UVD170U variable wavelength detector. Solvents 
for HPLC were of HPLC or analytical grade, supplied by Fischer or (in the case of 
buffers) freshly prepared using water obtained from an Elga Purelab Ultra-pure 
system. All buffers were thoroughly degassed using a vacuum pump prior to use. 
Conditions and gradients are described in the appropriate experimental chapters 
(sections 6.5 and 7.1.5). Gradients are shown graphically in appendix 1. Columns used 
include Phenomenex Gemini® 10 µm RP C18 110 Å 250 x 10 mm (part no. 00G-4436-
N0), Phenomenex Luna® 10 µm RP C18(2) 100 Å 250 x 10 mm (part no. 00G-4252-N0) 
and YMC-Actus Triart Prep C18-S 250 x 20 mm (part TA12S05-2520WX). Fractions from 
HPLC were lyophilised using a Thermo Electron Corporation MOLULYOD freeze dryer, 
with high vacuum (< 0.1 mbar) provided by a ThermoSavant RV8 belt-driven oil pump. 
 
5.5.3  Methods for spectral analysis 
Solid samples for NMR spectroscopy (10 mg for 1H; 20-50 mg for 13C) were prepared 
by dissolution in a suitable deuterated solvent, and added to an NMR tube to a depth 
of 45 mm. Liquid samples were added neat to a depth of 10-15 mm, topped up to a 
final depth of 45 mm using a suitable deuterated solvent. This was necessary to 
provide sufficient deuteration to allow locking of the spectrometer to the deuterium 
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signal, as an internal standard. Spectra were measured using an NMR spectrometer 
(section 5.4.1) of an appropriate field strength. 
 
Solid samples for Mass Spectrometry (MS) were submitted to the internal MS service 
at Cardiff University (5-20 mg). Samples were dissolved in solvent immediately prior 
to examination except samples which were only soluble in DMSO, which were 
analysed as a solid; liquid samples were submitted neat. Photosensitive samples were 
stored in the dark until immediately prior to examination. Samples were analysed 
using a Waters LCT Premier XE Time-of-Flight Spectrometer. Solid samples for IR 
analysis (1-5 mg) were milled together with KBr (spectroscopic grade). The resultant 
fine powder was formed into a disk using a GRASEBY SPECAC press (15 tonne) before 
analysis using a Jasco FT/IR-660 Plus spectrophotometer. Melting point (MP) 
measurements were collected using Gallenkamp Variable Heater apparatus fitted with 
an internal temperature probe and confirmed using a mercury thermometer, and are 
uncorrected. Chemical samples for UV-visible spectroscopy were prepared using a 
suitable solvent of HPLC or spectroscopic grade, measured in a capped Hellma 
semimicro CXA-145-307L far-UV quartz cuvette. A further description of UV 
spectroscopy is given in section 5.6.8.  
 
5.6 Techniques and Methods – Molecular Biology 
5.6.1 General experimental techniques & suppliers 
The pH of buffers and solutions were measured using a HANNA Instruments ‘pH 209’ 
device accurate to 2 decimal places, and were adjusted using the appropriate 
conjugate acid or base. All pH values given are at 20 °C unless otherwise stated. Liquid 
cultures were incubated with shaking in New Brunswick Scientific Innova 43 or Innova 
44 shakers, with variable temperature control between 10 °C and 40 °C. Temperatures 
of 37 °C were typically used for cell growth, and between 16-24 °C for protein 
expression. Enzymes obtained from commercial sources (thrombin, lysozyme) were 
purchased from Sigma-Aldrich. Pfu and Taq DNA polymerase and restriction 
endonucleases were obtained from New England Biolabs. RNase A was purchased 
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from Quiagen. Amylose resin, Ni-NTA and Chelating Metal Sepharose (fast flow) were 
obtained from GE Healthcare. Columns for FPLC were obtained from the same source. 
 
Sequencing of DNA samples was organised by the internal DNA sequencing service at 
Cardiff University’s School of Biosciences, operated by Dr Steven Turner. The 
sequencing operation was sub-contracted to Eurofins, and performed using ABI 
Genetic Analysers 3739xl machines (96 capillary), using the ddNTP chain termination 
method. Read-lengths of 900 – 1000 b.p. (after initial non-readable data) were 
typically obtained.  
 
5.6.2  Bacteriological culturing and protein expression 
5.6.2.1  Culture preservation 
Bacterial cultures were stored on LB-agar or TB-agar plates (supplemented with 
appropriate antibiotic(s), sealed using parafilm and stored at 4 °C in the dark. At 
periods not longer than 4 weeks, new cultures were prepared from a single colony on 
fresh medium, with periodic sequencing of the plasmid from the daughter cells to 
confirm fidelity. 
 
Storage for extended periods was performed by preparation of a 20 mL starter culture 
(as described in section 5.6.2.2) containing an appropriate antibiotic, incubated with 
shaking at 37 °C overnight. The resultant mixture was centrifuged, the cells washed 
with 0.9 % saline, and resuspended using a mixture of 0.5 mL LB media, 0.25 mL 
sterilised H2O and 0.25 mL glycerol. The resuspended mixture was flash frozen in 2 mL 
Eppendorf tubes using liquid N2, followed by storage at -80 °C. 
 
5.6.2.2  Microbial culturing 
An overnight ‘starter culture’ was made of the bacterium containing the desired 
construct by selecting a single colony from its storage plate, or by collecting a small 
number of cells using a red-hot sterile culture loop from a flash-frozen liquid sample 
prepared as described above. This was used to inoculate a small volume of LB media 
(100 mL was sufficient to allow subsequent large-scale expression in 3 L of growth 
media), which was treated with an appropriate antibiotic and incubated with shaking 
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at 37 °C overnight. The resultant mixture was centrifuged, cells were washed with 
0.9 % (w/v) saline and resuspended in a small volume of an appropriate growth media.  
 
Media for bacterial growth was made up as described in section 5.2.1. Prepared 
growth media was divided into baffled 2 L Erlenmeyer flasks (500 mL per flask) capped 
with air-permeable foam bungs and foil, and autoclaved. Flasks were sealed 
immediately upon sterilisation, and cooled media was stored at 4 °C in the dark until 
required. Immediately prior to use, cooled media was supplemented with appropriate 
antibiotic(s) under aseptic conditions and warmed to incubation temperature. To this, 
a portion of the starter-culture prepared as above was added, and the flasks were 
incubated at 37 °C until an OD600 between 0.6-0.8 (LB media), 1.2-1.6 (TB media), or 
0.5-0.7 (M9 minimal media) was reached. At this point, isopropyl-1-thio-β-D-
galactopyranoside (IPTG, 1-5 mM) was added, along with supplemental antibiotic(s) if 
required. The mixture was incubated as determined by expression tests (vide infra) 
and described for each construct in chapter 4; generally at 37 °C for 4 hours, or 20 °C 
overnight. Cells were harvested by centrifugation (30 minutes, 4500 RPM, 4 °C,), 
resuspended and washed with 0.9 % saline, recentrifuged, and stored at -20 °C until 
required. 
 
5.6.2.3  Expression efficiency testing 
The efficiency of bacterial expression was examined during the microbial culturing 
phase by collection of samples (2-5 mL) at timed intervals (generally 30 or 60 minutes) 
after supplementation of the media with IPTG (in varying concentrations). Cells within 
the sample was harvested as before, and the samples lysed using the alkaline lysis 
method (section 5.6.3.1). Whole-cell lysate was analysed using SDS-PAGE (discussed 
in section 5.6.4.1) to indicate levels of protein expression. 
 
5.6.2.4  Protein expression methodology 
The gene(s) of interest were located within a plasmid expression vector. Several 
vectors were used during this project (section 5.7.2) Those genes within a pMal-C2 
vector were under the control of a tac promoter, pET14b and pLysS vectors were 
under the control of a T7 promoter and lac operator, while pNCO113 and pRep4 
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vectors were similarly under control of T5 promoter containing a lac operator. 
Expression of genes contained within the expression vectors (pMal-C2, pEt-14b, 
pNCO113) was initiated by addition of IPTG (1-5 mM) to the bacterial growth medium, 
while the control vectors (pLysS and pRep4) were used to suppress basal levels of gene 
expression in specific strains, and expression of their genes was thus inhibited by 
addition of IPTG.  
 
5.6.3  Methods for cell lysis 
Buffers and solutions used in this section are given in sections 5.2.4 and 5.2.5 above. 
 
5.6.3.1  Alkaline lysis method 
This method was used for general-purpose periodical analysis of bacterial samples, for 
example during the expression test described in section 5.6.2.3. This method was also 
occasionally used to isolate intracellular DNA, as an alternative to the QIAprep kit 
(section 5.6.3.3). This method uses solutions I, II and III to lyse the cells and neutralise 
the alkaline mixture, before analysis using SDS-PAGE.  
 
A portion of cells were centrifuged (4000 RPM, 30 minutes, 4 °C). Solution I (150 µL) 
was used to resuspend the cells. Solution II (150 µL) was added, and the mixture gently 
mixed by pipetting or inversion. Solution III (150 µL) was added, which occasionally 
caused the precipitation of the potassium salt of SDS. In this case, addition of 1-2 drops 
of CHCl3 was added to dissolve this. After thorough mixing, the mixture was 
centrifuged (15000 RPM, 5 minutes, 4°C), and the supernatant collected by decanting. 
If analysis of the protein content of the cell lysate was required, the supernatant liquid 
was analysed by SDS-PAGE at this stage. 
 
To collect DNA, EtOH (1 mL) was added, and the mixture recentrifuged (15000 RPM, 
15 minutes, 4 °C). The cell pellet was retained, and dried at 37 °C for 30 minutes. Once 
dry, buffer TE (100 µL) and DNase-free RNase A (2 µL, 10 mg mL-1) was added to the 
solution. The mixture was incubated at 37 °C for 30 minutes, and the purified DNA was 
isolated by precipitation using the method described in section 5.6.3.2 below. 
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5.6.3.2  Purification of DNA by precipitation using EtOH 
Precipitation of plasmid DNA using EtOH was performed in order to provide purified 
(salt and RNA-free) DNA for further uses. To a solution (50 µL) of DNA obtained as 
above, or collected from a spin-column, NH4OAc (7.5 M, 50 µL) was added, along with 
2.5 volumes of absolute EtOH. The mixture was gently mixed, and allowed to stand at 
RT for 10-15 minutes. After centrifugation (13000 RPM, 15 minutes, RT), the 
supernatant was discarded, and the pellet resuspended in a solution of EtOH (80 % 
(v/v) aqueous, 250 µL), before further centrifugation (as before). The supernatant was 
again discarded, and the pellet of purified DNA dried at 37 °C in an oven before storage 
at -20 °C. Resuspension was generally performed using 50 µL of water, although lower 
volumes gave relative increases in DNA concentration. 
 
5.6.3.3  Lysis and purification using QIAprep ‘mini-prep’ plasmid isolation kit 
This method provided a fast and convenient method to collect both whole-cell lysates 
and to isolate intracellular DNA (which is its main purpose). It was performed using a 
mixture of buffers (P1, P2 and N3) to lyse the cells and neutralise the lysate, followed 
by purification of the intracellular DNA using the supplied anion-exchange (spin) 
columns. Retention of the DNA allowed purification by washing, before a reduction in 
the ionic strength of the washing solution enabled elution of the purified DNA. 
Purification was often supplemented by precipitation using EtOH (vide supra). 
 
To an overnight sample of cells which had been harvested by centrifugation, the cell 
pellet was resuspended in buffer P1 (250 µL) on ice. To this, buffer P2 (250 µL) was 
added, with gentle inversion of the tube to facilitate mixing. This was allowed to stand 
for 5 minutes, before addition of buffer N3 (350 µL), with immediate mixing. The 
mixture was centrifuged (13000 RPM, 10 minutes, 4 °C), and the supernatant liquid 
(cell lysate) collected. For purification of intracellular DNA, the supernatant was 
applied to a QIAprep spin column, and centrifuged (13000 RPM, 1 minute). The flow-
through was discarded, and buffer PB (500 µL) added before centrifugation (as 
before). Buffer PE (500 µL) was added, and centrifugation (as before) performed in 
duplicate, in order to fully remove all of the ethanolic buffer. Finally, DNA was eluted 
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from the column using sterilised H2O, followed by standing at RT for 5 minutes and 
centrifugation as before. Purified DNA was isolated from the flow-through. 
 
5.6.3.4  Sonication lysis of cells from large scale microbial culture 
Cell pellets obtained from large-scale microbial culture (section 5.6.2.2) were lysed 
using sonication. Rupture of the cell walls was necessary to release proteins over-
expressed by the inserted plasmid, which were expressed within the cytoplasm of the 
cell. This method was selected due to the fast, reliable disruption of large quantities 
of cells without addition of reagents to the mixture, with the main risk being from 
heating induced by the high-powered sonic probe, or excessive duration leading to 
degradation of the recombinant protein. All lysis using this method was performed 
while cooling the sample tube in a bath of crushed ice.  
 
Cell pellets were thoroughly resuspended in the relevant lysis buffer, before 
subjection of the mixture to sonication for an intermittent cycle to minimise inductive 
heating. SDS-PAGE was used to identify the optimal sonication pattern. PMSF was 
added pre-sonication to the lysis mixtures, except for those containing AsLOV2. Once 
lysed, the mixture was centrifuged (11000 RPM, 1 hour, 4 °C or 15000 RPM, 
45 minutes, 4 °C), and the supernatant decanted. This was filtered using a MillexGP 
syringe filter (0.22 µm) in order to remove any further suspended particles, before 
purification as necessary. 
 
5.6.4  Electrophoresis of protein and DNA samples 
All buffers and solutions used in this section are described above in section 5.2.3. 
 
5.6.4.1  Sodium Dodecyl Sulphate Polyacrylamide Electrophoresis (SDS-PAGE) 
SDS-PAGE was performed according to the discontinuous procedure of Laemmli243, in 
order to analyse the protein content of bacterial lysates and solutions. SDS is an 
anionic surfactant, capable of denaturing and solubilizing a protein sample. SDS also 
confers a charge to the protein proportional to its size, stabilising the protein in a rod-
like form by electrostatic repulsion. This negative charge allows electrophoretic 
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separation of different sized proteins through a gel of polymerised acrylamide, with 
motility of a given protein inversely proportional to its size.  
 
The gel was prepared using the discontinuous buffer system, using a resolving gel 
(where protein analysis occurs) topped by a low-strength stacking gel (confining 
separate protein samples). The resolving gel was prepared first; after mixing of the 
components, initiation of polymerisation was performed by a small volume of 
ammonium persulfate solution. The initiated solution was cast between two glass 
plates, with a recess (3 cm) at the top filled with isopropanol to give a defined level 
surface between layers. 
 
After completion of polymerisation, isopropanol was removed and the top of the gel 
rinsed with water before being thoroughly dried. After preparation of the stacking gel, 
initiation was again performed by APS, and the initiated solution added above the 
resolving gel in the unfilled recess between plates. Once added, a 10 or 15 well comb 
was inserted to leave defined areas in which to add the protein sample. Once 
polymerisation was complete, SDS-PAGE electrophoresis was performed immediately. 
The casting plate was fitted within the electrophoresis system, and submerged in SDS 
running buffer. The gel comb was removed, and checks for leaks were made. Protein 
samples were mixed in equivolume with SDS-sample buffer (section 5.2.3). The 
mixture was heated at 95 °C for 10 minutes, to ensure protein denaturation by the 
SDS. Prepared samples were loaded into the gel, alongside a standard marker 
containing a mixture of protein molecular weights (SM0431, section 5.7.4.1) to allow 
determination of relative protein masses.  
 
Electrophoresis was performed by passing a current of 50 mA (180 V) across the gel 
for approximately 1 hour, causing resolution of the protein samples. Larger proteins 
were more strongly retarded by the polyacrylamide gel, and thus did not move as far 
as smaller proteins. Upon completion, the gel was removed from the apparatus and 
separated from its glass plates, before staining with the SDS-PAGE staining solution 
(section 5.2.3). This was generally performed at room temperature for 1 hour. The gel 
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was destained with the destaining solution overnight, to leave visible bands of protein 
for characterisation (section 5.6.4.3). 
 
5.6.4.2  Agarose gel electrophoresis 
For analytical and preparative scale purification and separation of DNA fragments, 
agarose gel electrophoresis was used. Due to the innate negative charge of DNA, it 
can be separated electrophoretically through a gel of agarose, with motility inversely 
proportional to the DNA fragment size. Using this method, it was possible to separate 
both small fragments of DNA, and large plasmid vectors containing several genes.  
 
Due to the secondary structural effects of plasmids (such as supercoiling), circular DNA 
was nicked using an appropriate restriction enzyme. Typically, gels of 1 % (w/v) agarose 
were used for complete vectors (up to 8 k.b.p.), or 2 % for smaller DNA fragments (up 
to 2 k.b.p.). Electrophoresis was performed using a Bio-Rad mini-PROTEAN® Tetra 
system. 
 
Powdered agarose was suspended in diluted TAE buffer, and heated using a domestic 
microwave oven (with extreme caution) until the powder was fully dissolved. The 
solution was allowed to cool to 50 °C, and poured into the gel casting / running case, 
with a gel comb added to provide wells to accept the electrophoresis samples. The gel 
was cooled to 4 °C for 30 minutes. Samples for electrophoresis (2-5 µL for analytical; 
10-20 µL for preparative-scale uses) were mixed with DNA sample dye (2 µL of 6x 
concentration, section 5.2.3), along with a small volume of glycerol (for low DNA 
concentrations) if required. The solidified gel was placed into the electrophoresis tray 
filled with diluted TAE buffer, and completely submerged. The gel comb was removed 
and DNA samples loaded into the formed wells, with one well containing a DNA 
marker (0.1 k.b.p. or 1 k.b.p. ladder, section 5.7.4.2). The gel was subjected to 
electrophoresis at 80 mA for 120 minutes (with care taken to ensure the gel did not 
heat during the procedure), with performance monitored by observing the 
progression of the sample dye. 
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Following completion of electrophoresis, the gel was rinsed with water and 
submerged in a bath of freshly-prepared ethidium bromide (EtBr*, section 5.2.3) for 
30 minutes, and rinsed with water. Due to the strong intercalation effect of EtBr with 
DNA, bands containing DNA became visible under UV light, at concentrations as low 
as 10 ng. These were characterised as described below. 
* - By convention, ethidium bromide is abbreviated to EtBr. 
 
5.6.4.3  Gel visualisation 
Both SDS-PAGE and Agarose Gels were visualised using a Syngene Bio Imaging 
“Geneflash” light box, coupled to a Syngene UP-895MD video-graphic printer. This 
provided both a white and UV light source, and allowed photography of the gel to 
provide documentary evidence of the results. 
 
Polyacrylamide gels from SDS-PAGE were previously stained using Coomassie 
(Brilliant) blue, which leaves visible blue bands indicating the presence of protein. SDS-
PAGE gels were run alongside a sample of a molecular weight marker (SM0431; 
section 5.7.4.1) comprised of several proteins of known sizes. This was used to provide 
an accurate assessment of sample composition. 
 
Agarose gels stained using ethidium bromide were compared to a DNA ladder 
(1 k.b.p.; section 5.7.4.2) containing DNA fragments of known size, which was 
subjected to electrophoresis alongside DNA samples. Comparison of bands (visible 
under UV light after EtBr staining) within the sample allowed assessment of DNA size. 
 
5.6.5  Competent cells and transformation 
Chemically competent cells were made using two methods, to give “super competent” 
cells for use with low concentrations of DNA and products from PCR, and ordinarily 
competent cells which were used for procedures which were known to be successful, 
when a large excess of DNA was available or if several repetitions were to be 
performed. Both methods make use of positive cations which are able to aid the 
incorporation of DNA into the cell by preventing the unfavourable electrostatic charge 
between the negatively-charged DNA molecule and anions within the cell wall. The 
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use of rubidium is often reported244 to be superior to calcium for this purpose, along 
with the inclusion of other multivalent cations in the buffers used for super-competent 
cells. Buffers for these procedures are found in section 5.2.2. 
 
5.6.5.1  Chemically (ordinary) competent cells 
This method made use of buffers containing a high concentration of Ca2+ ions to 
facilitate formation of small pores in the cell wall of a bacterium, allowing exogenous 
DNA to be incorporated into the cell via a disruptive process such as heat-shocking.  
 
A small-scale culture of the desired strain of bacterium was grown overnight, of which 
a portion was used to inoculate a sterilised flask of LB growth medium (250 mL). This 
culture was inoculated with appropriate antibiotic (if available), and incubated at 37 °C 
with shaking until an OD600 of 0.5-0.6 was reached. The culture was immediately 
cooled on ice, and centrifuged when cool (4500 RPM, 30 minutes, 4°C). The cell pellet 
was resuspended in Buffer Ca (section 5.2.2) and centrifuged as before, which was 
repeated. Finally, the cells were resuspended in 10 mL of Buffer Ca. The cells were 
allowed to stand on ice overnight, with a maximum reported competency obtained 
after 24 hours245. At this point, aliquots (100 µL) were selected under aseptic 
conditions, and flash-frozen in liquid N2 before storage at -80 °C. Transformation 
efficiencies up to 5 x 103 transformants per µg DNA were obtained using these cells. 
 
5.6.5.2  Chemically (super) competent cells 
Using this method, a culture was grown as before to the point at which the cells were 
harvested by centrifugation. However, the cells were resuspended in buffer TFB I 
(150 mL), and stood on ice for a further 15 minutes. After centrifugation (4500 RPM, 
30 minutes, 4°C), the cell pellet was resuspended in buffer TFB II (20 mL), and flash 
frozen in aliquots (100 mL) before storage at -80 °C. Transformation efficiencies up to 
5 x 106 transformants per µg DNA were obtained using these cells. 
 
5.6.5.3  Transformation of plasmid DNA into competent cells 
Transformation describes the process of inserting plasmid DNA into an appropriate 
host bacterium. A number of bacterial strains were used during this project, with 
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several subtle nuances required for each. In all cases, each step was performed on ice 
unless otherwise stated. A sample of competent cells (100 µL) was thawed on ice, 
which were then added to the DNA to be transformed, containing approximately 1 ng 
of DNA. The mixture was thoroughly mixed and allowed to stand for 30 minutes, 
followed by heat-shocking at 42 °C in a water bath for 60 seconds. Cells were 
immediately cooled on ice for 15 minutes, after which LB media (1.5 mL) at 4 °C was 
added, and the mixture allowed to gradually warm to room temperature. After 45 
minutes from heat-shocking, cells were incubated at 37 °C for 1 hour, followed by 
centrifugation. The cell pellet was resuspended in LB media (150 µL), and plated on 
LB-agar plates prepared with appropriate antibiotics in order to provide selection for 
successful transformants.  
 
5.6.6 Site Directed Mutagenesis (SDM) using Polymerase Chain Reaction (PCR) 
5.6.6.1  Introduction to the Polymerase Chain Reaction (PCR) 
The Polymerase Chain Reaction246,247 is one of the key techniques performed in 
modern-day molecular biology, typically used to duplicate small quantities of DNA. 
When performed over a number of cycles, DNA is replicated almost exponentially, 
greatly increasing the amount present for other uses. The four key constituents of the 
PCR are (i) the template DNA, (ii) a set of short (20-30 b.p.) oligonucleotide “primers”, 
specific to known regions of the template DNA, (iii) deoxynucleotide triphosphate 
(dNTP) forms of the four DNA nucleobases, and (iv) a thermostable DNA polymerase, 
such as Taq or Pfu.  
 
The reaction takes place in a cycle of three steps (denaturing, annealing and extension 
or elongation), each occurring at different temperatures. During the denaturing step 
(94-96 °C), the double-stranded DNA template separates, to give single DNA strands. 
The temperature is then reduced to the melting temperature of the specific primers 
used (usually 45-60 °C), allowing the oligonucleotide to anneal to each strand of the 
DNA. The oligonucleotide anneals preferentially to the complimentary DNA strand, as 
it is both much smaller, and present in great excess.  
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Once annealing is complete, the temperature of the reaction is increased to the 
optimal temperature for the DNA polymerase (72 °C for both Taq and Pfu), allowing 
elongation to proceed. The DNA polymerase binds at the annealed primer, and adds 
dNTPs complimentary to the template strand of DNA, forming a new strand of DNA. 
An average rate of incorporation of 1000 nucleotides per minute is typically assumed, 
however this is reduced for DNA polymerases which possess 3’5’ exonuclease 
(proof-reading) activity, such as Pfu. After elongation, the cycle is then repeated, with 
the newly-formed DNA after each cycle also able to act as a template for further 
reactions, increasing the proportion of DNA in a near-exponential manner. 
 
The PCR is commonly performed using short (500 b.p. to 1.5 k.b.p.) sequences of DNA, 
although it is possible to perform the reaction with longer DNA strands (such as an 
entire plasmid) acting as the template. While larger lengths of DNA require extended 
elongation times, and their use carries an increased risk in undesired mutation due to 
processional errors by the DNA polymerase, the oligonucleotide primer may be 
located at any point of the DNA sequence, allowing the DNA polymerase to process in 
the usual 5’3’ direction until it has reproduced the entire strand of DNA. This vastly 
reduce the time required to prepare the reaction, as the gene of interest does not 
have to be isolated from the vector before the PCR. 
 
5.6.6.2  Site Directed Mutagenesis using the PCR 
A recent application of the PCR process has been to perform site directed mutagenesis 
(SDM) of an amino acid within a recombinant protein by mutation of an individual 
base pair(s) of the codon responsible for expression of the amino acid. Using a DNA 
primer complimentary to the template DNA containing a mismatch at the position 
where mutagenesis is desired allows incorporation of the template’s sequence in all 
daughter DNA created by the DNA polymerase. Further reactions using either strand 
of DNA (parental or daughter), each give rise to a mutant strand, which proportionally 
increases the quantity of mutant DNA with each successive round of PCR.  
 
Key to the success of this method is separation of the parental (original sequence) and 
daughter (mutant) DNA. The template DNA used for the PCR was obtained from XL1-
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blue cells, which possesses the dam+ genotype, leading to methylation of every 
adenine group in DNA within the cell. This allows differentiation between parental 
(original) and daughter (mutant) DNA created by the PCR, as adenine present within 
the daughter DNA is unmethylated. Treating the mixture using the restriction enzyme 
DpnI (see section 5.6.6.4) cleaves DNA between adenine and thymine in the sequence 
5’-GA(Me)*TC-3’ when adenine is methylated. This effectively removes the 
methylated parental DNA, preventing its subsequent transformation – while newly-
formed daughter (mutant) DNA is undamaged by DpnI, and free to be transformed. 
DNA created by the PCR was transformed into super-competent cells (2.6.5.2), with 
initial transformation efficiencies up to 1 x 102 transformants per µg DNA.  
 
5.6.6.3  Construction of AsLOV2(C450X) mutants 
Construction of several mutants of AsLOV(C450X) (where X = alanine, glycine, serine, 
methionine or aspartic acid) was performed using the methodology given in sections 
5.6.6.2 and 5.6.6.3 above. Oligonucleotides used to create the mutants using the PCR 
are described in section 5.7.3. 
 
5.6.6.4  Restriction digestion of DNA samples 
The ability to manipulate DNA by cutting is performed using enzymes known as 
restriction endonucleases. These enzymes recognise specific sequences of DNA, which 
are generally palindromic (enabling digestion of both the sense and anti-sense 
strands). The enzymes cut at a specific point within the restriction site, with two 
possible outcomes: cuts with an overhanging (also known as “sticky”) DNA section 
(either 5’ or 3’), or a cut with no overhanging section (known as a “blunt” cut). Other 
uses of restriction endonucleases include the differentiation between methylated and 
non-methylated DNA (described in section 5.6.6.2) and the nicking of cyclic DNA from 
plasmid vectors (cutting at a single site, to allow the ordinarily super-coiled cyclic DNA 
to relax, for accurate results using agarose electrophoresis). 
 
In cases where isolation of a DNA fragment was desired (for example, removal of a 
gene from a plasmid vector), digestion was necessary at both ends of the DNA 
fragment. This could be performed in two ways: (i) using two sequential digestions, 
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requiring inactivation of the first endonuclease before addition of the second, but 
allowing purification of the DNA after each reaction, or (ii) using a “double digestion”. 
The use of double digestions (with the mixture containing both endonucleases) was 
significantly faster to perform, but extra care was necessary to check the compatibility 
of the enzymes and buffers used.  
 
For analytical digestions, between 100-500 ng of DNA was used, treated with 1 unit 
(U) of the desired restriction endonuclease (1 U is defined by the manufacturer (New 
England Biolabs) as “the amount of enzyme required to completely digest 1 µg of 
substrate DNA in a reaction volume of 50 µL in 1 hour”) and buffer (appropriate to the 
enzyme) added to the required volume. The reaction was heated at 37 °C for 1 hour, 
and analysed using agarose gel electrophoresis (section 5.6.4.2). Preparative-scale 
digestions were performed using 1-5 µg of DNA, in a total reaction volume of 100-250 
µL, with appropriate volumes of buffer and 5-10 U of endonuclease. Incubation times 
up to 4 hours were used for single-enzyme reactions, and 6 hours for double-
digestions. Single-enzyme reactions were heat-inactivated in a hot water bath 
(temperatures specific to each endonuclease given in table 10 below) for 20 minutes 
after completion of the reaction. Conditions for double-digests were obtained from 
New England Biolabs. 
Enzyme 
Recognition 
Sequence 
Optimal 
NeBuffer 
Inactivation 
Temperature 
Comments 
BamHI 5’-G*GATCC-3’ 3 (+ BSA) -  
BamHI-HF 5’-G*GATCC-3’ 4 -  
DpnI 5’-GA(Me)*TC-3’ 4 80 °C Only cuts where 
adenine is methylated 
EcoRI 5’-G*AATTC-3’ 1-4 65 °C  
EcoRI-HF 5’-G*AATTC-3’ 4 65 °C  
HindIII 5’-A*AGCTT-3’ 2 65 °C  
HindIII-HF 5’-A*AGCTT-3’ 4 80 °C  
KpnI 5’-GGTAC*C-3’ 1 (+ BSA) -  
NdeI 5’CA*TATG-3’ 4 65 °C  
Table 10: Restriction endonucleases used during this research. All enzymes were 
provided by New England Biolabs. Cutting site within the recognition sequence is 
indicated by a star. All endonucleases (except DpnI) caused sticky-ended fragments  
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5.6.7  Purification of expressed proteins 
5.6.7.1  Amylose Affinity Chromatography 
Buffers used for amylose affinity chromatography of the C. ammoniagenes 
bifunctional RfK-FADS protein are described fully in section 5.2.7. Cells were thawed 
in buffer RfK 1, before addition of PMSF (5 mM). Cells were ultrasonically lysed and 
centrifuged (section 5.6.3.4), with the filtered lysate loaded onto a column (1 cm2 
x 6 cm) of amylose resin, which had been prepared according to the manufacturer’s 
instructions (GE Healthcare). After loading, the column was washed using 5 column 
volumes (c.v.) of buffer RfK 1. UV absorbance of the flow-through was monitored at 
280 nm, and once this decreased to zero, the RfK-FADS protein was eluted using buffer 
RfK 2. Fractions were collected and analysed by SDS-PAGE. 
 
5.6.7.2  Immobilised Metal Affinity Chromatography (IMAC)  
IMAC was performed to purify several protein samples, which are individually 
described in chapter 4. Buffers required are listed in sections 5.2.8 and 5.2.9.  
 
IMAC relies on the principle of a target protein coupled to residues or a further 
protein, which contains several surface amino acids with a high affinity for metal ions. 
Typically, histidine residues are most commonly used for this purpose, due to their 
high affinity for transition metals (particularly Ni, Cu, Zn and Fe). This can be utilised 
to purify a particular protein from a complex mixture, using a metal-chelating resin. 
Protein retained by the resin may be released using a buffer containing imidazole, 
which competes with the histidine residues and releases the protein. Nickel was most 
commonly used as it is strongly bound by the resin, while allowing efficient release of 
isolated proteins using gentle gradients of imidazole.  
 
Two metal-chelating resins were utilised – Ni-NTA and Chelating Sepharose Fast Flow 
(GE Healthcare) – retained within an XK 16/20 Column (GE Healthcare), equipped with 
an external jacket for cooling of the sample, if required. The column was capped with 
two QuickLock AK 16 adaptors, to enable visualisation of the entire resin bed to allow 
accurate monitoring of protein binding. The resin bed (5-20 mL) was cast with 
continual pouring, and the column packed by hand with headspace over the resin 
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minimised. Solutions were loaded onto the column and forced through the resin using 
a Watson-Marlow 101U/P peristaltic pump. Purified proteins were released with 
imidazole-containing buffers, with imidazole removed from the eluted protein by 
dialysis, FPLC (size-exclusion) or desalting (section 5.6.7.4) 
 
5.6.7.3  Fast Protein Liquid Chromatography (FPLC) 
FPLC was used to purify protein samples. This technique is similar to HPLC (section 
5.5.2.3), where a sample containing several analytes is forced through a 
chromatographic column (stationary phase) containing a solid medium which retards 
the progress of the analytes based upon their physical characteristics (size, polarity 
etc.), allowing separation. The buffer(s) used for the FPLC act as the mobile phase, 
with either a single buffer or a gradient of ionic strength used to facilitate separation. 
 
The apparatus for this included an Amersham Biosciences ÄKTA FPLC system, fitted 
with UPC-900, P-920, M-925 and Inv-907 modules and a Frac-950 autosampler unit. 
Columns used were Superdex® 75 or 200 size exclusion columns, or Q-Sepharose® 
anion exchange columns (Amersham Biosciences). Each was equilibrated with the 
desired mobile phase (5 c.v.), before samples were applied. The sample was eluted 
with absorbance of the eluent monitored at an appropriate wavelength. Fractions 
containing the target protein were examined by SDS-PAGE to confirm the presence of 
the desired protein, and concentrated by ultrafiltration if necessary. 
  
5.6.7.4  Desalting using FPLC 
A pre-packed HiPrep™ 26/10 desalting column was used to exchange the buffer of 
protein samples. The column was equilibrated with a minimum of 5 c.v. of the desired 
buffer. Pre-concentrated protein samples (up to 10 mL) were applied to the column 
at a flow rate of 2 mL min-1, followed by elution with a flow rate of 5 mL min-1. Fractions 
were examined by UV-visible spectroscopy (for chromophore-containing solutions) 
and SDS-PAGE, and similar fractions were combined. Electrical conductivity was also 
monitored, and used to indicate elution of the original buffer. 
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5.6.8  Spectroscopy of protein samples 
5.6.8.1  UV-visible spectroscopy 
UV spectra were measured using a Jasco UV-660 UV-visible spectrophotometer 
coupled to a variable-temperature control unit, able to maintain housing 
temperatures at +/- 0.5°C from 5 °C to above 60 °C. Flushing the chamber with N2 was 
used to prevent the formation of condensation on the surface of the sample cuvette 
at non-ambient temperatures. Spectra were recorded at 20 °C unless otherwise 
stated. Samples were examined in suitable solvents and measured within a capped 
Hellma semimicro CXA-145-307L far-UV quartz 1400 μL cuvette.  
 
Analysis of DNA concentrations was performed using a Thermo Scientific NANODROP 
1000 UV-visible Nanodrop Spectrophotometer, to determine sample concentrations 
and purity. 
 
5.6.8.2  Irradiation of AsLOV2 Samples 
Irradiation of samples was performed using a variable-power LED lighting apparatus 
created specifically for this project. This comprised a 12 V DC power supply powering 
an LED, controlled through a potentiometer. SMD LEDs were fitted to a removable 
base, allowing replacement of the LED to give alternative wavelengths. Light was 
focussed to a narrow beam using an encapsulating lens (14 ° beam angle, part no. 
OPC1-1). SMD LEDs (Philips LUMILEDS, Rebel range) of varying colours were adapted 
for use with this equipment; Royal Blue (440-460 nm, part number LXML-PR01-0425) 
and Clear White (400-800 nm part number LXML-PWC1-0900) were commonly used.  
 
Irradiation at lower wavelengths (254 and 365 nm) was provided by a Spectroline ENF-
240C/FE Dual Wavelength lamp, used previously for analysis of TLCs (section 5.3). 
Other wavelengths between 260 nm and 600 nm were obtained using a Perkin Elmer 
LS 55 Luminescence Spectrometer, with typical bandwidths of 2-10 nm. 
 
5.6.8.3  Circular Dichroism (CD) 
Circular Dichroism was performed using achiral buffers within an Applied 
Photophysics Chirascan spectrometer, coupled to a CD Photomultiplier (with a 
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detection range of 160-850 nm) and a Scanning Emission Monochromator 
(4.65 nm/mm band pass). All spectra were recorded at 20 °C, and have been 
normalised by calculation of the Mean Residue Ellipticity (MRE), as fully described in 
section 3.4.0. 
 
 
5.7 Bacterial strains & plasmid vectors 
5.7.1 Bacterial strains and genotypes 
 
E. coli 
Strain 
Genotype Source 
XL1-blue recA1, endA1, gyrA96(NaIr), thi-1, 
hsdR17, supE44, relA1, lac, dam  
[F’, proAB, lacIq ZΔM15, Tn10 (tetr)] 
Bullock et al., 1987 
obtained from Stratagene 
BL21 (DE3) F-, ompT, hsdSB(rB-, mB-), gal, dcm, 
λ(DE3) 
Promega 
BL21(DE3) 
[pLysS] 
F-, ompT, hsdSB(rB-, mB-), gal, dcm, 
λ(DE3), pLysS (Camr) 
Invitrogen 
BL21(DE3) 
STAR 
F-, ompT, hsdSB(rB-, mB-), gal, dcm, 
rne131, λ(DE3) 
Invitrogen 
M15 
[pRep4] 
NaIr, Strs, Lac-, Ara+, Gal+, Mtl-, F-, 
RecA+, Uvr+, Lon+ 
D. Stüeber, F. Hoffmann-La Roche 
Ltd.191; obtained from QIAgen 
JM101 supE, thi-1 ∆(lac-proAB) endA+ 
[F´, traD36, proAB, lacIq Z∆M15 
J. Messing et al.193, 1981 
obtained from Stratagene 
Table 11: Bacterial strains, genotypes and original sources from each cell line 
 
E. coli strains BL21(DE3)[pLysS] and M15[pRep4] each contain a plasmid (pLysS and 
pRep4, respectively) to regulate expression of other plasmids within the cell. Strains 
XL1-blue and JM101 require supplemental thiamine, as their ability to produce this 
was removed to prevent unwanted propagation outside of controlled conditions. 
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5.7.2 Plasmid vectors 
 
Plasmid Vector Description Source Resistance 
pMal-C2-RibfK-Ca Expression vector for E. coli, containing 
the gene from C. ammoniagenes 
encoding the bifunctional riboflavin 
kinase-FAD synthetase enzyme with an 
N-terminal maltose binding domain  
K. Kemter et 
al.,177 2004 
Amp 
pET14b-SpRfK Expression vector for E. coli, containing 
the gene for expression of the riboflavin 
kinase from Schizosaccharomyces 
pombe as an N-terminal 6xHis-tagged 
protein 
H. Collins, 
University of 
Canterbury, 
2010 
Amp 
pNCO113-
HISACT(C49S) 
Expression vector based on pNCO113 
(Stüeber et al.189), modified by Kay et 
al.4 to contain an N-terminal gene 
encoding the protein Hisactophilin from 
Dictyostelium discoideum190 with C-
terminal thrombin site, and further 
modified (Fischer et al.1) to mutate the 
single cysteine residue of hisactophilin 
(to ensure no effect with flavin) 
M. Fischer, 
G. Richter1, 
2007 
Amp 
pNCO113-
HISACT(C49S)-AsLOV2 
(WT) 
Expression vector as above, including 
the gene for expression of Avena sativa 
PHOT1-LOV2 protein (wild type) 
M. Fischer, 
G. Richter1, 
2007 
Amp 
pNCO113-
HISACT(C49S)-
AsLOV2(T418I, C450A) 
As above, with mutation of AsLOV2 
gene to replace cysteine 450 with 
alanine. A second mutation (threonine 
418 to isoleucine) was also present  
A. Wood, 
2012 
Amp 
pNCO113-
HISACT(C49S)-
AsLOV2(C450G) 
As above, with mutation of AsLOV2 
gene to replace cysteine 450 with 
glycine  
A. Wood, 
2012 
Amp 
pNCO113-
HISACT(C49S)-
AsLOV2(C450M) 
As above, with mutation of AsLOV2 
gene to replace cysteine 450 with 
methionine  
A. Wood, 
2012 
Amp 
pNCO113-
HISACT(C49S)-
AsLOV2(C450S) 
As above, with mutation to AsLOV2 
gene to replace cysteine 450 with serine  
A. Wood, 
2012 
Amp 
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pNCO113-
HISACT(C49S)-
AsLOV2(C450D) 
As above, with mutation of AsLOV2 
gene to replace cysteine 450 with 
aspartic acid  
A. Wood, 
2012 
Amp 
pRep4 Plasmid used to regulate expression by 
the T5 promoter. This plasmid expresses 
the lac repressor protein encoded by the 
lacI gene192; IPTG inactivates this gene 
allowing transcription 
QIAgen 
(within E. coli 
strain M15 
[pRep4]) 
Kan 
pLysS Plasmid used to supress basal 
expression from the T7 promoter by 
expression of T7 lysozyme, which acts as 
an inhibitor to T7 RNA polymerase. IPTG 
blocks expression of this gene, allowing 
transcription from the T7 promoter 
Novagen 
(within E. coli 
strain 
BL21(DE3) 
[pLysS]) 
Cam 
Table 12: Description of Plasmid Vectors. “Amp” refers to ampicillin, “Kan” refers to 
kanamycin, and “Cam” refers to chloramphenicol 
 
5.7.3 Oligonucleotide primers 
Primers were designed using the PrimerX tool248, and supplied by Eurofins MWG 
Operon. 
Name Sequence (5' --> 3') 
T5 Promoter (Fw) TCATAAAAAATTTATTTGCTTTGTGAGCGGATAACAATTATAATA 
T5 Promoter(Re) TATTATAATTGTTATCCGCTCACAAAGCAAATAAATTTTTTATGA 
AsLOV2-C217A (Fw) GAAATTCTGGGTCGTAACGCGCGTTTTCTTCAAGGTCCTG 
AsLOV2-C217A (Re) CAGGACCTTGAAGAAAACGCGCGTTACGACCCAGAATTTC 
AsLOV2-C217G (Fw) GAAATTCTGGGTCGTAACGGTCGTTTTCTTCAAGGTCCTG 
AsLOV2-C217G (Re) CAGGACCTTGAAGAAAACGACCGTTACGACCCAGAATTTC 
AsLOV2-C217M (Fw) GAAATTCTGGGTCGTAACATGCGTTTTCTTCAAGGTCCTG 
AsLOV2-C217M (Re) CAGGACCTTGAAGAAAACGCATGTTACGACCCAGAATTTC 
AsLOV2-C217S (Fw) GAAATTCTGGGTCGTAACTCTCGTTTTCTTCAAGGTCCTG 
AsLOV2-C217S (Re) CAGGACCTTGAAGAAAACGAGAGTTACGACCCAGAATTTC 
AsLOV2-C217D (Fw) GAAATTCTGGGTCGTAACGATCGTTTTCTTCAAGGTCCTG 
AsLOV2-C217D (Re) CAGGACCTTGAAGAAAACGATCGTTACGACCCAGAATTTC 
Table 13: Primers used for sequencing, or creation of site-specific mutants of Avena 
sativa PHOT1-LOV2 domains. The codon describing the desired mutation is 
underlined, and nucleobases altered (from the wild-type gene) are shown in bold type 
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5.7.4 Gel Ladders 
5.7.4.1  SDS-PAGE 
SDS-PAGE was analysed by comparison to a molecular weight marker (SM0431), 
supplied by Fermentas. This contained proteins of the following masses: 
MWt, kDa Protein Source 
116.0 β-galactosidase E. coli 
66.2 Bovine serum albumin (BSA) bovine plasma 
45.0 Ovalbumin avian (chicken) albumen 
35.0 Lactate dehydrogenase porcine muscle 
25.0 Rease Bsp98l E. coli 
18.4 β-lactoglobulin bovine milk 
14.4 Lysozyme avian (chicken) albumen 
Table 14: Components of protein molecular weight marker SM 0431 
 
5.7.4.2  Agarose Gel Electrophoresis 
Ladders for analysis of DNA products separated by agarose gel electrophoresis were 
supplied by New England Biolabs. Composition is described in table 15 below. 
 
1 k.b.p. ladder 
Kilobase pairs Mass (ng) DNA present 
10.0 42 
8.0 42 
6.0 50 
5.0 42 
4.0 33 
3.0 125 
2.0 48 
1.5 36 
1.0 42 
0.5 42 
Table 15: Components of 1 k.b.p. ladder DNA ladder, visible with staining using EtBr. 
Bold type indicates strongly-absorbing bands, for additional reference 
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Chapter 6 - Experimental - Chemical Synthesis 
6.0.1 Synopsis 
In this chapter, the experimental detail necessary to produce 5-deazariboflavin 
(section 6.1) and 1-deazariboflavin (section 6.2) is reported. In addition, the synthesis 
of 8-demethyl-5-deazariboflavin (section 6.3) is described, which has not been 
previously reported in the scientific literature, and serves as a good comparison for 
the efficiency of the formation of 5-deazariboflavin. The formation of several small 
molecules is also reported (section 6.4), which were used in an attempt to provide 
novel routes to prepare 1-deazariboflavin, 1,5-dideazariboflavin, 3-deazariboflavin 
and 3,5-dideazariboflavin (3.6). The rationale for this is described in chapter 2.  
 
Each successful reaction described is supported by appropriate experimental detail 
and appropriate spectroscopic information, for reference. Several reactions have 
been studied exhaustively using alternative conditions, reagents, or solvents; a 
general method has been given for these reactions, with alternative reagents, 
conditions and solvents (along with yields obtained) described in tabular form for 
brevity. In these cases, spectroscopy was compared to the product formed by the 
original reaction and is described only as necessary to assist later discussion. Each 
reaction was performed a minimum of three times, with average yields quoted. 
 
 
6.1 Synthesis of 5-Deazariboflavin 
This section describes the synthesis of 5-deazariboflavin 39.  
Figure104: Overall Synthetic Route to 5–deazariboflavin 39 
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6.1.1.1  Formation of 3,4-dimethyl-N(ribityl)-aniline 33 
 
3,4-Dimethylaniline 31 (3.00 g, 25 mmol), Na[(CN)BH3] (3.15 g, 50 mmol, 2 equiv.) and 
D-ribose (7.50 g, 50 mmol, 2 equiv.) were combined in a flame-dried 3-neck RBF and 
dried under high vacuum for 4 hours. Thoroughly dried MeOH (120mL) was added, 
and the mixture was stirred at reflux under an Ar / N2 atmosphere until completion 
(48 hours, determined by TLC). The solvent was removed under reduced pressure to 
furnish a dark brown viscous oil, which was dissolved in HCl(aq) (20mL, 1M) with 
shaking until gas evolution ceased. The pH of the mixture was adjusted to pH 7.0 using 
a saturated NaHCO3 solution (8mL) and washed using an aliquot of EtOAc (40 mL). 
Addition of EtOAc stimulated formation of a solid precipitate within the mixture, 
which was isolated by filtration to give a grey-white solid. This was dried under high 
vacuum for 4 hours to give a white powder, with spectroscopic analysis confirming 
formation of 3,4-dimethyl-N(ribityl)-aniline 33 (5.97 g, 23.4 mmol, 47 %). The aqueous 
layer was extracted using further EtOAc (4 x 40 mL), washed with brine (2 x 40mL) and 
dried over MgSO4. Solvent was removed under reduced pressure, and the light-brown 
crystals were recrystallised from 10 % EtOH(aq) to furnish purified 3,4-dimethyl-
N(ribityl)-aniline 33 as a white powder (2.36 g, 9.24 mmol, 18 %). The combined yield 
of 3,4-dimethyl-N(ribityl)-aniline 33 (8.33 g, 32.64 mmol) was therefore 65 %. 
 
TLC 10:1 CHCl3:MeOH RF: 0.82 (31), 0.18 (33), 0.00 (32); NinH staining;  MP 142-144 °C 
(lit. 142-143 °C 249); 1H NMR (400 MHz, MeOD-d3) δ (ppm) 6.90 (d, 1H, J = 8.2 Hz), 6.57 
(d, 1H, J = 2.4 Hz), 6.49 (dd, 1H, JAM = 2.4 Hz, JAX = 8.2 Hz), 4.91 (br s (solvent, residual)), 
3.93 (m, 1H), 3.78 (m, 2H), 3.65 (m, 2H), 3.45 (dd, 1H, JAM = 3.6 Hz, JAX = 12.8 Hz), 3.33 
(m, 2H), 3.10 (q, J = 8.0 Hz), 2.19 (s, 3H), 2.14 (s, 3H); 13C NMR (100 MHz) δ (ppm) 146.2 
(C), 136.7 (C), 129.6 (CH), 125.8 (C), 115.6 (CH), 111.3 (CH), 73.2 (CH), 72.5 (CH), 70.2 
(CH), 62.8 (CH2), 46.5  (CH2), 18.6 (CH3), 17.3 (CH3); EI MS (+) (m/z) 255 ([M], 100%); 
HR MS (APCI +) found 256.1539, calc. 256.1549 for [M+1]  
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6.1.1.2  Optimisation of conditions - 3,4-dimethyl-N(ribityl)-aniline 33 
Numerous solvents, reducing agents, reaction times and other conditions for this 
reaction were examined following the general method described above, with results 
shown in table 16 below. Full spectrometric data was obtained for each reaction 
(including TLC RF values, 1H and 13C NMR, and EI or ESI MS) and compared to that 
obtained for the original reaction. In all cases, each reaction was performed using two 
molar equivalents of D-ribose and the reducing agent selected. Solvent volumes 
required were adjusted for each reaction, with optimal volumes allowing solubility of 
the reagents at temperatures slightly below the reflux temperature of the solvent. 
Some solvents (THF, DCM, CHCl3) were unable to fully solubilise the reagents even at 
reflux; in these cases, a similar volume to those used in other reactions performed at 
similar scales was used.  
 
Alterations to the original reaction were carried out as direct substitutions (if 
possible), with changes made to the general reaction method only made when 
necessary due to solubility problems or with the use of additional reagents. 
Spontaneous product precipitation did not occur in all cases. All reaction mixtures 
were extracted using an appropriate volume of EtOAc (based upon reaction scale), 
until no further product remained in the aqueous layer (determined by TLC). Reactions 
performed using additional desiccants were performed with the desiccant added 
alongside all other solid reagents, and were removed by filtration immediately before 
initial concentration of the reaction mixture upon completion. Any product isolated 
was purified as necessary by recrystallisation.  
 
In the case of reactions performed using acidic catalysis, glacial acetic acid was pre-
dried using molecular sieves, and added to the reaction mixture dropwise after all 
components had fully dissolved. Reactions performed using DMAP were subjected to 
further purification by recrystallisation or flash chromatography to remove DMAP 
from the product after extraction. 
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Scale  
(aniline, mM) 
Reducing 
Agent 
Solvent 
Temperature 
(° C) 
Conditions Atmosphere 
Reaction 
Time (hours) 
Yield 
(%) 
1 12.5 Na[(CN)BH3] MeOH reflux - Ar/N2 48 57 
2 25.0 Na[(CN)BH3] MeOH reflux - Ar/N2 48 65 
3 25.0 Na[(CN)BH3] MeOH reflux - Ar/N2 72 64 
4 75.0 Na[(CN)BH3] MeOH reflux - Ar/N2 72 63 
5 0.83 Na[(CN)BH3] MeOH RT Undried solvent Air 72 - 
6 0.83 Na[(CN)BH3] MeOH reflux Undried solvent Air 72 22 
7 0.83 Na[(CN)BH3] MeOH reflux AcOH catalyst, 0.2 eq. Ar/N2 24 32 
8 0.83 Na[(CN)BH3] MeOH reflux AcOH catalyst, 0.2 eq. Ar/N2 48 19 
9 12.5 Na[(CN)BH3] MeOH reflux DMAP catalyst, 0.2 eq Ar/N2 72 39 
10 12.5 Na[(CN)BH3] MeOH reflux - Ar/N2 48 57 
11 0.83 Na[(AcO)3BH] MeOH reflux - Ar/N2 48 19 
12 0.83 Na[(CN)BH3] MeOH reflux 
Reducing agent added 
after 4 hrs 
Ar/N2 48 51 
13 0.83 Na[(CN)BH3] MeOH reflux 
AcOH added at 0 
hours, reducing agent 
added after 4 hours 
Ar/N2 24 23 
14 0.83 Na[(AcO)3BH] MeOH reflux 
Reducing agent added 
after 4 hours 
Ar/N2 48 31 
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Scale  
(aniline, mM) 
Reducing 
Agent 
Solvent 
Temperature 
(° C) 
Conditions Atmosphere 
Reaction 
Time (hours) 
Yield 
(%) 
15 0.83 Na[(AcO)3BH] MeOH reflux 
AcOH added at 0 hrs, 
reducing agent added 
after 4 hrs 
Ar/N2 24 7 
16 0.83 Na[(CN)BH3] MeOH reflux MgSO4 added, 5 eq. Ar/N2 48 64 
17 0.83 Na[(AcO)3BH] MeOH reflux MgSO4 added, 5 eq. Ar/N2 24 28 
18 0.83 Na[(AcO)3BH] MeOH reflux MgSO4 added, 5 eq. Ar/N2 48 54 
19 0.85 Na[(CN)BH3] THF RT - Ar/N2 72 44 
20 0.85 Na[(CN)BH3] THF reflux - Ar/N2 48 49 
21 0.85 Na[(AcO)3BH] THF RT - Ar/N2 72 8 
22 0.85 Na[(AcO)3BH] THF reflux - Ar/N2 48 33 
23 0.83 Na[(CN)BH3] MeCN RT - Ar/N2 48 - 
24 0.83 Na[(CN)BH3] MeCN reflux - Ar/N2 48 8 
25 0.83 Na[(CN)BH3] MeCN reflux AcOH catalyst, 0.2 eq. Ar/N2 24 - 
26 0.83 Na[(CN)BH3] EtOH reflux - Ar/N2 68 - 
27 0.83 Na[(CN)BH3] isopropanol reflux - Ar/N2 72 12 
28 0.83 Na[(CN)BH3] DCM reflux - Ar/N2 48 - 
29 0.83 Na[(CN)BH3] CHCl3 reflux - Ar/N2 72 18 
 
Table 8: Varying reaction conditions used for the formation of 3,4-dimethyl-N(ribityl)-aniline 
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6.1.2.1  Formation of 6-chlorouracil 35 (original method) 
 
To a freshly-prepared solution of aqueous NaOH (40 mL, 5 M, 192 mmol), 
2,4,6-trichloropyrimidine 34 (2.50 mL, 3.99 g, 21.7 mmol) was added dropwise, and the 
mixture heated to reflux. A solid white plaque was commonly observed above the reaction 
mixture after 16 hours, which was manually disrupted and slowly re-dissolved over 3 hours. 
After 72 hours, the reaction was cooled to room temperature, and the acidity of the solution 
adjusted to pH 1-2 using concentrated HCl (6 M, 10 mL). A white precipitate formed upon 
addition of the acid, and the mixture was maintained in an ice bath for 30 minutes to facilitate 
further precipitation. The fine white precipitate was collected by filtration under suction, and 
washed with warm deionised water (5 mL), acetone (5 mL), and dried under high vacuum, 
yielding 6-chlorouracil 35 (2.26 g, 15.4 mmol, 71 %) as a fine white powder.  
 
TLC 10:1 CHCl3:MeOH RF: 0.26 (35); 5:1 CHCl3:MeOH RF: 0.59 (35); NinH / I2 staining; MP 312-
315°C (deg; lit: deg >300°C250); 1H NMR (400 MHz, DMSO-d6) δ (ppm) 12.10 (br s, 1H,), 11.32 
(br s, 1H), 5.77 (s, 1H), 3.36 (br s, H2O); 13C NMR (100 MHz, DMSO-d6) δ (ppm) 162.7, 150.5, 
145.1, 99.7; EI MS (+) (m/z) 146 ([M+1], 100%) 
 
6.1.2.2  Formation of 6-chlorouracil 35 (survey of conditions) 
Alternative conditions for the formation of 6-chlorouracil 35 were examined leading to the 
enhanced method described in section 6.1.2.3. Each of these reactions was performed 
following the general method given in section 6.1.2.1 above, and is described in table 17 
below. The product of each reaction was isolated as before, by precipitation upon pH 
adjustment to pH 1-2, with full spectral data obtained for each product. However, TLC analysis 
revealed significant levels of 6-chlorouracil remaining in the aqueous layer, which was 
previously unrecovered. Extraction of the aqueous layer using EtOAc (table 17, reaction 18) 
significant improved isolation of 35, from 64 % by precipitation alone to 81 %. 
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 Scale 
(mM) 
Solvent Base Base conc. 
(M) 
Time 
(hours) 
Reaction 
Temperature 
Yield 
(%) 
1 2.5 H2O / HO- NaOH 2.0 12 100 °C 35 
2 35 H2O / HO- NaOH 2.2 48 100 °C 65 
3 82 H2O / HO- NaOH 2.5 48 100 °C 52 
4 10 H2O / HO- NaOH 2.0 72 100 °C 56 
5 22 H2O / HO- NaOH 5.0 72 100 °C 71 
6 8.5 H2O / HO- NaOH 2.6 96 100 °C 12 
7 1.7 H2O / HO- NaOH 1.0 48 100 °C 4 
8 1.7 H2O / HO- NaOH 3.0 48 100 °C 39 
9 1.7 H2O / HO- NaOH 5.0 48 100 °C 68 
10 1.7 H2O / HO- NaOH 5.0 48 RT 0 
11 1.7 H2O / HO- KOH 1.0 48 100 °C 20 
12 1.7 H2O / HO- KOH 3.0 48 100 °C 37 
13 1.7 H2O / HO- KOH 5.0 48 100 °C 52 
14 1.7 H2O / HO- KOH 5.0 48 RT 0 
15 1.7 H2O / HO- Mg(OH)2 3.0 72 100 °C 0 
16 3 toluene;  
H2O / HO- 
NaOH 2.5 72 100 °C 21 
17 8.2 DCM;  
H2O / HO- 
NaOH 2.5 72 40 °C 14 
18 10 H2O / HO- NaOH 5.0 48 100 °C 64 
81* 
 
Table 17: Conditions used for the formation of 6-chlorouracil 35. Reaction 18 gave a yield of 
64 % when the product was isolated by precipitation; however, extraction of the aqueous 
mother liquor using EtOAc allowed isolation of further 6-chlorouracil with combined (filtrate 
and extract) yields of 81 %. “RT” refers to an assumed room temperature between 15 and 
20 °C, with each reaction repeated in duplicate or more. 
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6.1.2.3  Formation of 6-chlorouracil (enhanced method) 
 
This reaction was initiated as described in section 6.1.2.1, using 1.15 mL (1.83 g, 10.0 mmol)  
of 2,4,6-trichloropyrimidine 34. Upon completion (48 hours, determined by TLC), the solution 
was cooled to room temperature and the pH adjusted to 6.5 using aqueous HCl (2 M, 6 mL); 
precipitation of 6-chlorouracil did not routinely occur under these conditions. The aqueous 
solution was extracted thoroughly using EtOAc (5 x 30 mL), the organic layer was washed 
using brine (2 x 30 mL) and dried over MgSO4. Removal of solvent under reduced pressure 
furnished 6-chlorouracil 35 (1.18 g, 8.05 mmol, 81 %) as a fine white solid. 
 
TLC 10:1 CHCl3:MeOH RF: 0.25 (35); 5:1 CHCl3:MeOH RF: 0.61 (35); NinH / I2 staining; MP 312-
315°C (deg; lit: deg >300°C250); 1H NMR (250 MHz, DMSO-d6) δ (ppm) 12.12 (br s, 1H,), 11.28 
(br s, 1H), 5.75 (s, 1H), 3.37 (br s, H2O), 13C NMR (62.5 MHz, DMSO-d6) δ (ppm) 162.4, 150.1, 
144.7, 99.6; EI MS (+) (m/z) 146 ([M], 100%) 
 
6.1.3.1  Formation of bicyclic intermediate 36 (original method) 
 
3,4-Dimethyl-N(ribityl)-aniline 33 (1.53 g, 6.0 mmol), 6-chlorouracil 35 (1.06 g, 7.2 mmol, 
1.2 equiv.) and malononitrile (160 mg, 2.4 mmol, 0.4 molar equiv.) were combined and dried 
under vacuum in flame-dried glassware. Thoroughly dried methanol (50 mL) was added, and 
the resulting suspension heated under N2 to reflux. Further malononitrile (80 mg, 1.2 mmol, 
0.2 molar equiv.) was added after 54 hours, with completion observed 94 hours. The reaction 
was cooled to room temperature, and solvent removed under reduced pressure. The product 
was dried under high vacuum for 4 hours, yielding crude bicyclic intermediate 36 as a viscous 
brown oil which was typically used for the subsequent reaction without further purification. 
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This reaction was repeated at several scales using a number of additives (described in section 
2.1.3) added at appropriate points of the reaction; the effect of these is detailed in the 
relevant discussion, although the method described above gave optimal results. All products 
were subjected to acetylation immediately following this reaction, after which purification of 
the acetylated product allowed accurate assessment of the yield over two steps. 
  
TLC 10:1 CHCl3:MeOH RF: 0.24 (35), 0.20 (36), 0.18 (33); 20:1 CHCl3:MeOH RF: 0.66 (35), 0.62 
(36), 0.12 (33); NinH / I2 staining; 36 exhibits blue-white fluorescence; 1H NMR (400 MHz, 
MeOD-d3) δ (ppm) 6.79 (d, 1H, J = 8.0 Hz), 6.47 (d, 1H, J = 2.2 Hz), 6.39 (dd, 1H, JAM = 2.2 Hz, 
JAX = 8.0 Hz), 5.63 (s, 1H), 4.51 (br s, 1H), 3.82 (m, 1H), 3.67 (m, 2H), 3.54 (m, 2H), 3.33 (dd, 
1H, JAM = 3.6 Hz, JAX = 12.8 Hz), 3.00 (m, 2H), 2.90 (dd, 1H, JAM = 8.0 Hz, JAX = 12.8 Hz), 2.08 (s, 
3H), 2.03 (s, 3H); EI MS (+) (m/z) 388 ([M + Na+], 65 %); 366 ([M+1], 100 %); ESI MS (-) 364 
([M-1], 100 %) 
 
6.1.3.2  Formation of bicyclic intermediate 36 (solvent-free heating) 
 
3,4-Dimethyl-N(ribityl)-aniline 33 (150 mg, 0.59 mmol) and 6-chlorouracil 35 (95 mg, 
0.65 mmol, 1.1 equiv.) were powdered together and dried under high vacuum for 4 hours. 
The solid mixture was heated under ambient pressure to 185°C for 15 minutes, with evolution 
of acidic vapours observed. The mixture was allowed to cool to room temperature, and 
washed with diethyl ether (5 mL) and filtered. The retentate was washed with further ether 
(5 mL) and dissolved in MeOH (10 mL). This was filtered again, and the filtrate was collected. 
Solvent was removed under vacuum to give bicyclic intermediate 36 as an orange-yellow solid 
(215 mg, 0.59 mmol, quantitative yield). 
 
TLC 20:1 CHCl3:MeOH RF: 0.65 (35), 0.61 (36), 0.11 (33); NinH / I2 staining; 36 exhibits blue-
white fluorescence; 1H NMR (400MHz, MeOD-d3) δ (ppm) 7.08 (d, 1H, J = 8.1 Hz), 6.88 (d, 1H, 
J = 2.0 Hz), 6.58 (s, 1H), 6.49 (dd, 1H, JAM = 2.4 Hz, JAX = 7.9 Hz), 5.78 (s, 2H), 4.00 (m, 1H), 3.77 
 204 
 
(m, 2H), 3.64 (m, 2H), 3.49 (dd, 1H, JAM = 3.6 Hz, JAX = 12.8 Hz), 3.34 (m, 1H), 3.11 (dd, 1H,  
JAM = 8.0 Hz, JAX = 12.8 Hz), 2.26 (s, 3H), 2.22 (s, 3H); 13C NMR δ (ppm) 136.8, 130.9, 129.9, 
128.4, 124.8, 115.9, 111.7, 99.5, 78.1, 77.8, 77.5, 73.3, 72.9, 70.6, 63.2, 19.0, 17.8; ESI MS (-) 
(m/z) 364 ([M-1], 100%); HR MS (ESI -) found 364.1510, calc. 364.1509 for [M-1] 
 
6.1.3.3  Attempted formation of intermediate 36 (in aqueous solution) 
This method was originally described by W.T. Ashton et al.109 in 1978, using a 1:1 mixture of 
deionised water and dioxane. This was repeated, and additionally the reaction was also 
performed using acetonitrile in place of dioxane. In both cases, this method was found to be 
unsuccessful in facilitating the coupling between 3,4-dimethyl-N(ribityl)-aniline 33 and 
6-chlorouracil 35, with a high proportion of starting materials recovered.  
 
A suspension of 3,4-dimethyl-N(ribityl)-aniline 33 (439 mg, 1.70 mmol, 2 equiv.) and 6-
chlorouracil 35 (125 mg, 0.85 mmol) in an equivolume mixture of water and dioxane (40 mL) 
was heated at reflux for 36 hours, followed by stirring at room temperature for 12 hours. The 
solution was adjusted to pH 11 using aqueous NaOH (30 mL, 2M), and extracted using DCM 
(3 x 50 mL). Organic solvent was washed with brine (50 mL) and dried over MgSO4, before 
rotary evaporation revealed no product isolation. The aqueous mixture was neutralised using 
HCl (15 mL, 1 M), before extraction using EtOAc (3 x 60 mL). Evaporation of the organic solvent 
and separation by FC allowed recovery of 3,4-dimethyl-N(ribityl)-aniline 33 in quantitative 
yield, and isolation of unreacted 6-chlorouracil 35 in yields up to 20 %. 
 
TLC 10:1 CHCl3:MeOH RF: 0.24 (35), 0.18 (33); NinH / I2 staining; FC stationary phase Silica gel 
using 10 : 1 CHCl3:MeOH, column bed 2.0 x 10 cm; FC mobile phase 10 : 1 CHCl3:MeOH 
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6.1.4.1  Protection of intermediate 36 (original method) 
 
The crude solid from reaction 3.1.3.1 (2.98 g, impure) was dissolved in pyridine (25 mL), and 
acetic anhydride (2.80 mL, 29.4 mmol, 5-fold excess calculated from prior reaction) was added 
dropwise. The solution was stirred vigorously at room temperature overnight. The solvent 
was removed under reduced pressure, and the orange-brown residue dissolved in 
dichloromethane (120 mL). This was washed with water (3 x 20 mL) and brine (20 mL), and 
the organic layer was dried over MgSO4. Solvent was removed using rotary evaporation to 
yield an orange oil, which was purified by FC. Product-containing fractions from FC were 
evaporated and the orange oil re-dissolved in CH2Cl2 (100 mL), washed with water (5 x 
100 mL), saturated aqueous NaHCO3 (2 x 50 mL) and brine (3 x 50 mL), before removal of the 
organic solvent under reduced pressure. The resultant orange-brown oil was dried under high 
vacuum for 2 days to yield bicyclic intermediate 37 as an orange-brown solid (1.51 g, 
2.83 mmol, 47 % yield over 2 steps). 
 
TLC 10:1 CHCl3:MeOH RF: 0.37-0.28 (37), 0.19 (36); 20:1 CHCl3:MeOH RF: 0.62 (36), 0.44-0.39 
(37); NinH / I2 staining; 36 and 37 exhibit blue-white fluorescence; FC stationary phase Silica 
gel using 50:1 CHCl3:MeOH, column bed 2.5 x 15 cm; FC mobile phase Initially 50:1 
CHCl3:MeOH, before increasing gradient of MeOH (to 20:1); 1H NMR (400MHz, CDCl3) δ (ppm) 
7.07 (d, 1H, J = 8.0 Hz), 6.85 (d, 1H, J = 2.4 Hz), 6.81 (dd, 1H, JAM = 2.4 Hz, JAX = 8.0 Hz), 5.24 (d, 
2H, J = 6.4 Hz), 5.14 (m, 1H), 4.22 (dd, 1H, JAM = 3.0 Hz, JAX = 12.2 Hz), 4.04 (dd, 1H, JAM = 6.2 
Hz, JAX = 12.2 Hz), 3.93 (m, 1H), 3.82 (dd, 1H, JAM = 1.8 Hz, JAX = 14.2 Hz), 3.36 (s, 1H), 2.19  
(s, 6H), 1.96 (s, 3H), 1.95 (s, 3H), 1.84 (s, 3H), 1.73 (s, 3H); 13C NMR (62.9 MHz, DMSO-d6)  
δ (ppm) 170.3, 169.8, 169.4, 169.0, 149.2, 140.6, 138.3, 136.3, 130.4, 128.3, 125.2, 70.3, 69.4, 
69.1, 61.7, 48.2, 20.6, 20.4, 20.1, 20.0, 19.8, 19.1; ESI MS (-) (m/z) 531 ([M-2], 100 %), 490  
([M-1-Ac], 40 %) 
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6.1.4.2  Protection of intermediate 36 (alternative methods) 
Numerous alternative methods for the effective formation of protected intermediate 37 were 
attempted, and are summarised in table 18 (vide infra). Each reaction was performed 
according to the general method given below. 
 
Crude product from the previous reaction (performed at scales of 0.50 mmol) was dissolved 
in a mixture of CH2Cl2 (10 mL) and pyridine (8 µL, 0.10 mmol, 0.2 equiv.). Acetic anhydride 
(240 µL, 2.54 mmol; 5 equiv.) was added dropwise, and the mixture stirred at room 
temperature for 16 hours. The solution diluted using CH2Cl2 (25 mL), washed with water (3 x 
20 mL), NaHCO3 (20 mL) and brine (20 mL), before drying over MgSO4 and removal of the 
solvent under reduced pressure. The resultant brown oil was dried under high vacuum to yield 
an orange-brown solid.  
 
TLC 10:1 CHCl3:MeOH RF: 0.36-0.26 (37), 0.17 (36); 20:1 CHCl3:MeOH RF: 0.65 (36), 0.48-0.42 
(37); NinH / I2 staining; 36 and 37 exhibit blue-white fluorescence; 1H NMR (400MHz, CDCl3) δ 
(ppm) 7.07 (d, 1H, J = 8.0 Hz), 6.85 (d, 1H, J = 2.4 Hz), 6.81 (dd, 1H, JAM = 2.4 Hz, JAX = 8.0 Hz), 
5.24 (d, 2H, J = 6.4 Hz), 5.14 (m, 1H), 4.22 (dd, 1H, JAM = 3.0 Hz, JAX = 12.2 Hz), 4.04 (dd, 1H, JAM 
= 6.2 Hz, JAX = 12.2 Hz), 3.93 (m, 1H), 3.82 (dd, 1H, JAM = 1.8 Hz, JAX = 14.2 Hz), 3.36 (s, 1H), 2.19 
(s, 6H), 1.96 (s, 3H), 1.95 (s, 3H), 1.84 (s, 3H), 1.73 (s, 3H); 13C NMR (62.9 MHz, DMSO-d6) δ 
(ppm) 170.5, 170.1, 169.8, 169.5, 149.6, 140.8, 138.1, 136.4, 130.6, 128.6, 124.9, 70.5, 69.8, 
69.2, 61.8, 48.3, 20.7, 20.7, 20.6, 20.5, 19.7, 19.3; ESI MS (+) (m/z) 532 ([M], 100 %), 474 
([M - OAc], 40 %). 
 
In cases where acetylation of the uracil moiety was observed, NMR spectra included the 
following additional resonances: 1H NMR at 1.99 ppm (794.1 Hz), as a singlet with a relative 
integration of 3H, and 13C NMR at 171.0 ppm and 22.5 ppm. MS gave a m/z value of 574 
([M], 25 %).  
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 Scale 
(mmol) 
Bulk 
Solvent 
Catalyst Acetate source Temp. Reaction Time 
(hrs) 
Yield 
(%) 
1 6.0 Pyridine - Acetic Anhydride RT 16 47 
2 0.5 CH2Cl2 Pyridine Acetic Anhydride RT 16 55 
3 0.5 CH2Cl2 - Acetic Anhydride RT 24 (incomplete) 15 
4 0.5 CH2Cl2 TEA Acetic Anhydride RT 16 24 
5 0.5 CH2Cl2 DMAP Acetic Anhydride RT 16 31 
6 0.5 CH2Cl2 Imidazole Acetic Anhydride RT 16 41 
7 4.5 CH2Cl2 Pyridine Acetic Anhydride RT 16 54 
8 0.5 THF Pyridine Acetic Anhydride RT 16 45 
9 0.4 THF TEA Acetic Anhydride RT 2 36 
10 0.4 THF TEA Acetic Anhydride RT 16 41 
11 0.5 CH2Cl2 Pyridine Acetyl chloride RT 4 0 * 
12 0.5 CH2Cl2 Pyridine Acetyl chloride 0 °C 4 0 * 
13 0.5 CH2Cl2 Pyridine Acetyl chloride -78 °C 4 0 * 
 
Table 18: Reactions performed to establish the optimal method for acetylation of bicyclic 
intermediate 36. “Scale” refers to the number of moles of riboaniline used for the initial 
formation of bicyclic 36; all yields reported were obtained over two steps. When used, 
0.2 equivalents of catalyst (calculated relative to riboaniline quantity) were used in all cases. 
5 equivalents (1.25 molar excess) of acetic anhydride was used, while 4.1 equivalents 
(1.03 molar excess) of acetyl chloride were used.  
 
*- starting materials (or degradation products) only were isolated from these reactions  
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6.1.5  Formation of 5-deazariboflavin tetraacetate 38 
 
Acetylated intermediate 37 (900 mg, 1.69 mmol) was dissolved in DMF (6 mL), and POCl3 
(0.6 mL, 990 mg, 6.35 mmol) was cautiously added dropwise over 10 minutes. The solution 
was allowed to stir at room temperature for 1 hour, before heating to 100°C for 15 minutes. 
The mixture was allowed to cool to room temperature, and ice (30 cm3) was added directly 
to the solution. A yellow-orange precipitate developed within the solution as it cooled. The 
pH of the mixture was adjusted to pH 7 using NH4OH (5% aqueous solution, 10mL), and the 
precipitate isolated by filtration under suction, before drying under high vacuum. Further 
product was isolated from the mother liquor by extraction using CHCl3 (3 x 20 mL). The 
product was isolated from the mixture by washing the organic solvent using a small volume 
of HCl (0.5 M, 5 mL) and washing with water (3 x 10 mL). The pH of the combined aqueous 
layers was adjusted to pH 9-10 using a saturated solution of NaHCO3, and re-extracted using 
CHCl3 (3 x 30 mL); combined organic layers were dried and concentrated under reduced 
pressure to yield additional 5-deazariboflavin tetraacetate 38. 
 
Spectroscopic data for both precipitated and extracted products were compared, and found 
to be identical. Thus, 5-deazariboflavin tetraacetate 38 was isolated in 72 % yield (665 mg, 
1.22 mmol) as a bright yellow solid, with a characteristic blue fluorescence. 
 
TLC 20:1 CHCl3:MeOH RF: 0.58 (38), 0.38-0.32 (37), 0.19 (36); I2 / CAM staining; 37 and 38 
exhibit blue fluorescence; 1H NMR (400 MHZ, CDCl3) δ (ppm) 8.81 (s, 1 H), 7.61 (s, 1 H), 7.53 
(s, 2 H), 5.39 (m, 2H), 5.30 (m, 1H), 4.40 (m, 1H), 4.28 (dd, 1H, JAM = 5.8 Hz, JAX = 12.0 Hz), 3.87 
(dd, 1H, JAM = 1.9 Hz, JAX = 14.2 Hz), 2.51 (s, 3H), 2.41 (s, 3H), 2.26 (s, 3H), 2.16 (s, 3H), 2.05 (s, 
3H), 2.02 (s, 3H); 13C NMR (62.9 MHz, CDCl3) δ (ppm) 170.5, 170.1, 169.8, 169.5, 161.1, 158.1, 
155.0, 138.1, 136.4, 130.6, 119.6, 116.1, 113.5, 70.3, 69.8, 69.1, 61.7, 21.4, 21.0, 20.6, 20.5, 
19.6, 19.0; ESI MS (+) (m/z) 544 ([M+1], 100 %), 502 ([M+1, -OAc], 25 %) 
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6.1.6 Deprotection of 5-deazariboflavin tetraacetate 38 
 
Crude 5-deazariboflavin tetraacetate 38 (250 mg, 0.460 mmol) was dissolved in methanolic 
ammonia (20 mL) and stirred at room temperature for 6 hours. The mixture was filtered (to 
remove a colourless precipitate), and the solvent was removed by rotary evaporation, yielding 
5-deazariboflavin 39 (109 mg, 0.290 mmol, 63 %) as a brilliant yellow powder.  
 
TLC 20:1 CHCl3:MeOH RF: 0.58 (38), 0.0 (39); 3:1:1 isopropanol:AcOH:H2O RF: 0.90 (39), 0.0 
(38); I2 / CAM staining; 38 and 39 exhibit blue fluorescence; 1H NMR (400 MHz, D2O) δ (ppm) 
8.80 (s, 1H), 7.92 (s, 1 H), 7.80 (s, 1H), 4.89 (m, 1 H), 4.63 (d, 1 H, J = 13.9 HZ), 4.23 (dd, 1 H, 
JAM = 5.8 Hz, JAX = 12.0 Hz), 3.70 (m, 4 H), 2.44 (s, 3 H), 2.34 (s, 3 H); 13C NMR (62.9 MHz, 
CDCl3) δ (ppm) 161.9, 157.4, 156.3, 145.9, 141.0 139.9, 133.5, 130.4, 119.7, 117.8, 113.8, 73.4, 
72.3, 69.7, 63.4, 46.1, 21.0, 19.0; ESI MS (+) (m/z) 398 ([M+Na+], 55 %), 376 ([M+1], 100 %); 
HR MS (ESI +) (m/z) found 398.1325, calc. for the sodium adduct, C18H21N3O6Na+ as 398.1323 
 
6.2 Synthesis of 1-Deazariboflavin 
This section describes the synthesis of 1-deazariboflavin from 1,2-diamino-4,5-
dimethylbenzene. An overview of the method used is shown in figure 105 below. 
 
Figure 105: Overall scheme for the synthesis of 1-deazariboflavin 48. 
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6.2.1 Boc- protection of 2-amino-4,5-dimethyphenylamine 40 
 
2-Amino-4,5-dimethyphenylamine 40 (1.00 g, 7.30 mmol), di-tert-butyldicarbonate 41 
(1.60 g, 7.30 mmol, 1.0 equiv.) and NaHCO3 (0.62 g, 8.34 mmol, 1.15 equiv.) were dissolved 
in an equivolume mixture of dioxane and H2O (total volume 100 mL). The mixture was stirred 
for three hours at room temperature, before dilution with additional H2O (150 mL) and 
extraction into CH2Cl2 (3 x 50 mL). Combined organic layers were washed with saturated 
NaHCO3 (50 mL), brine (50 mL), and dried over MgSO4. Solvent was removed under reduced 
pressure and the product dried under high vacuum for 4 hours, yielding 2-amino(N-Boc)-4,5-
dimethyphenylamine 42 as a red-orange solid (1.59 g, 6.73 mmol, 92%). 
 
TLC 4:1 hexane:EtOAc RF: 0.60 (41), 0.21 (42), 0.0 (40); 10:1 CHCl3:MeOH RF: 0.97 (41), 0.36 
(42), 0.0 (40); NinH / CAM / I2 staining; MP 153-155 °C; 1H NMR (400 MHz, CDCl3) δ (ppm) 
7.19 (s, 1H), 6.95 (s, 1H), 6.56(s, 1H), 6.12 (br s, 1H), 2.08 (s, 3H), 2.07 (s, 3H), 1.44 (s, 9H); 
13C NMR (125.7 MHz) δ (ppm) 154.1, 134.4, 134.3, 132.3, 127.9, 122.3, 118.6, 28.4, 19.3, 18.9; 
EI MS (+) (m/z) 236 ([M], 100%) 
 
6.2.2 Ribitylation of Boc-protected intermediate 42  
 
2-Amino(N-Boc)-4,5-dimethylphenylamine 42 (3.30 g, 14.0 mmol), D-ribose (5.25 g, 35 mmol, 
2.5 equiv.) and NaCNBH3 (1.57 g, 25 mmol, 1.8 equiv.) were dissolved in MeOH (150 mL) in a 
2-neck RBF. The mixture was heated at reflux for 48 hours, and following cooling the solvent 
was removed under reduced pressure. The brown residue was swiftly dissolved in 1 M HCl(aq) 
(50 mL) and swirled until gas evolution ceased. This was immediately neutralised using a 
saturated solution of NaHCO3 (75 mL) and extracted into ethyl acetate (5 x 75 mL). The 
combined organic layers were washed with brine (2 x 100 mL) and dried using Na2SO4. Solvent 
was removed, and the product was dried under high vacuum for 8 hours, to give ribitylated 
intermediate 43 as an orange-coloured solid (4.89 g, 13.20 mmol, 94%). 
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TLC 4:1 hexane :EtOAc RF: 0.14 (43), 0.21 (42); 10:1 CHCl3:MeOH RF: 0.68 (43), 0.36 (42); NinH 
/ CAM / I2 staining; MP 110-112 °C; 1H NMR (500MHz, MeOD-d3) δ (ppm) 6.77 (s, 1H), 6.51 (s, 
1H), 4.73, (H2O), 3.85-3.83 (m, 1H), 3.69 (dd, 1H, JAM = 3.5 Hz, JAX = 11.0 Hz), 3.64 (m, 1H), 3.54 
(dd, 2H, JAM = 6.5 Hz, JAX = 12.8 Hz), 3.33 (dd, 1H, JAM = 3.0 Hz, JAX = 12.8 Hz), 3.21 (m, 1H), 3.05 
(dd, 1H, JAM = 3.1 Hz, JAX = 8.0 Hz), 2.09 (s, 3H), 2.03 (s, 3H), 1.40 (s, 9H); 13C NMR (100 MHz) 
δ (ppm) 153.1, 132.9, 132.3, 131.8, 126.4, 122.0, 118.6, 74.4, 73.1, 70.7, 63.4, 46.5, 28.2, 19.3, 
18.9; EI MS (+) (m/z) 394 ([M+1+Na+], 65%), 370 ([M+1], 100 %); ESI MS (+) (m/z) 394 
([M+1+Na+], 80 %), 370 ([M+1], 100 %) 
 
6.2.3.1  Deprotection of intermediate 43 (original method) 
 
1-N(ribityl),2-N(Boc)-diamino-4,5-dimethylbenzene 43 (1.00 g, 2.70 mmol) was dissolved 
under anaerobic conditions in a solution of HCl (4 M) in dioxane (35 mL), and stirred at RT for 
16 hours. The mixture was washed with Et2O (2 x 30 mL), and the aqueous solvent removed 
under reduced pressure. The solid residue was dried under high vacuum for 8 hours, to yield 
deprotected intermediate 44 as a green solid (570 mg, 2.11 mmol, 78 %). 
 
TLC 10:1 CHCl3:MeOH RF: 0.68 (43), 0.00 (44); NinH / I2 staining; 1H NMR (400MHz, MeOD-d3) 
δ (ppm) 6.79 (s, 1H), 6.52 (s, 1H), 4.76, (H2O), 3.88-3.86 (m, 1H), 3.71 (dd, 1H, JAM = 3.5 Hz, JAX 
= 11.0 Hz), 3.67 (m, 1H), 3.55 (dd, 2H, JAM = 6.5 Hz, JAX = 12.8 Hz), 3.34 (dd, 1H, JAM = 3.0 Hz, 
JAX = 12.8 Hz), 3.24 (m, 1H), 3.06 (dd, 1H, JAM = 3.1 Hz, JAX = 8.0 Hz), 2.10 (s, 3H), 2.05 (s, 3H); 
13C NMR (100 MHz, D2O) δ (ppm) 131.9, 131.2, 126.4, 123.0, 115.6, 113.2, 74.8, 73.9, 72.4, 
64.0, 46.7, 19.2, 18.7; EI MS (+) (m/z) 294 ([M+1+Na+] 60%), 270 ([M], 100%) 
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6.2.3.2  Deprotection of intermediate 43 (using HCl gas) 
 
1-N(ribityl),2-N(Boc)-diamino-4,5-dimethylbenzene 43 (800 mg, 2.16 mmol) was dissolved in 
anhydrous THF (50 mL), and stirred at RT. A stream of HCl gas was bubbled directly through 
the reaction mixture for 30 minutes. Solvent was removed under reduced pressure, and the 
resultant green solid dried under high vacuum for 4 hours to yield the hydrochloride salt of 
deprotected intermediate 44 as a green solid (662 mg, 2.16 mmol, quantitative yield). 
 
TLC 10:1 CHCl3:MeOH RF: 0.66 (43), 0.00 (44); NinH / I2 staining; 1H NMR (250MHz, D2O) δ 
(ppm) 7.36 (s, 1H), 7.27 (s, 1H), 4.09 (m, 1H), 3.79-3.68 (m, 4H), 3.35 (s, 1H), 3.31 (s, 1H), 2.34 
(s, 3H), 2.32 (s, 3H); 13C NMR (D2O) δ (ppm) 128.7, 124.4, 120.4, 96.5, 93.6, 79.2, 78.7, 78.2, 
63.9, 61.1, 45.2, 27.4, 26.0 ESI MS (+) (m/z) 294 ([M+1+Na+] 85 %), 270 ([M], 100 %); ESI MS 
(-) (m/z) 306 ([M+1+35Cl], 100 %), 308 ([M+1+37Cl], 30 %), 269 ([M-1], 40 %) 
 
6.2.3.3  Deprotection of intermediate 43 (using aqueous HCl) 
 
1-N(ribityl),2-N(Boc)-diamino-4,5-dimethylbenzene 43 (1.20 g, 3.24 mmol) was dissolved in 
aqueous HCl (2M) and stirred at RT for 3 hours. The mixture was lyophilised, furnishing 
deprotected intermediate 44 as green crystals (876 mg, 3.24 mmol, quantitative yield). 
 
TLC 10:1 CHCl3:MeOH RF: 0.67 (43), 0.00 (44); NinH / I2 staining; 1H NMR (400MHz, D2O) 
δ (ppm) 7.07 (s, 1H), 6.76 (s, 1H), 3.92 (m, 1H), 3.83 (dd, 1H, JAM = 3.5 Hz, JAX = 11.2 Hz),  
3.66 (m, 1H), 3.62 (dd, 2H, JAM = 6.5 Hz, JAX = 12.8 Hz), 3.47 (dd, 1H, JAM = 3.0 Hz, JAX = 12.8 Hz), 
3.31 (m, 1H), 3.16 (dd, 1H, JAM = 3.1 Hz, JAX = 8.0 Hz), 2.14 (s, 3H), 2.08 (s, 3H); 
13C NMR (100 MHz, D2O) δ (ppm) 131.1, 130.4, 125.8, 124.0, 115.8, 113.2, 73.8, 72.9, 72.0, 
64.7, 47.2, 19.0, 18.5; EI MS (+) (m/z) 294 ([M+1+Na+] 30 %), 271 ([M+1], 100 %) 
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6.2.3.4  Formation of 5,6-dimethylbenzimidazole 
 
Deprotected ribitylated diamine 44 (200 mg, 0.740 mmol) formed under anaerobic conditions 
was dissolved in H2O (100 mL), and stirred vigorously at RT, with continuous aeration of the 
solution using compressed air. TLC at 156 hours indicated no reaction had occurred over the 
previous 24 hours (and was thus assumed to be complete). The mixture was extracted using 
EtOAc (3 x 30 mL), and the organic layer washed with saturated solutions of NaHCO3 (50 mL) 
and brine (2 x 50 mL), before drying over MgSO4. Solvent was removed by rotary evaporation 
to give the impure product as a crude brown solid. Recrystallization from Et2O furnished 
5,6-dimethylbenzimidazole 44b (15 mg, 0.103 mmol, 14 %) as a pale yellow crystalline solid. 
 
MP 203-205 °C (lit 202-206 °C); 1H NMR (400 MHz, CDCl3) δ (ppm) 8.00 (s, 1H), 7.44 (s, 2 H), 
2.38 (s, 6H); 13C NMR (100 MHz), δ (ppm) 139.9, 136.3, 132.0, 115.6, 20.4 ESI MS (+) (m/z) 
146 ([M], 100 %) 
 
6.2.4.1  Formation of diethyl-2-bromo-3-oxoglutarate 46 (original method) 
 
Diethyl-3-oxoglutarate 45 (1.60 mL, 1.79 g, 8.86 mmol) was stirred in a two-necked flask at 
65 °C. CO2 was bubbled through the solution, and bromine (650 µL, 2.00 g, 12.5 mmol, 1.4 
equiv.) was added dropwise. The solution stirred at 65 °C for 30 minutes, before being cooled 
to RT, whereupon CH2Cl2 (60 mL) was added. The organic solvent was washed using a 10 % 
(w/v) solution of Na2SO3, followed by saturated solutions of Na2SO4 (25 mL), NaHCO3 (25 mL) 
and brine (2 x 25 mL). The organic solvent was dried using MgSO4 and removed under reduced 
pressure to yield a crude red oil. Yield was not calculated due to fast degradation of the 
product; diethyl-2-bromo-3-oxoglutarate 46 was synthesised immediately prior to use, with 
an assumption of 50 % efficiency.  
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1H NMR (400MHz, CDCl3; impure due to degradation) δ (ppm) 5.05 (s, 1H), 4.21 (dq, 2H, JAM = 
3.1 Hz, JAX = 7.2 Hz), 4.15-4.08, (m, 3H), 4.02 (q, 1H, J = 7.0 Hz), 3.77 (q, 1H, J = 15.6 Hz), 3.54 
(s, 1H), 1.95 (s, 2H), 1.20 (m, 9H); 13C NMR (100MHz; impure due to degradation) δ (ppm) 
191.9, 171.1, 167.0, 78.0, 77.4, 63.5, 61.9, 61.6, 60.5, 48.9, 45.8, 21.6, 14.4, 14.0; APCI MS (+) 
(m/z) 362 ([M(81Br2)], 50%), 360 ([M(79Br81Br)], 100%), 358 ([M(79Br2)], 50%), 283 (C9H1381BrO5 
[M(81Br)+1], 100%), 281 ([M(79Br)+1], 100%) 
 
6.2.4.2  Formation of diethyl-2-bromo-3-oxoglutarate 46 (improved method) 
 
In a flame-dried three-neck-round bottom flask, diethyl-3-oxoglutarate 45 (2.90 mL, 3.50 g, 
20 mmol) was dissolved in dried CH2Cl2 (60 mL) under N2 at -78°C. Bromine (1.03 mL, 3.20 g, 
20 mmol, 1 equiv.) was added dropwise over 10 minutes. After 45 minutes, the flask was 
allowed to warm to room temperature and the stoppers removed to release an acidic vapour 
(HBr). The solution was filtered under suction, and solvent removed under reduced pressure 
to furnish a red oil. This was purified by passing it over a short column of silica, allowing 
isolation of diethyl-2-bromo-3-oxoglutarate 46 as a rose-coloured oil (4.0 mL). This was 
synthesised immediately prior to use; due to fast degradation of the compound, yield 
calculation was found to be unreliable. Instead, sufficient reagent was used to supply the 
subsequent reaction with between 1.2 to 1.5 equivalents of the brominated oxoglutarate 46, 
based on calculation from the quantity of 45 initially used. 
 
TLC 3:2 hexane:EtOAc RF: 0.99 (45), 0.55 (46); NinH / I2 staining; FC stationary phase Silica gel 
using 3:2 hexane:EtOAc, column bed 2.5 x 2.5 cm; FC mobile phase 3:2 hexane:EtOAc; 
1H NMR (400MHz, CDCl3) δ (ppm) 5.05 (s, 1H), 4.14 (dq, 4H, J = 7.2 Hz), 3.54, (s, 1H), 1.95  
(s, 1H), 1.20 (m, 6H); 13C NMR (100MHz) δ (ppm) 198.6, 168.6, 165.0, 63.1, 61.4, 60.5, 45.8, 
14.4, 14.2, 14.0; ESI MS (-) (m/z) 280 ([M(81Br)-2], 100%), 278 ([M(79Br)-2], 100%) 
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6.2.5.1 Coupling of aniline 44 and diethyl-2-bromo-3-oxoglutarate 46 (original method) 
 
1-(N(ribityl)),2-diamino-4,5-dimethylbenzene 44 (280 mg, 1.04 mmol) dissolved in DMF 
(10 mL) was mixed with a solution of diethyl-2-bromo-3-oxoglutarate 46 (600 mg, 2.1 mmol, 
2 equiv.) in CH2Cl2 (15 mL). Cs2CO3 (1.00 g, 3.1 mmol, 3 equiv.) was added, and the biphasic 
mixture stirred at RT for 36 hours, and filtered. The solution was diluted with H2O (60 mL) and 
extracted into ethyl acetate (5 x 50 mL), with addition of brine as necessary to facilitate 
separation of the layers. The combined organic layers were washed with further brine (2 x 
50 mL), and dried over MgSO4. Solvent was removed under reduced pressure to yield a dark-
red viscous oil. After purification by FC over silica, the product was dried under high vacuum 
for 8 hours to give the bicyclic intermediate 47 (257 mg, 0.57 mmol, 55 %) as a dark red oil. 
 
The reaction was repeated using several alternative bases (in appropriate relative quantities), 
including K2CO3 (giving 34 % yield), Na2CO3 (14 % yield), NaHCO3 (11 % yield), pyridine 
(4 % yield), imidazole, DMAP, NaOH and KOH. Product purity was assessed compared to the 
spectroscopic data given below. No product was isolated using imidazole, DMAP or the 
hydroxylic bases, and no base examined was more effective than Cs2CO3. 
 
TLC 20 : 1 CHCl3:MeOH RF: 0.49 (46), 0.07 (47), 0.00 (44); NinH / CAM / I2 staining; FC 
stationary phase Silica gel using 20 : 1 CHCl3:MeOH, column bed 2.5 x 10 cm; FC mobile phase 
20 : 1 CHCl3:MeOH; 1H NMR (250MHz, CDCl3) δ (ppm) 7.94 (s, 1H), 7.26, (s, 1H) 7.10 (br s, 1H), 
5.24 (s, 1H), 4.60 (m, 3H), 4.40 (q, 1H, J = 12Hz), 4.30 (m, 1H), 3.80 (m, 1H), 2.89 (s, 3H), 2.81 
(s, 3H), 1.25 (m, 3H); 13C NMR (62.5 MHz) δ (ppm) 162.5, 162.3, 148.3, 132.8, 132.5, 131.6, 
130.7, 123.1, 106.5, 77.7, 77.1, 76.6, 73.2, 62.9, 60.8, 40.7, 36.5, 31.4, 29.6, 15.0, 14.4;  
ESI MS (+) (m/z) 473 ([M+Na+], 65 %)  451 ([M+1], 100 %); HR MS (ESI +) (m/z) found 451.2336, 
calc. 451.2080 for [M] 
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6.2.5.2 Coupling of aniline 44 and diethyl-2-bromo-3-oxoglutarate 46 (enhanced method, 
and survey of solvents) 
 
1-(N(ribityl)),2-diamino-4,5-dimethylbenzene 44 (3.10 g, 11.5 mmol) was added to a stirring 
biphasic mixture of MeOH (30 mL) and CH2Cl2 (30 mL), containing diethyl-2-bromo-3-
oxoglutarate 47 (4.0 mL) and Cs2CO3 (2.40 g, 7.4 mmol, 0.64 equiv.). The mixture was stirred 
at RT for 48 hours, followed by filtration under suction, before solvent was removed under 
reduced pressure. The black residue was dissolved in H2O (100 mL) and extracted into ethyl 
acetate (5 x 50 mL), with brine added to facilitate separation of the layers. The combined 
organic layers were washed with further brine (2 x 50 mL), and dried over MgSO4. Solvent was 
removed under reduced pressure to furnish a dark-red viscous oil, which was purified by FC. 
Solvent was removed under reduced pressure, and the final product dried under high vacuum 
for 8 hours to give the final product 47 (4.00 g, 8.89 mmol, 77%) as a dark red oil. 
 
TLC 20 : 1 CHCl3:MeOH RF: 0.50 (46), 0.08 (47), 0.00 (44); NinH / CAM / I2 staining; FC 
stationary phase Silica gel using 20 : 1 CHCl3:MeOH, column bed 2.5 x 10 cm; FC mobile phase 
20 : 1 CHCl3:MeOH; 1H NMR (400 MHz, CDCl3) δ (ppm) 7.36, (s, 1H) 6.49 (s, 1H), 6.39 (s, 1H), 
5.24 (s, 1H), 4.65-4.52 (m, 4H), 4.37 (q, 1H, J = 7.0 Hz), 4.22 (m, 1H), 3.78 (m, 1H), 2.33 (s, 3H), 
2.26 (s, 3H), 1.30 (m, 3H); 13C NMR (62.5 MHz) δ (ppm) 168.3, 162.5, 162.3, 148.3, 132.8, 
132.5, 131.6, 130.7, 123.1, 106.5, 77.7, 77.1, 76.6, 73.2, 62.9, 60.8, 40.7, 36.5, 31.4, 29.6, 15.0, 
14.4; ESI MS (+) (m/z) 473 ([M+Na+], 45 %),  451 ([M+1], 100 %); HR MS (ESI +) (m/z) found 
451.2106, calc. 451.2080 for [M+1] 
 
 
This reaction was repeated using the alternative solvent mixtures given in table 19 below. 
Each reaction was performed using 250 mg (925 µM) of the determinant reactant. All 
products were purified by FC, and spectral data compared to that given above. 
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Primary Solvent 
Secondary 
Solvent 
Yield 
mass (mg) µmol % 
CH2Cl2 DMF   55 
CH2Cl2 Hexane - - 0 
CH2Cl2 EtOH 184 408 44 
CH2Cl2 MeOH 322 715 77 
CH2Cl2 H2O 34 75 8 
CH2Cl2 DMSO - - 0 
CHCl3 MeOH 270 599 65 
CHCl3 DMF 162 360 39 
Et2O MeOH 68 151 16 
Et2O H2O 45 100 11 
Table 19: Solvent mixtures used to examine the coupling between intermediates 44 and 46 
 
6.2.6  Formation of 1-deazariboflavin 48 
  
Bicyclic intermediate 47 (120 mg, 267 μmol) was dissolved at room temperature in 
methanolic ammonia (prepared at -78 °C. The solution was stirred at RT for 72 hours, with 
additional solvent (10 mL) added after 36 hours. Solvent was removed under reduced 
pressure and the resultant purple-brown solid dried under high vacuum for 8 hours to yield 
1-deazariboflavin 48 as a purple-black solid (92 mg, 245 μmol, 92%). 
 
TLC 3:1:1 isopropanol:AcOH:H2O RF: 0.87 (48), 0.00 (47); 47 exhibits some white fluorescence, 
while 48 exhibits a total lack of fluorescence; 1H NMR (400 MHz, D2O) δ (ppm) 7.48, (s, 1H) 
7.15 (s, 1H), 5.56 (s, 1H), 3.94 (m, 1H) 3.56 (m, 2H), 3.38 (m, 1H), 2.88 (q, 1H, J = 7.6 Hz), 2.79 
(m, 2H), 2.11 (s, 3H), 2.02 (s, 3H); 13C NMR (62.5 MHz, MeOD) δ (ppm) 167.3, 161.1, 148.0, 
146.7, 141.1, 136.0, 132.8, 131.3, 130.1, 122.9, 107.3, 76.0, 71.4, 70.2, 65.3, 53.8, 21.5, 18.1; 
ESI MS (-) (m/z) 412 ([M+37Cl], 15 %), 410 ([M+35Cl], 50 %), 374 ([M-1], 100 %)  
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6.3 Synthesis of 8-Demethyl-5-deazariboflavin 54 
This section describes the synthesis of the 5-deazariboflavin derivative, 8-demethyl-5-
deazariboflavin 54. This was performed using the optimal route found for the synthesis of 5-
deazariboflavin 39, using 4-methylaniline 49 in place of 3,4-dimethylaniline 31. 
Figure 106: Overview of the synthesis of 8-demethyl-5-deazariboflavin 54 
 
6.3.1 Reductive amination of 4-methylaniline 49 using D-ribose 
 
p-Toluidine 49 (5.00 g, 47 mmol), Na[(CN)BH3] (5.84 g, 93 mmol, 2 equiv.) and D-ribose 32 
(17.5 g, 117 mmol, 2.5 equiv.) were combined in a flame-dried 3-neck RBF and dried under 
high vacuum for 4 hours. Anhydrous MeOH (250mL) was added, and the mixture heated at 
reflux under Ar / N2 until completion. The solvent was removed under reduced pressure to 
give a dark brown solid, which was dissolved in HCl(aq) (50mL, 1M) and swirled until gas 
evolution ceased. The resulting suspension was carefully neutralised using saturated NaHCO3 
(100 mL) and washed with an aliquot of EtOAc (50 mL). As with the earlier formation of 
3,4-dimethyl-N-(ribityl)-aniline (vide supra), EtOAc stimulated formation of a white 
precipitate which was collected by filtration and dried under high vacuum to furnish 
(N-ribityl)-p-toluidine (2.00 g, 8.29 mmol) as a white solid. The aqueous layer was extracted 
with further EtOAc (4 x 50 mL), and combined organic fractions washed with brine (2 x 50mL) 
and dried over MgSO4. Solvent was removed under reduced pressure to give an impure pale 
yellow solid, which was purified by recrystallisation to give product 50 (6.11 g, 25.32 mmol) 
as a white solid. The combined yield of purified (N-ribityl)-p-toluidine from both precipitate 
and organic extraction (8.11 g, 33.6 mmol) was therefore 72%. 
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TLC 10:1 CHCl3:MeOH RF: 0.78 (49), 0.57 (50), 0.00 (32); NinH staining; MP 138-141 °C; 
 1H NMR (400 MHz, MeOD-d3) δ (ppm) 6.83 (d, 2H, J = 7.6 Hz), 6.52 (d, 2H, J = 8.5 Hz), 4.81 
(br s (hydroxylic), 4H), 3.81 (m, 1H), 3.67 (m, 2H), 3.54 (dd, 2H, JAM = 6.2 Hz, JAX = 9.8 Hz), 3.33 
(dd, 1H, JAM = 3.2 Hz, JAX = 12.8 Hz), 3.21 (m, 2H), 2.99 (dd, 1H, JAM = 8.0 Hz, JAX = 12.8 Hz), 2.09 
(s, 3H); 13C NMR (62.5 MHz, MeOD-d3) δ (ppm) 147.8, 130.5, 127.8, 115.0, 74.9, 74.4, 72.5, 
64.7, 42.4, 20.6;  ESI MS (+) (m/z) 264 ([M+Na+], 100 %) 242 ([M+1], 100 %); HR MS (EI +) 
found 241.1313, calculated as 241.1314 [M]  
 
6.3.2  Coupling of ribitylated aniline 50 and 6-chlorouracil 35 
 
Ribitylated aniline 50 (280 mg, 1.16 mmol), 6-chlorouracil 35 (203 mg, 1.39 mmol, 1.2 equiv.) 
and malononitrile (50 mg, 0.76 mmol, 0.66 equiv.) were combined in flame-dried glassware. 
Thoroughly dried MeOH (30 mL) was added, and the suspension heated under N2 to reflux. 
After 48 hours, further malononitrile (50mg, 0.76 mmol, 0.66 equiv.) was added. TLC at 96 
hours indicated complete consumption of starting materials, and the reaction was cooled to 
room temperature. Solvent was removed under reduced pressure, and the resultant brown 
solid was used for the subsequent reaction without further purification.  
 
TLC 20:1 CHCl3:MeOH RF: 0.65 (35), 0.12 (51), 0.21 (50); NinH / I2 staining; 51 exhibits blue 
fluorescence; ESI MS (-) (m/z) 351 ([M], 100%) 
 
6.3.3  Protection of ribityl side-chain of intermediate 51 
 
Crude intermediate 51 from the previous reaction was dissolved in a solution of pyridine 
(2.5 mL) and CH2Cl2 (10 mL). Acetic anhydride (0.65 mL, 6.89 mmol, 6-fold excess) was added 
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dropwise, and the mixture was stirred at room temperature for 16 hours. Solvent was 
removed under reduced pressure, and the orange-brown residue dissolved in water (20 mL) 
before extraction into CH2Cl2 (3 x 50 mL). Combined organic layers were washed with a 
saturated solution of NaHCO3 (50 mL), water (3 x 50 mL) and brine (2 x 50 mL), and dried over 
MgSO4. Solvent was removed under reduced pressure, and the resultant oil thoroughly dried 
under reduced pressure to furnished acetylated product 52 as a yellow-orange oil in 79 % 
yield (477 mg, 0.92 mmol) over two steps. 
 
TLC 20:1 CHCl3:MeOH RF: 0.34-0.42 [streak] (52), 0.12 (51); NinH / I2 staining; 51 and 52 each 
exhibit blue fluorescence; 1H NMR (400 MHz, CDCl3) δ (ppm), 7.19 (d, 2H, J = 8.2 Hz), 7.03 (d, 
2H J = 8.2 Hz), 5.20 (m, 1H), 4.28 (dd, 1H, JAM = 3.2 Hz, JAX = 12.4 Hz), 4.23-4.15 (m, 2H), 4.12-
4.03 (m, 2H), 3.85 (dd, 1H, JAM = 2.2 Hz, JAX = 14.6 Hz), 3.65 (m, 1H), 2.31 (s, 3H), 2.05 (s, 3H), 
2.02 (s, 3H), 2.01 (s, 3H), 1.90 (s, 3H); 13C NMR (62.5 MHz, CDCl3) δ (ppm) 177.2 (C), 171.8 (C), 
169.9 (C), 166.6 (C), 164.8 (C), 160.3 (C), 144.0 (C), 130.4 (CH), 126.9 (CH), 126.4 (CH), 73.3 
(CH), 72.5 (CH), 68.9 (CH), 63.8 (CH), 61.4 (CH2), 42.8 (CH2), 36.3 (CH3), 19.9 (CH3); EI MS (+) 
(m/z) molecular ion (C24H29N3O10, 519.19) was unobserved; characteristic fragmentation 
indicated product formation: 475 ([M+1-Ac], 100 %), 432 ([M-(Ac)2], 35 %) 
 
6.3.4  Formation of 8-demethyl-5-deazariboflavin tetraacetate 53 
 
Bicyclic acetylated intermediate 52 (400mg, 0.77 mmol) was dissolved in DMF (5 mL) with 
stirring. POCl3 (86 µL, 142 mg, 0.92 mmol, 1.2 equiv.) was added dropwise over 10 minutes, 
and the mixture stirred at room temperature for 30 minutes, before heating to 100°C for 60 
minutes. Once cooled to room temperature, ice (20 cm3) was added directly to the mixture, 
facilitating precipitation of a yellow-orange precipitate. The pH of the mixture was adjusted 
to pH 7 using NH4OH (5% aqueous solution, 15 mL), and the precipitate isolated by filtration 
under suction, before drying under high vacuum. The aqueous layer was extracted using 
CH2Cl2 (3 x 20 mL), and the combined organic fractions washed using HCl (0.5 M, 10 mL) 
 221 
 
followed by water (3 x 10 mL). The pH of the aqueous solution was adjusted to pH 9-10 using 
a saturated solution of NaHCO3, and re-extracted using CHCl3 (3 x 20 mL). Combined organic 
layers were dried and solvent removed under reduced pressure to yield additional product 
53 as a vibrant yellow solid, with a combined yield of 87 % (356 mg, 0.67 mmol). 
 
TLC 20:1 CHCl3:MeOH RF: 0.38-0.42 [streak] (52), 0.31 (53); NinH / I2 staining; 52 and 53 each 
exhibit blue fluorescence, 53 is particularly vivid 1H NMR (500 MHz, CDCl3) δ (ppm) 8.01 (s, 
1H), 7.19 (d, 1H, J = 6.4 Hz), 7.13 (dd, 1H, JAM = 1.6 Hz, JAX = 6.8 Hz), 5.30 (m, 1H), 5.20 (m, 1H), 
4.28 (dd, 1H, JAM = 2.4 Hz, JAX = 10.0 Hz), 4.17-4.05 (m, 2H), 3.75 (dd, 1H, JAM = 11.4 Hz, JAX = 
80.4 Hz), 2.95 (DMSO, residual), 2.36 (s, 3H), 2.11-2.02 (m, 12H) 13C NMR (125 MHz, CDCl3) δ 
(ppm), 177.3 (C), 172.2 (C), 169.2 (C), 164.2 (C), 162.5 (C), 157.2 (C), 151.0 (C), 138.0 (C), 130.4 
(CH), 128.0 (CH), 127.7, 122.8 (CH), 119.6 (CH), 114.0, 70.7 (CH), 69.8 (CH), 69.2 (CH), 61.9 
(CH2), 48.4 (CH2), 36.6 (CH3), 21.1 (CH3), 20.9 (CH3), 20.8 (CH3), 20.8 (CH3); ESI MS (-) (m/z) 
molecular ion (C24H29N3O10, 519.19) unobserved; fragmentation indicated product formation: 
485 ([M-1, -Ac], 100 %); EI MS (+) (m/z) molecular ion 53 was unobserved; fragmentation 
indicated product formation (predicted structures below): 303 (53c [M], 55 %), 243 (53d [M], 
15 %) 229 (53b [M], 60 %),  
 
 
6.3.5  Formation of 8-demethyl-5-deazariboflavin 54 
 
Crude acetylated intermediate 53 (300 mg, 0.567 mmol) was dissolved in methanolic 
ammonia (20 mL) and stirred at room temperature for 6 hours. The mixture was filtered, and 
the clarified solution concentrated by rotary evaporation, yielding crude 8-demethyl-5-
deazariboflavin as a yellow oil. Purified 8-demethyl-5-deazariboflavin 54 was isolated as a 
brilliant yellow powder in 58 % yield (119 mg, 0.329 mmol) by HPLC. 
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TLC 20:1 CHCl3:MeOH RF: 0.31 (53), 0.00 (54); 3:1:1 isopropanol:AcOH:H2O RF: 0.86 (54), 0.00 
(53); I2 / CAM staining; 53 and 54 each exhibit vivid blue fluorescence; 1H NMR (500 MHz, 
DMSO-d6) δ (ppm) 8.01 (s, 1H), 7.25 (d, 1H, J = 7.2 Hz), 6.88 (d, 1H, J = 6.4 Hz), 6.71 (br s, 1H), 
6.51 (d, 1H, J = 6.8 Hz), 3.80-3.75 (m, 1H), 3.63-3.56 (m, 2H), 3.49-3.39 (m, 3H), 3.29 (d, 1H), 
2.36 (s, 3H); 13C NMR (125 MHz, DMSO-d6) δ (ppm), 162.4, 155.8, 153.3, 148.5, 130.6 (CH), 
129.7 (CH), 128.5, 123.1, 121.8, 115.2 (CH), 112.8, 107.4 (CH), 73.9 (CH), 71.8 (CH), 70.6 (CH), 
63.6 (CH2), 46.4 (CH2), 23.0 (CH3); ESI MS (-) (m/z) 356 ([M-4], 100 %); ESI MS (+) (m/z) 
fragments indicated product formation; 240 (54b [M], 100 %), 121 (54c [M], 55 %)  
 
 
6.4 Attempted Formation of Multiple Riboflavin Analogues Using a  
Single Synthetic Method 
6.4.1.1  Synthesis of 2,6-dichloropyridine-1-oxide 56 
 
2,6-Dichloropyridine 55 (11.2 g, 75.7 mmol) was dissolved in a mixture of CF3CO2H (50 mL) 
and 35 % aqueous [v/v] H2O2 (14 mL), and heated at reflux for 16 hours. After cooling to RT, 
the mixture was basified (pH 14) using saturated aqueous NaHCO3 (50 mL), followed by NaOH 
(4.5 g), extracted using EtOAc (3 x 60 mL), and the combined organic extracts washed with 
saturated NaHCO3 (50 mL), brine (50 mL) and dried over Na2SO4. Solvent was removed under 
reduced pressure to give crude yellow crystals (97 %), which were purified by recrystallisation 
from EtOAc to give pure product 56 as colourless crystals (11.67 g, 71.2 mmol, 94 %). 
 
TLC 20:1 CHCl3:MeOH RF: 0.65-0.71 (56); 10:1 CHCl3:MeOH RF: 0.74-0.85 (56); MP 136-138 °C 
(lit 135-139 °C); 1H NMR (400MHz, CDCl3) δ (ppm) 7.57 (t, 1H, J = 7.8 Hz), 7.20 (d, 2H, J = 7.9 
Hz); 13C NMR (62.5 MHz, CDCl3) δ (ppm) 149.5, 139.9, 121.9; ESI MS (+) (m/z) 186 ([M + Na+], 
100 %), 164 ([M+1], 65 %); HR MS (ESI +) (m/z) found 185.9486, calc. 185.9489 for [M+Na+]; 
found 162.9675, calc. 162.9670 for [M] 
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6.4.1.2  Synthesis of 2,4,6-trichloropyridine 57 
 
2,6-Dichloropyridine-N(oxide) 56 (9.00 g, 54.9 mmol) was dissolved in undiluted POCl3 (10 mL) 
and heated at reflux for 16 hours. The mixture was allowed to cool to 0 °C, and ice (35 cm3) 
was cautiously added over the course of 2 hours. The pH of the solution was adjusted using a 
solution of Na2CO3 (0.5 M) until pH 7, followed by NaOH (2M) to pH 14. The solution was 
extracted into Et2O (3 x 80 mL), and the combined organic layers washed with NaHCO3 (50 
mL) and brine (50 mL) before drying over MgSO4. Solvent was removed under reduced 
pressure (at 40 °C) to give a green-brown oil, which crystallised upon cooling to RT to furnish 
green-grey needles (10.01 g, 54.9 mmol, quant.). 2,4,6-trichloropyridine 57 was recrystallised 
from pentane and ice-cold ethanol as large grey-white needles (9.02 g, 49.4 mmol, 83 %).  
 
TLC 20:1 CHCl3:MeOH RF: 0.98 (57) 0.66-0.71 (56); 10:1 CHCl3:MeOH RF: 0.94 (57), 0.74-0.85 
(56); MP 33-34 °C (lit 33-37 °C); 1H NMR (400MHz, CDCl3) δ (ppm) 8.07 (s, 1H); 13C NMR (62.5 
MHz, CDCl3) δ (ppm) 150.6, 147.2, 123.1; EI MS (+) (m/z) 185 ([M(37Cl2)], 25 %), 183 
([M(37Cl35Cl)], 95 %), 181 ([M(35Cl2)], 100 %)  
 
6.4.1.3  Attempted direct formation of 2,4,6-trichloropyridine 57 (unsuccessful) 
 
2,6-dichloropyridine 55 (1.48 g, 10.0 mmol) was dissolved in undiluted POCl3 (4 mL), and the 
solution heated at reflux for 16 hours. The mixture was allowed to cool to 0 °C, and ice 
(10 cm3) cautiously added over the course of 1 hour. The acidity of the solution was adjusted 
to pH 7 using Na2CO3 (10 mL, 0.5 M), followed by NaOH (2M) to adjust the pH to 14, before 
extraction using diethyl ether (3 x 50 mL); no product was isolated in this solvent. The aqueous 
layer was re-extracted using EtOAc (3 x 50 mL), and the combined organic layers washed with 
NaHCO3 (50 mL) and brine before drying over MgSO4. Solvent was removed under reduced 
pressure to yield a white crystalline solid. Spectroscopy indicated recovery of 2,6-
dichloropyridine 55 (1.46 g, 9.86 mmol, 99%). 
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TLC 20:1 CHCl3:MeOH RF: 0.82 (55); MP 84-86 °C (lit 83-86 °C); 1H NMR (400MHz, CDCl3) 
δ (ppm) 7.63 (t, 1H, J = 7.9 Hz), 7.28 (d, 2H, J = 7.6 Hz); EI MS (-) (m/z) 146 ([M-1], 100 %) 
 
6.4.2  Attempted conversion of 2,4,6-trichloropyridine 57 to pyridione 58 (unsuccessful) 
 
2,4,6-trichlropyridine 57 (500 mg, 2.74 mmol) was stirred in a refluxing aqueous solution of 
NaOH (10 mL, 5 M, 50 mmol) for 48 hours. The reaction was allowed to cool to RT, and the 
pH of the mixture adjusted to pH 2 using aqueous HCl (2 M). Acidification of the mixture 
facilitated precipitation of an off-white solid, which was collected by filtration under suction, 
washed with ice-cold water (5 mL), and recrystallised from acetone to furnish a white 
crystalline solid (138 mg, 0.85 mmol*, 31 % [*based on later MS evidence]). The aqueous 
filtrate was extracted thoroughly using EtOAc (5 x 30 mL), dried using brine (30 mL) and dried 
over MgSO4. Removal of solvent under reduced pressure afforded recovery of 
2,4,6-trichloropyridine 57 (305 mg, 1.81 mmol, 66 %). 
 
Spectroscopy was performed for the unknown (minor) product: 
TLC 20:1 CHCl3:MeOH RF: 0.98 (57) 0.14, 0.17 (unidentified products); 10:1 CHCl3:MeOH RF: 
0.94 (57), 0.34, 0.36 (unidentified products); MP 224-226 °C; 1H NMR (400 MHz, CDCl3) δ 
(ppm) 6.76 (d, 1H, J = 1.6 Hz), 6.69 (d, 1H, J = 1.6 Hz), 1.66 (br s); 13C NMR δ (ppm) 205.0, 
145.4, 135.2, 114.0; EI MS (+) (m/z) isotope pattern strongly indicated a dichlorinated 
product: 167 ([M(37Cl2)], 10 %), 165 ([M(37Cl35Cl), 65 %], 163 ([M(35Cl2)], 100 %) 
 
6.4.3  Attempted conversion of 2,4-dichloropyridine 55 to 2,6-pyridione 59 (unsuccessful) 
 
A solution of 2,6-dichloropyridine 55 (1.00 g, 6.76 mmol) in refluxing aqueous NaOH (6 mL, 
5 M, 4.5 equiv.) was stirred for 48 hours. The reaction was allowed to cool to RT, the pH of 
the mixture was adjusted to between pH 1-2 using aqueous HCl (25 mL, 1 M), and the mixture 
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cooled at 4°C overnight, with no precipitation observed. The aqueous mixture was extracted 
using EtOAc (3 x 20 mL). The organic layer was washed with a saturated solution of NaHCO3 
(30 mL), brine (30 mL), and dried over MgSO4. Removal of solvent under reduced pressure 
furnished a white crystalline solid, identified as starting material 55 (982 mg, 98%). 
 
TLC 20:1 CHCl3:MeOH RF: 0.82 (55) MP 84-86 °C (lit 83-86 °C) 1H NMR (400MHz, CDCl3)  
δ (ppm) 7.63 (t, 1H, J = 7.8 Hz), 7.28 (d, 2H, J = 7.8 Hz) EI MS(-) (m/z) 146 ([M-1], 100 %) 
 
6.4.4 2-chloro-4,6-dimethoxypyridine 60 and 4-chloro-2,6-dimethoxy-pyridine 61 
 
To a freshly-prepared solution of NaOMe (20 mL) under Ar / N2, 2,4,6-trichloropyridine 57 
(850 mg, 4.70 mmol) was added, and the solution heated under reflux for 16 hours. Solvent 
was removed under reduced pressure, and H2O (20 mL) cautiously added. The product was 
extracted into CH2Cl2 (3 x 20 mL); combined organic layers were washed with brine, and dried 
over MgSO4. Solvent was removed under reduced pressure, and the yellow residue was 
purified by FC. Elution with CHCl3:MeOH (10:1, v/v) furnished 2-chloro-4,6-dimethoxylpyridine 
60 (major product) as a colourless crystalline solid, which was recrystallised from pentane 
(203 mg, 1.17 mmol, 25 %); 4-chloro-2,6-dimethoxypyridine 61 (minor product) was isolated 
as a colourless crystalline solid (31 mg, 0.18 mmol, 4 %).  
 
FC stationary phase Silica gel using 10 : 1 CHCl3:MeOH, column bed 2.0 x 15 cm; FC mobile 
phase 10 : 1 CHCl3:MeOH 
 
2-chloro-4,6-dimethoxylpyridine 60 
TLC 10:1 CHCl3:MeOH RF: 0.94 (60); 4 : 1 hexane : EtOAc RF: 0.81 (60) MP 82-84 °C (lit 
81-85 °C) 1H NMR (400 MHz, CDCL3) δ (ppm) 6.49 (d, 1H, J = 2.0 Hz), 6.10 (d, 1H, J = 1.6 Hz), 
3.89 (s, 3H), 3.79 (s, 3H) EI MS (+) (m/z) 172 ([M], 100 %) HR MS (EI +) found 172.0159, calc. 
172.0165 for [M (35Cl)] 
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4-chloro-2,6-dimethoxypyridine 61 
TLC 10:1 CHCl3:MeOH RF: 0.80 (61); 4 : 1 hexane : EtOAc RF: 0.69 (61) MP 63-65 °C (lit 63-
66 °C) 1H NMR (400 MHz, CDCL3) δ (ppm) 6.38 (s, 2H), 3.74 (s, 6H) EI MS (+) (m/z) 173 ([M+1], 
100 %) HR MS (EI +) found 172.0159, calc. 172.0165 for [M (35Cl)  
 
6.4.5 Attempted coupling of ribitylated aniline 33 and chloro dimethoxypyridines 60 or 61 
 
Several methods to perform this reaction were attempted, based on the methods described 
in sections 6.1.3.1 - 6.1.3.3; however in all cases, the reaction failed to produce any products. 
Residues isolated from these reactions after purification (FC or recrystallisation) were 
determined from the spectroscopic evidence as initial reactants which had not undergone 
reaction. No products or side-products indicating degradation were visible. 
 
6.4.6  Formation of 2,4,6-piperidinetrione 66 
The synthesis of diethyl-2-cyano-3-iminoglutarate 65 was originally described by Baron et 
al.173, under the synonym ethyl-β-imino-α-cyanoglutarate; the cyclisation of this to form 
2,4,6-piperidinetrione 66 was originally described by Weinstock et al.106. 
 
6.4.6.1  Preparation of diethyl-2-cyano-3-iminoglutarate 65 
 
Ethyl cyanoacetate (11.3 g, 10.6 mL, 100 mmol) was dissolved in freshly-prepared sodium 
ethoxide (15 mL), and the solution heated under reflux for 3 hours. Once cool, H2O (10 mL) 
was added cautiously, followed by aqueous HCl (5 mL, 2 M), to yield a purple solution which 
was extracted using Et2O (3 x 80 mL). Combined organic layers were washed with a saturated 
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solution of NaHCO3 (50 mL) and brine (50 mL), before drying over MgSO4; concentration 
under reduced pressure furnished impure product 65 as a red oil. This was allowed to stand 
overnight, forming red needles, which were collected under suction and recrystallised from 
aqueous EtOH to furnish diethyl-2-cyano-3-iminoglutarate 65 (18.24g, 81 mmol, 81 %) as 
large white needles. 
 
MP 52-53 °C (lit 52-54 °C;) 1H NMR (400 MHz, DMSO-d6) δ (ppm) 9.10 (br s, 1H), 8.85 (br s, 
1H), 4.17 (dq, 4H, JAM = 3.6 Hz, JAX = 4.4 Hz), 3.56 (s, 2H), 3.34 (s, 1H), 1.21 (dt, JAM = 2.3 Hz,  
JAX = 7.1 Hz); APCI MS (+) (m/z) 227 ([M+1], 100 %) HR MS (APCI +) found 227.1022, calc. 
227.1032 for [M+1] 
 
6.4.6.2  Cyclisation of diethyl-2-cyano-3-iminoglutarate to 2,4,6-piperidine-trione 66 
 
Diethyl-2-cyano-3-iminoglutarate 65 (15.4 g, 68 mmol) was suspended in concentrated (12 M) 
HCl (10 mL), and stirred at reflux for 3 hours forming a yellow solution. Solvent was removed 
under reduced pressure to furnish a pale-yellow solid, which was washed with Et2O (20 mL) 
and collected by filtration. The solid retentate was dissolved in H2O (50 mL), and the pH 
rapidly adjusted to 13-14 using solid NaOH (0.5 g), before boiling for 2 hours (with evolution 
of an alkaline gas smelling strongly of NH3). Once cool, the pH was carefully adjusted to pH 7 
using HCl (1M); care was taken not to over-acidify the mixture. The pale yellow solution was 
allowed to stand undisturbed overnight at RT, with the colour becoming significantly more 
vibrant. Solvent was removed under reduced pressure to yield the sodium adduct of 
piperidinetrione 66 as a luminous yellow powder (9.20 g, 61 mmol, 90 %). 
 
MP: >360 °C (deg; lit: deg > 330 °C); 1H NMR (400 MHz, D2O) δ (ppm) 3.16 (s, 2 H) [No 
resonance for NH was visible due solvent exchange; 13C NMR (100 MHz, D2O) δ (ppm) 40.34; 
13C NMR DEPT 45 δ (ppm) 40.34 (CH2); 13C NMR DEPT 90 [no resonance]; 13C NMR DEPT 135 
(100 MHz) δ (ppm) Positive Polarisation: 40.34 Negative Polarisation: [no resonance];  
EI MS(-) (m/z) 126 ([M-1], 100%); HR MS (EI+) found 127.0267, calc. 127.0269 for [M]  
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6.4.7  Coupling of 3,4-dimethyl-N(ribityl)-aniline 33 and 2,4,6-piperidinetrione 66  
Each of these reactions was unsuccessful at furnishing the desired products. Of the isolated 
products, in all cases 3,4-dimethyl-N(ribityl)-aniline 33 was typically recovered in high yield; 
2,4,6-piperidinetrione 66 was recovered in lower yield due to degradation, giving several 
unassignable low molecular weight compounds. Reaction 3.4.7.1 was repeated using 1-(N-
ribityl),2-(N-Boc)-diamino-4,5-dimethyl-benzene 43 and 4-methyl-N(ribityl)-aniline 50; no 
reaction was again observed, with staring materials isolated as before. 
 
6.4.7.1  Aqueous coupling method (unsuccessful) 
 
3,4-dimethyl-N(ribityl)-aniline 33 (500 mg, 1.96 mmol) and 2,4,6-piperidinetrione 66 (300 mg, 
2.00 mmol) were suspended in a mixture of MeOH (10 mL) and H2O (60 mL). The mixture was 
heated at reflux for 24 hours, with no reaction was observed. Aqueous HCl (10 mL) was added, 
and reflux maintained for 16 hours. The mixture was cooled to RT, with no precipitation 
observed; the solution was extracted using EtOAc (3 x 50 mL), and the organic layer washed 
using NaHCO3 (2 x 50 mL), brine, and dried over MgSO4. Solvent was removed under reduced 
pressure to furnish 3,4-dimethyl-N(ribityl)-aniline 33 (455 mg, 1.78 mmol, 91 %). 2,4,6-
piperidinetrione 66 (and degradation products) were identified within the aqueous layer. 
 
6.4.7.2  Solvent free heating method (unsuccessful) 
 
3,4-dimethyl-N(ribityl)-aniline 33 (500 mg, 1.96 mmol) and 2,4,6-piperidinetrione 66 (300 mg, 
2.00 mmol) were powdered together in a RBF and dried under high vacuum for 4 hours. The 
solid mixture was heated to between 180–200 °C for 20 minutes, before being allowed to cool 
to RT. The brown solid was washed with Et2O (5 mL) [although TLC indicated no dissolution of 
any compound into the organic solvent] and filtered. The solid retentate was dissolved in 
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water and extracted using EtOAc (3 x 40 mL). The organic layer was washed with NaHCO3 
(50 mL) and brine, dried over MgSO4, before solvent removal under reduced pressure 
furnished 3,4-dimethyl-N(ribityl)-aniline 33 (quant.). As seen previously (reaction 3.4.7.1), 
2,4,6-piperidinetrione 66 (and degradation products) were identified in the aqueous layer. 
 
6.4.7.3  Malononitrile catalysed coupling method (unsuccessful) 
 
3,4-dimethyl-N(ribityl)-aniline 33 (500 mg, 1.96 mmol), 2,4,6-piperidinetrione 66 (300 mg, 
2.00 mmol), malononitrile (50 mg, 0.76 mmol) and 18-crown-6 (530 mg, 2.01 mmol) were 
suspended in thoroughly dried MeOH (50 mL) and heated under an Ar / N2 atmosphere at 
reflux for 48 hours; no reaction was observed, with starting materials noted using TLC. A 
further portion of malononitrile (50 mg, 0.76 mmol) was added, and reflux maintained for a 
further 72 hours. The mixture was filtered and the solvent removed under reduced pressure; 
the viscous solid was dissolved in water (50 mL) and extracted using EtOAc (5 x 50 mL). 
Combined organic layers were washed using NaHCO3 (2 x 50 mL) and brine, before drying 
over MgSO4. Solvent was removed under reduced pressure to furnish 3,4-dimethyl-N(ribityl)-
aniline 33 (495 mg, 99 %). 2,4,6-piperidinetrione 66 (and degradation products) were 
identified by TLC and MS within the aqueous layer. 
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6.5 HPLC purification of Riboflavin Analogues  
Preparative-scale purification of the riboflavin analogues formed was performed using HPLC 
(section 5.5.2.3), following established protocols251,178,179. The gradient used is shown 
graphically in appendix 1..Phenomenex Luna, or YMC-Actus Triart columns (section 5.5.2.3) 
were used, with injection volumes of 2-10 mL. Mobile phase composition was acetonitrile 
(“A”) and H2O (containing 0.01 % v/v TFA; “B”) with an initial linear gradient (table 20), and a 
flow rate of 5 mL minute-1. Flavin products were detected by monitoring the absorbance of 
the eluent from the column at a fixed wavelength, relative to the cofactor eluted. 
 
Time 
(minutes) 
Gradient 
(% A) 
 Retention Time 
(minutes) 
Product Eluted Wavelength 
monitored (nm) 
0 0  14.10-16.05 Riboflavin 450 
25 50  14.26-16.63 5-deazaRf 400 
30 50  14.36-15.36 1-deazaRf 535 
35 0  14.95-17.20 8-demethyl-5-deazaRf 450, 400 
 
Table 20: Gradient used for separation of deazariboflavin products, and retention times of 
each riboflavin analogue  
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Chapter 7 - Experimental Detail - Molecular Biology 
7.0.1 Introduction 
In this chapter, the unique experimental conditions required for the effective expression and 
purification of several enzymes within various strains of E. coli are reported, in addition to the 
general description of methods presented in section 5.6. Where applicable, additional 
experiments utilising the recombinant proteins are also described. Instruments and apparatus 
required are listed in section 5.4.2; all buffers and solutions are listed in section 5.2. 
 
7.1 C.ammoniagenes RfK-FADS 
7.1.1 Expression of C.ammoniagenes RfK-FADS  
Expression of the C.ammoniagenes RfK-FADS protein was performed using the general 
method given in section 5.6.2.2. The pre-prepared1 pMAL-C2-RibfK-Ca construct containing 
the necessary gene was transformed into E. coli strains XL1-blue and BL21(DE3); expression 
was performed in both, with BL21(DE3) giving optimal yields. Typical liquid culture volumes 
were 3 L, with IPTG concentrations of 1-2 mmol used to induce protein expression at optimal 
cell density. Expression was allowed to continue for 4 hours at 37 °C, after which the cells 
were harvested using the general method (2.6.2.2). Typical wet cell masses of 10 gL-1 were 
obtained using strain XL1-blue, while strain BL21(DE3) gave 14 gL-1. Harvested cells were 
stored at -20°C until purification.  
 
7.1.2 Cell lysis – Ca-RfK-FADS 
Cell lysis was performed in RfK 1, following sonication as described in section 5.6.3.4.  
 
7.1.3 Purification of Ca-RfK-FADS 
Amylose affinity chromatography was used to purify the Ca-RfK-FADS protein, as described in 
section 5.6.7.1. The eluted protein solution was concentrated by ultrafiltration followed by 
dialysis into buffer RfK 3. Activity remained for 7 days (maintained at pH 7.5, 4°C).  
    
7.1.4 Formation of FMN and FAD analogues using Ca-RfK-FADS 
Phosphorylation of riboflavin and 5-deazariboflavin using Ca-RfK-FADS was performed in 
buffer RfK 4. Non-phosphorylated flavin or analogue concentrations up to 20 mg L-1 were 
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used, with 5 equivalents of ATP. Concentrations of Ca-RfK-FADS up to 100 µM were added 
immediately prior to reaction. The enzymatic mixture was incubated at 37 °C with shaking 
overnight and assayed using TLC, with a complex mixture of products observed. Relative 
intensities of each flavin form were used to estimate reaction progress; upon reaching the 
estimated point of equilibrium between FMN and FAD, the mixture was lyophilised and stored 
at -20 °C until purification. 
 
7.1.5 Purification of flavin cofactors; conversion of 5-deazaFAD to  5-deazaFMN 
Preparative-scale purification of the phosphorylated products 5-deazaFMN and 5-deazaFAD 
was performed using HPLC (section 5.5.2.3) following established protocols251,178,179. The 
gradient used is shown graphically in appendix 1. A Phenomenex Luna column (5.5.2.3) was 
used, with injection volumes between 2-10 mL. Mobile phase composition was acetonitrile 
(“A”) and 0.01 M potassium phosphate, pH 7 (“B”). A gradient of these solvents was used to 
give separation, using a stepwise gradient (table 21), with a flow rate of 5 mL minute-1.  
Time 
(minutes) 
Gradient 
(% A) 
 Retention Time 
(minutes) 
Product 
Eluted 
0 15  7.35-9.45 5-deazaFAD 
14 15  20.05-20.90 5-deazaFMN 
15 35  28.70-29.70 5-deazaRf 
24 35    
25 65    
29 65    
30 90    
35 90    
Table 21: Gradient used for separation of 5-deazaFAD, FMN and Rf, and retention times of 
each. Chromatogram and gradient plot is shown graphically in appendix 1 
 
The major product of the enzymatic phosphorylation was 5-deazaFAD (typically in ratios 
greater than 20:1 compared to 5-deazaFMN, estimated by HPLC). Cleavage of the 
phosphoanhydride bond of 5-deazaFAD was achieved using 1.2 equivalents of TFA added to 
an aqueous solution of purified 5-deazaFAD, resulting in complete cleavage of the 
phosphoanhydride after 2 hours. HPLC of the neutralised lyophilised mixture allowed 
isolation of 5-deazaFMN.  
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7.2  S. pombe RfK 
7.2.1 Expression of Sp-RfK  
During a collaborative side project with Professor Martin Warren and Dr. Hannah Collins 
(University of Kent, Canterbury), I was gifted a plasmid construct containing the Riboflavin 
Kinase (RfK) gene from Schizosaccharomyces pombe183 (GenBank®2,3 ref: NM_001023386.2), 
within a pET-14b plasmid vector. This plasmid was transformed into E. Coli strains XL1-blue 
and BL21(DE3); expression within BL21(DE3) was performed according to the general method 
given in section 5.6.2.2. Culture volumes between 1.5–3 L were used, with IPTG 
concentrations of 1-2 mmol used to induce protein expression. Once induced, expression was 
allowed to continue for 2 hours at 37 °C, or 4 hours at 20 °C, after which the cells were 
harvested (5.6.2.2). Typical wet cell masses of 12 gL-1 were obtained using LB media, and 
19 gL-1 using TB media; harvested products were stored at -20°C until purification.  
 
7.2.2 Cell lysis – Sp-RfK 
Cell lysis was performed in buffer SpRfKLYS, according to the general method given in section 
5.6.3.4. Additional dilution of the cell lysate (1:1, using buffer SpRfK 1) after initial 
centrifugation prevented precipitation of the recombinant protein during purification.  
 
7.2.3 Purification of Sp-RfK 
IMAC purification of the Sp-RfK protein was performed using a column of Ni-sepharose, 
following the general method given in section 5.6.7.2. An XK 16/20 Column (GE Healthcare), 
equipped with an external jacket for cooling and capped with two QuickLock AK 16 adaptors 
was packed with metal-chelating Sepharose fast flow resin (GE Healthcare). The resin bed (5-
20 mL) was cast with continual pouring, with headspace over the resin minimised. Solutions 
were loaded onto the column using a Watson-Marlow 101U/P peristaltic pump (flow rate 0.5-
5.0 mL minute-1), and the column pre-equilibrated with 10 column volumes (c.v.) of buffer Sp-
RfK 1. Filtered lysate was loaded, and the bound sample washed using buffer Sp-RfK 1 (2 c.v.), 
followed by Sp-RfK 2 (5 c.v.). Elution was achieved using buffer Sp-RfK 3, after which the 
purified protein solution was concentrated by ultrafiltration and dialysed into buffer Sp-RfK 4 
to remove imidazole. Long-term storage of the protein was possible after flash-freezing. 
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7.2.4 Formation of FMN analogues using Sp-RfK 
Phosphorylation of 5-deazariboflavin and 1-deazariboflavin using Sp-RfK utilised a portion of 
the prepared protein sample within buffer Sp-RfK 5. Reactions were performed at 37 °C with 
shaking, typically utilising 5 equivalents of ATP to give completion in 1 hour, although lower 
ATP concentrations (1.2 equivalents) still gave complete reaction in 4 hours. Once complete, 
the enzymatic mixture was lyophilised and stored at -20 °C until purification. 
 
7.2.5 Purification of FMN analogues formed using Sp-RfK 
Purification of the phosphorylated products (5-deazaFMN and 1-deazaFMN) was performed 
on a preparative scale using HPLC following the same protocol used for the purification of the 
Ca-RfK-FADS mixtures251,178,179, with the same gradient (appendix 1) and conditions (section 
7.1.5) giving similar retention times.  
 
Since using HPLC for preparative isolation of the product was particularly time consuming, an 
alternative method of purification was attempted in cases where subsequent reaction or use 
of the cofactor would not be hindered or otherwise affected by the presence of low-
concentration contaminants (such as ADP) within the reaction. Upon completion of the 
enzymatic reaction, the crude mixture was passed over the IMAC column previously used to 
separate the Sp-RfK from other intracellular proteins. As the polyhistidine tag was not 
removed from the protein, it was possible to remove the kinase from the solution of FMN. 
The mixture was subsequently lyophilised prior to storage at -20 °C. 
 
7.3 A. sativa LOV2  
7.3.1 Expression of AsLOV2(WT) and mutant proteins 
The modified pNCO113-HISACT(C49S)-AsLOV2(WT) vector prepared by Fisher, Kay et al.1,4 
was used for the expression of the wild-type Avena sativa PHOT1-LOV2 domain. This was 
maintained within E. coli strain XL1-blue, and expressed within BL21(DE3) cells. Alternative 
strains of E. coli examined for expression of this plasmid include M15[pRep4] and JM101, 
although JM101 furnished lower protein yields than BL21(DE3) or M15[pRep4]. Mutant 
derivatives of the wild-type AsLOV2 gene (referred to subsequently as AsLOV2(C450X)) were 
expressed using a mutated vector within strain JM101.  
 236 
 
 
Culture growth was performed in line with the general method given in section 5.6.2.2, in TB 
media (LB was found to be ineffective). Culture volumes between 0.5-3 L were used, with 
IPTG concentrations of 1-5 mmol used to induce protein expression. However, while an OD600 
of 0.6-0.8 was used for expression of the C450X mutants, an OD600 between 1.2-1.4 was 
possible for expression of the wild-type LOV2 domain, as the richness of the TB growth media 
allowed significantly extended bacterial growth245. After induction, expression was 
performed overnight at 16-20 °C, after which the cells were harvested as before. Typical wet 
cell masses between 18 - 26 g L-1 were obtained; harvested products were stored at -20°C 
until purification.  
 
7.3.2 Cell Lysis – AsLOV2(WT) and AsLOV2(C450X) 
Frozen cells were resuspended and thawed in an equivolume quantity of buffer LOVR. 
Immediately prior to cell lysis, this was diluted using two volumes of buffer LOVLYS. Cells were 
sonnicated using an intermittent cycle of 5 seconds sonication, followed by 15 seconds of no 
disruption, for 10 minutes, as more vigorous sonication led to extensive fragmentation of the 
hisactophilin-AsLOV2 fusion protein. After lysis, the mixture was centrifuged (15000 RPM, 30 
minutes, 4 °C); the supernatant was decanted, and centrifugation twice repeated. The 
centrifuged lysate was finally filtered using a MillexGP syringe filter (0.22 µm). 
 
7.3.3 Purification of AsLOV2(WT) and AsLOV2(C450X) 
Purification of the cell lysate was performed using an IMAC procedure similar to that used for 
the purification of Sp-RfK (section 7.2.3, vide supra). The vivid yellow lysate was passed over 
a column of Ni-Sepharose (fast-flow) resin using a peristaltic pump (flow rate 0.5 – 2.0 mL 
minute-1), which had been packed and pre-equilibrated using buffer LOVA. Binding of the 
hisactophilin-AsLOV2 protein was indicated visually, as the yellow protein appeared green 
when immobilised on the blue resin (figure 87, section 3.3.6). The column was washed with a 
minimum of 5 column volumes of buffer LOVA, and protein samples for analysis containing 
the native FMN cofactor were eluted using buffer LOVC.  
 
Eluted fractions were analysed using SDS-PAGE, and concentrated via ultrafiltration if 
necessary. Fractions containing the purified protein were combined, and imidazole was 
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removed by dialysis using buffer LOVD, or by passing the solution through a pre-packed 
HiPrep™ 26/10 desalting column equilibrated with buffer LOVD. 
  
7.3.4 Cofactor Exchange within the AsLOV2(WT) and AsLOV2(C450X) Domains 
Replacement of the native FMN cofactor with either of the enzymatically modified analogues 
(5-deazaFMN or 1-deazaFMN) was performed prior to elution of the protein sample from the 
IMAC resin. After washing of the retained protein, buffer LOVB (containing 1.0-4.5 M 
guanidine thiocyanate; 3 column volumes) was applied to the column, causing denaturing and 
elution of the native FMN cofactor. Thiocyanate was removed by washing with 2 column 
volumes of buffer LOVA or a 2 % saline solution. A solution of the desired FMN analogue to be 
incorporated (typically 20 mM, although 10 mM was also effective) was cycled over the 
retained denatured sample continuously for 16 hours at 4 ° C. Care was taken to ensure both 
the column and deazaFMN solution remained in the dark, to prevent photo-degradation of 
the cofactor. After 16 hours, the synthetic FMN analogue solution was removed and the 
column thoroughly washed with buffer LOVA; successful incorporation of the analogue was 
immediately observable by the retained protein adopting the colour of the synthetic cofactor. 
Protein was eluted from the column using the method described in section 7.3.3 above.  
 
Samples prepared using this method were allowed to stand overnight at 4 °C in the dark, as 
any misfolded or apoprotein-form proteins readily precipitated from the mixture, which were 
removed by centrifugation (4000 RPM, 30 minutes, 4°C) prior to removal of imidazole as 
before. Typical incorporation efficiencies above 80 % (determined upon the concentration of 
FMN eluted) were obtained using this method. 
 
7.3.5 Site Directed Mutagenesis (SDM) of AsLOV2(WT) to form AsLOV2(C450X) mutants 
Mutagenesis of the AsLOV2 gene was performed based upon the PCR-based whole plasmid 
method of Weiner et al.213, using the original vector pNCO113-HISACT(C49S)-AsLOV2(WT) 
isolated from E. coli XL1-blue and thoroughly purified to remove any salts. An introduction to 
the technique is given in section 5.6.6. 
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Primers (listed in table 13, section 5.7.3) incorporating the desired mutation(s) to alter the 
gene transcribed by the codon originally expressing cysteine 450 of AsLOV2 (C450) were 
designed using the PrimerX tool248, and supplied by Eurofins MWG Operon. 
 
A typical PCR mixture for the SDM process was comprised of: 
Volume Mixture Component 
39 µL ddH2O 
5 µL Pfu DNA polymerase buffer (10 x) 
2 µL DNA primer, forward (2 nanomoles) 
2 µL DNA primer, reverse (2 nanomoles) 
1 µL dNTP mixture (100 µM) 
1 µL parental DNA (20 ng) 
Table 22: Typical composition of a PCR mixture for SDM of the AsLOV2 gene 
 
All reactant mixtures were kept on ice until initiation of the PCR. Pfu DNA polymerase (1 µL) 
was added immediately before initiation of the reaction. 16 cycles of the PCR were performed 
using an elongation time of between 10-15 minutes per cycle, to allow sufficient time for the 
polymerase to complete its synthesis. Upon completion of the PCR cycle, all products were 
digested using DpnI, which cut any methylated DNA present. As the parental DNA was 
methylated (the newly-formed daughter DNA was not), this allowed selection of only the 
daughter (mutant) DNA.  
 
Purified DNA was transformed into E. coli strain XL1-blue, and plated on LB-Agar plates 
containing ampicillin to allow selection. Transformants were grown in liquid cultures, before 
the DNA was extracted and sequenced to confirm desired mutation and to ensure no other 
undesired alterations (including frame-shifting and silent mutations). Mutant DNA was 
subsequently transformed into E. coli strain JM101 for expression (as described in sections 
7.3.1 to 7.3.4, above). 
 
7.3.6 Spectroscopic examination of AsLOV2(WT) and AsLOV2(C450X) 
Spectroscopic examination of all AsLOV2 – derived protein samples was performed as 
described in section 5.6.8, in buffer LOVD, at pH 8.0. Spectra of the wild-type protein 
containing the native cofactor, 5-deaza FMN and 1-deazaFMN are shown in the appropriate 
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experimental sections, along with selected spectra of the AsLOV2-mutant proteins. UV-visible 
spectra for each mutant sample were largely identical to the wild-type (dark state) spectrum, 
with the primary absorbance wavelength (and accompanying vibronic side-bands) 
determined by the cofactor bound by the protein. Key spectral characteristics of each sample 
are summarised in table 23 below. 
 
Protein 
Sample 
Cofactor 
Primary 
Absorbance 
Wavelength, nm 
Vibronic Side-Band Wavelength, nm 
Most Intense Least Intense 
Wild-Type native FMN 447 473 422 
 5-deazaFMN 404 428 384 
 1-deazaFMN 535 503 570 
C450M native FMN 447 472 421 
 5-deazaFMN 404 428 383 
 1-deazaFMN 535 502 570 
C450S native FMN 447 473 422 
 5-deazaFMN 404 428 384 
 1-deazaFMN 535 503 571 
C450D native FMN 448 474 422 
 5-deazaFMN 404 428 384 
 1-deazaFMN 535 503 570 
C450G native FMN 447 473 422 
 5-deazaFMN 404 427 383 
 1-deazaFMN 535 502 571 
C450A(T418I) native FMN 447 473 422 
 5-deazaFMN 404 428 384 
 1-deazaFMN 533 502 570 
 
Table 23: Summary of UV-visible spectral results for the incorporation of synthetic flavins 
into several mutant derivatives of AsLOV2. The primary absorbance (determined by 
absorbance of the cofactor) is shown, along with the wavelength observed for the vibronic 
side-bands surrounding this. All of those listed (except for the wild-type protein containing 
native FMN or 5-deazaFMN) were inactive to photoirradiation. Note that for all samples 
containing 1-deazaFMN, the relative intensity of the side bands is the reverse of the intensity 
found for native FMN and 5-deazaFMN 
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7.4  Additional Experiments 
7.4.1 Examination of possible photo-stimulated reaction between FMN, 5-deazaFMN (and 
5-deazaRf), and two cysteine based Michael acceptors 
A range of solutions containing 5-deazaRf and 5-deazaFMN were prepared, at concentrations 
between 50 μM and 250 μM. Freshly prepared solutions of free-(L)-cysteine and fully-reduced 
glutathione in H2O (100 mM or 300 mM) were mixed with an equivolume quantity of each 
flavin solution (giving minimum solution concentrations of 0.25 μM flavin and 50 mM cysteine 
or glutathione). 
 
UV-visible spectra were immediately recorded, and compared to the spectrum of a similarly-
diluted flavin solution containing no thiol. No difference between the two spectra was 
observed. Re-examination after several hours (stored in the dark) showed no decrease in 
flavin absorbance in the cysteine-containing mixture. 
 
The cysteine and glutathione-containing samples were irradiated at 400 nm for periods from 
30 seconds to 300 seconds, and the UV spectra immediately recorded. In every case, no 
change was found to any UV spectrum compared to pre-irradiation levels, suggesting no 
formation of a flavin-cysteine bond. 
 
These experiments were repeated using FMN (with irradiation at 450 nm), with the same 
result observed. 
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Appendix 1 – Graphical Representation of HPLC gradients 
Formation of Riboflavin Analogues   
The gradient used for the purification of riboflavin analogues (as described in section 6.5) is 
shown below. The aqueous mobile phase is shown in blue; acetonitrile is shown in yellow. 
 
 
Formation of FMN Analogues 
The gradient used for the purification of the enzymatically formed flavin cofactors (as 
described in section 7.1.5) is shown below. The aqueous mobile phase is shown in blue; 
acetonitrile is shown in yellow. 
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Appendix 2 – Codon Usage Report, Generated by OPTIMIZER 
The gene encoding AsLOV2(WT) was compared to Escherichia coli K12, to identify relative 
codon optimisation. The AsLOV2(WT) gene was referred to as the “Query”. 
 
The OPTIMIZER tool generated an Optimized [sic] sequence, an Alignment Report of the  
Query and Optimized DNA sequence, and Individual Codon Optimization Summary. 
 DNA Sequence CAI % GC % AT 
 Query GAATTTCTTGCTACTACACTTGAACGTATTGAGAAGAAC
TTTGTCATTACTGACCCACGTTTGCCAGATAATCCCATT
ATCTTCGCGTCCGATAGTTTCTTGCAGTTGACAGAATAT
TCGCGAGAAGAAATTCTGGGTCGTAACTGCCGTTTTCTT
CAAGGTCCTGAAACCGATCGCGCGACAGTGCGCAAAA
TTCGTGATGCCATCGATAACCAAACAGAGGTCACTGTA
CAGCTGATTAATTATACAAAGAGTGGTAAAAAGTTCTG
GAACCTCTTTCACTTGCAGCCTATGCGTGATCAGAAGG
GTGATGTCCAGTACTTTATTGGTGTCCAGTTGGATGGT
ACCGAACATGTCCGTGATGCGGCCGAGCGTGAGGGTG
TCATGCTGATTAAGAAAACTGCAGAAAATATTGATGAG
GCGGCAAAAGAACTTCCAGATGCTAATCTGCGTCCAGA
GGATTTGTGGGCTAACTAA 
0.446 44.7 55.3 
Optimized GAATTCCTGGCGACCACCCTGGAACGTATCGAAAAAAA
CTTCGTTATCACCGACCCGCGTCTGCCGGACAACCCGAT
CATCTTCGCGTCTGACTCTTTCCTGCAGCTGACCGAATA
CTCTCGTGAAGAAATCCTGGGTCGTAACTGCCGTTTCCT
GCAGGGTCCGGAAACCGACCGTGCGACCGTTCGTAAA
ATCCGTGACGCGATCGACAACCAGACCGAAGTTACCGT
TCAGCTGATCAACTACACCAAATCTGGTAAAAAATTCTG
GAACCTGTTCCACCTGCAGCCGATGCGTGACCAGAAAG
GTGACGTTCAGTACTTCATCGGTGTTCAGCTGGACGGT
ACCGAACACGTTCGTGACGCGGCGGAACGTGAAGGTG
TTATGCTGATCAAAAAAACCGCGGAAAACATCGACGAA
GCGGCGAAAGAACTGCCGGACGCGAACCTGCGTCCGG
AAGACCTGTGGGCGAACTAA 
1.000 53.7 46.3 
 
Abbreviations:  
CAI  Codon Adaptation Index 
% GC  Percentage of G+C nucleobases 
% AT  Percentage of A+T nucleobases 
|  Unchanged Nucleotide 
*  Transversion Change (Purine <-> Pyrimidine) 
#  Transitional Change (Purine <-> Purine or Pyrimidine <-> Pyrimidine) 
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Alignment Report 
 
Query GAA  TTT   CTT   GCT   ACT   ACA  CTT  GAA  CGT  ATT  GAG  AAG  AAC  TTT  GTC  ATT  ACT  GAC  CCA  CGT  
  | | |  | | #   | | *   | | *   | | #  | | *   | | *  | | |   | | |   | | #  | | #  | | # | | |   | | # | | #  | | #  | | #  | | |   | | #  | | |  
Optim. GAA  TTC   CTG  GCG  ACC  ACC  CTG  GAA  CGT  ATC  GAA  AAA  AAC  TTC  GTT  ATC  ACC  GAC  CCG  CGT  
  
Query TTG  CCA  GAT   AAT  CCC  ATT  ATC  TTC  GCG  TCC  GAT  AGT  TTC  TTG  CAG   TTG  ACA  GAA  TAT  TCG  
 # | |    | | #    | | #    | | #   | | *     | | #   | | |     | | |    | | |     | | #   | | #    * * |    | | |   # | |     | | |     # | |    | | *    | | |    | | #    | | *  
Optim. CTG  CCG GAC  AAC  CCG  ATC  ATC  TTC  GCG  TCT  GAC  TCT  TTC  CTG  CAG  CTG  ACC  GAA  TAC  TCT  
  
Query CGA  GAA  GAA  ATT  CTG   GGT  CGT  AAC  TGC  CGT  TTT   CTT  CAA   GGT  CCT  GAA  ACC  GAT  CGC  GCG  
  | | *     | | |    | | |     | | #   | | |     | | |     | | |     | | |     | | |     | | |    | | #    | | *    | | #    | | |      | | *    | | |     | | |    | | #    | | #    | | |   
Optim. CGT  GAA  GAA  ATC  CTG  GGT  CGT  AAC  TGC  CGT  TTC  CTG  CAG  GGT  CCG  GAA  ACC  GAC  CGT  GCG  
  
Query ACA  GTG  CGC  AAA  ATT  CGT  GAT  GCC  ATC  GAT   AAC  CAA  ACA  GAG  GTC  ACT  GTA  CAG  CTG  ATT  
  | | *    | | *    | | #     | | |    | | #   | | |    | | #     | | *    | | |    | | #    | | |     | | #    | | *    | | #    | | #    | | #   | | *    | | |     | | |    | | #  
Optim. ACC  GTT  CGT   AAA  ATC  CGT GAC  GCG  ATC  GAC  AAC  CAG  ACC  GAA  GTT  ACC  GTT  CAG  CTG ATC  
  
Query AAT  TAT   ACA  AAG  AGT  GGT  AAA  AAG  TTC  TGG  AAC  CTC  TTT  CAC  TTG   CAG  CCT  ATG  CGT  GAT  
 | | #    | | #    | | *    | | #    * * |   | | |      | | |   | | #    | | |     | | |    | | |      | | *    | | #   | | |   # | |     | | |      | | *   | | |     | | |     | | #  
Optim. AAC  TAC  ACC  AAA  TCT   GGT  AAA  AAA  TTC  TGG  AAC  CTG  TTC  CAC  CTG  CAG  CCG  ATG  CGT  GAC  
  
Query CAG  AAG  GGT  GAT  GTC  CAG  TAC  TTT  ATT  GGT  GTC  CAG  TTG  GAT   GGT  ACC  GAA  CAT  GTC  CGT  
  | | |     | | #    | | |     | | #   | | #    | | |     | | |    | | #   | | #   | | |     | | #    | | |    # | |    | | #    | | |     | | |     | | |     | | #    | | #   | | |  
Optim. CAG  AAA  GGT  GAC  GTT  CAG  TAC  TTC  ATC  GGT  GTT  CAG  CTG  GAC  GGT  ACC  GAA  CAC  GTT  CGT  
  
Query GAT  GCG  GCC  GAG  CGT  GAG  GGT  GTC  ATG  CTG  ATT  AAG  AAA  ACT  GCA  GAA  AAT  ATT   GAT  GAG  
  | | #    | | |      | | *    | | #    | | |     | | #    | | |     | | #   | | |     | | |    | | #   | | #    | | |     | | #   | | #    | | |     | | #   | | #    | | #    | | #  
Optim. GAC  GCG  GCG  GAA  CGT  GAA  GGT  GTT  ATG  CTG  ATC  AAA  AAA  ACC  GCG  GAA  AAC  ATC  GAC  GAA  
  
Query GCG  GCA  AAA  GAA  CTT   CCA   GAT   GCT   AAT   CTG  CGT  CCA  GAG  GAT  TTG   TGG  GCT  AAC  TAA  
  | | |     | | #    | | |     | | |     | | *    | | #     | | #    | | *     | | #     | | |     | | |    | | #    | | #    | | #    # | |    | | |     | | *    | | |     | | |  
Optim. GCG  GCG  AAA  GAA  CTG  CCG  GAC   GCG  AAC   CTG  CGT  CCG  GAA  GAC  CTG  TGG  GCG  AAC  TAA  
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Individual Codon Optimization Summary 
Each codon of the standard genetic code is listed, with the amino acid encoded indicated in brackets. Usage of each codon in the query sequence 
and optimized sequence is shown. 
 
Codons Query Optimized Codons Query Optimized Codons Query Optimized Codons Query Optimized 
GCA (A) 2 0 GCC (A) 2 0 GCG (A) 4 11 GCT (A) 3 0 
TGC (C) 1 1 TGT (C) 0 0 GAC (D) 1 13 GAT (D) 12 0 
GAA (E) 9 15 GAG (E) 6 0 TTC (F) 3 8 TTT (F) 5 0 
GGA (G) 0 0 GGC (G) 0 0 GGG (G) 0 0 GGT (G) 7 7 
CAC (H) 1 2 CAT (H) 1 0 ATA (I) 0 0 ATC (I) 2 11 
ATT (I) 9 0 AAA (K) 4 9 AAG (K) 5 0 TTA (L) 0 0 
TTG (L) 6 0 CTA (L) 0 0 CTC (L) 1 0 CTG (L) 4 15 
CTT (L) 4 0 ATG (M) 2 2 AAC (N) 5 9 AAT (N) 4 0 
CCA (P) 4 0 CCC (P) 1 0 CCG (P) 0 7 CCT (P) 2 0 
CAA (Q) 2 0 CAG (Q) 6 8 AGA (R) 0 0 AGG (R) 0 0 
CGA (R) 1 0 CGC (R) 2 0 CGG (R) 0 0 CGT (R) 9 12 
AGC (S) 0 0 AGT (S) 2 0 TCA (S) 0 0 TCC (S) 1 0 
TCG (S) 1 0 TCT (S) 0 4 ACA (T) 5 0 ACC (T) 2 11 
ACG (T) 0 0 ACT (T) 4 0 GTA (V) 1 0 GTC (V) 6 0 
GTG (V) 1 0 GTT (V) 0 8 TGG (W) 2 2 TAC (Y) 1 3 
TAT (Y) 2 0 TAA (.) 1 1 TGA (.) 0 0 TAG (.) 0 0 
 
